oxidopamine has been researched along with Parkinson Disease in 1457 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, the intriguing ability of several anesthetics to readily inhibit GSK3β within the cortex and hippocampus led us to investigate the effects of brief isoflurane anesthesia on striatal GSK3β signaling in naïve rats and in a rat model of early-stage PD." | 7.85 | Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease. ( Forsberg, MM; Jalkanen, AJ; Kohtala, S; Leikas, JV; Rantamäki, T; Theilmann, W, 2017) |
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 7.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| "Arachidonic acid (AA) signaling is upregulated in the caudate-putamen and frontal cortex of unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, a model for asymmetrical Parkinson disease." | 7.76 | Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. ( Bazinet, RP; Bhattacharjee, AK; Lee, HJ; Rapoport, SI, 2010) |
| "In order to observe neuronal toxical effect of Levodopa and investigate if using Levodopa together with Ginkgo Bilobar Extract (EGb) would be an workable method to treat Parkinson disease, rat models of Parkinson disease (PD) were made by injecting 6-OHDA stereotaxically to right side of the mesencephic ventral tegmental area (VTA) and substantia nigra pars compacta (SNc)." | 7.72 | Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats. ( Cao, F; Sun, S; Tong, ET, 2003) |
| "It has previously been reported that intracerebroventricular administration of neurotensin (30 micrograms) reduced muscular rigidity and tremors, induced by a neurochemical lesion with 6-hydroxydopamine in the posterolateral hypothalamus of rats." | 7.68 | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat. ( Jolicoeur, FB; Rivest, R; St-Pierre, S, 1991) |
| "Parkinson disease is a neurodegenerative disorder distinguished by dopaminergic shortage in the striatum and the accumulation of α-synuclein neuronal aggregates in the brains of patients." | 5.72 | Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways. ( Lian, M; Liu, X; Mao, Y; Shao, J, 2022) |
| "In this model of 6-OHDA-induced parkinsonism, Gst treatment in all three doses showed a dose dependent symptomatic improvement in motor imbalance (P < 0." | 5.72 | Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease. ( Eyvari-Brooshghalan, S; Haddadi, R; Nourouzi, N; Sabahi, M; Sadeghian, Z, 2022) |
| "With Parkinson's disease being a major neurodegenerative disorder, afflicting millions of people globally, and with disease modification challenges, SKIP may hold promise for future therapeutic development." | 5.62 | Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP. ( Gozes, I; Ivashko-Pachima, Y; Seroogy, KB; Sharabi, Y, 2021) |
| "levodopa is the gold standard for the treatment of Parkinson disease, but prolonged levodopa treatment often leads to the development of abnormal involuntary movements." | 5.56 | Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms. ( Gao, H; Li, W, 2020) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium." | 5.43 | Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. ( Chau, KY; Hong, CT; Schapira, AH, 2016) |
| "Cannabidivarin (CBDV), a structural analog of cannabidiol (CBD), has received attention in recent years owing to its anticonvulsant property and potential for treating autism spectrum disorder." | 4.31 | Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. ( Jin, S; Jin, T; Li, H; Liu, C; Liu, Y; Long, H; Lu, Y; Peng, Y; Wang, F; Wang, X; Zhao, L, 2023) |
| "Taken together, the present preclinical study showed that while morphine can attenuate lipopolysaccharide-induced inflammation and cell death, both naloxone and L-NAME can abolish this effect." | 4.31 | Regulation of the Endogenous Opiate Signaling Pathway against Oxidative Stress and Inflammation: A Considerable Approach for Exploring Preclinical Treatment of Parkinson's Disease. ( Cadet, P; Neuwirth, LS; Zhu, W, 2023) |
| " To investigate the causative relationship between neuro-inflammation and dyskinesias, we assessed if striatal M1 and M2 microglia numbers correlated with dyskinesia severity and whether the anti-inflammatories, minocycline and indomethacin, reverse these numbers and mitigate against dyskinesia." | 4.31 | The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias. ( Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B, 2023) |
| "Studies have shown that hydrogen sulfide (H2S) exerts a neuroprotective effect and may have a therapeutic value for treating neurodegenerative diseases including Parkinson's disease." | 3.88 | Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease. ( Babayan-Tazehkand, A; Haghdoost-Yazdi, H; Rastgoo, N; Sarbazi-Golezari, A; Sarookhani, MR, 2018) |
| " MATERIAL AND METHODS In the present study, we evaluated the beneficial effects and underlying mechanisms of punicalagin (PN) in human neuroblastoma SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA) to mimic PD in vitro." | 3.88 | Punicalagin Exerts Beneficial Functions in 6-Hydroxydopamine-Treated SH-SY5Y Cells by Attenuating Mitochondrial Dysfunction and Inflammatory Responses. ( Chu, J; Han, W, 2018) |
| " Therefore, the intriguing ability of several anesthetics to readily inhibit GSK3β within the cortex and hippocampus led us to investigate the effects of brief isoflurane anesthesia on striatal GSK3β signaling in naïve rats and in a rat model of early-stage PD." | 3.85 | Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease. ( Forsberg, MM; Jalkanen, AJ; Kohtala, S; Leikas, JV; Rantamäki, T; Theilmann, W, 2017) |
| "Long-term levodopa (l-dopa) treatment is associated with the development of l-dopa-induced dyskinesias in the majority of patients with Parkinson disease (PD)." | 3.85 | Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. ( Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I, 2017) |
| "Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients." | 3.83 | Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. ( Eskow Jaunarajs, KL; Figge, DA; Standaert, DG, 2016) |
| " Pretreatment of human neuroblastoma SH-SY5Y cells with DBL, but not with another Chaga-derived catechol-containing compound, caffeic acid, dose-dependently improved the survival of 6-OHDA-treated cells." | 3.80 | 3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway. ( Gunjima, K; Hashida, K; Hori, O; Konishi, T; Matsugo, S; Nakamura, Y; Takakura, K; Tomiyama, R; Yamada, T, 2014) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 3.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| "Arachidonic acid (AA) signaling is upregulated in the caudate-putamen and frontal cortex of unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, a model for asymmetrical Parkinson disease." | 3.76 | Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. ( Bazinet, RP; Bhattacharjee, AK; Lee, HJ; Rapoport, SI, 2010) |
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| "Although alpha-synuclein is the main structural component of the insoluble filaments that form Lewy bodies in Parkinson disease (PD), its physiological function and exact role in neuronal death remain poorly understood." | 3.73 | Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. ( Chung, KC; Kim, J; Lee, CH; Lee, HJ; Lee, ST; Oh, YJ; Paik, SR; Park, SM; Sung, JY; Um, JW, 2005) |
| "The work shows the effects of caffeine after the intrastriatal injection of 6-OHDA in rats, considered as a model of Parkinson disease (PD)." | 3.73 | Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. ( Aguiar, LM; Cunha, GM; Freitas, RM; Macêdo, DS; Nobre, HV; Oliveira, AA; Sousa, FC; Vasconcelos, SM; Viana, GS, 2006) |
| "In order to observe neuronal toxical effect of Levodopa and investigate if using Levodopa together with Ginkgo Bilobar Extract (EGb) would be an workable method to treat Parkinson disease, rat models of Parkinson disease (PD) were made by injecting 6-OHDA stereotaxically to right side of the mesencephic ventral tegmental area (VTA) and substantia nigra pars compacta (SNc)." | 3.72 | Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats. ( Cao, F; Sun, S; Tong, ET, 2003) |
| " We now examined the possible protective effects of VIP against toxicity of dopamine, 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium ion (MPP+) in neuronal cultures [rat pheochromocytoma (PC12), human neuroblastoma (SH-SY5Y) and rat cerebellar granular cells]." | 3.70 | Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. ( Brenneman, DE; Fridkin, M; Gozes, I; Melamed, E; Offen, D; Sherki, Y, 2000) |
| "It has previously been reported that intracerebroventricular administration of neurotensin (30 micrograms) reduced muscular rigidity and tremors, induced by a neurochemical lesion with 6-hydroxydopamine in the posterolateral hypothalamus of rats." | 3.68 | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat. ( Jolicoeur, FB; Rivest, R; St-Pierre, S, 1991) |
| "Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common chronic neurodegenerative disorders, characterized by motoric dysfunction or cognitive decline in the early stage, respectively, but often by both symptoms in the advanced stage." | 2.66 | Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. ( Barilar, JO; Homolak, J; Knezovic, A; Perhoc, AB; Riederer, P; Salkovic-Petrisic, M, 2020) |
| "Treatment with lactacystin, a proteasome inhibitor, significantly suppressed 6-hydroxydopamine (6-OHDA)-induced toxicity and oxidative stress in PC12 cells." | 2.49 | [Dopaminergic neuroprotection via Nrf2-ARE pathway activation: identification of an activator from green perilla leaves]. ( Izumi, Y, 2013) |
| "Animal models of Parkinson's disease (PD) have been widely used in the past four decades to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder." | 2.48 | Animal models of Parkinson's disease. ( Armentero, MT; Blandini, F, 2012) |
| "Improvements in modelling Parkinson's disease in rodents contribute to the advancement of scientific knowledge and open innumerable pathways for the development of new therapeutic interventions." | 2.48 | Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model? ( Dunnett, SB; Lelos, MJ; Lindgren, HS, 2012) |
| "Animal models have been invaluable to Parkinson's disease (PD) research." | 2.46 | Neurotoxic in vivo models of Parkinson's disease recent advances. ( Cannon, JR; Greenamyre, JT, 2010) |
| "Of these, neuroinflammation is one candidate that appears to accumulate more support with each passing year." | 2.46 | Modeling neuroinflammatory pathogenesis of Parkinson's disease. ( Barnum, CJ; Tansey, MG, 2010) |
| "Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment." | 2.43 | Neural repair strategies for Parkinson's disease: insights from primate models. ( Kordower, JH; O'Malley, J; Soderstrom, K; Steece-Collier, K, 2006) |
| "The development of animal models of Parkinson's disease is of great importance in order to test substitutive or neuroprotective strategies for Parkinson's disease." | 2.42 | Animal models of Parkinson's disease in rodents induced by toxins: an update. ( Breidert, T; Cohen-Salmon, C; Feger, J; Hirsch, EC; Höglinger, G; Launay, JM; Parain, K; Prigent, A; Rousselet, E; Ruberg, M, 2003) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| "The symptoms of Parkinson's disease (PD) were first described nearly two centuries ago and its characteristic pathology identified nearly a century ago, yet its pathogenesis is still poorly understood." | 2.41 | An inflammatory review of Parkinson's disease. ( Halliday, GM; Orr, CF; Rowe, DB, 2002) |
| "The etiology of Parkinson's disease is not known." | 2.41 | Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. ( Grünblatt, E; Mandel, S; Youdim, MB, 2000) |
| "Parkinson's disease affects one out of every 100 people above the age of 55." | 2.40 | Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. ( Hastings, TG; Zigmond, MJ, 1997) |
| "Chlorogenic acid (CGA) is a polyphenolic substance derived from various medicinal plants." | 1.91 | Chlorogenic acid delays the progression of Parkinson's disease via autophagy induction in ( He, CL; Long, T; Pan, R; Qin, DL; Qiu, WQ; Tang, Y; Teng, JF; Wu, AG; Wu, JM; Yu, CL; Yu, L; Zhou, XG, 2023) |
| "The melatonin treatment blocked the loss of spine density of stubby type." | 1.91 | The effects of regular swimming exercise and melatonin on the neurons localized in the striatum of hemiparkinsonian rats. ( Boracı, H; Gergin, S; Kirazlı, Ö; Şehirli, ÜS; Yananlı, HR; Yıldız, SD, 2023) |
| "Continuous SGB prevention inhibited mechanical hyperalgesia at 2, 3 and 4 weeks post modeling, and significantly reversed mechanical hyperalgesia at 3 and 4 weeks post modeling, compared with those of Saline group (p < 0." | 1.91 | Continuous SGB Inhibits Occurrence and Maintenance of Mechanical Hyperalgesia via Reducing Inflammatory Cytokines in Striatum and PAG of PD Nociception Rat Models. ( Huang, W; Li, M; Liu, G; Shi, Y; Zeng, Y, 2023) |
| "Parkinsonism was induced by 6-hydroxydopamine (6-OHDA, 8 μg/2μl/rat)." | 1.91 | Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. ( Ebadi, SA; Eyvari Brooshghalan, S; Haddadi, R; Mohajjel Nayebi, A; Sabahi, M; Sadeghian, Z, 2023) |
| "The pathogenesis of Parkinson's disease (PD) is very complex and still needs further exploration." | 1.91 | The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model. ( Chen, L; Jia, R; Liu, Y; Shuai, K; Wu, XM; Zhou, C; Zhu, L, 2023) |
| "NSCs transplantation combined with ethyl stearate ameliorated the behavioral deficits of PD rats." | 1.91 | Neural stem cells transplantation combined with ethyl stearate improve PD rats motor behavior by promoting NSCs migration and differentiation. ( Chen, D; Huang, J; Li, C; Li, H; Li, X; Yang, X; Ye, S; Yi, L; Zheng, Q; Zhong, J, 2023) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that are presently incurable." | 1.91 | Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine. ( Banerji, B; Biswas, SC; Das, AK; Pramanik, SK; Sanphui, P, 2023) |
| "The molecular processes behind Parkinson's disease (PD) remain under debate although mitochondrial oxidative stress generation has been proposed as a fundamental contributor." | 1.91 | Protective effects of 24-epibrassinolide against the 6-OHDA zebrafish model of Parkinson's disease. ( Félix, L; Gomes, A; Monteiro, SM; Venâncio, C, 2023) |
| "L-DOPA is the standard treatment for Parkinson's disease (PD), but chronic treatment typically leads to L-DOPA-induced dyskinesia (LID)." | 1.91 | Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats. ( Bishop, C; Centner, A; Conti Mazza, MM; Werner, DF, 2023) |
| "Its role in Parkinson's disease (PD) has not been well characterized." | 1.91 | Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. ( Bae, EK; Chen, YH; Hung, TW; Wang, YS; Wu, KJ; Yu, SJ, 2023) |
| "The underlying mechanism of Parkinson's disease are still unidentified, but excitotoxicity, oxidative stress, and neuroinflammation are considered key actors." | 1.91 | Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson's disease models. ( Alfonsetti, M; Antonosante, A; Ardini, M; Benedetti, E; Castelli, V; Catanesi, M; Cimini, A; d'Angelo, M; Sette, M, 2023) |
| "We confirmed the presence of orofacial pain after unilateral 6-OHDA-injection, which improved after aerobic exercise training." | 1.91 | Exercise Improves Orofacial Pain and Modifies Neuropeptide Expression in a Rat Model of Parkinson's Disease. ( Binda, KH; Chacur, M; Martins, DO, 2023) |
| "Physical exercise benefits Parkinson's disease (PD) patients but the mechanism is unclear." | 1.91 | Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson's disease. ( Binda, KH; Brooks, DJ; Chacur, M; Landau, AM; Real, CC, 2023) |
| "Gut dysbiosis has been involved in the pathogenesis and progression of Parkinson's disease (PD), but the mechanisms through which gut microbiota (GM) exerts its influences deserve further study." | 1.91 | Zooming into Gut Dysbiosis in Parkinson's Disease: New Insights from Functional Mapping. ( Buommino, E; Coretti, L; De Caro, C; Lembo, F; Mattace Raso, G; Opallo, N; Pirozzi, C; Turco, L, 2023) |
| " Involuntary movements were assessed by two blinded raters prior and every 30 min after drug dosing using the Clinical Dyskinesia Rating Scale (CDRS)." | 1.91 | Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration. ( Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G, 2023) |
| "The debilitating effects of Parkinson's disease (PD) progress over time and are pathophysiologically characterized by the formation of Lewy bodies due to the accumulation of α-synuclein aggregates resulting in the death of dopaminergic neurons." | 1.91 | 6-hydroxydopamine affects multiple pathways to induce cytotoxicity in differentiated LUHMES dopaminergic neurons. ( Ali, N; Compher, J; Jones, CD; Maffi, SK; McLaughlin, Q; Sane, MS; Tang, H, 2023) |
| "Cabergoline co-treatment with L-dopa reduced LID, striatal preprodynorphin mRNA expression, and hypertrophy of the entopeduncular nucleus, indicating that cabergoline has an anti-LID effect independent of the L-dopa-sparing effect." | 1.72 | Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. ( Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K, 2022) |
| "Animal models of Parkinson's disease are useful to evaluate new treatments and to elucidate the etiology of the disease." | 1.72 | Comparative analysis of striatal [ ( Avendaño-Estrada, A; Ávila-Rodríguez, MA; Verdugo-Díaz, L, 2022) |
| "Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss." | 1.72 | Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease. ( Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W, 2022) |
| "Patients with Parkinson's disease (PD) often suffer from delayed gastric emptying, but the underlying mechanism remains unclear." | 1.72 | Impaired nitrergic relaxation in pyloric sphincter of the 6-OHDA Parkinson's disease rat. ( Fan, RF; Fan, YY; Wang, T; Yu, X; Zhang, Y; Zheng, LF; Zhu, JX, 2022) |
| "In the context of Parkinson's disease (PD), the sensitivity of dopaminergic neurons in the substantia nigra pars compacta to oxidative stress is considered a key factor of PD pathogenesis." | 1.72 | Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity. ( Burtscher, J; Harris, G; Hartung, T; Hogberg, HT; Katt, ME; Pamies, D; Searson, PC; Smirnova, L; Wiersma, D; Zhao, L, 2022) |
| " Oxidative stress is regarded as an important starting factor for neuronal cell loss and necrosis, is one of the causes of Parkinson's disease (PD), and is considered to be the cause of adverse reactions caused by the current PD commonly used treatment drug levodopa (l-DA)." | 1.72 | Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells. ( Chen, H; Chen, J; Chen, S; Li, Q; Liu, J; Lu, Y; Shao, F; Tang, M; Wu, W; Xu, Z; Yang, D; Zhai, L, 2022) |
| "camphorata (SCMAC) against Parkinson's disease (PD), as well as the underlying mechanism using an in vitro 6-hydroxydopamine (6-OHDA)-induced PC12 cell model." | 1.72 | Solid-state-cultured mycelium of Antrodia camphorata exerts potential neuroprotective activities against 6-hydroxydopamine-induced toxicity in PC12 cells. ( Dong, XL; Guan, RF; Sun, PL; Wu, WC; Xu, MT; Yang, K; Ying, YM; Zou, XG, 2022) |
| "In advanced stages of Parkinson's disease (PD), dyskinesia and motor fluctuations become seriously debilitating and therapeutic options become scarce." | 1.72 | D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice. ( Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C, 2022) |
| "Exploration of lead compounds against Parkinson's disease (PD), a neurodegenerative disease, is of great important." | 1.72 | Neuroprotective Effect of Dioscin against Parkinson's Disease via Adjusting Dual-Specificity Phosphatase 6 (DUSP6)-Mediated Oxidative Stress. ( Gao, M; Li, L; Mao, Z; Peng, J; Zhao, X, 2022) |
| "Many patients with Parkinson's disease (PD) experience cognitive or memory impairments with few therapeutic options available to mitigate them." | 1.72 | Task-specific effects of biological sex and sex hormones on object recognition memories in a 6-hydroxydopamine-lesion model of Parkinson's disease in adult male and female rats. ( Aldarondo, D; Kritzer, MF; Patwardhan, A; Pinizzotto, CC, 2022) |
| "Reactive astrogliosis and the over-production of proinflammatory factors are key pathogenetic processes in Parkinson's disease (PD)." | 1.72 | High-Frequency Repetitive Transcranial Magnetic Stimulation Regulates Astrocyte Activation by Modulating the Endocannabinoid System in Parkinson's Disease. ( Bai, Y; Du, W; Gao, F; Jiang, X; Kang, X; Liu, X; Mou, X; Pang, J; Sun, X; Yuan, H; Zhang, B; Zhao, C; Zhao, R, 2022) |
| "Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra with no effective cure available." | 1.72 | MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease. ( Abreu, R; Barão, M; Bernardino, L; Cristóvão, AC; Esteves, M; Fernandes, H; Ferreira, L; Ferreira, R; Martins, PAT; Saraiva, C; Serra-Almeida, C, 2022) |
| "Recent evidence highlights Parkinson's disease (PD) initiation in the gut as the prodromal phase of neurodegeneration." | 1.72 | Dual-Hit Model of Parkinson's Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice-Neuroprotective and Anti-Inflammatory Effects of Butyrate. ( Avagliano, C; Calignano, A; Coretti, L; De Biase, D; De Caro, C; Lama, A; Lembo, F; Mattace Raso, G; Meli, R; Mollica, MP; Paciello, O; Pirozzi, C; Turco, L, 2022) |
| " We then assessed the efficacy of bitopertin on dyskinesia in the context of acute challenge and chronic administration studies." | 1.72 | Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. ( Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L, 2022) |
| "Treatment with mangiferin and 7-NI significantly increases locomotor parameters in 6-OHDA lesioned rats." | 1.72 | Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats. ( Chaudhary, MJ; Nath, R; Pal, R; Tiwari, PC, 2022) |
| "Parkinson disease is a neurodegenerative disorder distinguished by dopaminergic shortage in the striatum and the accumulation of α-synuclein neuronal aggregates in the brains of patients." | 1.72 | Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways. ( Lian, M; Liu, X; Mao, Y; Shao, J, 2022) |
| "In this model of 6-OHDA-induced parkinsonism, Gst treatment in all three doses showed a dose dependent symptomatic improvement in motor imbalance (P < 0." | 1.72 | Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease. ( Eyvari-Brooshghalan, S; Haddadi, R; Nourouzi, N; Sabahi, M; Sadeghian, Z, 2022) |
| "We hypothesized that hyperalgesia of 6-OHDA rats may be related to increased excitability of SDH neurons, and functional change of 5-HT3 receptor may reverse the hyperalgesia of 6-OHDA lesioned rats and decrease cell excitability of SDH neurons." | 1.72 | Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease. ( An, MQ; Dai, YP; Dong, LG; Gu, HY; Li, CJ; Liu, CF; Liu, LB; Mao, CJ; Wang, F; Zhang, LG, 2022) |
| " Such movements are considered restrictive problem associated with the chronic use of L-dopa in Parkinson's disease (PD) treatment; the thing that renders the definite pathological mechanism unclear." | 1.72 | Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats. ( Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF, 2022) |
| "Parkinson's disease was induced by administration of (20 µg/5 µl at the rate of 1 µl/min) 6-OHDA and exercise training was given to mice by motorized rodent treadmill for a period of 14 days after the confirmation of PD." | 1.72 | Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6. ( Fu, J; Guo, J; Tripathi, A; Yang, J, 2022) |
| "To establish Parkinson's Disease (PD) model in cell culture conditions, SH-SY5Y cells were exposed to 200 µM 6-OHDA for 1 day." | 1.62 | Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson's disease. ( Cicek, B; Ferah Okkay, I; Hacimuftuoglu, A; Mendil, AS; Okkay, U; Yesilyurt, F; Yilmaz, A, 2021) |
| "However, unwanted involuntary movements known as L-DOPA-induced dyskinesias (LIDs) develop with prolonged use of this dopamine precursor." | 1.62 | Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. ( Caulfield, ME; Stancati, JA; Steece-Collier, K, 2021) |
| "Motor symptoms of Parkinson's disease (PD)-bradykinesia, akinesia, and tremor at rest-are consequences of the neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) and dopaminergic striatal deficit." | 1.62 | The 6-hydroxydopamine Rat Model of Parkinson's Disease. ( Corrêa, MR; Dos Santos, KB; Godoy, LD; Guimarães, RP; Padovan-Neto, FE; Ribeiro, DL, 2021) |
| "We found that the 10 mg/kg l-dopa dosing regimen induced LID in all animals (n = 5) and induced significant angiogenesis in the striatum and substantia nigra." | 1.62 | The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia. ( Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D, 2021) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "Levodopa-induced dyskinesia (LID) is experienced by most patients of Parkinson's disease (PD) upon the long-term use of the dopamine precursor levodopa." | 1.62 | Inhibition of striatal dopamine D ( Feng, J; Gao, S; Liu, J; Liu, W; Sun, Y; Wang, Y; Yao, L; Zhang, G; Zhang, Q; Zhou, Y, 2021) |
| "The abnormal involuntary movements scale measured L-DOPA and dopamine D1- and D2-receptor agonist-induced dyskinesia." | 1.62 | Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. ( Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B, 2021) |
| "Deep brain stimulation (DBS) in Parkinson's disease (PD) alters neuronal function and network communication to improve motor symptoms." | 1.62 | Motor Thalamic Deep Brain Stimulation Alters Cortical Activity and Shows Therapeutic Utility for Treatment of Parkinson's Disease Symptoms in a Rat Model. ( Akhtar, K; Feustel, P; Fiber, K; Gupta, M; Indajang, J; Kao, TJ; Kim, G; Kochman, EM; Mahoney, E; Mamone, G; Martin, C; Mikkilineni, S; Molho, ES; Pilitsis, JG; Ravi, M; Sachs, N; Shin, DS; Terrelonge, DL; Tucker, HR; Unger, K; Watkins, H, 2021) |
| "Pramipexole (PPX) has anti-inflammatory and antioxidant properties." | 1.62 | Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway. ( Gao, H; Jiang, S; Mao, JP; Wang, D; Wang, YL; Yang, XL, 2021) |
| "The effect of marijuana on Parkinson's disease is controversial and Medical marijuana may benefit for motor and non-motor symptoms of patients with Parkinson's disease." | 1.62 | Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats. ( Haghparast, E; Komeili, G; Sheibani, V, 2021) |
| "Parkinson's disease is a progressive neurodegenerative disorder in which dopaminergic neurons located in the substantia nigra are gradually lost." | 1.62 | Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models. ( Dehghani Ashkezari, M; Seifati, SM; Zarrin, P, 2021) |
| "Dyskinesia is a serious complication of Parkinson's disease during levodopa (L-DOPA) treatment." | 1.62 | Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats. ( Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ, 2021) |
| "With Parkinson's disease being a major neurodegenerative disorder, afflicting millions of people globally, and with disease modification challenges, SKIP may hold promise for future therapeutic development." | 1.62 | Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP. ( Gozes, I; Ivashko-Pachima, Y; Seroogy, KB; Sharabi, Y, 2021) |
| "However, several features of Parkinson's disease (PD) have not been accounted for by this simple "classical rate model" framework, including the observation in patients with PD that movements guided by external stimuli are less impaired than otherwise identical movements generated based on internal goals." | 1.62 | Disrupted basal ganglia output during movement preparation in hemiparkinsonian mice is consistent with behavioral deficits. ( Felsen, G; Lintz, MJ; Tekriwal, A; Thompson, JA, 2021) |
| "Parkinson's disease is characterized by a loss of dopaminergic neurons in the ventral midbrain." | 1.56 | Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease. ( Alonso-Gil, S; Morales-Garcia, JA; Perez-Castillo, A; Santos, Á, 2020) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Parkinson's disease is a neurodegenerative disease characterized by a loss of dopaminergic substantia nigra neurons and depletion of dopamine." | 1.56 | mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease. ( Abd-Elrahman, KS; Bureau, SC; Derksen, A; Dwyer, Z; Farmer, K; Ferguson, SSG; Fortin, T; Hayley, S; Prowse, NA; Rowe, EM; Rudyk, CA; Thompson, AM, 2020) |
| "Motor symptoms of Parkinson's disease (PD) are caused by degeneration and progressive loss of nigrostriatal dopamine neurons." | 1.56 | Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo. ( Bespalov, MM; Domanskyi, A; Karelson, M; Kopra, J; Korhonen, I; Mahato, AK; Piepponen, TP; Pulkkinen, N; Renko, JM; Ronken, E; Saarma, M; Sidorova, YA; Tuominen, RK; Visnapuu, T; Voutilainen, MH, 2020) |
| "Cardiac dysautonomia is a common nonmotor symptom of Parkinson's disease (PD) associated with loss of sympathetic innervation to the heart and decreased plasma catecholamines." | 1.56 | Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration. ( Bondarenko, V; Emborg, ME; Fleddermann, RA; Matsoff, HN; Mejia, A; Metzger, JM; Moore, CF; Simmons, HA; Zinnen, AD, 2020) |
| "Linalool (LIN) is a monoterpene, responsible for the aroma of essential oils in some species." | 1.56 | L-linalool exerts a neuroprotective action on hemiparkinsonian rats. ( da Costa, RO; de Araújo, DP; de Barros Viana, GS; de Lucena, JD; Gadelha-Filho, CVJ; Lima, FAV; Neves, KRT, 2020) |
| " Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment." | 1.56 | D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. ( Brevard, J; Fonseca, KR; Gray, DL; Kozak, R; Popiolek, M; Trapa, P; Young, D, 2020) |
| "Current therapeutic strategies for Parkinson's disease (PD) aim to delay progression or replace damaged neurons by restoring the original neuronal structures." | 1.56 | A co-culture nanofibre scaffold model of neural cell degeneration in relevance to Parkinson's disease. ( Abeywickrama, N; Chemmarappally, JM; De Girolamo, LA; Fornari, E; Hargreaves, AJ; Pegram, HCN; Stevens, B, 2020) |
| "Parkinson's disease is a neurodegenerative disorder partly caused by the loss of the dopamine neurons of the nigrostriatal pathway." | 1.56 | Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. ( Barrot, M; Bezard, E; Bido, S; Dovero, S; Faivre, F; Joshi, A; Sánchez-Catalán, MJ, 2020) |
| "Patients with Parkinson's disease (PD) are often characterized by functional gastrointestinal disorders." | 1.56 | Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. ( Antonioli, L; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Dolfi, A; Errede, M; Fornai, M; Garelli, F; Ippolito, C; Nericcio, A; Pellegrini, C; Segnani, C; Virgintino, D, 2020) |
| " The results indicated that the chronic administration of either DHM or PRE-084 attenuated the Dicer cKO-induced loss of DA neurons and motor impairments, although the two drugs acted through different mechanisms." | 1.56 | Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. ( Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT, 2020) |
| "Respiratory disturbances present in Parkinson's disease (PD) are not well understood." | 1.56 | Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease. ( Andrzejewski, K; Boguszewski, PM; Jampolska, M; Joniec-Maciejak, I; Kaczyńska, K; Zaremba, M, 2020) |
| "Although pain is a prevalent nonmotor symptom in Parkinson's disease (PD), it is undertreated, in part because of our limited understanding of the underlying mechanisms." | 1.56 | Reversal of hyperactive subthalamic circuits differentially mitigates pain hypersensitivity phenotypes in parkinsonian mice. ( Cao, JL; Gu, W; Luan, Y; Tang, D; Wu, H; Wu, Y; Xiao, C; Zhou, C, 2020) |
| "Parkinson's disease is a neurodegenerative disorder that affects the central nervous system and is mainly characterized by the loss of dopaminergic neurons and pro-oxidant mechanisms." | 1.56 | Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations. ( Aragão Catunda Junior, FE; Basto Souza, R; da Cunha Ferreira, NM; de Sousa Dos Reis, TD; Hardy Lima Pontes, N; Maranguape Silva da Cunha, R; Moreira Vasconcelos, CF; Vasconcelos Aguiar, LM, 2020) |
| "Patients with Parkinson's disease (PD) manifest nonmotor and motor symptoms." | 1.56 | Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model. ( de Almeida, AG; de la Rosa, T; Gonçalves, VC; Pinheiro, DJLL; Scorza, CA; Scorza, FA, 2020) |
| "levodopa is the gold standard for the treatment of Parkinson disease, but prolonged levodopa treatment often leads to the development of abnormal involuntary movements." | 1.56 | Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms. ( Gao, H; Li, W, 2020) |
| "The pathogenesis of Parkinson's disease is not clearly understood." | 1.56 | Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease. ( Kawahara, M; Kobayashi, N; Kubota, M; Shimoda, M; Sugizaki, T; Tanaka, KI, 2020) |
| "Mirtazapine-treated neuron-conditioned medium (Mir-NCM) induced astrocyte proliferation and upregulated MT expression via 5-HT1A receptors on astrocytes." | 1.56 | Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection. ( Asanuma, M; Kagawa, D; Kikuoka, R; Kitamura, Y; Kubota, N; Maeda, M; Miyazaki, I; Moriyama, M; Murakami, S; Sato, A; Sendo, T, 2020) |
| "In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses." | 1.51 | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. ( Albarrán-Bravo, S; Ávalos-Fuentes, JA; Cortés, H; Erlij, D; Florán, B; Leyva-García, N; Rangel-Barajas, C; Rodriguez-Sánchez, M, 2019) |
| " The population-based human study analyzed the data from the Taiwan Longitudinal Health Insurance Database 2005 between January 2005 and December 2013 and then used the DXM dose-response curve to investigate the trend of its protective effect against PD." | 1.51 | The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study. ( Cheng, CY; Chien, WC; Chiu, CH; Huang, YS; Kao, LT; Li, IH; Liu, CT; Ma, KH; Shih, JH; Shiue, CY, 2019) |
| "Parkinson's disease is characterized by motor symptoms (akinesia, rigidity, etc." | 1.51 | Electrocortical high frequency activity and respiratory entrainment in 6-hydroxydopamine model of Parkinson's disease. ( Castro-Zaballa, S; Cavelli, M; Costa, G; Gonzalez, J; Lima, MMS; Prunell, G; Torterolo, P; Velásquez, N, 2019) |
| "Parkinson's disease is the second most common neurodegenerative disease." | 1.51 | The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K/AKT and IKK/IκBα/NF-κB pathway. ( Bi, K; Fan, K; Gong, G; Jia, Y; Li, Y; Sun, Y; Wu, B; Yan, T, 2019) |
| "The motor and nonmotor symptoms of Parkinson's disease (PD) correlate with the formation and propagation of aberrant α-synuclein aggregation." | 1.51 | Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease. ( Choi, JY; Ham, S; Kim, H; Lee, Y; Lee, YS; Maeng, HJ; Paek, SM; Song, BR; Yoon, JH, 2019) |
| "Parkinson's disease is characterized by neurodegeneration and learning deficiency." | 1.51 | The effect of preventive exercise on the neuroprotection in 6-hydroxydopamine-lesioned rat brain. ( Alaei, H; Esfarjani, F; Marandi, SM; Rezaee, Z, 2019) |
| "One such symptom is mild cognitive impairment (PD-MCI), which is comprised of deficits in executive function such as working memory, attention, cognitive flexibility, and spatial memory." | 1.51 | Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson's disease. ( King, KM; Kortagere, S; Marshall, CA, 2019) |
| "Parkinson's disease is a progressive neurodegenerative disease characterized by progressive and selective death of dopaminergic neurons." | 1.51 | Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. ( Asadi-Shekaari, M; Eftekhar-Vaghefi, SH; Elyasi, L; Esmaeili-Mahani, S, 2019) |
| "Baicalin was reported to have neuroprotective effects." | 1.51 | Baicalin alleviates 6-hydroxydopamine-induced neurotoxicity in PC12 cells by down-regulation of microRNA-192-5p. ( Fu, Y; Gao, J; Kang, C; Kang, M; Liu, X; Wang, L, 2019) |
| "Chronic pain is the most common non-motor symptom among Parkinson's disease (PD) patients, with 1." | 1.51 | Effects of subthalamic deep brain stimulation with gabapentin and morphine on mechanical and thermal thresholds in 6-hydroxydopamine lesioned rats. ( Feustel, P; Kaszuba, BC; Maietta, T; Pilitsis, JG; Shin, DS; Slyer, J; Stapleton, A; Walling, I, 2019) |
| "Most of the Parkinson's disease (PD) cases are sporadic, although several genes are directly related to PD." | 1.51 | Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins. ( Callizot, N; Combes, M; Henriques, A; Poindron, P, 2019) |
| "Anxiety in Parkinson's disease may represent a physiological reaction to the development of other symptoms during disease progression." | 1.51 | Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. ( Bassani, TB; da Cunha, C; de O Guaita, G; Santiago, RM; Vieira, JCF; Vital, MABF; Zanoveli, JM, 2019) |
| " Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract." | 1.51 | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. ( Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019) |
| "Parkinson's disease is the second most common neurodegenerative disease caused by degeneration of dopamine neurons in the substantia nigra." | 1.51 | ( Af Bjerkén, S; Dudka, I; Laterveer, R; Virel, A, 2019) |
| "Gastrodin is an active ingredient from Gastrodia elata Blume." | 1.51 | Gastrodin protects dopaminergic neurons via insulin-like pathway in a Parkinson's disease model. ( Cao, X; Li, Z; Yan, J; Yang, Z; Zhao, N, 2019) |
| "Parkinson's disease is characterized by progressive decline in motor function due to degeneration of nigrostriatal dopaminergic neurons, as well as other deficits including cognitive impairment and behavioural abnormalities." | 1.48 | 5-HT ( Boger, HA; Corum, D; Lynn, MK; Schnellmann, RG; Scholpa, NE, 2018) |
| "Varenicline tartrate is a partial agonist at α4β2 and full agonist at α7 neuronal nAChR subunits." | 1.48 | Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra. ( Açikalin, Ö; Bölükbaşi Hatip, F; Hatip-Al-Khatib, I; Kataoka, Y; Tan, R; Yamauchi, A, 2018) |
| " Bioavailability studies also suggest the contribution of SFN metabolites, including erucin (ERN), to the neuroprotective effects of SFN." | 1.48 | Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease. ( Cantelli-Forti, G; D'Amico, M; Djemil, A; Hrelia, P; Morroni, F; Pruccoli, L; Sita, G; Tarozzi, A, 2018) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "MiR-221 plays a protective role in Parkinson's Disease via regulating PC12 cell viability and apoptosis by targeting PTEN." | 1.48 | Protective role of microRNA-221 in Parkinson's disease. ( Hu, JM; Li, L; Wu, M; Xu, J, 2018) |
| "Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease." | 1.48 | Proteomic analysis of human glutathione transferase omega (hGSTO1) stable transfection in a 6-hydroxydopamine-induced neuronal cells. ( Ketterman, AJ; Kumrapich, B; Roytrakul, S; Saisawang, C; Wipasa, J; Wongtrakul, J, 2018) |
| "However, the role of Drosha in Parkinson's disease (PD) has not been well established." | 1.48 | Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson's disease. ( Feng, D; Huang, L; Lei, J; Lu, F; Mao, Z; Nie, T; Tao, K; Wang, R; Yang, Q; Yang, S; Zhu, G, 2018) |
| " We also examined the bioavailability and behavioral improvement in a 6-hydroxydopamine-lesioned rat model of PD following 2 weeks' FUS-liposomal combinatorial treatment." | 1.48 | Efficient treatment of Parkinson's disease using ultrasonography-guided rhFGF20 proteoliposomes. ( Guo, K; Huang, Z; Li, X; Niu, J; Song, L; Xia, F; Xie, J; Zhang, X; Zhao, X; Zhao, Y; Zhuge, D, 2018) |
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| " In this study, we found that CaMKIIa was found to form complexes with GluN2B after chronic administration of L-dopa in adult rat striatal neurons." | 1.48 | Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats. ( Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR, 2018) |
| "Preclinical Research & Development Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects approximately 10 million people worldwide." | 1.48 | Evaluation of phytomedicinal potential of perillyl alcohol in an in vitro Parkinson's Disease model. ( Anis, E; Fatima, M; Firdaus, F; Islam, SN; Mobarak Hossain, M; Zafeer, MF, 2018) |
| "Parkinson's disease is characterized by neurodegeneration of the dopaminergic neurons in the substantia nigra pars compacta." | 1.48 | Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI. ( Butler, B; Felfli, M; Lambert, J; Lehéricy, S; Perlbarg, V; Petiet, A; Privat, AL; Valabrègue, R, 2018) |
| "Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy." | 1.48 | Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. ( Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S, 2018) |
| "Parkinson's disease is accompanied by nonmotor symptoms including cognitive impairment, which precede the onset of motor symptoms in patients and are regulated by dopamine (DA) receptors and the mesocorticolimbic pathway." | 1.48 | Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. ( Mishra, A; Shukla, R; Shukla, S; Singh, S; Srivastava, N, 2018) |
| "Many patients of advanced Parkinson's disease (PD) suffer from intractable axial symptoms (severe gait and postural impairments), which were recently speculated to be more relevant to cholinergic degeneration in the brainstem than dopaminergic degeneration in the substantia nigra compacta (SNc)." | 1.46 | Selective cholinergic depletion of pedunculopontine tegmental nucleus aggravates freezing of gait in parkinsonian rats. ( Cai, J; Chang, J; Li, M; Li, N; Wang, Q; Wen, P; Xiao, H; Xie, Z; Zhang, W; Zhou, M, 2017) |
| "The pathological hallmark of Parkinson's disease (PD) is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), and the resulting striatal dopamine deficiency, which are responsible for the classic motor features." | 1.46 | Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease. ( Aguilar, E; Iglesias, E; Marin, C; Obeso, JA; Quiroga-Varela, A, 2017) |
| "The motor symptoms of Parkinson's disease (PD) are linked to abnormally correlated and coherent activity in the cortex and subthalamic nucleus (STN)." | 1.46 | Loss of Hyperdirect Pathway Cortico-Subthalamic Inputs Following Degeneration of Midbrain Dopamine Neurons. ( Atherton, JF; Bevan, MD; Chu, HY; Kovaleski, RF; McIver, EL, 2017) |
| "Neurodegenerative diseases, as Parkinson's disease (PD), involve irreversible neural cell damage and impairment." | 1.46 | Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine. ( Albani, D; Boeri, L; Chierchia, A; Chirico, N; Forloni, G; Giordano, C; Raimondi, I; Raimondi, MT; Riva, GA; Tunesi, M, 2017) |
| "The role of astrocytes in Parkinson's disease is still not well understood." | 1.46 | Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model. ( Morales, I; Rodriguez, M; Rodriguez-Sabate, C; Sanchez, A, 2017) |
| "Parkinson's disease is a common, debilitating, neurodegenerative disorder for which the current gold standard treatment, levodopa (L-DOPA) is symptomatic." | 1.46 | Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease. ( Cronin, A; Grealy, M, 2017) |
| "Pretreatment with acacetin significantly inhibited neurotoxicity and neuronal cell death through reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP) dysfunction." | 1.46 | Acacetin inhibits neuronal cell death induced by 6-hydroxydopamine in cellular Parkinson's disease model. ( Kim, HR; Kim, MJ; Kim, SM; Kwon, SH; Lee, SH; Park, YJ; Shin, MS; Yun, SP, 2017) |
| "Parkinson's disease is a progressive neurological disorder, marked by the loss of dopaminergic neurons in the nigrostriatal pathway that leads to abnormal gait, rigidity, slowness of movement, and tremor." | 1.46 | Step Sequence Is a Critical Gait Parameter of Unilateral 6-OHDA Parkinson's Rat Models. ( Baldwin, HA; Harvey, BK; Koivula, PP; Necarsulmer, JC; Whitaker, KW, 2017) |
| "Parkinson's disease is characterized by the progressive loss of dopaminergic neurons from the substantia nigra, a process that leads to a dopamine deficiency in the striatum." | 1.46 | Dissociation between dopaminergic response and motor behavior following intrastriatal, but not intravenous, transplant of bone marrow mononuclear stem cells in a mouse model of Parkinson's disease. ( Azevedo, BN; Calice da Silva, C; da Costa, JC; Machado, DC; Martins, LAM; Zimmer, ER, 2017) |
| "Montelukast, which plays an anti-inflammatory role, is used to treat patients with asthma." | 1.46 | Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease. ( Jang, H; Kim, S; Kim, SR; Lee, JM; Oh, YS; Park, SM, 2017) |
| "Ellagic acid is a natural phenolic compound with potent antioxidant and anti-inflammatory properties." | 1.46 | Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling. ( Baluchnejadmojarad, T; Rabiee, N; Roghani, M; Zabihnejad, S, 2017) |
| "Troxerutin is a natural bioflavonoid with nephro- and hepato-protective, antioxidant, and anti-inflammatory properties." | 1.46 | Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson's disease: Possible involvement of PI3K/ERβ signaling. ( Baluchnejadmojarad, T; Jamali-Raeufy, N; Rabiee, N; Roghani, M; Zabihnejad, S, 2017) |
| "Whether the treatment of Parkinson's disease has to be initiated with levodopa or a D2 agonist like pramipexole remains debatable." | 1.43 | Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease. ( Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR, 2016) |
| "Parkinson's disease is the second most common neurodegenerative disorder with selective and progressive decline of nigral dopaminergic neurons." | 1.43 | Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease. ( Baluchnejadmojarad, T; Kiasalari, Z; Roghani, M, 2016) |
| "Motor symptoms of Parkinson's disease (PD) follow the degeneration of dopaminergic neurons in the substantia nigra pars compacta." | 1.43 | Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease. ( Anderson, CJ; Dorval, AD; King, NO, 2016) |
| "Domperidone treatment in intact animals evoked a significant increase in normoxic tidal volume, while haloperidol potentiated tidal volume increase in response to hypoxia." | 1.43 | Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease. ( Andrzejewski, K; Budzińska, K; Kaczyńska, K; Zaremba, M, 2016) |
| "Patients suffering from Parkinson's disease (PD) display cognitive and neuropsychiatric dysfunctions, especially with disease progression." | 1.43 | Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease. ( Dunnett, SB; Kelly, CM; Lelos, MJ; Morgan, RJ; Rosser, AE; Torres, EM, 2016) |
| " The water solubility and improved bioavailability may help reduce medication frequency associated with l-DOPA treatment of PD." | 1.43 | DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ( Atlas, D, 2016) |
| "Parkinson's disease is a slowly progressing neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra (SN), leading to severe impairment in motor and non-motor functions." | 1.43 | 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis. ( Collmann, FM; Dollé, F; Faber, C; Faust, A; Fricke, IB; Hermann, S; Jacobs, AH; Kuhlmann, MT; Schäfers, K; Schwamborn, JC; Viel, T; Vrachimis, A; Wachsmuth, L; Worlitzer, MM, 2016) |
| "The dyskinesia of Parkinson's Disease is most likely due to excess levels of dopamine in the striatum." | 1.43 | Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. ( Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K, 2016) |
| "Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium." | 1.43 | Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. ( Chau, KY; Hong, CT; Schapira, AH, 2016) |
| "Levodopa can inhibit beta activity in the PPN of parkinsonian rats but cannot relieve parkinsonian patients' axial symptoms clinically." | 1.43 | The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats. ( Chang, J; Li, M; Li, X; Luo, F; Wang, J; Wang, N; Wang, Q; Wen, P; Xiao, H; Xie, Z; Yang, Y; Zhang, W; Zhou, M, 2016) |
| "Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson's disease (PD) therapy." | 1.43 | LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. ( Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E, 2016) |
| "Chronic pain is one of the most common non-motor symptoms of Parkinson's disease (PD) affecting up to 85% of patients." | 1.43 | Subthalamic deep brain stimulation alters neuronal firing in canonical pain nuclei in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. ( Gee, LE; Pilitsis, JG; Ramirez-Zamora, A; Shin, DS; Walling, I, 2016) |
| " One of the hallmarks of the disease is the toxic accumulation of proteins within susceptible neurons due to major impairment in the degradation/clearance protein systems." | 1.43 | Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease. ( Alberch, J; Altas, B; Canal, M; Kawabe, H; Malagelada, C; Man, HY; Martín-Flores, N; Pérez-Sisqués, L; Romaní-Aumedes, J, 2016) |
| "Levodopa (l-DOPA) has been proved to reverse the pathologic neuron activities in many brain regions related to Parkinson's disease (PD)." | 1.43 | Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease. ( Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X, 2016) |
| "Cell replacement therapy in Parkinson's disease (PD) aims at re-establishing dopamine neurotransmission in the striatum by grafting dopamine-releasing cells." | 1.43 | Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease. ( Boronat-García, A; Drucker-Colín, R; Guerra-Crespo, M; Millán-Aldaco, D; Palomero-Rivero, M, 2016) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| "The most effective treatment of Parkinson's disease (PD) L-DOPA is associated with major side effects, in particular L-DOPA-induced dyskinesia, which motivates development of new treatment strategies." | 1.42 | Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor. ( Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH, 2015) |
| " The enhanced stability and bioavailability of PEGylated rhFGF-2 make this molecule a great therapeutic candidate for neurodegenerative diseases such as PD and mood disorders." | 1.42 | PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease. ( Chen, G; Feng, J; Feng, W; Huang, Z; Niu, J; Shi, L; Wang, Y; Ye, C; Zhu, G, 2015) |
| "Rutin-pretreated PC12 attenuated the Park2, Park5, Park7, Casp3, and Casp7 genes which were expressed significantly in the 6-OHDA-treated PC12 cells." | 1.42 | Quercetin glycosides induced neuroprotection by changes in the gene expression in a cellular model of Parkinson's disease. ( Haleagrahara, N; Magalingam, KB; Radhakrishnan, A; Ramdas, P, 2015) |
| "Parkinson's disease is one of the most common neurologic disorder, affecting about 1-4% of persons older than 60 years." | 1.42 | PPARβ/δ and γ in a rat model of Parkinson's disease: possible involvement in PD symptoms. ( Alecci, M; Antonosante, A; Benedetti, E; Cimini, A; Cristiano, L; Di Giacomo, E; Falcone, R; Fidoamore, A; Florio, TM; Giordano, A; Ippoliti, R; Massimi, M, 2015) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "Constipation is common in Parkinson's disease (PD), in which monoamines (dopamine [DA], norepinephrine [NE], and 5-hydroxytryptamine [5-HT]) play an important role." | 1.42 | Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats. ( Fan, R; Feng, X; Hong, F; Li, L; Li, Y; Liu, C; Wang, P; Zhang, X; Zhang, Y; Zheng, L; Zhu, J, 2015) |
| "The treatment of Parkinson's disease (PD) using stem cells has long been the focus of many researchers, but the ideal therapeutic strategy has not yet been developed." | 1.42 | Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease. ( Chang, KA; Choi, HS; Kim, HJ; Oh, JH; Park, HG; Ra, JC; Suh, YH, 2015) |
| " Rats were dosed orally with Tozadenant, a selective A2A receptor antagonist, and three different doses of Radiprodil, an NR2B-selective NMDA receptor antagonist." | 1.42 | Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs. ( De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X, 2015) |
| "The long-term use of levodopa (L-DOPA) in Parkinson's disease (PD) results in the development of abnormal involuntary movements called L-DOPA-induced dyskinesias." | 1.40 | Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease. ( González-Aparicio, R; Moratalla, R, 2014) |
| "Although the cardinal features of Parkinson's disease (PD) are motor symptoms, PD also causes cognitive deficits including cognitive flexibility and working memory, which are strongly associated with prefrontal cortex (PFC) functions." | 1.40 | Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease. ( Darvas, M; Henschen, CW; Palmiter, RD, 2014) |
| "Caffeine is a methylxanthine known as a non-selective inhibitor of A2A and A1 adenosine receptors in the brain and shown to be a neuroprotective drug." | 1.40 | Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. ( Cavalheiro, EA; Cerqueira, GS; Correia, AO; de Barros Viana, GS; de Castro Brito, GA; Machado-Filho, JA; Montenegro, AB; Naffah-Mazzacoratti, Mda G; Neves, KR; Nobre, ME, 2014) |
| "Dopamine (DA) neurons in sporadic Parkinson's disease (PD) display dysregulated gene expression networks and signaling pathways that are implicated in PD pathogenesis." | 1.40 | miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. ( Kim, W; Kong, B; Lee, Y; McKenna, ND; Rooney, RJ; Seo, H; Simunovic, F; Sonntag, KC; Stephens, RM; Wang, Y; Yi, M, 2014) |
| "In animal models of Parkinson's disease, striatal overactivation of ERK1/2 via dopamine (DA) D1 receptors is the hallmark of a supersensitive molecular response associated with dyskinetic behaviors." | 1.40 | Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. ( Alcacer, C; Bimpisidis, Z; Cenci, MA; Engblom, D; Fieblinger, T; Maslava, N; Sandberg, S; Sebastianutto, I, 2014) |
| "Respiratory disturbances accompany Parkinson's disease." | 1.40 | Respiratory activity in the 6-hydroxydopamine model of Parkinson's disease in the rat. ( Andrzejewski, K; Budzinska, K, 2014) |
| "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease." | 1.40 | G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. ( Ferger, B; Hengerer, B; Oeckl, P, 2014) |
| "In a rat model of Parkinson's disease, intrastriatal 6-OHDA lesions resulted in decreased levels of CRT and ERp57 in the midbrain." | 1.40 | Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease. ( Barger, SW; Chen, H; Kuang, XL; Li, M; Li, Y; Liu, F; Liu, Y; Qu, J; Shan, G; Snider, BJ; Wu, S; Xiao, J, 2014) |
| " The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole." | 1.40 | Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. ( Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2014) |
| "Rat models with 6-OHDA-induced Parkinson's disease were treated with curcumin, DFO, or both and the effect of different treatments on dopamine level was examined." | 1.40 | Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease. ( Cui, X; Jiang, F; Li, Z; Liu, J; Lv, H; Niu, Y; Wang, L; Wang, W; Yu, S; Yuan, J; Zhang, H, 2014) |
| "05mg/kg) and high (1mg/kg) dosage and monitored their conditioned place preference Saline was administered on alternating days." | 1.40 | Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression. ( Campbell, JC; Chen, N; De La Cruz, P; Jeyamohan, SB; Pilitsis, JG; Shin, D, 2014) |
| "Depression is a neuropsychiatric disorder that is commonly found in patients with Parkinson's disease (PD)." | 1.40 | Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease. ( Dal Pont, GC; Luciano, TF; Paganini, CS; Pinho, RA; Pozzi, BG; Quevedo, J; Souza, CT; Souza, PS; Tuon, T; Valvassori, SS, 2014) |
| " These results reveal a new interaction between CaMKIIα and D2Rs in striatal neurons which is sensitive to long-term administration of levodopa in PD rats." | 1.40 | Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats. ( Liu, Z; Wang, Q; Xie, C; Zhang, S, 2014) |
| " However, long-term administration of L-DOPA produces motor complications." | 1.40 | The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats. ( Liu, Z; Ma, Y; Song, L; Wu, N; Yang, X, 2014) |
| "In the 6-OHDA mouse model of Parkinson's disease, doxycycline administered at a dose that both induces/represses conditional transgene expression in the tetracycline system, mitigates the loss of dopaminergic neurons in the substantia nigra compacta and nerve terminals in the striatum." | 1.39 | Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. ( Bel, ED; Lazzarini, M; Martin, S; Mitkovski, M; Stühmer, W; Vozari, RR, 2013) |
| "Patients with Parkinson's disease show unbalanced capability to manage self-paced vs externally driven movements, or automatic-associated movements with respect to the intended voluntary movements." | 1.39 | Switching ability of over trained movements in a Parkinson's disease rat model. ( Alecci, M; Confalone, G; Florio, TM; Sciarra, A; Sotgiu, A, 2013) |
| "Curcumin (200 mg/kg) was administered daily for 7 days starting instantaneously after 6-OHDA injection." | 1.39 | Ameliorating effects of curcumin on 6-OHDA-induced dopaminergic denervation, glial response, and SOD1 reduction in the striatum of hemiparkinsonian mice. ( Jaroensuppaperch, EO; Tripanichkul, W, 2013) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| "However, its expression and role in Parkinson's disease has not been well understood." | 1.39 | The expression and release of Hsp60 in 6-OHDA induced in vivo and in vitro models of Parkinson's disease. ( Feng, Mj; Liu, Z; Lu, X; Zhang, L; Zhou, P, 2013) |
| "Treatment with Piperine markedly inhibited poly(ADP-ribose) polymerase activation, pro-apoptotic Bax levels and elevation of Bcl-2 levels." | 1.39 | Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model. ( Ahmad, A; Ishrat, T; Islam, F; Khan, A; Khan, MM; Safhi, MM; Shrivastava, P; Tabassum, R; Vaibhav, K, 2013) |
| "infusion of l-dopa induced abnormal involuntary movements of a similar severity." | 1.39 | Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. ( Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R, 2013) |
| "These results suggest that Parkinson's disease also affects the serotonergic system, while both the dopaminergic and serotonergic systems can be partially restored in a rat model of PD after E14 mesencephalic tissue transplantation." | 1.39 | PET imaging of serotonin transporters with 4-[18F]-ADAM in a Parkinsonian rat model. ( Chang, YP; Cheng, CY; Chou, TK; Huang, SY; Huang, WS; Li, IH; Liao, MH; Ma, KH; Shiue, CY; Tao, CC; Weng, SJ, 2013) |
| "To explore a novel therapy against Parkinson's disease through enhancement of α7 nicotinic acetylcholine receptor (nAChR), we evaluated the neuroprotective effects of 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (DMXBA; GTS-21), a functionally selective α7 nAChR agonist, in a rat 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonian model." | 1.39 | 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats. ( Hisahara, S; Kawamata, J; Kem, W; Kitamura, Y; Matsumura, A; Matsushita, T; Shimohama, S; Suzuki, S; Takata, K, 2013) |
| "Probucol is a lipid-lowering phenolic compound with anti-inflammatory and antioxidant properties that has been recently reported as protective in neurotoxicity and neurodegeneration models." | 1.39 | Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. ( Colle, D; Dos Santos, AA; Farina, M; Figueiredo, CP; Moreira, EL; Peres, KC; Ribeiro, RP; Santos, DB, 2013) |
| "Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons." | 1.39 | The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease. ( Agari, T; Date, I; Kadota, T; Kameda, M; Kikuchi, Y; Liang, H; Shinko, A; Thomas Tayra, J; Vcelar, B; Wakamori, T; Wang, F; Weik, R; Yasuhara, T, 2013) |
| "Movement disability in advanced Parkinson's disease (PD) can be treated by high frequency stimulation (HFS) of the subthalamic nucleus (STN) but some patients experience psychiatric side-effects including depression, which is strongly linked to decreases in 5-hydroxytryptamine (5-HT)." | 1.38 | A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission. ( Hartung, H; Sharp, T; Steinbusch, HW; Tan, SK; Temel, Y; Visser-Vandewalle, V, 2012) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "Rutin has been shown to have antioxidant and anti-inflammatory actions, and thus was tested for its beneficial effects using 6-OHDA-induced PD rat model." | 1.38 | Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease. ( Ahmad, A; Islam, F; Javed, H; Khan, A; Khan, MM; Raza, SS; Safhi, MM, 2012) |
| " However, long-term administration of L-DOPA can induce abnormal side effects." | 1.38 | Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. ( Abe, M; Inden, M; Kitamura, Y; Minamino, H; Takata, K; Tooyama, I; Yoshimoto, K, 2012) |
| "Although patients with Parkinson's disease show impairments in cognitive performance even at the early stage of the disease, the synaptic mechanisms underlying cognitive impairment in this pathology are unknown." | 1.38 | Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. ( Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A, 2012) |
| "Pramipexole (PPX) is a dopamine agonist that is FDA-approved for treatment of motor dysfunction in Parkinson's disease and restless leg syndrome." | 1.38 | Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. ( Napier, TC; Riddle, JL; Rokosik, SL, 2012) |
| "These dyskinesias have been severe in a number of patients and represent one of the main obstacles for further development of the cell therapy in PD." | 1.38 | Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. ( Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C, 2012) |
| "BACKGROUND AND PURPOSE Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss; however, the noradrenergic system exhibits degeneration as well." | 1.38 | Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. ( Giordano, G; Harkavyi, A; Lever, R; Rampersaud, N; Whitton, J; Whitton, P, 2012) |
| "Clinical symptoms of Parkinson's disease (PD) arise from the loss of substantia nigra neurons resulting in bradykinesia, rigidity, and tremor." | 1.38 | Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death. ( Fahey, MT; Jong, YJ; O'Malley, KL; Pandey, N, 2012) |
| "Thus, in Parkinson's disease (PD), DAT loss could affect DA clearance and locomotor activity." | 1.38 | Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. ( Apple, DM; Chotibut, T; Jefferis, R; Salvatore, MF, 2012) |
| "Parkinson's disease is characterized by motor deficits caused by loss of midbrain dopaminergic neurons." | 1.37 | Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. ( Andersson, A; Dannaeus, K; Delfani, K; Di Monte, DA; Haegerstrand, A; Häggblad, J; Hill, MP; Isacson, R; Janson Lang, AM; McCormack, AL; Nielsen, E; Palmer, T; Patrone, C; Rönnholm, H; Wikstrom, L; Zachrisson, O; Zhao, M, 2011) |
| "While limb motor deficits of Parkinson's disease are well characterized, the effects of striatal dopamine depletion on the motor cortex is poorly understood." | 1.37 | Striatal dopamine depletion induces forelimb motor impairments and disrupts forelimb movement representations within the motor cortex. ( Kleim, JA; Plowman, EK; Thomas, NJ, 2011) |
| "Patients with Parkinson's disease (PD) lose body weight primarily due to decreased body fat mass." | 1.37 | Possible regulatory factors for intra-abdominal fat mass in a rat model of Parkinson's disease. ( Aoyama, T; Arai, C; Kuranuki, S; Nakamura, T; Terada, S, 2011) |
| "Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra." | 1.37 | Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011) |
| "Parkinson's disease is a common neurodegenerative disorder characterized by a profound motor disability that is traceable to the emergence of synchronous, rhythmic spiking in neurons of the external segment of the globus pallidus (GPe)." | 1.37 | HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. ( Chan, CS; Chetkovich, DM; Fleming, SM; Gertler, TS; Glajch, KE; Goldberg, AB; Guzman, JN; Kita, H; Lewis, AS; Mercer, JN; Osten, P; Shigemoto, R; Surmeier, DJ; Tkatch, T, 2011) |
| "L-dopa therapy for Parkinson's disease leads to dyskinesias or abnormal involuntary movement (AIMs) for which there are few treatment options." | 1.37 | Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. ( Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M, 2011) |
| "Parkinson's disease is characterized by a progressive loss of dopaminergic neurons in the substantia nigra." | 1.37 | CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. ( Bachstetter, AD; Bickford, PC; Gemma, C; Hudson, CE; Pabon, MM, 2011) |
| "A central problem in the treatment of Parkinson's disease (PD) is the development of motor disturbances like L: -DOPA-induced dyskinesia (LID) after long-term treatment." | 1.37 | Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease. ( Beck, J; Gerlach, M; Riederer, P; van den Buuse, M, 2011) |
| "Postural instability, a symptom of Parkinson's disease (PD) patients, leads to frequent falls and difficulty in forward motion during gait." | 1.37 | Three-dimensional motion analysis of postural adjustments during over-ground locomotion in a rat model of Parkinson's disease. ( Dunnett, SB; Holt, CA; Klein, A; Madete, JK, 2011) |
| "Studies of Parkinson's disease (PD) have been hindered by lack of access to affected human dopaminergic (DA) neurons." | 1.37 | LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. ( Byers, B; Byrne, J; Cord, B; Dolmetsch, RE; Gujar, P; Kee, K; Langston, W; Nguyen, HN; Palmer, TD; Pera, RR; Schüle, B; Shcheglovitov, A, 2011) |
| "The neuropathological hallmark of Parkinson's disease is the loss of dopaminergic neurons in the pars compacta of the substantia nigra (SNc)." | 1.37 | In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6- ( Aguilar, E; Marin, C; Mullol, J; Planas, AM; Soria, G; Tudela, R, 2011) |
| "However, the effects of tenuigenin on Parkinson's disease remain unclear." | 1.37 | Neuroprotective effects of tenuigenin in a SH-SY5Y cell model with 6-OHDA-induced injury. ( Liang, Z; Lu, L; Shi, F; Wang, X; Wang, Y; Zhang, Z, 2011) |
| "In the present work a rat model of Parkinson's disease was used to analyze the expression of striatal proteins and, more specifically, mortalin expression." | 1.37 | Mortalin inhibition in experimental Parkinson's disease. ( Binaglia, L; Calabresi, P; Chiasserini, D; de Iure, A; Koya, K; Orvietani, PL; Susta, F; Tantucci, M; Tozzi, A, 2011) |
| " Chronic use of (-)-15 reduced L-DOPA-induced dyskinesia (LID) without attenuating the antiparkinsonian effect." | 1.37 | Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. ( Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S, 2011) |
| "Quercetin treatment (30mg/kg body weight) over 14 consecutive days markedly increased the striatal dopamine and antioxidant enzyme levels compared with similar measurements in the group treated with 6-OHDA alone." | 1.37 | Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. ( Haleagrahara, N; Kumari, M; Mitra, NK; Siew, CJ, 2011) |
| "DJ-1, Parkinson's disease PARK7, acts as an oxidative stress sensor in neural cells." | 1.37 | Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7. ( Ariga, H; Funayama, R; Honda, T; Inden, M; Ito, N; Kitamura, Y; Nishimura, K; Niwa, R; Taira, T; Takahashi, K; Takata, K; Taniguchi, T, 2011) |
| "Early phases of Parkinson's disease (PD) are characterized by a mild reduction of dopamine (DA) in striatum and by emergence of psychiatric disturbances that precede overt motor symptoms." | 1.36 | Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease. ( Ajmone-Cat, MA; Alleva, E; Armida, M; Branchi, I; Carnevale, D; Cassano, T; D'Andrea, I; Minghetti, L; Morgese, MG; Pèzzola, A; Popoli, P; Potenza, RL, 2010) |
| "The unilaterally lesioned rat model of Parkinson's disease allows examination of this hypothesis by direct comparison of beta activity in basal ganglia output in non-lesioned and dopamine cell lesioned hemispheres during motor activity." | 1.36 | Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat. ( Avila, I; Bergstrom, DA; Brazhnik, E; Castañeda, E; Parr-Brownlie, LC; Walters, JR, 2010) |
| " However, the stability and bioavailability of EGCG are restricted." | 1.36 | A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine. ( Chan, TH; Chang, RC; Chao, J; Ho, YS; Huie, MJ; Lai, CS; Lam, WH; Lau, WK; Wang, M; Yu, MS; Yuen, WH, 2010) |
| "L-DOPA-induced dyskinesia in Parkinson's disease is associated with large increases in brain dopamine (DA) levels following drug dosing, but the precise significance of this phenomenon is not understood." | 1.36 | L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. ( Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H, 2010) |
| "rTMS was given to rats with Parkinson's disease induced by 6-OHDA, daily for 4 weeks to examine the protective effects." | 1.36 | The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease. ( Liu, Z; Song, L; Yang, X, 2010) |
| " However, the symptomatic relief provided by long-term administration may be compromised by L: -DOPA-induced dyskinesia (LID) that presents as adverse fluctuations in motor responsiveness and progressive loss of motor control." | 1.36 | The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. ( Gil, S; Koh, H; Lee, J; Park, C, 2010) |
| "Individuals in the early stage of Parkinson's disease exhibit cognitive impairments as a result of hemisphere damage." | 1.36 | Lateralized response of oxytocinase activity in the medial prefrontal cortex of a unilateral rat model of Parkinson's disease. ( Alba, F; Banegas, I; de Gasparo, M; Duran, R; Prieto, I; Ramírez, M; Segarra, AB; Vives, F, 2010) |
| "In a mouse model of Parkinson's disease, direct-pathway activation completely rescued deficits in freezing, bradykinesia and locomotor initiation." | 1.36 | Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. ( Deisseroth, K; Freeze, BS; Kay, K; Kravitz, AV; Kreitzer, AC; Parker, PR; Thwin, MT, 2010) |
| "Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-dopa-induced dyskinesia (LIDs)." | 1.36 | Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. ( Belujon, P; Grace, AA; Lodge, DJ, 2010) |
| "Parkinson's disease is a multifactorial, neurodegenerative disease where etiopathogenetic mechanisms are not fully understood." | 1.36 | Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. ( Glocker, MO; Haas, SJ; Kreutzer, M; Lessner, G; Mikkat, S; Schmitt, O; Wree, A, 2010) |
| "Degenerating neurons of Parkinson's disease (PD) patient brains exhibit granules of phosphorylated extracellular signal-regulated protein kinase 1/2 (ERK1/2) that localize to autophagocytosed mitochondria." | 1.35 | Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. ( Chu, CT; Dagda, RK; Kulich, SM; Zhu, J, 2008) |
| " Edaravone might be a hopeful therapeutic option for PD, although the high therapeutic dosage remains to be solved for the clinical application." | 1.35 | Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. ( Agari, T; Baba, T; Date, I; Jing, M; Kameda, M; Leung, H; Matsui, T; Miyoshi, Y; Morimoto, T; Muraoka, K; Shingo, T; Tajiri, N; Uozumi, T; Wang, F; Yasuhara, T; Yuan, WJ, 2008) |
| "Graft-induced dyskinesias (GIDs), side-effects found in clinical grafting trials for Parkinson's disease (PD), may be associated with the withdrawal of immunosuppression." | 1.35 | The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. ( Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q, 2008) |
| " We detected a time-dependent action of quercetin and distinguished an early protective effect from a late toxic one." | 1.35 | Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. ( Kääräinen, TM; Männistö, PT; Ossola, B; Raasmaja, A, 2008) |
| "In addition to classic motor symptoms, Parkinson's disease (PD) is characterized by cognitive and emotional deficits, which have been demonstrated to precede motor impairments." | 1.35 | Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. ( Cargnin-Ferreira, E; Da Cunha, C; Dombrowski, PA; Figueiredo, CP; Tadaiesky, MT; Takahashi, RN, 2008) |
| "6-OHDA-induced Parkinson's disease rat model involves chronic inflammation, mitochondrial dysfunction, and oxidative stress, and the loss of the dopaminergic neurons in the substantia nigra is the predominant lesion." | 1.35 | Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. ( Gong, QH; Jin, F; Lu, YF; Shi, JS; Wu, Q, 2008) |
| "Patients with Parkinson's disease that receive transplants of foetal ventral mesencephalic tissue, the graft cell preparation is likely to contain, in addition to dopamine neurons, serotonin neurons that will vary in number depending on the landmarks used for dissection." | 1.35 | Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. ( Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C, 2009) |
| "Current treatments for Parkinson's disease rely on a dopamine replacement strategy and are reasonably effective, particularly in the early stages of the disease." | 1.35 | Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. ( Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM, 2009) |
| " This may allow for cell composition analysis and dosing to optimize the benefit to an individual patient." | 1.35 | Future of cell and gene therapies for Parkinson's disease. ( Isacson, O; Kordower, JH, 2008) |
| "Parkinson's disease is associated with increased oscillatory firing patterns in basal ganglia output, which are thought to disrupt thalamocortical activity." | 1.35 | Parafascicular thalamic nucleus activity in a rat model of Parkinson's disease. ( Bergstrom, DA; Parr-Brownlie, LC; Poloskey, SL; Walters, JR, 2009) |
| "Chronic L-DOPA pharmacotherapy in Parkinson's disease is often accompanied by the development of abnormal and excessive movements known as L-DOPA-induced dyskinesia." | 1.35 | Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. ( Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V, 2009) |
| "A pretreatment with apomorphine-induced sensitization, but it was minimal when compared to that induced by nicotine." | 1.35 | Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats. ( Da Cunha, C; Ferro, MM; Gregório, ML; Silveira, JL; Vital, MA; Wietzikoski, EC, 2009) |
| "Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata." | 1.35 | Histaminergic activity in a rodent model of Parkinson's disease. ( Brus, H; Brus, R; Drab, J; Jochem, J; Körossy, E; Kostrzewa, RM; Noras, L; Nowak, P; Szkilnik, R, 2009) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| " Neuroprotective effects of Lf-modified NPs were examined in the 6-OHDA-lesioned PD model via a regimen of multiple dosing intravenous administrations." | 1.35 | Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. ( Han, L; Huang, R; Jiang, C; Ke, W; Li, J; Pei, Y; Ren, F, 2009) |
| "New strategies for the treatment of Parkinson's disease (PD) are shifted from dopamine (DA) replacement to regeneration or restoration of the nigro-striatal system." | 1.35 | Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease. ( Chen, S; Fan, X; Gu, Q; Le, W; Li, L; Li, X; Ming, M; Yang, D, 2009) |
| "Patients with Parkinson's disease develop motor disturbances often accompanied by peripheral autonomic dysfunctions, including gastrointestinal disorders, such as dysphagia, gastric stasis and constipation." | 1.35 | Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. ( Balestra, B; Bazzini, E; Blandini, F; Cervio, M; Clavenzani, P; Colucci, M; De Giorgio, R; Faniglione, M; Greco, R; Levandis, G; Nappi, G; Tassorelli, C; Tonini, M; Vigneri, S, 2009) |
| " While it has been suggested that the daily dose of l-DOPA can play a critical role, the mechanisms linking l-DOPA dosage to the occurrence of motor complications have not yet been explored." | 1.35 | l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. ( Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B, 2008) |
| "Bilobalide was administered 5, 10, and 20 mg/kg (ip) once a day for 7 d, starting 6 d prior to the 6- OHDA infusion." | 1.35 | Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra. ( Fei, XF; Gu, ZL; Li, LY; Liang, ZQ; Qin, ZH; Zhao, XL, 2008) |
| "Parkinson's disease is a neurodegenerative disorder with uncertain aetiology and ill-defined pathophysiology." | 1.35 | Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. ( Ferrari, CC; Pitossi, FJ; Pott Godoy, MC; Sarchi, MI; Tarelli, R, 2008) |
| "The treatment with lactacystin induced the nuclear translocation of NF-E2-related factor 2 (Nrf2) and increased the level of mRNA for gamma-glutamylcysteine synthetase, a rate-limiting enzyme in glutathione synthesis." | 1.34 | Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. ( Akaike, A; Izumi, Y; Katsuki, H; Kume, T; Sawada, H; Shimohama, S; Yamamoto, N, 2007) |
| "Many current theories of Parkinson's disease (PD) suggest that oxidative stress is involved in the neurodegenerative process." | 1.34 | GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. ( Cass, WA; Smith, MP, 2007) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| "In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually emerge as a prominent side-effect in response to previously beneficial doses of the drug." | 1.34 | Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. ( Björklund, A; Carlsson, T; Carta, M; Kirik, D, 2007) |
| "Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD)." | 1.34 | Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. ( Borlongan, CV; Hara, K; Kim, KM; Maki, M; Matsukawa, N; Morgan, JC; Sethi, KD; Xu, L; Yasuhara, T; Yu, G, 2007) |
| "Pergolide was as effective as l-DOPA in reversing the lesion-induced elevation of ERK2 phosphorylation in response to acute apomorphine administration (0." | 1.34 | Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. ( Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV, 2007) |
| "Symptoms of Parkinson's disease involve motor disorders, including dysphagia and aspiration." | 1.34 | Assessing an eating disorder induced by 6-OHDA and the possibility of nerve regeneration therapy by transplantation of neural progenitor cells in rats. ( Dohi, T; Kitayama, T; Morioka, N; Morita, K; Onitsuka, Y; Song, L, 2007) |
| "Melatonin has multiple roles including neuroprotection." | 1.34 | Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. ( McMillan, CR; Niles, LP; Sharma, R, 2007) |
| "Histaminergic agents were given prior and daily for 1, 7 or 14 days after 6-OHDA infusion." | 1.34 | Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ( Chen, Z; Hu, DN; Liu, CQ; Liu, FX; Luo, JH, 2007) |
| "The causes of nigrostriatal neuron degeneration in Parkinson's disease (PD) are not known, but it has been suggested that exogenous or endogenous factors or neurotoxins may play a role." | 1.33 | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. ( Delville, Y; Fleming, SM; Schallert, T, 2005) |
| " In a primary culture of E14 murine ventral mesencephalic neurons, earlier treatment with the higher dosage of GDNF suppressed 6-OHDA-induced loss of dopaminergic neurons better than later treatment." | 1.33 | Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. ( Date, I; Kameda, M; Kobayashi, K; Matsui, T; Miyoshi, Y; Muraoka, K; Shingo, T; Takeuchi, A; Wenji, Y; Yano, A; Yasuhara, T, 2005) |
| "The MFB lesion model mimics end-stage Parkinson's disease." | 1.33 | Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. ( Ebinger, G; Michotte, Y; Sarre, S; Yuan, H, 2005) |
| "To examine neurotrophic abnormality in Parkinson's disease (PD), we measured the protein content of EGF, TGFalpha, and HB-EGF in post-mortem brains of patients with Parkinson's disease and age-matched control subjects." | 1.33 | Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. ( Iwakura, Y; Kakita, A; Mizuno, M; Nawa, H; Piao, YS; Takahashi, H; Takei, N, 2005) |
| "Functional neuro-imaging studies of Parkinson's disease (PD) patients and animal models show inconsistent cortical responses to sensory stimulation: some present increased sensorimotor cortex activation contradicting classical basal ganglia-cortex circuitry models, whereas others show decreased activation." | 1.33 | Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study. ( Ben-Hur, T; Bergman, H; Goelman, G; Pelled, G, 2005) |
| "The etiology of sporadic Parkinson's disease is unknown; however, oxidative stress is thought to play a major role in disease pathogenesis." | 1.33 | Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. ( Jakel, RJ; Johnson, DA; Johnson, JA; Kern, JT, 2005) |
| "Dyskinesias are a common consequence of dopaminergic therapy in patients with Parkinson's disease." | 1.33 | Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. ( Chu, Y; Collier, TJ; Kordower, JH; Maries, E; Olaru, E; Shannon, K; Sortwell, CE; Steece-Collier, K, 2006) |
| " Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD." | 1.33 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005) |
| "Current treatments for Parkinson's disease (PD) rely on a dopamine replacement strategy and are reasonably effective, particularly in the early stages of the disease." | 1.33 | Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. ( Dunnett, SB; Monville, C; Torres, EM, 2005) |
| "The poor survival of dopamine grafts in Parkinson's disease is one of the main obstacles to the widespread application of this therapy." | 1.33 | Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. ( Castro, MG; Dunnett, SB; Lowenstein, PR; Monville, C; Torres, EM, 2005) |
| " Mutant (A30P and A53T) alpha-synuclein isoforms cause increased vulnerability of cells towards various toxic insults and enhance dopamine transporter (DAT)-mediated toxicity of the selective dopaminergic neurotoxin and mitochondrial complex I inhibitor MPP(+) in vitro." | 1.33 | Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. ( Lehmensiek, V; Lenk, T; Liebau, S; Schwarz, J; Storch, A; Tan, EM; Zettlmeisl, H, 2006) |
| " Dose-response studies with 6-hydroxydopamine revealed that the application of 200 microg per animal caused hypokinetic signs (decreased ambulatory activity, increased inactivity, and reduced motor coordination), which paralleled several signs of degeneration of nigrostriatal dopaminergic neurons (dopamine depletion in the caudate-putamen, and decreased mRNA levels for tyrosine hydroxylase and superoxide dismutase-1 and -2 in the substantia nigra)." | 1.33 | Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. ( de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C, 2006) |
| " Further microinjections of lower doses (5 and 10 nmol) revealed a dose-response effect." | 1.33 | Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. ( Ackerson, LC; Lam, HA; Maidment, NT; Phillips, JM, 2006) |
| "Calcitriol has been implicated as an agent that has neuroprotective effects in various animal models of diseases, possibly by upregulating glial cell line-derived neurotrophic factor (GDNF)." | 1.33 | Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. ( Cass, WA; Fletcher-Turner, A; Smith, MP; Yurek, DM, 2006) |
| "Benserazide is commonly used for Parkinson's disease in combination with L-DOPA as a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor." | 1.32 | Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. ( Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H, 2003) |
| "Parkinson's disease is a neurodegenerative disorder associated with the selective death of dopaminergic neurons." | 1.32 | Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. ( Klann, E; Lin, E; Perez, RG; Ugarte, SD; Zigmond, MJ, 2003) |
| "Bromocriptine is a selective agonist for dopamine D2-receptors and is used in the treatment of Parkinson's disease." | 1.32 | Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats. ( Atsumi, M; Iga, T; Kawakami, J; Kotaki, H; Sato, H; Sawada, Y; Sugiyama, E; Yamada, Y, 2003) |
| "The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment." | 1.32 | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. ( Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D, 2003) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "The causes of sporadic Parkinson's disease (PD) are poorly understood." | 1.32 | Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. ( Bower, KA; Chen, G; Fang, S; Luo, J; Ma, C; Thiele, CJ, 2004) |
| " This phenomenon, referred to as sensitization, is believed to be related to the motor response complications (dyskinesias, on-off states) that occur during chronic administration of levodopa in Parkinson's disease patients." | 1.32 | Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. ( Delfino, MA; Ferrario, JE; Gershanik, OS; Murer, MG; Stefano, AV; Taravini, IR, 2004) |
| "Although L-dopa remains the most effective treatment of Parkinson disease, its long-term administration is hampered by the appearance of dyskinesia." | 1.32 | Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. ( Corvol, JC; Féger, J; Girault, JA; Hanoun, N; Hervé, D; Hirsch, EC; Muriel, MP; Valjent, E, 2004) |
| "Adenosine A2A receptors are a new target for drug development in Parkinson's disease." | 1.32 | Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. ( Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV, 2004) |
| "Intermittent L-DOPA treatment induced hypertrophy of the lesioned-side of medial globus pallidus and substantia nigra reticulata of 6-hydroxydopamine-lesioned rats with behavioral sensitization to L-DOPA." | 1.32 | Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease. ( Baba, M; Ichinohe, N; Kimura, T; Matsunaga, M; Mori, F; Tomiyama, M; Wakabayashi, K, 2004) |
| "Mutations in familial Parkinson's disease (PD) have been associated with the failure of protein degradation through the ubiquitin-proteasome system (UPS)." | 1.32 | Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. ( Elkon, H; Melamed, E; Offen, D, 2004) |
| "Treatments for Parkinson's disease based on replacement of lost dopamine have several problems." | 1.31 | Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. ( Brotchie, JM; Nash, JE, 2002) |
| " The safer and effective administration of lower doses of CsA combined with enhanced BBB permeability using Cereport, offers a novel way of producing protective effects in the CNS without the toxic liabilities of high-dose CsA." | 1.31 | Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. ( Bartus, RT; Borlongan, CV; Emerich, DF; Hoffer, BJ, 2002) |
| "Parkinson's disease is a major neurological disorder that primarily affects the nigral dopaminergic cells." | 1.31 | Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. ( Anichtchik, OV; Haycock, JW; Huotari, M; Männistö, PT; Panula, P; Peitsaro, N, 2000) |
| " Since both H(2)O(2) and 6-OHDA may injure cells via free radical and reactive oxygen species, the neuroprotection seen here may operate via a reversal of such a toxic mechanism." | 1.31 | Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. ( Borlongan, CV; Chen, HH; Cherng, TL; Hoffer, BJ; Wang, JY; Wang, Y; Wu, JN, 2001) |
| "In animal models of Parkinson's disease, gene transfer of aromatic L-amino acid decarboxylase (AADC) leads to an increase in the capacity of the striatum to decarboxylate exogenous L-DOPA." | 1.31 | Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. ( Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R, 2001) |
| " Chronic administration of L-DOPA to normal or 6-OHDA-lesioned rats had no effect on alpha-synuclein mRNA expression in the SN, striatum or nucleus accumbens." | 1.31 | 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. ( Cannizzaro, C; Dass, B; Jenner, P; Owen, A; Rose, S; Tel, BC; Zeng, BY, 2002) |
| "One of the hallmarks of Parkinson's disease (PD) is pathological structure, termed Lewy body, containing inclusions of ubiquitinated proteins in the dopaminergic neurons in the substantia nigra." | 1.31 | 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. ( Elkon, H; Melamed, E; Offen, D, 2001) |
| "Parkinson's disease is characterized by a massive loss of nigral dopamine neurons that results in a reduction of dopamine concentrations in the striatum." | 1.30 | Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. ( Abrous, DN; Agid, Y; Bernard, V; Bloch, B; Hirsch, EC; Laribi, O; Levey, AI; Muriel, MP, 1999) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "Altered glial function in the substantia nigra in Parkinson's disease may lead to the release of toxic substances that cause dopaminergic cell death or increase neuronal vulnerability to neurotoxins." | 1.30 | Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. ( Jenner, P; McNaught, KS, 1999) |
| "In rodent models of Parkinson's disease such as reserpinized or 6-hydroxydopamine substantia nigra lesioned rats, blockade of glutamate receptors of the NMDA (N-methyl-D-aspartate) or the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptor subtypes and concomitant treatment with L-DOPA (L-3,4-dihydroxyphenylalanine) or direct dopamine agonists restores locomotor activity and induces rotations." | 1.29 | Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. ( Eblen, F; Kockgether, T; Löschmann, PA; Wachtel, H; Wüllner, U, 1995) |
| "The 6-hydroxydopamine rat model of Parkinson's disease was combined with intracerebral drug infusions to examine the influence of glutamate receptors on striatal output activity." | 1.29 | Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease. ( Marshall, JF; Schuller, JJ, 1995) |
| "Since this "axial apraxia' is not ameliorated by L-DOPA therapy, it has been concluded that dopamine (DA) does not play a role in recruiting axial rotation of the body [14]." | 1.29 | Spatio-temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue: relevance to axial apraxia in humans. ( Martens, DJ; Miklyaeva, EI; Pellis, SM; Whishaw, IQ, 1996) |
| "Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)." | 1.28 | Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991) |
| "Chronic L-DOPA treatment of Parkinson's disease frequently leads to the development of motoric overstimulation and hyperkinetic movements." | 1.28 | Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. ( Carey, RJ, 1991) |
| "[3H]Vesamicol binding was characterized in human brain post mortem." | 1.28 | Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. ( Agid, Y; Brice, A; Duyckaerts, C; Hauw, JJ; LeMoal, M; Mayo, W; Ruberg, M; Simon, H, 1990) |
| " These results indicate that chronic administration of either bromocriptine or L-Dopa will reverse the DA receptor denervation supersensitivity in striatum seen following 6-OHDA lesion." | 1.27 | Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. ( Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1984) |
| "In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine." | 1.27 | Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986) |
| "To simulate an animal model of Parkinson's disease, MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) was administered to five monkeys." | 1.27 | Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. ( Imai, H; Itakura, T; Kamei, I; Komai, N; Naka, Y; Nakai, K; Nakakita, K, 1988) |
| "Pergolide was more potent than bromocriptine or lergotrile." | 1.26 | Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway. ( Duvoisin, RC; Heikkila, RE; Manzino, L, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (2.13) | 18.7374 |
| 1990's | 104 (7.14) | 18.2507 |
| 2000's | 369 (25.33) | 29.6817 |
| 2010's | 642 (44.06) | 24.3611 |
| 2020's | 311 (21.35) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, N | 1 |
| Sawada, H | 1 |
| Izumi, Y | 3 |
| Kume, T | 2 |
| Katsuki, H | 1 |
| Shimohama, S | 3 |
| Akaike, A | 2 |
| Feng, Y | 3 |
| Zhou, S | 4 |
| Sun, J | 2 |
| Srivastava, R | 1 |
| Choudhury, PK | 1 |
| Dev, SK | 1 |
| Rathore, V | 1 |
| Mahendru, D | 1 |
| Jain, A | 1 |
| Bansal, S | 1 |
| Malik, D | 1 |
| Dhir, N | 1 |
| Sharma, AR | 1 |
| Sarma, P | 1 |
| Prakash, A | 1 |
| Nahar, U | 1 |
| Bhatia, A | 1 |
| Bhattacharyya, S | 1 |
| Medhi, B | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Shahini, F | 1 |
| Zarrindast, MR | 2 |
| Forouzandeh, M | 2 |
| Bigdeli, MR | 1 |
| Mostafavi, H | 2 |
| Nadri, S | 1 |
| Eskandari, M | 2 |
| Ferah Okkay, I | 1 |
| Okkay, U | 1 |
| Cicek, B | 1 |
| Yilmaz, A | 1 |
| Yesilyurt, F | 1 |
| Mendil, AS | 1 |
| Hacimuftuoglu, A | 1 |
| Bariotto-Dos-Santos, K | 2 |
| Ribeiro, DL | 2 |
| Guimarães, RP | 2 |
| Padovan-Neto, FE | 4 |
| Fougère, M | 1 |
| van der Zouwen, CI | 1 |
| Boutin, J | 1 |
| Neszvecsko, K | 1 |
| Sarret, P | 1 |
| Ryczko, D | 1 |
| Xu, Q | 3 |
| Qin, W | 1 |
| Wu, FZ | 1 |
| Lin, Y | 3 |
| Hong, LT | 1 |
| Chen, D | 6 |
| Hu, XF | 1 |
| Cai, J | 4 |
| Caulfield, ME | 1 |
| Stancati, JA | 2 |
| Steece-Collier, K | 6 |
| Molska, GR | 1 |
| Paula-Freire, LIG | 1 |
| Sakalem, ME | 1 |
| Köhn, DO | 1 |
| Negri, G | 1 |
| Carlini, EA | 1 |
| Mendes, FR | 1 |
| Riedesel, AK | 1 |
| Helgers, SOA | 1 |
| Abdulbaki, A | 1 |
| Hatipoglu Majernik, G | 1 |
| Alam, M | 3 |
| Krauss, JK | 5 |
| Schwabe, K | 5 |
| Fazli-Tabaei, S | 1 |
| Khakpai, F | 1 |
| Song, WS | 1 |
| Sung, CY | 2 |
| Ke, CH | 1 |
| Yang, FY | 2 |
| Sophiabadi, M | 1 |
| Rastgoo, N | 3 |
| Haghdoost-Yazdi, H | 5 |
| Dos Santos, KB | 1 |
| Godoy, LD | 1 |
| Corrêa, MR | 1 |
| Cai, M | 1 |
| Zhuang, W | 2 |
| Lv, E | 1 |
| Liu, Z | 9 |
| Wang, Y | 35 |
| Zhang, W | 12 |
| Fu, W | 2 |
| Batista, LA | 1 |
| Cabral, LM | 2 |
| Moreira, TS | 7 |
| Takakura, AC | 8 |
| Sato, F | 1 |
| Nakamura, Y | 2 |
| Ma, S | 3 |
| Kochi, T | 1 |
| Hisaoka-Nakashima, K | 1 |
| Wang, D | 5 |
| Liu, K | 2 |
| Wake, H | 1 |
| Nishibori, M | 1 |
| Morioka, N | 2 |
| He, CL | 2 |
| Tang, Y | 3 |
| Wu, JM | 2 |
| Long, T | 2 |
| Yu, L | 2 |
| Teng, JF | 1 |
| Qiu, WQ | 1 |
| Pan, R | 1 |
| Yu, CL | 2 |
| Qin, DL | 2 |
| Wu, AG | 2 |
| Zhou, XG | 2 |
| Endepols, H | 1 |
| Zlatopolskiy, BD | 1 |
| Zischler, J | 1 |
| Alavinejad, N | 1 |
| Apetz, N | 1 |
| Vus, S | 1 |
| Drzezga, A | 1 |
| Neumaier, B | 1 |
| Yu, H | 1 |
| Liu, X | 8 |
| Chen, B | 3 |
| Vickstrom, CR | 1 |
| Friedman, V | 1 |
| Kelly, TJ | 1 |
| Bai, X | 1 |
| Zhao, L | 8 |
| Hillard, CJ | 2 |
| Liu, QS | 1 |
| Hiramatsu, S | 1 |
| Morizane, A | 2 |
| Kikuchi, T | 1 |
| Doi, D | 1 |
| Yoshida, K | 1 |
| Takahashi, J | 2 |
| Virel, A | 3 |
| Johansson, J | 1 |
| Axelsson, J | 1 |
| Ericsson, M | 1 |
| Laterveer, R | 2 |
| Ögren, M | 1 |
| Orädd, G | 2 |
| Jakobson Mo, S | 1 |
| Af Bjerkén, S | 2 |
| Piri, H | 1 |
| Sharifi, S | 1 |
| Nigjeh, S | 1 |
| Ferreira, AFF | 2 |
| Singulani, MP | 2 |
| Ulrich, H | 1 |
| Feng, ZP | 1 |
| Sun, HS | 1 |
| Britto, LR | 6 |
| Özduran, G | 1 |
| Becer, E | 1 |
| Vatansever, HS | 1 |
| Yücecan, S | 1 |
| Md Hamzah, N | 1 |
| Lim, SM | 1 |
| Vijayanathan, Y | 1 |
| Lim, FT | 1 |
| Abdul Majeed, AB | 1 |
| Tan, MP | 1 |
| Ramasamy, K | 1 |
| Lazarova, M | 3 |
| Tancheva, L | 3 |
| Chayrov, R | 1 |
| Tzvetanova, E | 1 |
| Alexandrova, A | 1 |
| Popatanasov, A | 2 |
| Uzunova, D | 2 |
| Stefanova, M | 2 |
| Stankova, I | 1 |
| Kalfin, R | 6 |
| He, HJ | 1 |
| Xiong, X | 1 |
| Zhang, XR | 2 |
| Zhao, X | 4 |
| Chen, L | 9 |
| Xie, CL | 3 |
| Nourmohammadi, S | 1 |
| Yousefi, S | 1 |
| Manouchehrabadi, M | 1 |
| Farhadi, M | 1 |
| Azizi, Z | 1 |
| Torkaman-Boutorabi, A | 1 |
| Nishijima, H | 3 |
| Mori, F | 3 |
| Kimura, T | 2 |
| Miki, Y | 2 |
| Kinoshita, I | 2 |
| Nakamura, T | 4 |
| Kon, T | 2 |
| Suzuki, C | 2 |
| Wakabayashi, K | 2 |
| Tomiyama, M | 4 |
| Mazzocchi, M | 1 |
| Goulding, SR | 1 |
| Morales-Prieto, N | 1 |
| Foley, T | 1 |
| Collins, LM | 3 |
| Sullivan, AM | 9 |
| O'Keeffe, GW | 7 |
| Wu, Q | 3 |
| Wei, J | 5 |
| He, YN | 1 |
| Chen, X | 5 |
| Law, BY | 1 |
| Gramage, E | 1 |
| Sáiz, J | 1 |
| Fernández-Calle, R | 1 |
| Martín, YB | 1 |
| Uribarri, M | 1 |
| Ferrer-Alcón, M | 1 |
| Barbas, C | 1 |
| Herradón, G | 1 |
| Guo, Y | 4 |
| Guan, Y | 2 |
| Zhu, H | 7 |
| Sun, T | 1 |
| Huang, Y | 4 |
| Ma, C | 4 |
| Emery, R | 1 |
| Guan, W | 2 |
| Wang, C | 3 |
| Liu, C | 5 |
| Avendaño-Estrada, A | 1 |
| Verdugo-Díaz, L | 1 |
| Ávila-Rodríguez, MA | 1 |
| Yu, S | 2 |
| Peng, HR | 1 |
| Zhang, YK | 1 |
| Yin, YQ | 1 |
| Zhou, JW | 1 |
| Magalingam, KB | 2 |
| Somanath, SD | 1 |
| Ramdas, P | 3 |
| Haleagrahara, N | 5 |
| Radhakrishnan, AK | 2 |
| Kostrzewa, RM | 4 |
| Ouchi, M | 1 |
| Kitta, T | 2 |
| Chiba, H | 1 |
| Higuchi, M | 1 |
| Togo, M | 1 |
| Abe-Takahashi, Y | 1 |
| Shinohara, N | 1 |
| Huang, SY | 2 |
| Dong, ZS | 1 |
| Chen, ZH | 1 |
| Zeng, ZW | 1 |
| Zhao, WQ | 1 |
| Guan, YQ | 1 |
| Li, CH | 1 |
| Kim, J | 7 |
| Park, I | 1 |
| Jang, S | 2 |
| Choi, M | 2 |
| Kim, D | 1 |
| Sun, W | 3 |
| Choe, Y | 2 |
| Choi, JW | 1 |
| Moon, C | 1 |
| Park, SH | 1 |
| Choe, HK | 2 |
| Kim, K | 3 |
| Fan, YY | 1 |
| Zhang, Y | 11 |
| Fan, RF | 1 |
| Wang, T | 10 |
| Yu, X | 2 |
| Zheng, LF | 2 |
| Zhu, JX | 3 |
| Pamies, D | 1 |
| Wiersma, D | 1 |
| Katt, ME | 1 |
| Burtscher, J | 1 |
| Harris, G | 1 |
| Smirnova, L | 1 |
| Searson, PC | 1 |
| Hartung, T | 1 |
| Hogberg, HT | 1 |
| Droguerre, M | 1 |
| Brot, S | 1 |
| Vitrac, C | 1 |
| Benoit-Marand, M | 1 |
| Belnoue, L | 1 |
| Patrigeon, M | 1 |
| Lainé, A | 1 |
| Béré, E | 1 |
| Jaber, M | 3 |
| Gaillard, A | 4 |
| Liu, J | 16 |
| Lu, Y | 5 |
| Tang, M | 1 |
| Shao, F | 1 |
| Yang, D | 3 |
| Chen, S | 6 |
| Xu, Z | 2 |
| Zhai, L | 1 |
| Chen, J | 5 |
| Li, Q | 5 |
| Wu, W | 2 |
| Chen, H | 6 |
| Elabi, OF | 1 |
| Pass, R | 1 |
| Sormonta, I | 1 |
| Nolbrant, S | 1 |
| Drummond, N | 1 |
| Kirkeby, A | 1 |
| Kunath, T | 1 |
| Parmar, M | 2 |
| Lane, EL | 9 |
| Zou, XG | 1 |
| Xu, MT | 1 |
| Dong, XL | 1 |
| Ying, YM | 1 |
| Guan, RF | 1 |
| Wu, WC | 1 |
| Yang, K | 1 |
| Sun, PL | 1 |
| Lee, EJ | 1 |
| Choi, Y | 1 |
| Lee, HJ | 8 |
| Hwang, DW | 2 |
| Lee, DS | 2 |
| Jalgaonkar, S | 1 |
| Gajbhiye, S | 1 |
| Sayyed, M | 1 |
| Tripathi, R | 1 |
| Khatri, N | 1 |
| Parmar, U | 1 |
| Shankar, A | 1 |
| Tanimura, A | 1 |
| Shen, W | 1 |
| Wokosin, D | 2 |
| Surmeier, DJ | 4 |
| Cohen, SR | 1 |
| Terry, ML | 1 |
| Coyle, M | 2 |
| Wheelis, E | 1 |
| Centner, A | 4 |
| Smith, S | 1 |
| Glinski, J | 3 |
| Lipari, N | 3 |
| Budrow, C | 1 |
| Manfredsson, FP | 5 |
| Bishop, C | 11 |
| Gupta, S | 1 |
| Tiwari, V | 3 |
| Tiwari, P | 1 |
| Mishra, A | 6 |
| Hanif, K | 1 |
| Shukla, S | 6 |
| Paz, RM | 2 |
| Stahl, AM | 1 |
| Rela, L | 1 |
| Murer, MG | 5 |
| Tubert, C | 1 |
| Chen, W | 2 |
| Zheng, Q | 2 |
| Huang, Q | 1 |
| Li, M | 18 |
| Huang, Z | 5 |
| Han, J | 3 |
| Wu, P | 2 |
| Wu, C | 2 |
| Fan, Y | 3 |
| Hao, X | 2 |
| Zhu, M | 4 |
| Tseng, KY | 3 |
| Kuo, TT | 2 |
| Wang, V | 2 |
| Huang, EY | 2 |
| Ma, KH | 6 |
| Olson, L | 7 |
| Hoffer, BJ | 7 |
| Chen, YH | 6 |
| Li, H | 7 |
| Jiang, H | 4 |
| Li, L | 11 |
| Yan, Z | 2 |
| Feng, J | 3 |
| Bagán, A | 1 |
| Morales-García, JA | 5 |
| Griñán-Ferré, C | 1 |
| Díaz, C | 2 |
| Pérez Del Palacio, J | 1 |
| Ramos, MC | 1 |
| Vicente, F | 1 |
| Pérez, B | 1 |
| Brea, J | 1 |
| Loza, MI | 1 |
| Pallàs, M | 1 |
| Escolano, C | 1 |
| Mao, Z | 3 |
| Gao, M | 1 |
| Peng, J | 2 |
| Pinizzotto, CC | 1 |
| Patwardhan, A | 1 |
| Aldarondo, D | 1 |
| Kritzer, MF | 1 |
| Chang, CH | 1 |
| Chang, ST | 1 |
| Liao, VH | 1 |
| Kang, X | 2 |
| Zhang, B | 2 |
| Du, W | 1 |
| Zhao, R | 1 |
| Bai, Y | 1 |
| Jiang, X | 5 |
| Pang, J | 1 |
| Zhao, C | 3 |
| Mou, X | 1 |
| Gao, F | 1 |
| Yuan, H | 3 |
| Sun, X | 5 |
| Esteves, M | 2 |
| Abreu, R | 1 |
| Fernandes, H | 1 |
| Serra-Almeida, C | 1 |
| Martins, PAT | 1 |
| Barão, M | 1 |
| Cristóvão, AC | 3 |
| Saraiva, C | 2 |
| Ferreira, R | 2 |
| Ferreira, L | 1 |
| Bernardino, L | 2 |
| Ni, W | 1 |
| Zhou, J | 1 |
| Ling, Y | 1 |
| Lu, X | 6 |
| Niu, D | 1 |
| Zeng, Y | 2 |
| Qiu, Y | 2 |
| Si, Y | 1 |
| Wang, J | 13 |
| Wang, Z | 7 |
| Hu, J | 2 |
| Wang, K | 4 |
| Su, W | 2 |
| Jia, J | 4 |
| Wang, X | 21 |
| Quan, HH | 1 |
| Xu, WX | 1 |
| Qi, YZ | 1 |
| Li, QR | 1 |
| Zhou, H | 2 |
| Huang, J | 3 |
| Abrishamdar, M | 1 |
| Farbood, Y | 3 |
| Sarkaki, A | 3 |
| Rashno, M | 1 |
| Badavi, M | 1 |
| Pang, CCC | 1 |
| Sørensen, MH | 1 |
| Lee, K | 2 |
| Luk, KC | 1 |
| Trojanowski, JQ | 1 |
| Lee, VMY | 1 |
| Noble, W | 1 |
| Chang, RCC | 1 |
| Avagliano, C | 1 |
| Coretti, L | 2 |
| Lama, A | 1 |
| Pirozzi, C | 2 |
| De Caro, C | 2 |
| De Biase, D | 1 |
| Turco, L | 2 |
| Mollica, MP | 1 |
| Paciello, O | 1 |
| Calignano, A | 1 |
| Meli, R | 1 |
| Lembo, F | 2 |
| Mattace Raso, G | 2 |
| Thomasi, BBM | 1 |
| Valdetaro, L | 1 |
| Ricciardi, MCG | 1 |
| Hayashide, L | 1 |
| Fernandes, ACMN | 1 |
| Mussauer, A | 1 |
| da Silva, ML | 1 |
| da Cunha Faria-Melibeu, A | 1 |
| Ribeiro, MGL | 1 |
| de Mattos Coelho-Aguiar, J | 1 |
| Campello-Costa, P | 1 |
| Moura-Neto, V | 1 |
| Tavares-Gomes, AL | 1 |
| Frouni, I | 2 |
| Kang, W | 1 |
| Bédard, D | 1 |
| Belliveau, S | 1 |
| Kwan, C | 2 |
| Hadj-Youssef, S | 1 |
| Bourgeois-Cayer, É | 1 |
| Ohlund, L | 1 |
| Sleno, L | 1 |
| Hamadjida, A | 2 |
| Huot, P | 2 |
| Huang, YL | 2 |
| Zhang, JN | 2 |
| Hou, TZ | 1 |
| Gu, L | 2 |
| Yang, HM | 2 |
| Zhang, H | 7 |
| Tiwari, PC | 1 |
| Chaudhary, MJ | 1 |
| Pal, R | 1 |
| Nath, R | 1 |
| Alarcon-Gil, J | 1 |
| Sierra-Magro, A | 2 |
| Sanz-SanCristobal, M | 2 |
| Alonso-Gil, S | 4 |
| Cortes-Canteli, M | 1 |
| Niso-Santano, M | 1 |
| Martínez-Chacón, G | 1 |
| Fuentes, JM | 1 |
| Santos, A | 4 |
| Perez-Castillo, A | 4 |
| Mallet, D | 1 |
| Goutaudier, R | 1 |
| Barbier, EL | 1 |
| Carnicella, S | 3 |
| Colca, JR | 1 |
| Fauvelle, F | 1 |
| Boulet, S | 3 |
| Yang, S | 3 |
| Huh, E | 2 |
| Moon, GH | 1 |
| Ahn, J | 1 |
| Woo, J | 1 |
| Han, HS | 1 |
| Lee, HH | 1 |
| Chung, KS | 1 |
| Lee, KT | 1 |
| Oh, MS | 6 |
| Lee, JY | 2 |
| Nascimento, ALF | 1 |
| Medeiros, POS | 1 |
| Pedrão, LFAT | 1 |
| Queiroz, VC | 1 |
| Oliveira, LM | 3 |
| Novaes, LS | 1 |
| Caetano, AL | 1 |
| Munhoz, CD | 3 |
| Falquetto, B | 2 |
| Calabrese, V | 1 |
| Picconi, B | 8 |
| Heck, N | 1 |
| Campanelli, F | 1 |
| Natale, G | 1 |
| Marino, G | 1 |
| Sciaccaluga, M | 1 |
| Ghiglieri, V | 5 |
| Tozzi, A | 4 |
| Anceaume, E | 1 |
| Cuoc, E | 1 |
| Caboche, J | 2 |
| Conquet, F | 1 |
| Calabresi, P | 9 |
| Charvin, D | 1 |
| Zhu, F | 1 |
| Zhou, W | 2 |
| Tang, Q | 1 |
| Yu, Q | 2 |
| Huo, S | 1 |
| Chen, K | 1 |
| Lei, T | 1 |
| Xiao, Z | 1 |
| Zhang, X | 15 |
| Cai, S | 1 |
| Bi, W | 1 |
| Yang, Y | 8 |
| Du, H | 1 |
| Wu, Y | 3 |
| Wang, Q | 10 |
| Guo, L | 4 |
| Qu, B | 1 |
| Song, C | 1 |
| Zhu, S | 2 |
| Gong, N | 1 |
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Lu, Q | 2 |
| Gouda, NA | 1 |
| Quan, G | 1 |
| Nada, H | 1 |
| Elkamhawy, A | 1 |
| Lee, D | 1 |
| Lee, CH | 5 |
| Cho, J | 1 |
| de la Rosa, T | 2 |
| Calvo, VS | 1 |
| Gonçalves, VC | 3 |
| Ferreira, CB | 1 |
| Souza, FDC | 1 |
| Scerni, DA | 1 |
| Scorza, FA | 5 |
| Jang, HJ | 1 |
| Chung, KC | 3 |
| Shao, J | 1 |
| Lian, M | 1 |
| Mao, Y | 1 |
| Rees, D | 1 |
| Beynon, AL | 1 |
| Lelos, MJ | 5 |
| Smith, GA | 2 |
| Roberts, LD | 1 |
| Phelps, L | 1 |
| Dunnett, SB | 16 |
| Morgan, AH | 1 |
| Brown, RM | 1 |
| Wells, T | 1 |
| Davies, JS | 1 |
| Muhammad, F | 1 |
| Liu, Y | 14 |
| Wang, N | 4 |
| Zhou, Y | 7 |
| Yang, H | 3 |
| Sisalli, MJ | 1 |
| Della Notte, S | 1 |
| Secondo, A | 1 |
| Ventra, C | 1 |
| Annunziato, L | 1 |
| Scorziello, A | 1 |
| Sadeghian, Z | 2 |
| Eyvari-Brooshghalan, S | 1 |
| Sabahi, M | 2 |
| Nourouzi, N | 1 |
| Haddadi, R | 5 |
| Sokouti, H | 1 |
| Mohajeri, D | 1 |
| Nourazar, MA | 1 |
| Li, CJ | 2 |
| Zhang, LG | 2 |
| Liu, LB | 1 |
| An, MQ | 2 |
| Dong, LG | 2 |
| Gu, HY | 2 |
| Dai, YP | 1 |
| Wang, F | 9 |
| Mao, CJ | 4 |
| Liu, CF | 4 |
| Lee, DW | 1 |
| Ryu, YK | 2 |
| Chang, DH | 1 |
| Park, HY | 2 |
| Go, J | 2 |
| Maeng, SY | 1 |
| Hwang, DY | 1 |
| Kim, BC | 1 |
| Kim, KS | 8 |
| Kamińska, K | 2 |
| Lenda, T | 2 |
| Konieczny, J | 2 |
| Lorenc-Koci, E | 1 |
| Rajneesh, CP | 1 |
| Hsieh, TH | 4 |
| Chen, HC | 1 |
| Liou, JC | 2 |
| Lin, BS | 1 |
| George Wu, CW | 1 |
| Lai, CH | 1 |
| Peng, CW | 2 |
| Guo, SY | 1 |
| Guan, RX | 1 |
| Chi, XD | 1 |
| Sui, AR | 1 |
| Zhao, W | 1 |
| Supratik, K | 1 |
| Yang, JY | 1 |
| Zhao, J | 3 |
| Li, S | 8 |
| Azar, YO | 1 |
| Badawi, GA | 1 |
| Zaki, HF | 1 |
| Ibrahim, SM | 1 |
| Gergin, S | 1 |
| Kirazlı, Ö | 2 |
| Boracı, H | 2 |
| Yıldız, SD | 1 |
| Yananlı, HR | 1 |
| Şehirli, ÜS | 2 |
| Sheta, R | 1 |
| Teixeira, M | 1 |
| Idi, W | 1 |
| Pierre, M | 1 |
| de Rus Jacquet, A | 1 |
| Emond, V | 1 |
| Zorca, CE | 1 |
| Vanderperre, B | 1 |
| Durcan, TM | 1 |
| Fon, EA | 1 |
| Calon, F | 1 |
| Chahine, M | 1 |
| Oueslati, A | 1 |
| Perlikowska, R | 1 |
| Silva, J | 1 |
| Alves, C | 1 |
| Susano, P | 1 |
| Pedrosa, R | 1 |
| Agrawal, S | 2 |
| Kumari, R | 3 |
| Sophronea, T | 1 |
| Kumari, N | 2 |
| Luthra, PM | 3 |
| Pinheiro Campos, AC | 1 |
| Martinez, RCR | 1 |
| Auada, AVV | 1 |
| Lebrun, I | 1 |
| Fonoff, ET | 1 |
| Hamani, C | 1 |
| Pagano, RL | 1 |
| Xu, J | 3 |
| Li, Y | 13 |
| Huang, W | 2 |
| Shi, Y | 2 |
| Liu, G | 2 |
| Abidar, S | 1 |
| Hritcu, L | 2 |
| Nhiri, M | 1 |
| Kip, E | 1 |
| Bentall, L | 1 |
| Underwood, CF | 1 |
| Hughes, SM | 1 |
| Parr-Brownlie, LC | 3 |
| Guo, J | 7 |
| Yang, J | 7 |
| Fu, J | 3 |
| Tripathi, A | 3 |
| Castela, I | 4 |
| Casado-Polanco, R | 3 |
| Rubio, YV | 3 |
| da Silva, JA | 3 |
| Marquez, R | 3 |
| Pro, B | 3 |
| Moratalla, R | 7 |
| Redgrave, P | 3 |
| Costa, RM | 3 |
| Obeso, J | 5 |
| Hernandez, LF | 3 |
| Alharbi, M | 3 |
| Alshammari, A | 3 |
| Kaur, G | 3 |
| Kalra, S | 3 |
| Mehan, S | 3 |
| Suri, M | 3 |
| Chhabra, S | 3 |
| Kumar, N | 3 |
| Alanazi, WA | 3 |
| Alshanwani, AR | 3 |
| Al-Ghamdi, AH | 3 |
| Narula, AS | 3 |
| Zhang, JX | 3 |
| Zhou, KG | 3 |
| Yin, YX | 3 |
| Jin, LJ | 3 |
| Tong, WF | 3 |
| Yu, LH | 3 |
| Ye, XC | 3 |
| Jiang, M | 4 |
| Kim, HY | 3 |
| Yoon, HH | 5 |
| Seong, H | 3 |
| Seo, DK | 3 |
| Choi, SW | 3 |
| Kang, KS | 3 |
| Jeon, SR | 5 |
| Pan, S | 3 |
| Wang, L | 10 |
| Dong, X | 3 |
| Zhou, A | 3 |
| Xing, H | 3 |
| Cesaroni, V | 2 |
| Blandini, F | 13 |
| Cerri, S | 6 |
| Gan, X | 2 |
| Ren, J | 3 |
| Huang, T | 2 |
| Wu, K | 2 |
| Duan, Y | 2 |
| Si, W | 3 |
| Lai, MC | 2 |
| Liu, WY | 3 |
| Liou, SS | 2 |
| Liu, IM | 2 |
| Cohen, S | 2 |
| Jin, T | 1 |
| Long, H | 1 |
| Jin, S | 1 |
| Peng, Y | 2 |
| Anderson, KA | 1 |
| Whitehead, BJ | 1 |
| Petersen, ED | 1 |
| Kemme, MR | 1 |
| Wedster, A | 1 |
| Hochgeschwender, U | 1 |
| Sandstrom, MI | 2 |
| Ibarra-Gutiérrez, MT | 1 |
| Serrano-García, N | 1 |
| Orozco-Ibarra, M | 1 |
| Rivas-Santisteban, R | 1 |
| Lillo, J | 1 |
| Raïch, I | 1 |
| Muñoz, A | 4 |
| Lillo, A | 1 |
| Rodríguez-Pérez, AI | 5 |
| Labandeira-García, JL | 9 |
| Navarro, G | 1 |
| Franco, R | 2 |
| Idrissi, SE | 1 |
| Fath, N | 1 |
| Ibork, H | 1 |
| Taghzouti, K | 1 |
| Alamy, M | 1 |
| Abboussi, O | 1 |
| Li, X | 9 |
| Sun, L | 3 |
| He, Z | 1 |
| Gan, J | 2 |
| He, M | 2 |
| Casanova, Y | 1 |
| Negro, S | 1 |
| Barcia, E | 1 |
| Eyvari Brooshghalan, S | 2 |
| Ebadi, SA | 1 |
| Mohajjel Nayebi, A | 1 |
| Pereira, CPM | 1 |
| Francis-Oliveira, J | 1 |
| Britto, LRG | 2 |
| Miranda, NC | 1 |
| Aquino, YC | 1 |
| Lin, CY | 3 |
| Huang, YC | 1 |
| Wu, CR | 2 |
| Wu, HT | 1 |
| Fu, RH | 5 |
| Tsai, CW | 6 |
| Yiğit, EN | 1 |
| Sönmez, E | 1 |
| Yüksel, İ | 1 |
| Aksan Kurnaz, I | 1 |
| Çakır, T | 1 |
| Ren, Z | 1 |
| Ding, H | 2 |
| Zhou, M | 6 |
| Yang, N | 2 |
| Chan, P | 1 |
| Yuan, Y | 1 |
| Lian, P | 1 |
| Cao, X | 4 |
| Xu, Y | 4 |
| Jia, R | 1 |
| Shuai, K | 1 |
| Zhou, C | 2 |
| Zhu, L | 1 |
| Wu, XM | 1 |
| Chen, WS | 1 |
| Lin, TY | 1 |
| Kuo, CH | 1 |
| Hsieh, DJ | 1 |
| Kuo, WW | 1 |
| Liao, SC | 1 |
| Kao, HC | 1 |
| Ju, DT | 1 |
| Lin, YJ | 1 |
| Huang, CY | 1 |
| Sun, S | 2 |
| Shi, X | 1 |
| Fang, H | 1 |
| Sun, Y | 5 |
| Han, H | 3 |
| He, Q | 1 |
| Zhu, ZW | 1 |
| Chen, F | 2 |
| Wang, M | 8 |
| Corsi, S | 1 |
| Scheggi, S | 1 |
| Pardu, A | 1 |
| Braccagni, G | 1 |
| Caruso, D | 1 |
| Cioffi, L | 1 |
| Diviccaro, S | 1 |
| Gentile, M | 1 |
| Fanni, S | 1 |
| Stancampiano, R | 2 |
| Gambarana, C | 1 |
| Melcangi, RC | 1 |
| Frau, R | 1 |
| Carta, M | 8 |
| Greig, NH | 2 |
| Jung, J | 1 |
| Choi, HI | 1 |
| Yi, L | 1 |
| Yang, X | 9 |
| Zhong, J | 1 |
| Ye, S | 2 |
| Li, C | 1 |
| Pramanik, SK | 1 |
| Sanphui, P | 1 |
| Das, AK | 1 |
| Banerji, B | 1 |
| Biswas, SC | 1 |
| Castelnovo, LF | 1 |
| Thomas, P | 1 |
| Gomes, A | 1 |
| Monteiro, SM | 1 |
| Venâncio, C | 1 |
| Félix, L | 1 |
| Zhang, Z | 8 |
| Li, J | 6 |
| Ma, Y | 3 |
| Zhang, P | 4 |
| Lin, J | 1 |
| Lopes-Nunes, J | 1 |
| Santos, T | 1 |
| Vale, A | 1 |
| Murakami, Y | 2 |
| Furukawa, T | 1 |
| Kambey, PA | 1 |
| Wu, J | 2 |
| Tang, C | 1 |
| Buberwa, W | 1 |
| Saro, A | 1 |
| Nyalali, AMK | 1 |
| Gao, D | 2 |
| Mahoney-Rafferty, EC | 1 |
| Tucker, HR | 2 |
| Akhtar, K | 2 |
| Herlihy, R | 1 |
| Audil, A | 1 |
| Shah, D | 1 |
| Gupta, M | 2 |
| Kochman, EM | 2 |
| Feustel, PJ | 1 |
| Molho, ES | 2 |
| Pilitsis, JG | 5 |
| Shin, DS | 4 |
| Conti Mazza, MM | 1 |
| Werner, DF | 1 |
| Ye, P | 1 |
| Bi, L | 1 |
| Yang, M | 4 |
| Huang, G | 1 |
| Hou, Y | 4 |
| Li, Z | 6 |
| Yee Tong, HH | 1 |
| Cui, M | 2 |
| Jin, H | 6 |
| Di Bisceglie Caballero, S | 1 |
| Ces, A | 1 |
| Liberge, M | 2 |
| Ambroggi, F | 1 |
| Amalric, M | 7 |
| Ouagazzal, AM | 3 |
| Kasanga, EA | 2 |
| Han, Y | 1 |
| Navarrete, W | 1 |
| McManus, R | 1 |
| Shifflet, MK | 1 |
| Parry, C | 1 |
| Barahona, A | 1 |
| Nejtek, VA | 1 |
| Richardson, JR | 1 |
| Salvatore, MF | 3 |
| Chernov, MM | 1 |
| Swan, CB | 1 |
| Leiter, JC | 1 |
| Wu, KJ | 1 |
| Hung, TW | 1 |
| Wang, YS | 1 |
| Bae, EK | 1 |
| Yu, SJ | 3 |
| Yu, J | 1 |
| Meng, J | 1 |
| Qin, Z | 1 |
| Yu, Y | 3 |
| Liang, Y | 2 |
| Min, D | 1 |
| Antonosante, A | 2 |
| Castelli, V | 1 |
| Sette, M | 1 |
| Alfonsetti, M | 1 |
| Catanesi, M | 1 |
| Benedetti, E | 2 |
| Ardini, M | 1 |
| Cimini, A | 2 |
| d'Angelo, M | 1 |
| Beura, SK | 1 |
| Yadav, P | 1 |
| Panigrahi, AR | 1 |
| Singh, SK | 1 |
| Andreska, T | 1 |
| Lüningschrör, P | 1 |
| Wolf, D | 1 |
| McFleder, RL | 1 |
| Ayon-Olivas, M | 1 |
| Rattka, M | 2 |
| Drechsler, C | 1 |
| Perschin, V | 1 |
| Blum, R | 1 |
| Aufmkolk, S | 1 |
| Granado, N | 1 |
| Sauer, M | 1 |
| Monoranu, C | 1 |
| Volkmann, J | 2 |
| Ip, CW | 1 |
| Stigloher, C | 1 |
| Sendtner, M | 1 |
| Binda, KH | 2 |
| Chacur, M | 2 |
| Martins, DO | 1 |
| Landau, AM | 2 |
| Brooks, DJ | 1 |
| Real, CC | 4 |
| Helf, C | 1 |
| Kober, M | 2 |
| Markert, F | 1 |
| Lanto, J | 1 |
| Overhoff, L | 1 |
| Badstübner-Meeske, K | 1 |
| Storch, A | 3 |
| Fauser, M | 2 |
| Cui, H | 1 |
| Elford, JD | 1 |
| Alitalo, O | 1 |
| Perez-Pardo, P | 1 |
| Tampio, J | 1 |
| Huttunen, KM | 1 |
| Kraneveld, A | 1 |
| Forsberg, MM | 3 |
| Myöhänen, TT | 1 |
| Jalkanen, AJ | 2 |
| Zeljkovic Jovanovic, M | 1 |
| Stanojevic, J | 1 |
| Stevanovic, I | 1 |
| Stekic, A | 1 |
| Bolland, SJ | 1 |
| Jasnic, N | 1 |
| Ninkovic, M | 1 |
| Zaric Kontic, M | 1 |
| Ilic, TV | 1 |
| Rodger, J | 1 |
| Nedeljkovic, N | 1 |
| Dragic, M | 1 |
| Sakakibara, O | 1 |
| Shimoda, M | 2 |
| Yamamoto, G | 1 |
| Higashi, Y | 1 |
| Ikeda-Imafuku, M | 1 |
| Ishima, Y | 1 |
| Kawahara, M | 2 |
| Tanaka, KI | 2 |
| Opallo, N | 1 |
| Buommino, E | 1 |
| Grigoriou, S | 1 |
| Espa, E | 2 |
| Odin, P | 2 |
| Timpka, J | 1 |
| von Grothusen, G | 1 |
| Jakobsson, A | 1 |
| Cenci, MA | 15 |
| Han, C | 1 |
| Dou, K | 1 |
| Yao, W | 1 |
| Yao, M | 1 |
| Wan, Q | 1 |
| Xie, A | 1 |
| Mani, S | 1 |
| Bouchnak, H | 1 |
| Pradeloux, S | 1 |
| Kraiem, J | 1 |
| Soulet, D | 2 |
| Messaoudi, I | 1 |
| Li, R | 1 |
| Wu, Z | 1 |
| Tang, G | 1 |
| Park, TY | 1 |
| Jeon, J | 1 |
| Lee, N | 1 |
| Song, B | 1 |
| Kim, JH | 2 |
| Lee, SK | 1 |
| Liu, D | 4 |
| Cha, Y | 1 |
| Kim, M | 1 |
| Leblanc, P | 1 |
| Herrington, TM | 1 |
| Carter, BS | 1 |
| Schweitzer, JS | 1 |
| Su, HC | 1 |
| Sun, YT | 1 |
| Yang, MY | 1 |
| Wu, CY | 1 |
| Hsu, CM | 1 |
| Akan, T | 1 |
| Aydın, Y | 1 |
| Korkmaz, OT | 2 |
| Ulupınar, E | 2 |
| Saydam, F | 1 |
| Menezes-Rodrigues, FS | 1 |
| de Oliveira, MP | 1 |
| Araújo, EA | 1 |
| Ferraz, HB | 1 |
| Finsterer, J | 3 |
| Olszewer, E | 2 |
| Taha, MO | 1 |
| Scorza, CA | 5 |
| Caricati-Neto, A | 1 |
| Barroso-Chinea, P | 4 |
| Salas-Hernández, J | 1 |
| Cruz-Muros, I | 1 |
| López-Fernández, J | 1 |
| Freire, R | 1 |
| Afonso-Oramas, D | 1 |
| Firouzan, B | 1 |
| Iravanpour, F | 1 |
| Abbaszadeh, F | 1 |
| Akparov, V | 1 |
| Zaringhalam, J | 1 |
| Ghasemi, R | 1 |
| Maghsoudi, N | 3 |
| Viegas, MPC | 1 |
| Santos, LEC | 1 |
| Aarão, MC | 1 |
| Cecilio, SG | 1 |
| Medrado, JM | 1 |
| Pires, AC | 1 |
| Rodrigues, AM | 1 |
| Moret, MA | 1 |
| Almeida, AG | 1 |
| Chen, XY | 2 |
| Feng, SN | 1 |
| Bao, Y | 1 |
| Zhou, YX | 1 |
| Ba, F | 1 |
| Gao, X | 1 |
| He, D | 1 |
| He, Y | 3 |
| Wang, H | 5 |
| Ye, B | 1 |
| Fu, S | 1 |
| Zhang, JB | 1 |
| Silva da Fonsêca, V | 1 |
| Augusto Izidoro, M | 1 |
| Guimarães de Almeida, AC | 1 |
| Luiz Affonso Fonseca, F | 1 |
| Alexandre Scorza, F | 1 |
| Nascimento, GC | 1 |
| Jacob, G | 1 |
| Milan, BA | 1 |
| Leal-Luiz, G | 1 |
| Malzone, BL | 1 |
| Vivanco-Estela, AN | 1 |
| Escobar-Espinal, D | 1 |
| Dias, FJ | 1 |
| Del-Bel, E | 2 |
| Liu, W | 5 |
| Zhang, R | 1 |
| Feng, H | 1 |
| Luo, J | 5 |
| Gronlier, E | 1 |
| Volle, J | 1 |
| Coizet, V | 1 |
| Paccard, A | 1 |
| Habermacher, C | 1 |
| Roche, Y | 1 |
| Roucard, C | 1 |
| Duveau, V | 1 |
| David, O | 1 |
| Statz, M | 1 |
| Schleuter, F | 1 |
| Weber, H | 1 |
| Plocksties, F | 1 |
| Timmermann, D | 1 |
| Ali, N | 1 |
| Sane, MS | 1 |
| Tang, H | 1 |
| Compher, J | 1 |
| McLaughlin, Q | 1 |
| Jones, CD | 1 |
| Maffi, SK | 1 |
| Hong, SY | 1 |
| Chen, HJ | 1 |
| Uspalenko, NI | 1 |
| Mosentsov, AA | 1 |
| Khmil, NV | 1 |
| Pavlik, LL | 1 |
| Belosludtseva, NV | 1 |
| Khunderyakova, NV | 1 |
| Shigaeva, MI | 1 |
| Medvedeva, VP | 1 |
| Malkov, AE | 1 |
| Kitchigina, VF | 1 |
| Mironova, GD | 1 |
| Flores, AJ | 2 |
| Bartlett, MJ | 2 |
| Seaton, BT | 1 |
| Samtani, G | 1 |
| Sexauer, MR | 1 |
| Weintraub, NC | 1 |
| Siegenthaler, JR | 1 |
| Lu, D | 1 |
| Heien, ML | 1 |
| Porreca, F | 1 |
| Sherman, SJ | 4 |
| Falk, T | 4 |
| Singh, A | 2 |
| Panhelainen, A | 1 |
| Voutilainen, MH | 4 |
| Liu, H | 2 |
| Dong, H | 1 |
| Jia, W | 2 |
| Wang, G | 2 |
| Zhong, L | 1 |
| Gong, L | 1 |
| Zhu, W | 1 |
| Neuwirth, LS | 1 |
| Cadet, P | 1 |
| Murphy, EM | 1 |
| Lindgren, HS | 4 |
| Rentsch, P | 1 |
| Egan, T | 1 |
| Kuriakose, A | 1 |
| Stayte, S | 1 |
| Vissel, B | 1 |
| Slézia, A | 1 |
| Hegedüs, P | 1 |
| Rusina, E | 1 |
| Lengyel, K | 1 |
| Solari, N | 1 |
| Kaszas, A | 1 |
| Balázsfi, D | 1 |
| Botzanowski, B | 1 |
| Acerbo, E | 1 |
| Missey, F | 1 |
| Williamson, A | 1 |
| Hangya, B | 1 |
| Mendes-Pinheiro, B | 2 |
| Campos, J | 2 |
| Marote, A | 2 |
| Soares-Cunha, C | 1 |
| Nickels, SL | 1 |
| Monzel, AS | 1 |
| Cibrão, JR | 1 |
| Loureiro-Campos, E | 1 |
| Serra, SC | 1 |
| Barata-Antunes, S | 2 |
| Duarte-Silva, S | 1 |
| Pinto, L | 1 |
| Schwamborn, JC | 3 |
| Salgado, AJ | 3 |
| Zhao, G | 2 |
| Zhang, DY | 1 |
| Liu, XL | 1 |
| Qiao, DC | 1 |
| Kuang, P | 2 |
| Lao, W | 2 |
| Ji, Y | 4 |
| Albarrán-Bravo, S | 1 |
| Ávalos-Fuentes, JA | 1 |
| Cortés, H | 1 |
| Rodriguez-Sánchez, M | 1 |
| Leyva-García, N | 1 |
| Rangel-Barajas, C | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
| Liu, CT | 1 |
| Kao, LT | 1 |
| Shih, JH | 1 |
| Chien, WC | 1 |
| Chiu, CH | 2 |
| Huang, YS | 2 |
| Cheng, CY | 3 |
| Shiue, CY | 3 |
| Li, IH | 4 |
| Xicoy, H | 1 |
| Brouwers, JF | 1 |
| Kalnytska, O | 1 |
| Wieringa, B | 1 |
| Martens, GJM | 1 |
| Mei, M | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Ding, J | 1 |
| Lu, M | 1 |
| Hu, G | 2 |
| Cavelli, M | 1 |
| Prunell, G | 1 |
| Costa, G | 1 |
| Velásquez, N | 1 |
| Gonzalez, J | 1 |
| Castro-Zaballa, S | 1 |
| Lima, MMS | 1 |
| Torterolo, P | 1 |
| Wei, L | 2 |
| Chen, C | 6 |
| Ding, L | 1 |
| Mo, M | 1 |
| Zou, J | 2 |
| Lu, Z | 3 |
| Wu, H | 6 |
| Dai, Y | 1 |
| Xu, P | 2 |
| Giuliano, C | 1 |
| Siani, F | 2 |
| Mus, L | 1 |
| Ghezzi, C | 2 |
| Pacchetti, B | 1 |
| Bigogno, C | 1 |
| Oñate, M | 1 |
| Catenaccio, A | 1 |
| Salvadores, N | 1 |
| Saquel, C | 1 |
| Martinez, A | 3 |
| Moreno-Gonzalez, I | 1 |
| Gamez, N | 1 |
| Soto, P | 1 |
| Soto, C | 1 |
| Hetz, C | 2 |
| Court, FA | 2 |
| Singh, S | 6 |
| Bano, S | 1 |
| Fine, JM | 1 |
| Stroebel, BM | 1 |
| Faltesek, KA | 1 |
| Terai, K | 1 |
| Haase, L | 1 |
| Knutzen, KE | 1 |
| Kosyakovsky, J | 1 |
| Bowe, TJ | 1 |
| Fuller, AK | 1 |
| Frey, WH | 2 |
| Hanson, LR | 1 |
| Yan, T | 1 |
| Gong, G | 1 |
| Fan, K | 1 |
| Wu, B | 2 |
| Bi, K | 1 |
| Jia, Y | 2 |
| Pak, ME | 1 |
| Ahn, SM | 1 |
| Jung, DH | 1 |
| Ha, KT | 1 |
| Shin, HK | 1 |
| Choi, BT | 1 |
| Xue, B | 1 |
| Xiao, W | 1 |
| Tian, H | 1 |
| Ghahari, L | 1 |
| Safari, M | 1 |
| Rahimi Jaberi, K | 1 |
| Jafari, B | 1 |
| Safari, K | 1 |
| Madadian, M | 1 |
| Ham, S | 2 |
| Kim, H | 6 |
| Yoon, JH | 2 |
| Song, BR | 1 |
| Choi, JY | 1 |
| Lee, YS | 1 |
| Paek, SM | 1 |
| Maeng, HJ | 2 |
| Lee, Y | 3 |
| Rezaee, Z | 2 |
| Marandi, SM | 2 |
| Alaei, H | 4 |
| Esfarjani, F | 2 |
| Ko, YH | 1 |
| Kwon, SH | 2 |
| Kim, SK | 1 |
| Lee, BR | 1 |
| Hur, KH | 1 |
| Kim, YJ | 3 |
| Kim, SE | 2 |
| Lee, SY | 1 |
| Jang, CG | 1 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 2 |
| Bortolanza, M | 4 |
| Ferreira-Junior, NC | 1 |
| Ding, F | 1 |
| Tian, Y | 2 |
| Zhang, M | 2 |
| Kishimoto, Y | 1 |
| Johnson, J | 1 |
| Fang, W | 1 |
| Halpern, J | 1 |
| Marosi, K | 1 |
| Geisler, JG | 1 |
| Mattson, MP | 1 |
| Voronin, MV | 1 |
| Kadnikov, IA | 1 |
| Voronkov, DN | 1 |
| Seredenin, SB | 1 |
| Song, L | 6 |
| Lyu, E | 1 |
| Farmer, K | 1 |
| Abd-Elrahman, KS | 1 |
| Derksen, A | 1 |
| Rowe, EM | 1 |
| Thompson, AM | 1 |
| Rudyk, CA | 1 |
| Prowse, NA | 1 |
| Dwyer, Z | 1 |
| Bureau, SC | 1 |
| Fortin, T | 1 |
| Ferguson, SSG | 1 |
| Hayley, S | 1 |
| Sikora, J | 2 |
| Kieffer, BL | 1 |
| Paoletti, P | 1 |
| Farzam, A | 1 |
| Chohan, K | 1 |
| Strmiskova, M | 1 |
| Hewitt, SJ | 1 |
| Park, DS | 1 |
| Pezacki, JP | 1 |
| Özcelik, D | 1 |
| Chi, H | 1 |
| Li, F | 3 |
| Chen, Z | 6 |
| Vaz, RL | 1 |
| Sousa, S | 1 |
| Chapela, D | 1 |
| van der Linde, HC | 1 |
| Willemsen, R | 1 |
| Correia, AD | 1 |
| Outeiro, TF | 1 |
| Afonso, ND | 1 |
| J, B | 1 |
| Das, A | 1 |
| Sakthivel, KM | 1 |
| Mahato, AK | 2 |
| Kopra, J | 1 |
| Renko, JM | 2 |
| Visnapuu, T | 2 |
| Korhonen, I | 1 |
| Pulkkinen, N | 1 |
| Bespalov, MM | 2 |
| Domanskyi, A | 1 |
| Ronken, E | 1 |
| Piepponen, TP | 1 |
| Tuominen, RK | 3 |
| Karelson, M | 2 |
| Sidorova, YA | 2 |
| Saarma, M | 5 |
| Tsai, WL | 1 |
| Chen, HY | 1 |
| Huang, YZ | 1 |
| Kuo, CW | 1 |
| Chen, KY | 2 |
| Varešlija, D | 1 |
| Tipton, KF | 2 |
| Davey, GP | 1 |
| McDonald, AG | 1 |
| Tibar, H | 1 |
| Naudet, F | 2 |
| Kölbl, F | 1 |
| Ribot, B | 1 |
| Faggiani, E | 1 |
| N'Kaoua, G | 1 |
| Renaud, S | 1 |
| Lewis, N | 1 |
| Benazzouz, A | 3 |
| Metzger, JM | 1 |
| Matsoff, HN | 1 |
| Zinnen, AD | 1 |
| Fleddermann, RA | 1 |
| Bondarenko, V | 1 |
| Simmons, HA | 1 |
| Mejia, A | 1 |
| Moore, CF | 1 |
| Emborg, ME | 2 |
| Zhai, H | 2 |
| Kang, Z | 1 |
| Ma, J | 1 |
| Chen, G | 4 |
| Torikoshi, S | 1 |
| Shimogawa, T | 1 |
| Samata, B | 1 |
| Miyamoto, S | 1 |
| de Lucena, JD | 2 |
| Gadelha-Filho, CVJ | 1 |
| da Costa, RO | 1 |
| de Araújo, DP | 2 |
| Lima, FAV | 3 |
| Neves, KRT | 3 |
| de Barros Viana, GS | 4 |
| Kostrzewa, JP | 1 |
| Mehrabani, M | 1 |
| Nematollahi, MH | 1 |
| Tarzi, ME | 1 |
| Juybari, KB | 1 |
| Abolhassani, M | 1 |
| Sharifi, AM | 1 |
| Paseban, H | 1 |
| Saravani, M | 1 |
| Mirzamohammadi, S | 1 |
| Kim, HS | 4 |
| Kim, SH | 1 |
| Cho, BP | 1 |
| Young, D | 1 |
| Popiolek, M | 1 |
| Trapa, P | 1 |
| Fonseca, KR | 1 |
| Brevard, J | 1 |
| Gray, DL | 1 |
| Kozak, R | 1 |
| Teixeira, FG | 2 |
| Vilaça-Faria, H | 2 |
| Domingues, AV | 2 |
| Barilar, JO | 1 |
| Knezovic, A | 1 |
| Perhoc, AB | 1 |
| Homolak, J | 1 |
| Riederer, P | 5 |
| Salkovic-Petrisic, M | 1 |
| Castello, J | 1 |
| Cortés, M | 1 |
| Malave, L | 1 |
| Kottmann, A | 1 |
| Sibley, DR | 1 |
| Friedman, E | 2 |
| Rebholz, H | 1 |
| Nam, MH | 1 |
| Choi, I | 1 |
| Min, J | 1 |
| Márquez, I | 1 |
| Muñoz, MF | 1 |
| Ayala, A | 2 |
| López, JC | 1 |
| Vargas, JP | 1 |
| Díaz, E | 1 |
| Chemmarappally, JM | 1 |
| Pegram, HCN | 1 |
| Abeywickrama, N | 1 |
| Fornari, E | 1 |
| Hargreaves, AJ | 1 |
| De Girolamo, LA | 1 |
| Stevens, B | 1 |
| Faivre, F | 1 |
| Sánchez-Catalán, MJ | 1 |
| Dovero, S | 2 |
| Bido, S | 2 |
| Joshi, A | 1 |
| Bezard, E | 10 |
| Barrot, M | 1 |
| Pellegrini, C | 2 |
| Ippolito, C | 1 |
| Segnani, C | 1 |
| Dolfi, A | 1 |
| Errede, M | 1 |
| Virgintino, D | 1 |
| Fornai, M | 2 |
| Antonioli, L | 2 |
| Garelli, F | 1 |
| Nericcio, A | 1 |
| Colucci, R | 2 |
| Blandizzi, C | 2 |
| Bernardini, N | 2 |
| Zheng, C | 1 |
| Tan, Y | 1 |
| Zeng, W | 1 |
| Cheng, C | 2 |
| Nie, S | 1 |
| Guo, CH | 1 |
| Cao, T | 1 |
| Zheng, LT | 1 |
| Waddington, JL | 1 |
| Zhen, XC | 1 |
| Nejm, MB | 1 |
| Guimarães-Marques, MJ | 1 |
| Oliveira, LF | 1 |
| Damasceno, L | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Fonseca, F | 1 |
| Leça, R | 1 |
| de Almeida, ACG | 1 |
| Andrzejewski, K | 4 |
| Jampolska, M | 1 |
| Zaremba, M | 3 |
| Joniec-Maciejak, I | 1 |
| Boguszewski, PM | 1 |
| Kaczyńska, K | 3 |
| Le, W | 2 |
| Gülhan, R | 1 |
| Yıldız Sercan, D | 1 |
| Koski, SK | 1 |
| Leino, S | 1 |
| Panula, P | 2 |
| Rannanpää, S | 1 |
| Salminen, O | 1 |
| Parra-Cid, C | 1 |
| Orozco-Castillo, E | 1 |
| García-López, J | 1 |
| Contreras-Figueroa, E | 1 |
| Ramos-Languren, LE | 1 |
| Ibarra, C | 1 |
| Carreón-Rodríguez, A | 1 |
| Aschner, M | 1 |
| Königsberg, M | 1 |
| Santamaría, A | 2 |
| Luan, Y | 1 |
| Tang, D | 1 |
| Gu, W | 1 |
| Cao, JL | 1 |
| Xiao, C | 1 |
| Rosa, I | 2 |
| Di Censo, D | 2 |
| Ranieri, B | 2 |
| Di Giovanni, G | 4 |
| Scarnati, E | 1 |
| Alecci, M | 4 |
| Galante, A | 2 |
| Florio, TM | 4 |
| Moreira Vasconcelos, CF | 1 |
| da Cunha Ferreira, NM | 1 |
| Hardy Lima Pontes, N | 1 |
| de Sousa Dos Reis, TD | 1 |
| Basto Souza, R | 1 |
| Aragão Catunda Junior, FE | 1 |
| Vasconcelos Aguiar, LM | 1 |
| Maranguape Silva da Cunha, R | 1 |
| Yue, Y | 1 |
| Qiao, B | 1 |
| Narbute, K | 2 |
| Pilipenko, V | 2 |
| Pupure, J | 2 |
| Klinovičs, T | 1 |
| Auders, J | 1 |
| Jonavičė, U | 2 |
| Kriaučiūnaitė, K | 2 |
| Pivoriūnas, A | 3 |
| Kluša, V | 2 |
| Leija-Salazar, M | 1 |
| Bermúdez de León, M | 1 |
| González-Horta, A | 1 |
| González-Hernández, B | 1 |
| Silva, D | 1 |
| Sousa, RA | 1 |
| Pinheiro, DJLL | 1 |
| de Almeida, AG | 1 |
| Zygogianni, O | 1 |
| Kouroupi, G | 1 |
| Taoufik, E | 1 |
| Matsas, R | 2 |
| Imai, Y | 2 |
| Li, W | 3 |
| Gao, H | 5 |
| Turan, D | 1 |
| Abdik, H | 1 |
| Sahin, F | 1 |
| Avşar Abdik, E | 1 |
| Warnecke, AMP | 1 |
| Kang, MS | 1 |
| Jakowec, MW | 2 |
| Davies, DL | 1 |
| Travagli, RA | 1 |
| Browning, KN | 1 |
| Camilleri, M | 1 |
| de Campos, BH | 1 |
| de Jager, L | 1 |
| Reginato, GS | 1 |
| Pereira, RS | 1 |
| Crestani, CC | 2 |
| Pinge-Filho, P | 1 |
| Martins-Pinge, MC | 2 |
| Thieme, K | 1 |
| Malta, MB | 1 |
| E Rocha, KC | 1 |
| Tuppy, M | 2 |
| Potje, SR | 1 |
| Antoniali, C | 1 |
| Rodrigues, AC | 1 |
| Wasel, O | 1 |
| Freeman, JL | 1 |
| Stefani, A | 1 |
| Cerroni, R | 1 |
| Pierantozzi, M | 1 |
| D'Angelo, V | 1 |
| Grandi, L | 1 |
| Spanetta, M | 1 |
| Galati, S | 1 |
| Bao, X | 2 |
| Lei, J | 2 |
| Shen, Z | 1 |
| Wang, R | 5 |
| Elyasi, L | 2 |
| Jahanshahi, M | 1 |
| Jameie, SB | 1 |
| Hamid Abadi, HG | 1 |
| Nikmahzar, E | 1 |
| Khalili, M | 2 |
| Jameie, M | 2 |
| Fatemi, I | 2 |
| Abdollahi, A | 1 |
| Shamsizadeh, A | 2 |
| Allahtavakoli, M | 1 |
| Roohbakhsh, A | 1 |
| Abuthawabeh, R | 1 |
| Abuirmeileh, AN | 3 |
| Alzoubi, KH | 3 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| El Nebrisi, E | 1 |
| Javed, H | 2 |
| Ojha, SK | 1 |
| Oz, M | 1 |
| Shehab, S | 1 |
| Kubota, M | 1 |
| Kobayashi, N | 1 |
| Sugizaki, T | 1 |
| Huang, YN | 1 |
| Liao, YH | 1 |
| Kuo, TY | 1 |
| Lu, XJ | 1 |
| Fu, X | 1 |
| Zhan, Y | 1 |
| Xia, CL | 1 |
| Alipour Nosrani, E | 1 |
| Tamtaji, OR | 1 |
| Alibolandi, Z | 1 |
| Sarkar, P | 1 |
| Ghazanfari, M | 1 |
| Azami Tameh, A | 1 |
| Taghizadeh, M | 1 |
| Banikazemi, Z | 1 |
| Hadavi, R | 1 |
| Naderi Taheri, M | 1 |
| Kim, OH | 1 |
| Park, JH | 1 |
| Son, JI | 1 |
| Kim, KY | 4 |
| Booth, S | 1 |
| Ramadan, A | 1 |
| Zhang, D | 4 |
| Lu, L | 3 |
| Kirouac, G | 1 |
| Jackson, MF | 1 |
| Anderson, C | 1 |
| Ko, JH | 1 |
| Kikuoka, R | 1 |
| Miyazaki, I | 5 |
| Kubota, N | 1 |
| Maeda, M | 1 |
| Kagawa, D | 1 |
| Moriyama, M | 1 |
| Sato, A | 1 |
| Murakami, S | 2 |
| Kitamura, Y | 8 |
| Sendo, T | 1 |
| Asanuma, M | 4 |
| Güttler, C | 1 |
| Altschüler, J | 2 |
| Tanev, K | 1 |
| Böckmann, S | 1 |
| Haumesser, JK | 1 |
| Nikulin, VV | 1 |
| Kühn, AA | 1 |
| van Riesen, C | 1 |
| Praveen Rajneesh, C | 1 |
| Lin, JH | 1 |
| Nehal, N | 1 |
| Nabi, B | 1 |
| Rehman, S | 1 |
| Pathak, A | 1 |
| Iqubal, A | 1 |
| Khan, SA | 1 |
| Yar, MS | 1 |
| Parvez, S | 2 |
| Baboota, S | 2 |
| Ali, J | 2 |
| Antonazzo, M | 1 |
| Gomez-Urquijo, SM | 1 |
| Ugedo, L | 3 |
| Morera-Herreras, T | 2 |
| Burgaz, S | 2 |
| García, C | 3 |
| Gómez-Cañas, M | 2 |
| Navarrete, C | 1 |
| García-Martín, A | 1 |
| Rolland, A | 2 |
| Del Río, C | 1 |
| Casarejos, MJ | 1 |
| Muñoz, E | 3 |
| Gonzalo-Consuegra, C | 1 |
| Fernández-Ruiz, J | 4 |
| Rababa'h, AM | 1 |
| Vecchia, DD | 2 |
| Kanazawa, LKS | 2 |
| Wendler, E | 2 |
| Hocayen, PAS | 1 |
| Vital, MABF | 4 |
| Takahashi, RN | 3 |
| Da Cunha, C | 6 |
| Miyoshi, E | 2 |
| Andreatini, R | 3 |
| Shrigley, S | 1 |
| Nilsson, F | 1 |
| Mattsson, B | 3 |
| Fiorenzano, A | 1 |
| Mudannayake, J | 1 |
| Bruzelius, A | 1 |
| Ottosson, DR | 1 |
| Björklund, A | 14 |
| Hoban, DB | 1 |
| Saso, L | 1 |
| Atanasov, AG | 1 |
| Yao, L | 1 |
| Gao, S | 1 |
| Zhang, G | 1 |
| Zhang, Q | 4 |
| Chambers, NE | 1 |
| Sergio, J | 1 |
| Lanza, K | 1 |
| Saito, C | 1 |
| Topping, B | 1 |
| Clark, SD | 2 |
| Umemoto, H | 1 |
| Yasugi, S | 1 |
| Tsuda, S | 1 |
| Yoda, M | 1 |
| Ishiguro, T | 1 |
| Kaba, N | 1 |
| Itoh, T | 1 |
| Chang, KA | 3 |
| Pichla, M | 1 |
| Bartosz, G | 1 |
| Stefaniuk, I | 1 |
| Sadowska-Bartosz, I | 1 |
| Hou, YF | 1 |
| Shan, C | 2 |
| Zhuang, SY | 1 |
| Zhuang, QQ | 1 |
| Ghosh, A | 1 |
| Zhu, KC | 1 |
| Kong, XK | 1 |
| Wang, SM | 2 |
| Gong, YL | 1 |
| Yang, YY | 1 |
| Tao, B | 2 |
| Sun, LH | 1 |
| Zhao, HY | 1 |
| Guo, XZ | 1 |
| Wang, WQ | 1 |
| Ning, G | 1 |
| Gu, YY | 1 |
| Li, ST | 1 |
| Liu, JM | 1 |
| Fiametti, LO | 1 |
| Correa, CN | 1 |
| Castro, LM | 1 |
| Mahoney, E | 1 |
| Kao, TJ | 1 |
| Mamone, G | 1 |
| Mikkilineni, S | 1 |
| Ravi, M | 1 |
| Watkins, H | 1 |
| Terrelonge, DL | 1 |
| Martin, C | 1 |
| Unger, K | 1 |
| Kim, G | 1 |
| Fiber, K | 1 |
| Indajang, J | 1 |
| Sachs, N | 1 |
| Feustel, P | 2 |
| McQuade, RM | 1 |
| Singleton, LM | 1 |
| Lee, S | 2 |
| Constable, R | 1 |
| Di Natale, M | 1 |
| Ringuet, MT | 1 |
| Berger, JP | 1 |
| Kauhausen, J | 1 |
| Parish, CL | 2 |
| Finkelstein, DI | 2 |
| Furness, JB | 1 |
| Diwakarla, S | 1 |
| Wang, YL | 2 |
| Mao, JP | 1 |
| Jiang, S | 2 |
| Yang, XL | 1 |
| Komeili, G | 1 |
| Haghparast, E | 1 |
| Sheibani, V | 2 |
| Abuhamdah, SM | 1 |
| Ashraf, A | 1 |
| Chang, JC | 2 |
| Chao, YC | 1 |
| Chang, HS | 1 |
| Wu, YL | 1 |
| Chang, HJ | 1 |
| Lin, YS | 1 |
| Cheng, WL | 1 |
| Lin, TT | 1 |
| Liu, CS | 3 |
| Valkonen, K | 1 |
| Maegawa, H | 2 |
| Niwa, H | 2 |
| Kumari, M | 2 |
| Kutty, MK | 1 |
| Zarrin, P | 1 |
| Dehghani Ashkezari, M | 1 |
| Seifati, SM | 1 |
| Chiang, PK | 1 |
| Zheng, CQ | 1 |
| Fan, HX | 1 |
| Li, XX | 1 |
| Li, JJ | 1 |
| Sheng, S | 1 |
| Zhang, F | 2 |
| Ivashko-Pachima, Y | 1 |
| Seroogy, KB | 1 |
| Sharabi, Y | 1 |
| Gozes, I | 2 |
| Ghasemloo, E | 1 |
| Hosseini, M | 2 |
| Mousavi, SS | 1 |
| Antipova, V | 1 |
| Holzmann, C | 1 |
| Hawlitschka, A | 1 |
| Witt, M | 1 |
| Wree, A | 4 |
| Tekriwal, A | 1 |
| Lintz, MJ | 1 |
| Thompson, JA | 1 |
| Felsen, G | 1 |
| Chalorak, P | 2 |
| Sanguanphun, T | 1 |
| Limboonreung, T | 1 |
| Meemon, K | 2 |
| Ma, YF | 1 |
| Lin, YA | 1 |
| Huang, CL | 1 |
| Hsu, CC | 1 |
| Wang, S | 4 |
| Yeh, SR | 1 |
| Tsai, YC | 1 |
| Wang, CT | 1 |
| Zhang, XQ | 1 |
| Zhang, CY | 2 |
| Lv, DJ | 1 |
| Yang, YP | 2 |
| Xia, KL | 1 |
| Liu, JY | 2 |
| Hu, LF | 2 |
| Xu, GY | 1 |
| Zuo, F | 1 |
| Xiong, F | 1 |
| Ge, W | 1 |
| Ay, M | 2 |
| Langley, M | 1 |
| Anantharam, V | 4 |
| Kanthasamy, A | 4 |
| Kanthasamy, AG | 4 |
| Xie, MQ | 1 |
| Chen, ZC | 1 |
| Huang, HJ | 1 |
| Wang, TT | 1 |
| Ding, YQ | 1 |
| Qi, SS | 1 |
| Zhang, C | 1 |
| Chen, SX | 1 |
| Zhou, P | 2 |
| Shao, CC | 1 |
| Liao, M | 1 |
| Sun, CY | 1 |
| Leikas, JV | 1 |
| Kohtala, S | 1 |
| Theilmann, W | 1 |
| Rantamäki, T | 1 |
| Guo, X | 1 |
| Liu, T | 3 |
| Zhao, D | 3 |
| Kong, Y | 1 |
| Hu, W | 1 |
| Zhao, H | 5 |
| Ketzef, M | 1 |
| Spigolon, G | 2 |
| Johansson, Y | 1 |
| Bonito-Oliva, A | 2 |
| Fisone, G | 4 |
| Silberberg, G | 1 |
| Taouki, I | 1 |
| Tasiudi, E | 1 |
| Lalioti, ME | 1 |
| Kyrousi, C | 1 |
| Skavatsou, E | 1 |
| Kaplani, K | 1 |
| Lygerou, Z | 1 |
| Kouvelas, ED | 2 |
| Mitsacos, A | 2 |
| Giompres, P | 2 |
| Taraviras, S | 2 |
| Wei, X | 3 |
| Fu, Y | 4 |
| Jenner, P | 13 |
| Lu, JH | 2 |
| Tang, B | 2 |
| Jin, K | 1 |
| Chotibut, T | 2 |
| Meadows, S | 1 |
| McInnis, T | 1 |
| Cantu, MA | 1 |
| La Cognata, V | 1 |
| Maugeri, G | 1 |
| D'Amico, AG | 1 |
| Saccone, S | 1 |
| Federico, C | 1 |
| Cavallaro, S | 1 |
| D'Agata, V | 1 |
| Ashrafi, A | 1 |
| Garcia, P | 1 |
| Kollmus, H | 1 |
| Schughart, K | 1 |
| Del Sol, A | 1 |
| Buttini, M | 1 |
| Glaab, E | 1 |
| Hadadianpour, Z | 1 |
| Fatehi, F | 1 |
| Ayoobi, F | 1 |
| Kaeidi, A | 1 |
| Slominsky, PA | 1 |
| Shadrina, MI | 1 |
| Kolomin, TA | 1 |
| Stavrovskaya, AV | 1 |
| Filatova, EV | 1 |
| Andreeva, LA | 1 |
| Illarioshkin, SN | 1 |
| Myasoedov, NF | 1 |
| Prajapati, P | 1 |
| Sripada, L | 1 |
| Singh, K | 1 |
| Roy, M | 1 |
| Bhatelia, K | 1 |
| Dalwadi, P | 1 |
| Singh, R | 1 |
| McCabe, K | 1 |
| Concannon, RM | 1 |
| McKernan, DP | 1 |
| Dowd, E | 6 |
| Rumpel, R | 3 |
| Schwarz, LM | 1 |
| Ratzka, A | 4 |
| Jin, X | 2 |
| Grothe, C | 5 |
| Garcia, PC | 2 |
| Xiao, H | 5 |
| Li, N | 2 |
| Wen, P | 4 |
| Xie, Z | 3 |
| Chang, J | 4 |
| Luo, F | 5 |
| Gasparotto, J | 1 |
| Ribeiro, CT | 1 |
| Bortolin, RC | 1 |
| Somensi, N | 1 |
| Rabelo, TK | 1 |
| Kunzler, A | 1 |
| Souza, NC | 1 |
| Pasquali, MAB | 1 |
| Moreira, JCF | 1 |
| Gelain, DP | 2 |
| Quiroga-Varela, A | 3 |
| Aguilar, E | 3 |
| Iglesias, E | 2 |
| Obeso, JA | 5 |
| Marin, C | 7 |
| Kumar, S | 2 |
| Krishnamurthy, S | 1 |
| Joventino, IP | 1 |
| Joventino, FP | 1 |
| de Almeida, AC | 1 |
| do Carmo, MR | 1 |
| Leal, LKAM | 2 |
| de Andrade, GM | 1 |
| Matsui, H | 1 |
| Sugie, A | 1 |
| Chu, HY | 2 |
| McIver, EL | 2 |
| Kovaleski, RF | 1 |
| Atherton, JF | 2 |
| Bevan, MD | 3 |
| Chierchia, A | 1 |
| Chirico, N | 1 |
| Boeri, L | 1 |
| Raimondi, I | 1 |
| Riva, GA | 1 |
| Raimondi, MT | 1 |
| Tunesi, M | 1 |
| Giordano, C | 1 |
| Forloni, G | 2 |
| Albani, D | 2 |
| Su, WT | 1 |
| Wang, XM | 3 |
| Zhou, B | 1 |
| Wen, M | 1 |
| Lin, X | 4 |
| Gou, Y | 1 |
| Li, HW | 1 |
| Tang, L | 1 |
| Morales, I | 2 |
| Sanchez, A | 2 |
| Rodriguez-Sabate, C | 2 |
| Rodriguez, M | 3 |
| Gine, E | 1 |
| Hernandez-Encinas, E | 1 |
| Aguilar-Morante, D | 1 |
| Sanchez-Lanzas, R | 1 |
| Castaño, JG | 1 |
| Crabbé, M | 1 |
| Van der Perren, A | 2 |
| Weerasekera, A | 1 |
| Himmelreich, U | 1 |
| Baekelandt, V | 3 |
| Van Laere, K | 2 |
| Casteels, C | 2 |
| Scholpa, NE | 1 |
| Lynn, MK | 1 |
| Corum, D | 1 |
| Boger, HA | 2 |
| Schnellmann, RG | 1 |
| Tan, R | 1 |
| Bölükbaşi Hatip, F | 1 |
| Açikalin, Ö | 1 |
| Yamauchi, A | 1 |
| Kataoka, Y | 1 |
| Hatip-Al-Khatib, I | 1 |
| Ju, B | 1 |
| Zhang, YZ | 1 |
| Yin, HL | 1 |
| Liu, YJ | 1 |
| Wang, SS | 1 |
| Zeng, ZL | 1 |
| Yang, XP | 1 |
| Wang, HT | 1 |
| Li, JF | 1 |
| Cronin, A | 1 |
| Grealy, M | 1 |
| Bonilla-Porras, AR | 1 |
| Arevalo-Arbelaez, A | 1 |
| Alzate-Restrepo, JF | 1 |
| Velez-Pardo, C | 1 |
| Jimenez-Del-Rio, M | 1 |
| Kim, SM | 2 |
| Park, YJ | 1 |
| Shin, MS | 1 |
| Kim, HR | 1 |
| Kim, MJ | 2 |
| Lee, SH | 4 |
| Yun, SP | 1 |
| Baluchnejadmojarad, T | 5 |
| Eftekhari, SM | 1 |
| Jamali-Raeufy, N | 2 |
| Haghani, S | 1 |
| Zeinali, H | 1 |
| Roghani, M | 5 |
| Zhu, J | 8 |
| Zhao, YX | 1 |
| Johnston, TH | 1 |
| Versi, E | 1 |
| Howson, PA | 1 |
| Ravenscroft, P | 3 |
| Fox, SH | 1 |
| Hill, MP | 2 |
| Reidenberg, BE | 1 |
| Corey, R | 1 |
| Brotchie, JM | 4 |
| Padmanabhan, S | 1 |
| Burke, RE | 4 |
| Sarookhani, MR | 1 |
| Sarbazi-Golezari, A | 1 |
| Babayan-Tazehkand, A | 2 |
| Jiang, Y | 4 |
| Mu, H | 1 |
| Hua, H | 1 |
| Duan, D | 1 |
| Yan, X | 1 |
| Meng, Q | 1 |
| Wang, A | 1 |
| Sun, K | 1 |
| Lima, JC | 1 |
| Botelho, MT | 1 |
| Morroni, F | 4 |
| Sita, G | 4 |
| Djemil, A | 2 |
| D'Amico, M | 1 |
| Pruccoli, L | 1 |
| Cantelli-Forti, G | 4 |
| Hrelia, P | 4 |
| Tarozzi, A | 4 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Bharti, S | 1 |
| Singh, J | 1 |
| Tsai, RT | 1 |
| Liu, SP | 2 |
| Chen, CS | 2 |
| Tsai, MC | 1 |
| Chien, SH | 1 |
| Hung, HS | 2 |
| Lin, SZ | 4 |
| Shyu, WC | 2 |
| Garrido-Gil, P | 2 |
| Dominguez-Meijide, A | 2 |
| Guerra, MJ | 4 |
| Wu, M | 1 |
| Hu, JM | 1 |
| Hsueh, SC | 1 |
| Lai, JH | 1 |
| Wu, CC | 1 |
| Yu, YW | 1 |
| Luo, Y | 2 |
| Chiang, YH | 2 |
| Aimé, P | 1 |
| Dai, D | 1 |
| Ramalingam, N | 1 |
| Crary, JF | 1 |
| Greene, LA | 8 |
| Levy, OA | 2 |
| Zhu, Z | 1 |
| Ding, X | 1 |
| Cui, G | 3 |
| Hua, F | 2 |
| Xiang, J | 2 |
| Haddadi, H | 1 |
| Rajaei, Z | 2 |
| Shahidani, S | 1 |
| Nogueira, PCN | 1 |
| Santos, ADC | 1 |
| Costa, RO | 1 |
| Jataí Gadelha-Filho, CV | 1 |
| Silveira, ER | 1 |
| Viana, GSB | 1 |
| Caro Aponte, PA | 1 |
| Otálora, CA | 1 |
| Guzmán, JC | 1 |
| Turner, LF | 1 |
| Alcázar, JP | 1 |
| Mayorga, EL | 1 |
| Sharma, D | 1 |
| Zhang, N | 1 |
| Wu, S | 2 |
| Duan, J | 2 |
| Wang, W | 4 |
| Song, H | 1 |
| Tong, J | 1 |
| Han, F | 2 |
| Wongtrakul, J | 1 |
| Saisawang, C | 1 |
| Kumrapich, B | 1 |
| Wipasa, J | 1 |
| Roytrakul, S | 1 |
| Ketterman, AJ | 1 |
| Marshall, CA | 1 |
| King, KM | 1 |
| Kortagere, S | 1 |
| Tamano, H | 1 |
| Nishio, R | 1 |
| Morioka, H | 1 |
| Takeda, A | 1 |
| Sarukhani, M | 1 |
| Sarbazi Golezari, A | 1 |
| Dargahi, T | 2 |
| Nayebi, AM | 3 |
| Aly, AE | 1 |
| Harmon, BT | 1 |
| Padegimas, L | 1 |
| Sesenoglu-Laird, O | 1 |
| Cooper, MJ | 1 |
| Waszczak, BL | 2 |
| Du, TT | 1 |
| Chen, YC | 1 |
| Lu, YQ | 1 |
| Meng, FG | 1 |
| Zhang, JG | 1 |
| Xi, Y | 1 |
| Feng, D | 2 |
| Tao, K | 2 |
| Qin, H | 1 |
| Murphy, MP | 2 |
| Yang, Q | 4 |
| Kim, HW | 1 |
| Lee, HS | 1 |
| Kang, JM | 1 |
| Bae, SH | 1 |
| Kim, C | 1 |
| Schwarz, J | 2 |
| Kim, GJ | 1 |
| Kim, JS | 1 |
| Cha, DH | 1 |
| Chang, SW | 2 |
| Lee, TH | 1 |
| Moon, J | 2 |
| Lu, F | 1 |
| Zhu, G | 2 |
| Nie, T | 1 |
| Huang, L | 2 |
| Eftekhar-Vaghefi, SH | 1 |
| Asadi-Shekaari, M | 1 |
| Esmaeili-Mahani, S | 2 |
| Segura-Aguilar, J | 1 |
| Dos-Santos-Pereira, M | 2 |
| Raisman-Vozari, R | 1 |
| Tumas, V | 2 |
| Del Bel, E | 1 |
| Niu, J | 2 |
| Xie, J | 5 |
| Guo, K | 1 |
| Xia, F | 1 |
| Zhuge, D | 1 |
| Zhao, Y | 3 |
| Na, S | 1 |
| Li, K | 1 |
| Yang, Z | 2 |
| Xie, X | 1 |
| Yue, J | 1 |
| Moriarty, N | 1 |
| Cabré, S | 1 |
| Alamilla, V | 1 |
| Pandit, A | 1 |
| Fernandes-Junior, SA | 1 |
| Carvalho, KS | 1 |
| Cheng, S | 1 |
| Tereshchenko, J | 2 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 4 |
| Konstantinova, P | 1 |
| Déglon, N | 2 |
| Kügler, S | 2 |
| Chung, S | 2 |
| Son, GH | 1 |
| Rhee, K | 1 |
| Zhang, YM | 2 |
| Du, CX | 1 |
| Zhang, J | 3 |
| Lv, SX | 1 |
| Wang, XS | 1 |
| Zhang, ZR | 1 |
| Chen, SY | 1 |
| Shao, B | 1 |
| Chu, J | 1 |
| Han, W | 1 |
| Anis, E | 1 |
| Zafeer, MF | 1 |
| Firdaus, F | 1 |
| Islam, SN | 1 |
| Fatima, M | 1 |
| Mobarak Hossain, M | 1 |
| Perlbarg, V | 1 |
| Lambert, J | 1 |
| Butler, B | 1 |
| Felfli, M | 1 |
| Valabrègue, R | 1 |
| Privat, AL | 1 |
| Lehéricy, S | 1 |
| Petiet, A | 1 |
| Chen, HH | 2 |
| Chang, PC | 1 |
| Wey, SP | 1 |
| Chen, PM | 1 |
| Chan, MH | 1 |
| Su, J | 1 |
| Huang, P | 1 |
| Qin, M | 1 |
| Sang, X | 1 |
| Cai, Y | 1 |
| Liu, F | 2 |
| Wu, R | 1 |
| Sun, Q | 1 |
| Gardoni, F | 4 |
| Morari, M | 6 |
| Kulisevsky, J | 2 |
| Brugnoli, A | 2 |
| Novello, S | 1 |
| Pisanò, CA | 1 |
| Caccia, C | 1 |
| Mellone, M | 4 |
| Melloni, E | 1 |
| Padoani, G | 1 |
| Sosti, V | 1 |
| Vailati, S | 1 |
| Keywood, C | 1 |
| Hernando, S | 1 |
| Requejo, C | 1 |
| Herran, E | 1 |
| Ruiz-Ortega, JA | 2 |
| Lafuente, JV | 1 |
| Gainza, E | 1 |
| Pedraz, JL | 1 |
| Igartua, M | 1 |
| Hernandez, RM | 1 |
| Cao, Z | 1 |
| Ma, H | 2 |
| Feng, T | 1 |
| Omura, T | 1 |
| Matsuda, H | 1 |
| Nomura, L | 1 |
| Imai, S | 1 |
| Denda, M | 1 |
| Nakagawa, S | 1 |
| Yonezawa, A | 1 |
| Nakagawa, T | 2 |
| Yano, I | 1 |
| Matsubara, K | 1 |
| Vetel, S | 1 |
| Sérrière, S | 1 |
| Vercouillie, J | 1 |
| Vergote, J | 3 |
| Chicheri, G | 1 |
| Deloye, JB | 1 |
| Dollé, F | 2 |
| Bodard, S | 2 |
| Tronel, C | 1 |
| Nadal-Desbarats, L | 1 |
| Lefèvre, A | 1 |
| Emond, P | 1 |
| Chalon, S | 3 |
| Klissurov, R | 1 |
| Stoeva, S | 1 |
| Pajpanova, T | 1 |
| Ikeda-Matsuo, Y | 1 |
| Miyata, H | 1 |
| Mizoguchi, T | 1 |
| Ohama, E | 1 |
| Naito, Y | 1 |
| Uematsu, S | 1 |
| Akira, S | 1 |
| Sasaki, Y | 1 |
| Tanabe, M | 1 |
| Salari, S | 1 |
| Bagheri, M | 1 |
| Quintino, L | 1 |
| Avallone, M | 1 |
| Brännstrom, E | 1 |
| Kavanagh, P | 1 |
| Lockowandt, M | 1 |
| Garcia Jareño, P | 1 |
| Breger, LS | 1 |
| Lundberg, C | 2 |
| Kang, C | 1 |
| Kang, M | 1 |
| Gao, J | 1 |
| Varier, KM | 1 |
| Sumathi, T | 1 |
| Ning, B | 1 |
| Deng, M | 1 |
| Fang, Y | 1 |
| Casarrubea, M | 1 |
| Crescimanno, G | 2 |
| Aiello, S | 1 |
| Santangelo, A | 1 |
| Busatta, D | 1 |
| Cassioli, E | 1 |
| Sun, C | 2 |
| Shao, Y | 1 |
| Zhou, Z | 1 |
| Li, A | 1 |
| Dzirkale, Z | 1 |
| Tunaitis, V | 2 |
| Jarmalavičiūtė, A | 2 |
| Jansone, B | 1 |
| Feyzollahzadeh, S | 1 |
| Yu, C | 1 |
| Guo, M | 2 |
| Zheng, X | 1 |
| Ali, S | 1 |
| Huang, H | 1 |
| Zhang, L | 7 |
| Qie, S | 1 |
| Pain, S | 2 |
| Gulhan, Z | 1 |
| Kaszuba, BC | 1 |
| Maietta, T | 1 |
| Walling, I | 2 |
| Stapleton, A | 1 |
| Slyer, J | 1 |
| Park, J | 1 |
| Leem, H | 1 |
| Cho, M | 1 |
| Ucar, B | 1 |
| Humpel, C | 1 |
| Callizot, N | 1 |
| Combes, M | 1 |
| Henriques, A | 1 |
| Poindron, P | 1 |
| Yan, Y | 1 |
| Shi, K | 1 |
| Hou, L | 1 |
| Qiao, D | 1 |
| Gaba, B | 1 |
| Khan, T | 1 |
| Haider, MF | 1 |
| Alam, T | 1 |
| Machado, MMF | 1 |
| Bassani, TB | 2 |
| Cóppola-Segovia, V | 1 |
| Moura, ELR | 1 |
| Zanata, SM | 1 |
| Vieira, JCF | 1 |
| Santiago, RM | 1 |
| de O Guaita, G | 1 |
| Zanoveli, JM | 1 |
| Feng, CW | 1 |
| Chen, NF | 1 |
| Wen, ZH | 1 |
| Yang, WY | 1 |
| Kuo, HM | 1 |
| Sung, PJ | 1 |
| Su, JH | 1 |
| Cheng, SY | 1 |
| Chen, WF | 2 |
| Wang, YC | 2 |
| Chang, CY | 1 |
| Hsieh, W | 1 |
| Yang, CS | 1 |
| Fletcher, EJR | 1 |
| Jamieson, AD | 1 |
| Williams, G | 1 |
| Doherty, P | 1 |
| Duty, S | 2 |
| Sun, F | 1 |
| Deng, Y | 2 |
| Han, X | 1 |
| Liu, Q | 3 |
| Manzoor, R | 1 |
| Yuan, L | 1 |
| Hu, K | 1 |
| Betharia, S | 1 |
| Rondόn-Ortiz, AN | 1 |
| Brown, DA | 1 |
| Schor, JS | 1 |
| Nelson, AB | 1 |
| Dudka, I | 1 |
| Yan, J | 3 |
| Zhao, N | 1 |
| Marques, NF | 1 |
| Binder, LB | 1 |
| Roversi, K | 1 |
| Sampaio, TB | 1 |
| Constantino, LC | 1 |
| Prediger, RD | 1 |
| Tasca, CI | 1 |
| Huang, N | 1 |
| Chen, M | 1 |
| Nie, J | 1 |
| Shi, J | 1 |
| Jin, F | 2 |
| Farrand, AQ | 1 |
| Helke, KL | 1 |
| Aponte-Cofresí, L | 1 |
| Gooz, MB | 1 |
| Gregory, RA | 1 |
| Hinson, VK | 1 |
| Eskandarian Boroujeni, M | 1 |
| Aliaghaei, A | 1 |
| Gardaneh, M | 2 |
| Boi, L | 1 |
| Pisanu, A | 1 |
| Scerba, MT | 1 |
| Tweedie, D | 1 |
| Mulas, G | 2 |
| Fenu, S | 3 |
| Carboni, E | 2 |
| Spiga, S | 2 |
| Carta, AR | 5 |
| Cosgrove, KE | 1 |
| Kondapalli, J | 1 |
| Lee, J | 5 |
| Pinares-Garcia, P | 1 |
| Loke, H | 1 |
| Vilain, E | 1 |
| Harley, VR | 1 |
| Eo, H | 1 |
| Kwon, Y | 1 |
| Sim, Y | 1 |
| Choi, JG | 3 |
| Jeong, JS | 1 |
| Du, XF | 1 |
| Soh, HY | 1 |
| Hong, SP | 1 |
| Kim Pak, Y | 1 |
| Mansouri, MT | 1 |
| Sameri, MJ | 1 |
| Naghizadeh, B | 1 |
| Rafeirad, M | 1 |
| Susín, C | 1 |
| Pérez, DI | 1 |
| Palomo, V | 1 |
| Pérez, C | 1 |
| Conde, S | 1 |
| Gil, C | 1 |
| Reinhardt, P | 1 |
| Schmid, B | 2 |
| Burbulla, LF | 1 |
| Schöndorf, DC | 1 |
| Wagner, L | 1 |
| Glatza, M | 1 |
| Höing, S | 1 |
| Hargus, G | 1 |
| Heck, SA | 1 |
| Dhingra, A | 1 |
| Wu, G | 1 |
| Müller, S | 1 |
| Brockmann, K | 1 |
| Kluba, T | 1 |
| Maisel, M | 1 |
| Krüger, R | 1 |
| Berg, D | 3 |
| Tsytsyura, Y | 1 |
| Thiel, CS | 1 |
| Psathaki, OE | 1 |
| Klingauf, J | 1 |
| Kuhlmann, T | 1 |
| Klewin, M | 1 |
| Müller, H | 1 |
| Gasser, T | 2 |
| Schöler, HR | 1 |
| Sterneckert, J | 1 |
| Frau, L | 2 |
| Morelli, M | 7 |
| Simola, N | 4 |
| Shi, Z | 1 |
| Zhao-Wilson, X | 1 |
| Guan, P | 1 |
| Duan, X | 1 |
| Chang, YZ | 1 |
| Zhao, B | 4 |
| Bolondi, C | 2 |
| Zolezzi Moraga, JM | 1 |
| Liu, TW | 1 |
| Ma, ZG | 1 |
| Xie, JX | 3 |
| Lev, N | 2 |
| Barhum, Y | 3 |
| Ben-Zur, T | 1 |
| Melamed, E | 6 |
| Steiner, I | 1 |
| Offen, D | 6 |
| Chong, CM | 1 |
| Zhou, ZY | 1 |
| Razmovski-Naumovski, V | 1 |
| Cui, GZ | 1 |
| Zhang, LQ | 1 |
| Sa, F | 1 |
| Hoi, PM | 1 |
| Chan, K | 1 |
| Lee, SM | 3 |
| Long-Smith, CM | 1 |
| Wyatt, SL | 1 |
| Toulouse, A | 2 |
| Nolan, YM | 2 |
| Lazzarini, M | 1 |
| Martin, S | 1 |
| Mitkovski, M | 1 |
| Vozari, RR | 1 |
| Stühmer, W | 1 |
| Bel, ED | 1 |
| Landers, MR | 1 |
| Kinney, JW | 1 |
| Allen, DN | 1 |
| van Breukelen, F | 1 |
| Jin, W | 1 |
| Sun, HM | 1 |
| Yan, JH | 1 |
| Xue, H | 1 |
| Dong, F | 1 |
| Li, WS | 1 |
| Ji, FQ | 1 |
| Zhou, DS | 1 |
| Im, HJ | 1 |
| Lee, HK | 1 |
| Jang, J | 1 |
| Youn, H | 1 |
| Jin, Y | 1 |
| Kim, SU | 1 |
| Kim, EE | 1 |
| Kim, YS | 3 |
| Chan, HH | 1 |
| Zhuo, L | 1 |
| Tsai, MJ | 1 |
| Weng, CF | 1 |
| Yu, NC | 1 |
| Liou, DY | 1 |
| Kuo, FS | 1 |
| Huang, MC | 1 |
| Huang, WC | 1 |
| Tam, K | 1 |
| Shyue, SK | 1 |
| Cheng, H | 1 |
| Zhu, HY | 2 |
| Pei, X | 3 |
| Wu, LY | 3 |
| Qi, ZM | 2 |
| Wang, YY | 2 |
| Liu, B | 2 |
| Zhou, HG | 1 |
| Confalone, G | 1 |
| Sciarra, A | 1 |
| Sotgiu, A | 1 |
| Kuruvilla, KP | 1 |
| Nandhu, MS | 1 |
| Paul, J | 1 |
| Paulose, CS | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 3 |
| Schnitzler, A | 1 |
| Walters, JR | 3 |
| Brazhnik, E | 2 |
| Tripanichkul, W | 1 |
| Jaroensuppaperch, EO | 1 |
| Ciucci, MR | 2 |
| Schaser, AJ | 1 |
| Russell, JA | 1 |
| Han, B | 3 |
| Shen, J | 3 |
| Gao, Y | 3 |
| Jiang, D | 1 |
| Shi, S | 1 |
| Liu, L | 2 |
| Ding, B | 1 |
| Yagnik, G | 1 |
| Zhou, F | 1 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| Xiong, Y | 2 |
| Gao, DS | 2 |
| Zhang, S | 7 |
| Xue, ZF | 1 |
| Huang, LP | 2 |
| Fang, RM | 1 |
| He, YP | 2 |
| Fang, YQ | 2 |
| Virgone-Carlotta, A | 1 |
| Uhlrich, J | 1 |
| Akram, MN | 1 |
| Ressnikoff, D | 1 |
| Chrétien, F | 1 |
| Domenget, C | 1 |
| Gherardi, R | 1 |
| Despars, G | 1 |
| Jurdic, P | 1 |
| Honnorat, J | 1 |
| Nataf, S | 2 |
| Touret, M | 2 |
| Santra, S | 1 |
| Xu, L | 3 |
| Shah, M | 2 |
| Johnson, M | 1 |
| Dutta, A | 1 |
| Heuer, A | 2 |
| Klein, A | 6 |
| Vinh, NN | 1 |
| Özer, M | 2 |
| Wesemann, M | 3 |
| Zachrisson, O | 2 |
| Zhao, M | 1 |
| Andersson, A | 1 |
| Dannaeus, K | 1 |
| Häggblad, J | 2 |
| Isacson, R | 1 |
| Nielsen, E | 1 |
| Patrone, C | 1 |
| Rönnholm, H | 1 |
| Wikstrom, L | 1 |
| Delfani, K | 1 |
| McCormack, AL | 1 |
| Palmer, T | 1 |
| Di Monte, DA | 1 |
| Janson Lang, AM | 1 |
| Haegerstrand, A | 1 |
| Plowman, EK | 1 |
| Thomas, NJ | 1 |
| Kleim, JA | 2 |
| Lopez, S | 2 |
| Pallottino, S | 1 |
| Acher, F | 1 |
| Feng, Mj | 1 |
| Takeshima, M | 2 |
| Torigoe, N | 1 |
| Miyoshi, K | 2 |
| Gunjima, K | 1 |
| Tomiyama, R | 1 |
| Takakura, K | 1 |
| Yamada, T | 1 |
| Hashida, K | 1 |
| Konishi, T | 1 |
| Matsugo, S | 1 |
| Hori, O | 2 |
| Campeau, L | 1 |
| Soler, R | 2 |
| Sittadjody, S | 1 |
| Pareta, R | 1 |
| Nomiya, M | 1 |
| Zarifpour, M | 1 |
| Opara, EC | 1 |
| Yoo, JJ | 1 |
| Andersson, KE | 2 |
| Chetrit, J | 1 |
| Taupignon, A | 1 |
| Froux, L | 1 |
| Morin, S | 1 |
| Bouali-Benazzouz, R | 1 |
| Kadiri, N | 1 |
| Gross, CE | 3 |
| Bioulac, B | 1 |
| Park, HJ | 4 |
| Park, KH | 2 |
| Shin, KS | 2 |
| Lee, MK | 2 |
| Lobb, CJ | 1 |
| Zaheer, AK | 1 |
| Smith, Y | 1 |
| Jaeger, D | 2 |
| Hernandes, MS | 2 |
| Santos, GD | 1 |
| Café-Mendes, CC | 2 |
| Lima, LS | 1 |
| Scavone, C | 1 |
| González-Aparicio, R | 1 |
| Gao, L | 2 |
| She, H | 1 |
| Zeng, J | 1 |
| Jones, DP | 1 |
| Gao, G | 2 |
| Francardo, V | 3 |
| Aureli, C | 1 |
| Cassano, T | 3 |
| Masci, A | 1 |
| Francioso, A | 1 |
| Martire, S | 1 |
| Cocciolo, A | 1 |
| Chichiarelli, S | 1 |
| Romano, A | 1 |
| Gaetani, S | 1 |
| Mancini, P | 1 |
| Fontana, M | 1 |
| d'Erme, M | 1 |
| Mosca, L | 1 |
| Yue, X | 2 |
| Hariri, DJ | 1 |
| Caballero, B | 1 |
| Kaut, O | 1 |
| Mount, DW | 1 |
| Wüllner, U | 3 |
| Yamamoto, T | 1 |
| Uchiyama, T | 1 |
| Sakakibara, R | 1 |
| Taniguchi, J | 1 |
| Kuwabara, S | 1 |
| Szkilnik, R | 3 |
| Brus, R | 3 |
| Malinowska-Borowska, J | 1 |
| Nowak, D | 1 |
| Waliczek, M | 1 |
| Nowak, P | 4 |
| Guo, B | 1 |
| Xu, D | 1 |
| Duan, H | 1 |
| Du, J | 1 |
| Stott, SRW | 1 |
| Barker, RA | 2 |
| Gavin, AM | 1 |
| Walsh, S | 3 |
| Wyatt, S | 2 |
| Bao, XQ | 1 |
| Kong, XC | 1 |
| Kong, LB | 1 |
| Sun, H | 2 |
| Lin, L | 4 |
| Du, Y | 1 |
| Yuan, S | 1 |
| Zheng, Z | 1 |
| Mo, SJ | 1 |
| Feng, QQ | 1 |
| Zhan, ML | 1 |
| OuYang, LS | 1 |
| Chen, JC | 1 |
| Ma, YX | 1 |
| Wu, JJ | 2 |
| Lei, WL | 1 |
| Harn, HJ | 1 |
| Chang, WL | 1 |
| Chen, YM | 1 |
| Huang, JE | 1 |
| Li, RJ | 1 |
| Tsai, SY | 1 |
| Maddalena, A | 1 |
| Song, J | 2 |
| Zheng, L | 3 |
| Feng, X | 2 |
| Fan, R | 2 |
| Hong, F | 2 |
| Willis, GL | 5 |
| Moore, C | 3 |
| Armstrong, SM | 2 |
| Darvas, M | 1 |
| Henschen, CW | 1 |
| Palmiter, RD | 1 |
| Machado-Filho, JA | 1 |
| Correia, AO | 1 |
| Montenegro, AB | 1 |
| Nobre, ME | 1 |
| Cerqueira, GS | 1 |
| Neves, KR | 1 |
| Naffah-Mazzacoratti, Mda G | 1 |
| Cavalheiro, EA | 1 |
| de Castro Brito, GA | 1 |
| Shukla, A | 2 |
| Mohapatra, TM | 1 |
| Parmar, D | 1 |
| Seth, K | 4 |
| Kim, W | 1 |
| McKenna, ND | 1 |
| Yi, M | 1 |
| Simunovic, F | 1 |
| Kong, B | 1 |
| Rooney, RJ | 1 |
| Seo, H | 1 |
| Stephens, RM | 1 |
| Sonntag, KC | 1 |
| Schlachetzki, JC | 1 |
| Marxreiter, F | 1 |
| Regensburger, M | 1 |
| Kulinich, A | 1 |
| Winner, B | 1 |
| Winkler, J | 1 |
| Liao, J | 1 |
| Qin, B | 1 |
| Deng, C | 2 |
| Huang, XF | 2 |
| Grieb, B | 1 |
| Engler, G | 1 |
| Sharott, A | 1 |
| von Nicolai, C | 1 |
| Streichert, T | 1 |
| Papageorgiou, I | 1 |
| Schulte, A | 1 |
| Westphal, M | 1 |
| Lamszus, K | 1 |
| Engel, AK | 1 |
| Moll, CK | 1 |
| Hamel, W | 1 |
| Gavin, A | 1 |
| O'Connor, C | 1 |
| Keeshan, K | 1 |
| Doo, AR | 1 |
| Kim, SN | 1 |
| Hahm, DH | 1 |
| Yoo, HH | 1 |
| Park, JY | 1 |
| Lee, H | 1 |
| Jeon, S | 1 |
| Park, SU | 1 |
| Fieblinger, T | 1 |
| Sebastianutto, I | 2 |
| Alcacer, C | 1 |
| Bimpisidis, Z | 2 |
| Maslava, N | 2 |
| Sandberg, S | 1 |
| Engblom, D | 1 |
| Budzinska, K | 2 |
| Farajniya, S | 1 |
| Brooshghalan, SE | 1 |
| Sharifi, H | 2 |
| Ye, Y | 1 |
| Ren, Q | 1 |
| Xu, C | 2 |
| Zhou, Q | 1 |
| Huang, S | 2 |
| Shin, E | 2 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Oeckl, P | 1 |
| Hengerer, B | 1 |
| Ferger, B | 2 |
| Valdés, P | 1 |
| Mercado, G | 1 |
| Vidal, RL | 1 |
| Molina, C | 1 |
| Parsons, G | 1 |
| Galleguillos, D | 1 |
| Armentano, D | 1 |
| Schneider, BL | 2 |
| Büchele, F | 1 |
| Döbrössy, M | 3 |
| Hackl, C | 1 |
| Jiang, W | 2 |
| Papazoglou, A | 4 |
| Nikkhah, G | 10 |
| Farajnia, S | 1 |
| Kim, DH | 2 |
| Lee, IH | 2 |
| Nam, ST | 1 |
| Hong, J | 2 |
| Hwang, JS | 1 |
| Seok, H | 1 |
| Choi, H | 1 |
| Lee, DG | 1 |
| Kim, JI | 1 |
| Asaithambi, A | 1 |
| Gosh, A | 1 |
| Sánchez-González, A | 1 |
| Mendieta, L | 1 |
| Palafox, V | 1 |
| Candalija, A | 1 |
| Luna, F | 1 |
| Aguilera, J | 1 |
| Limón, ID | 1 |
| Takeda, R | 1 |
| Ishida, Y | 3 |
| Ebihara, K | 1 |
| Abe, H | 1 |
| Matsuo, H | 1 |
| Ikeda, T | 1 |
| Koganemaru, G | 1 |
| Kuramashi, A | 1 |
| Funahashi, H | 1 |
| Magata, Y | 1 |
| Kawai, K | 2 |
| Nishimori, T | 1 |
| Ostock, CY | 2 |
| Lindenbach, D | 2 |
| Goldenberg, AA | 2 |
| Kampton, E | 1 |
| Qu, L | 1 |
| Wang, XL | 1 |
| Li, ZZ | 1 |
| Gao, GD | 1 |
| Iqbal, J | 1 |
| Ke, M | 1 |
| Qing, H | 1 |
| Migliore, MM | 1 |
| Ortiz, R | 1 |
| Dye, S | 1 |
| Campbell, RB | 1 |
| Amiji, MM | 1 |
| Kuang, XL | 1 |
| Xiao, J | 1 |
| Shan, G | 1 |
| Snider, BJ | 1 |
| Qu, J | 1 |
| Barger, SW | 1 |
| Arodin, L | 1 |
| Miranda-Vizuete, A | 1 |
| Swoboda, P | 1 |
| Fernandes, AP | 1 |
| Beppe, GJ | 1 |
| Dongmo, AB | 1 |
| Foyet, HS | 1 |
| Tsabang, N | 1 |
| Olteanu, Z | 1 |
| Cioanca, O | 1 |
| Hancianu, M | 1 |
| Dimo, T | 1 |
| Kim-Han, JS | 2 |
| Harmon, S | 1 |
| Sakiyama-Elbert, SE | 1 |
| O'Malley, KL | 3 |
| Malmlöf, T | 1 |
| Feltmann, K | 1 |
| Konradsson-Geuken, Å | 1 |
| Schneider, F | 1 |
| Alken, RG | 1 |
| Svensson, TH | 1 |
| Schilström, B | 1 |
| Shi, L | 1 |
| Ye, C | 1 |
| Feng, W | 1 |
| Berghauzen-Maciejewska, K | 2 |
| Kuter, K | 3 |
| Kolasiewicz, W | 3 |
| Głowacka, U | 2 |
| Dziubina, A | 1 |
| Ossowska, K | 4 |
| Wardas, J | 2 |
| Wang, HS | 1 |
| Huang, C | 1 |
| Lv, H | 1 |
| Jiang, F | 1 |
| Niu, Y | 1 |
| Yuan, J | 1 |
| Cui, X | 1 |
| Sarookhani, M | 1 |
| Faraj, A | 1 |
| Fraidouni, N | 1 |
| Yaghoubidoust, MH | 1 |
| Azhdari-Zarmehri, H | 1 |
| Tatenhorst, L | 2 |
| Tönges, L | 2 |
| Saal, KA | 2 |
| Koch, JC | 2 |
| Szegő, ÉM | 2 |
| Lingor, P | 2 |
| Shinko, A | 2 |
| Agari, T | 5 |
| Kameda, M | 6 |
| Yasuhara, T | 10 |
| Kondo, A | 2 |
| Tayra, JT | 1 |
| Sato, K | 4 |
| Sasaki, T | 1 |
| Sasada, S | 1 |
| Takeuchi, H | 1 |
| Wakamori, T | 2 |
| Borlongan, CV | 8 |
| Date, I | 10 |
| Dong, W | 1 |
| Guo, S | 3 |
| Zhao, S | 1 |
| He, S | 1 |
| Khatib, S | 1 |
| Finberg, JP | 4 |
| Artoul, F | 1 |
| Lavner, Y | 1 |
| Mahmood, S | 1 |
| Tisch, U | 1 |
| Haick, H | 1 |
| Aluf, Y | 1 |
| Vaya, J | 1 |
| Rao, MS | 1 |
| Zeng, X | 1 |
| Qi, B | 1 |
| Gong, T | 1 |
| Romaní-Aumedes, J | 2 |
| Canal, M | 2 |
| Martín-Flores, N | 2 |
| Pérez-Fernández, V | 1 |
| Wewering, S | 1 |
| Fernández-Santiago, R | 1 |
| Ezquerra, M | 1 |
| Pont-Sunyer, C | 1 |
| Lafuente, A | 1 |
| Alberch, J | 3 |
| Luebbert, H | 1 |
| Tolosa, E | 3 |
| Malagelada, C | 4 |
| Radhakrishnan, A | 1 |
| Engeln, M | 1 |
| Bastide, MF | 2 |
| Toulmé, E | 1 |
| Dehay, B | 1 |
| Bourdenx, M | 1 |
| Doudnikoff, E | 2 |
| Boué-Grabot, E | 1 |
| Pisani, A | 2 |
| Fernagut, PO | 2 |
| Feyder, M | 1 |
| Södersten, E | 1 |
| Santini, E | 1 |
| Vialou, V | 1 |
| LaPlant, Q | 1 |
| Watts, EL | 1 |
| Hansen, K | 1 |
| Nestler, EJ | 1 |
| Campbell, JC | 1 |
| Jeyamohan, SB | 1 |
| De La Cruz, P | 1 |
| Chen, N | 1 |
| Shin, D | 1 |
| Jin, HJ | 1 |
| Song, MY | 1 |
| Tuon, T | 2 |
| Valvassori, SS | 2 |
| Dal Pont, GC | 1 |
| Paganini, CS | 1 |
| Pozzi, BG | 1 |
| Luciano, TF | 1 |
| Souza, PS | 1 |
| Quevedo, J | 2 |
| Souza, CT | 2 |
| Pinho, RA | 2 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Xie, C | 1 |
| Cordero-Llana, Ó | 1 |
| Houghton, BC | 1 |
| Rinaldi, F | 1 |
| Taylor, H | 1 |
| Yáñez-Muñoz, RJ | 2 |
| Uney, JB | 1 |
| Wong, LF | 1 |
| Caldwell, MA | 2 |
| Mei, J | 3 |
| Niu, C | 3 |
| Wu, N | 1 |
| Faergemann, E | 1 |
| Strömberg, I | 5 |
| Zhang, FL | 1 |
| Zheng, Y | 1 |
| Zhang, WJ | 1 |
| Jia, YJ | 1 |
| Song, HL | 1 |
| An, HT | 1 |
| Zhang, HB | 1 |
| Qian, YJ | 1 |
| Tong, YL | 1 |
| Dong, L | 1 |
| Kim, YH | 2 |
| Shin, ES | 1 |
| Ariza, D | 2 |
| Sisdeli, L | 1 |
| Fazan, R | 1 |
| Deng, MZ | 1 |
| Borrajo, A | 1 |
| Valenzuela, R | 3 |
| Lanciego, JL | 3 |
| de la Crompe, B | 1 |
| Mallet, N | 1 |
| Boraud, T | 1 |
| Huang, LC | 1 |
| Zheng, W | 2 |
| Eagle, AL | 1 |
| Olumolade, OO | 1 |
| Otani, H | 1 |
| Schwerk, A | 1 |
| Roch, M | 1 |
| Gossen, M | 1 |
| Winter, C | 2 |
| Berg, J | 1 |
| Kurtz, A | 1 |
| Steiner, B | 2 |
| Xu, H | 4 |
| Du, X | 1 |
| Ba, XH | 1 |
| Hohmann, M | 1 |
| Baumgärtner, W | 1 |
| Batelli, S | 1 |
| Invernizzi, RW | 1 |
| Negro, A | 2 |
| Calcagno, E | 1 |
| Rodilossi, S | 1 |
| Wang, WW | 1 |
| Zhang, SF | 1 |
| Yuan, ML | 1 |
| Che, JY | 1 |
| Yuan, WE | 1 |
| Liu, ZG | 1 |
| Yin, SM | 3 |
| Yu, DQ | 3 |
| Li, SL | 1 |
| An, D | 2 |
| Sun, YP | 3 |
| Wang, DM | 2 |
| Zhang, WQ | 3 |
| Kumar, JB | 1 |
| Falcone, R | 1 |
| Di Giacomo, E | 1 |
| Cristiano, L | 1 |
| Fidoamore, A | 1 |
| Massimi, M | 1 |
| Ippoliti, R | 1 |
| Giordano, A | 1 |
| Marei, HE | 1 |
| Lashen, S | 1 |
| Farag, A | 1 |
| Althani, A | 1 |
| Afifi, N | 1 |
| A, AE | 1 |
| Rezk, S | 1 |
| Pallini, R | 2 |
| Casalbore, P | 1 |
| Cenciarelli, C | 1 |
| Ba, M | 1 |
| Kong, M | 1 |
| Ma, G | 1 |
| Andres, DS | 1 |
| Cerquetti, D | 1 |
| Merello, M | 1 |
| Morimoto, Y | 1 |
| Kudo, C | 1 |
| Hanamoto, H | 1 |
| Boku, A | 1 |
| Sugimura, M | 1 |
| Kato, T | 1 |
| Yoshida, A | 1 |
| Iderberg, H | 1 |
| McCreary, AC | 2 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Zheng, T | 1 |
| Lv, Q | 1 |
| Lei, X | 1 |
| Yin, X | 1 |
| Czarnecka, A | 1 |
| Kaminer, J | 1 |
| Thakur, P | 1 |
| Evinger, C | 2 |
| Molinet-Dronda, F | 1 |
| Gago, B | 1 |
| Juri, C | 2 |
| Collantes, M | 1 |
| Delgado, M | 1 |
| Prieto, E | 1 |
| Ecay, M | 1 |
| Peñuelas, I | 1 |
| Kosmowska, B | 1 |
| Zhang, YA | 1 |
| Guo, W | 1 |
| Li, G | 2 |
| Wang, P | 1 |
| Stojkovska, I | 1 |
| Wagner, BM | 1 |
| Morrison, BE | 1 |
| Collier, TJ | 5 |
| O'Malley, J | 2 |
| Rademacher, DJ | 1 |
| Sisson, KA | 1 |
| Sortwell, CE | 5 |
| Paumier, KL | 2 |
| Gebremedhin, KG | 1 |
| Smith, RC | 1 |
| O'Bryan, LM | 1 |
| Mitchell, PJ | 1 |
| Leung, D | 1 |
| Ghanem, M | 1 |
| Wilson, JM | 1 |
| Hanson, JC | 1 |
| Sossick, S | 1 |
| Cooper, J | 1 |
| Merchant, KM | 1 |
| Lu, J | 1 |
| O'Neill, MJ | 3 |
| Pahuja, R | 1 |
| Shukla, RK | 1 |
| Bhatnagar, P | 1 |
| Chauhan, LK | 1 |
| Saxena, PN | 1 |
| Arun, J | 1 |
| Chaudhari, BP | 1 |
| Patel, DK | 1 |
| Singh, SP | 1 |
| Shukla, R | 2 |
| Khanna, VK | 1 |
| Kumar, P | 1 |
| Chaturvedi, RK | 3 |
| Gupta, KC | 1 |
| Barna, BF | 1 |
| Alves-Dos-Santos, L | 1 |
| Chiavegatto, S | 1 |
| Ciesielska, A | 2 |
| Sharma, N | 1 |
| Beyer, J | 1 |
| Forsayeth, J | 3 |
| Bankiewicz, K | 1 |
| Keber, U | 1 |
| Klietz, M | 1 |
| Carlsson, T | 5 |
| Oertel, WH | 5 |
| Weihe, E | 1 |
| Schäfer, MK | 1 |
| Höglinger, GU | 2 |
| Depboylu, C | 1 |
| Fidalgo, C | 1 |
| Ko, WK | 1 |
| Tronci, E | 3 |
| Chuan, Q | 1 |
| Duan, SJ | 1 |
| Wang, SY | 1 |
| Zhu, Q | 1 |
| Wang, LJ | 1 |
| Urs, NM | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 2 |
| Taravini, IR | 2 |
| Larramendy, C | 1 |
| Gomez, G | 1 |
| Saborido, MD | 1 |
| Spaans, F | 1 |
| Fresno, C | 1 |
| González, GA | 1 |
| Fernández, E | 2 |
| Gershanik, OS | 2 |
| Pivoraitė, U | 1 |
| Venalis, A | 1 |
| Weng, SJ | 2 |
| Wu, SC | 1 |
| Chou, TK | 2 |
| Huang, WS | 3 |
| Liao, MH | 3 |
| Stenslik, MJ | 1 |
| Potts, LF | 1 |
| Sonne, JW | 1 |
| Cass, WA | 3 |
| Turchan-Cholewo, J | 1 |
| Pomerleau, F | 1 |
| Huettl, P | 1 |
| Ai, Y | 1 |
| Gash, DM | 1 |
| Gerhardt, GA | 2 |
| Bradley, LH | 1 |
| Shi, H | 1 |
| Zu, J | 1 |
| Shen, X | 2 |
| Ding, R | 1 |
| Pan, X | 1 |
| Wei, H | 1 |
| Fan, Q | 1 |
| Kiasalari, Z | 2 |
| Kim, CH | 2 |
| Han, BS | 3 |
| Kim, DJ | 1 |
| Shin, J | 1 |
| Rajan, S | 1 |
| Nguyen, QT | 1 |
| Sohn, M | 1 |
| Kim, WG | 2 |
| Han, M | 1 |
| Jeong, I | 1 |
| Lee, EH | 2 |
| Tu, Y | 1 |
| Naffin-Olivos, JL | 1 |
| Park, CH | 3 |
| Ringe, D | 1 |
| Yoon, HS | 1 |
| Petsko, GA | 1 |
| Tsai, KL | 1 |
| Cheng, YY | 1 |
| Leu, HB | 1 |
| Lee, YY | 1 |
| Chen, TJ | 1 |
| Liu, DH | 1 |
| Kao, CL | 1 |
| Parker, KL | 1 |
| Chen, KH | 1 |
| Kingyon, JR | 1 |
| Cavanagh, JF | 1 |
| Narayanan, NS | 1 |
| Xiao, JJ | 1 |
| Yin, M | 1 |
| Wang, ZJ | 1 |
| Wang, XP | 1 |
| Panicker, N | 1 |
| Saminathan, H | 1 |
| Neal, M | 1 |
| Harischandra, DS | 1 |
| Gordon, R | 1 |
| Kanthasamy, K | 1 |
| Lawana, V | 1 |
| Sarkar, S | 1 |
| Zhang, K | 1 |
| Chammas, C | 1 |
| Soghomonian, JJ | 1 |
| Voshavar, C | 1 |
| Dutta, AK | 1 |
| Paolone, G | 1 |
| Arcuri, L | 1 |
| Mercatelli, D | 1 |
| Mu, X | 1 |
| Yuan, X | 1 |
| Du, LD | 1 |
| He, GR | 1 |
| Du, GH | 1 |
| Lu-Nguyen, NB | 1 |
| Broadstock, M | 1 |
| Corenblum, MJ | 1 |
| Badowski, M | 1 |
| Harris, DT | 1 |
| Madhavan, L | 1 |
| Choi, HS | 1 |
| Kim, HJ | 2 |
| Oh, JH | 1 |
| Park, HG | 1 |
| Ra, JC | 1 |
| Suh, YH | 3 |
| Hernandez-Baltazar, D | 1 |
| Zavala-Flores, LM | 1 |
| Villanueva-Olivo, A | 1 |
| Michel, A | 2 |
| Downey, P | 1 |
| Van Damme, X | 1 |
| De Wolf, C | 1 |
| Schwarting, R | 1 |
| Scheller, D | 1 |
| Zhao, TT | 1 |
| Lee, KE | 1 |
| Meng, X | 2 |
| Johnson, AM | 1 |
| Grant, LM | 1 |
| Schallert, T | 9 |
| King, NO | 1 |
| Anderson, CJ | 1 |
| Dorval, AD | 1 |
| Ballabeni, V | 1 |
| Barocelli, E | 1 |
| Jing, X | 1 |
| Ren, M | 1 |
| Lou, H | 1 |
| Hajj, R | 1 |
| Milet, A | 1 |
| Toulorge, D | 1 |
| Cholet, N | 1 |
| Laffaire, J | 1 |
| Foucquier, J | 1 |
| Robelet, S | 1 |
| Mitry, R | 1 |
| Guedj, M | 1 |
| Nabirotchkin, S | 1 |
| Chumakov, I | 1 |
| Cohen, D | 1 |
| Bensaid, M | 1 |
| Michel, PP | 1 |
| Hirsch, EC | 6 |
| François, C | 2 |
| Maurice, N | 2 |
| Deltheil, T | 1 |
| Melon, C | 5 |
| Degos, B | 1 |
| Mourre, C | 1 |
| Kerkerian-Le Goff, L | 8 |
| Chassain, C | 1 |
| Salin, P | 5 |
| Vitale, F | 1 |
| Couraud, S | 1 |
| Durif, F | 1 |
| Gubellini, P | 4 |
| Zheng, H | 1 |
| Xia, H | 1 |
| Tamburrino, A | 1 |
| Churchill, MJ | 1 |
| Wan, OW | 1 |
| Colino-Sanguino, Y | 1 |
| Ippolito, R | 1 |
| Bergstrand, S | 1 |
| Wolf, DA | 1 |
| Herz, NJ | 1 |
| Sconce, MD | 1 |
| Meshul, CK | 3 |
| Decressac, M | 2 |
| Dal Bo, G | 1 |
| Calcagno, M | 1 |
| Monzón-Sandoval, J | 1 |
| Gutierrez, H | 1 |
| Wu, SL | 1 |
| Liu, KH | 1 |
| Chuang, CS | 2 |
| Cheng, FC | 2 |
| Su, HL | 2 |
| Wei, YH | 1 |
| Kuo, SJ | 1 |
| Machado, V | 1 |
| Haas, SJ | 3 |
| von Bohlen Und Halbach, O | 1 |
| Krieglstein, K | 2 |
| Unsicker, K | 1 |
| Spittau, B | 1 |
| Song, P | 1 |
| Gao, R | 1 |
| Rao, G | 1 |
| Ma, B | 1 |
| Sui, N | 1 |
| Deng, H | 1 |
| Tang, T | 1 |
| Tan, Z | 1 |
| Han, Z | 1 |
| Lu, T | 1 |
| Zhu, Y | 1 |
| Chen, Q | 1 |
| Tratnjek, L | 1 |
| Glavan, G | 1 |
| Višnjar, T | 1 |
| Živin, M | 1 |
| Tseng, WT | 2 |
| Hsu, YW | 2 |
| Pan, TM | 2 |
| Morgan, RJ | 1 |
| Kelly, CM | 2 |
| Torres, EM | 5 |
| Rosser, AE | 2 |
| Atlas, D | 1 |
| Kumaravelu, K | 1 |
| Brocker, DT | 1 |
| Grill, WM | 1 |
| Kim, HD | 2 |
| Jeong, KH | 2 |
| Jung, UJ | 2 |
| Kim, SR | 4 |
| Deng, J | 1 |
| Sun, M | 2 |
| Zhao, YZ | 1 |
| Jin, RR | 1 |
| Yang, W | 1 |
| Xiang, Q | 2 |
| Yu, WZ | 1 |
| Lin, Q | 2 |
| Tian, FR | 1 |
| Mao, KL | 1 |
| Lv, CZ | 1 |
| Wáng, YX | 1 |
| Lu, CT | 1 |
| Garea-Rodríguez, E | 2 |
| Eesmaa, A | 1 |
| Lindholm, P | 2 |
| Schlumbohm, C | 1 |
| König, J | 1 |
| Meller, B | 1 |
| Helms, G | 1 |
| Fuchs, E | 2 |
| Geng, X | 2 |
| Lei, C | 2 |
| Qu, Q | 1 |
| He, T | 1 |
| Yao, X | 2 |
| Fricke, IB | 1 |
| Viel, T | 1 |
| Worlitzer, MM | 2 |
| Collmann, FM | 1 |
| Vrachimis, A | 1 |
| Faust, A | 1 |
| Wachsmuth, L | 1 |
| Faber, C | 1 |
| Kuhlmann, MT | 1 |
| Schäfers, K | 1 |
| Hermann, S | 1 |
| Jacobs, AH | 1 |
| Nezhadi, A | 1 |
| Esmaeilpour, K | 1 |
| Shabani, M | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| da-Silva, CA | 1 |
| Sgroi, S | 1 |
| Capper-Loup, C | 1 |
| Paganetti, P | 1 |
| Kaelin-Lang, A | 1 |
| Tomas, D | 2 |
| Stanic, D | 2 |
| Chua, HK | 1 |
| White, K | 1 |
| Boon, WC | 1 |
| Horne, M | 1 |
| Jin, J | 1 |
| Lin, W | 1 |
| Tao, J | 1 |
| Silva, TP | 1 |
| Poli, A | 1 |
| Hara, DB | 1 |
| Yelkenli, İH | 1 |
| Şener, E | 1 |
| Kuş, G | 1 |
| Filiz, Z | 1 |
| Tunçel, N | 1 |
| Oh, JY | 1 |
| Choi, SL | 1 |
| Nam, YJ | 1 |
| Jo, A | 1 |
| Kwon, A | 1 |
| Shin, EY | 1 |
| Kim, EG | 1 |
| Kim, HK | 1 |
| Hong, CT | 1 |
| Chau, KY | 1 |
| Schapira, AH | 1 |
| Wang, ZY | 1 |
| Lian, H | 1 |
| Zhou, L | 1 |
| Cai, QQ | 1 |
| Stanic, J | 1 |
| Cirnaru, MD | 1 |
| Perez-Carrion, M | 1 |
| Zianni, E | 1 |
| Di Luca, M | 3 |
| Piccoli, G | 1 |
| Noor, NA | 1 |
| Mohammed, HS | 1 |
| Mourad, IM | 1 |
| Khadrawy, YA | 1 |
| Aboul Ezz, HS | 1 |
| Jung, HY | 1 |
| Kang, YM | 1 |
| Lee, KS | 2 |
| Sohn, MJ | 1 |
| Yang, PH | 1 |
| Huang, YD | 1 |
| Zhang, XY | 1 |
| Lei, P | 1 |
| Bush, AI | 1 |
| Su, ZJ | 1 |
| Zhang, QH | 1 |
| Hegarty, SV | 1 |
| O'Leary, E | 1 |
| Solger, F | 1 |
| Stanicka, J | 1 |
| Fluri, F | 1 |
| Krstić, M | 1 |
| Asan, E | 1 |
| Padel, T | 1 |
| Özen, I | 1 |
| Boix, J | 1 |
| Barbariga, M | 1 |
| Gaceb, A | 1 |
| Roth, M | 1 |
| Paul, G | 3 |
| Clark, AR | 1 |
| Carter, AB | 1 |
| Hager, LE | 1 |
| Price, EM | 1 |
| Figge, DA | 1 |
| Eskow Jaunarajs, KL | 2 |
| Standaert, DG | 2 |
| Bez, F | 1 |
| Fan, LL | 4 |
| Deng, B | 1 |
| Yan, JB | 1 |
| Hu, ZH | 1 |
| Ren, AH | 1 |
| Hu, YM | 1 |
| Yang, DW | 1 |
| Xue, Y | 1 |
| Yang, YT | 1 |
| Liu, HY | 1 |
| Chen, AQ | 1 |
| Sheng, Q | 1 |
| Liu, HX | 1 |
| Pang, YY | 1 |
| Gee, LE | 1 |
| Ramirez-Zamora, A | 1 |
| Tremblay, M | 1 |
| Silveira, MM | 1 |
| Kaur, S | 2 |
| Hosking, JG | 1 |
| Adams, WK | 1 |
| Baunez, C | 5 |
| Winstanley, CA | 1 |
| Runeberg-Roos, P | 1 |
| Piccinini, E | 1 |
| Penttinen, AM | 1 |
| Mätlik, K | 1 |
| Heikkinen, H | 1 |
| Kuure, S | 1 |
| Peränen, J | 2 |
| Airavaara, M | 1 |
| Kalkkinen, N | 2 |
| Penn, R | 1 |
| Niswender, CM | 2 |
| Jones, CK | 2 |
| Bubser, M | 2 |
| Thompson Gray, A | 1 |
| Blobaum, AL | 2 |
| Engers, DW | 2 |
| Rodriguez, AL | 1 |
| Loch, MT | 1 |
| Daniels, JS | 2 |
| Lindsley, CW | 2 |
| Hopkins, CR | 3 |
| Javitch, JA | 1 |
| Conn, PJ | 2 |
| Gu, XS | 1 |
| Liu, S | 2 |
| Sanders, TH | 1 |
| Pérez-Sisqués, L | 1 |
| Altas, B | 1 |
| Man, HY | 1 |
| Kawabe, H | 1 |
| Martins, WB | 1 |
| Rodrigues, SA | 1 |
| Silva, HK | 1 |
| Dantas, CG | 1 |
| Júnior, Wde L | 1 |
| Filho, LX | 1 |
| Cardoso, JC | 1 |
| Gomes, MZ | 1 |
| Achour, I | 1 |
| Arel-Dubeau, AM | 1 |
| Renaud, J | 1 |
| Legrand, M | 1 |
| Attard, E | 1 |
| Germain, M | 1 |
| Martinoli, MG | 1 |
| Boronat-García, A | 2 |
| Palomero-Rivero, M | 1 |
| Guerra-Crespo, M | 2 |
| Millán-Aldaco, D | 1 |
| Drucker-Colín, R | 3 |
| Lerner, RP | 1 |
| Agorastos, S | 1 |
| Scherrer, S | 1 |
| Dewey, SL | 1 |
| Eidelberg, D | 1 |
| Ztaou, S | 1 |
| Camon, J | 1 |
| Guiraudie-Capraz, G | 1 |
| Beurrier, C | 1 |
| Tentillier, N | 1 |
| Etzerodt, A | 1 |
| Olesen, MN | 1 |
| Rizalar, FS | 1 |
| Jacobsen, J | 1 |
| Bender, D | 1 |
| Moestrup, SK | 1 |
| Romero-Ramos, M | 1 |
| Sever, M | 1 |
| Turkyilmaz, M | 1 |
| Sevinc, C | 1 |
| Cakir, A | 1 |
| Ocalan, B | 1 |
| Cansev, M | 1 |
| Guler, MO | 1 |
| Tekinay, AB | 1 |
| Yang, CP | 1 |
| Zhang, ZH | 1 |
| Zhang, LH | 1 |
| Rui, HC | 1 |
| Haining, RL | 1 |
| Jones, TM | 1 |
| Hernandez, A | 1 |
| Smith, ES | 2 |
| Hardy, GA | 1 |
| Zhao, P | 1 |
| Yang, L | 1 |
| Wood, K | 1 |
| Zhu, X | 1 |
| Baldwin, HA | 1 |
| Koivula, PP | 1 |
| Necarsulmer, JC | 1 |
| Whitaker, KW | 1 |
| Harvey, BK | 2 |
| Cossu, G | 1 |
| Pillai, E | 1 |
| Simbula, G | 1 |
| Jadžić, D | 1 |
| Angius, F | 1 |
| Spolitu, S | 1 |
| Batetta, B | 1 |
| Lecca, D | 1 |
| Giuffrida, A | 3 |
| Dolatshahi, M | 1 |
| Mansouri, SM | 1 |
| Khodadadi, A | 1 |
| Cao, LF | 1 |
| Peng, XY | 1 |
| Wang, B | 1 |
| Zhou, FM | 1 |
| Cheng, RX | 1 |
| Chen, LH | 1 |
| Luo, WF | 1 |
| Ueno, T | 1 |
| Ueno, S | 1 |
| Shan, L | 1 |
| Chen, Y | 2 |
| Kalaani, J | 1 |
| Roche, J | 1 |
| Hamade, E | 1 |
| Badran, B | 1 |
| Prestoz, L | 1 |
| Barros, AS | 1 |
| Crispim, RYG | 1 |
| Cavalcanti, JU | 1 |
| Souza, RB | 1 |
| Lemos, JC | 1 |
| Cristino Filho, G | 1 |
| Bezerra, MM | 1 |
| Pinheiro, TFM | 1 |
| de Vasconcelos, SMM | 1 |
| Macêdo, DS | 3 |
| Aguiar, LMV | 1 |
| Srivastava, N | 3 |
| Maasz, G | 1 |
| Zrinyi, Z | 1 |
| Reglodi, D | 4 |
| Petrovics, D | 1 |
| Rivnyak, A | 1 |
| Kiss, T | 1 |
| Jungling, A | 1 |
| Tamas, A | 4 |
| Pirger, Z | 1 |
| Cai, Q | 1 |
| Gu, H | 1 |
| Fang, J | 1 |
| Jin, L | 1 |
| Choi, DH | 3 |
| Kang, K | 1 |
| Han, DW | 1 |
| Favier, M | 2 |
| Carcenac, C | 3 |
| Drui, G | 2 |
| Vachez, Y | 1 |
| Savasta, M | 3 |
| Kang, Y | 1 |
| Noh, JR | 1 |
| Hwang, JH | 1 |
| Han, SS | 1 |
| Oh, WK | 1 |
| Masaki, Y | 1 |
| Matsumura, A | 2 |
| Calice da Silva, C | 1 |
| Azevedo, BN | 1 |
| Machado, DC | 1 |
| Zimmer, ER | 1 |
| Martins, LAM | 1 |
| da Costa, JC | 1 |
| Jang, H | 1 |
| Kim, S | 2 |
| Lee, JM | 2 |
| Oh, YS | 1 |
| Park, SM | 2 |
| Mori, MA | 1 |
| Delattre, AM | 2 |
| Carabelli, B | 1 |
| Pudell, C | 1 |
| Staziaki, PV | 1 |
| Visentainer, JV | 1 |
| Montanher, PF | 1 |
| Ferraz, AC | 2 |
| Rabiee, N | 2 |
| Zabihnejad, S | 2 |
| F Hernández, L | 1 |
| Ruiz-DeDiego, I | 1 |
| Jattujan, P | 1 |
| Nobsathian, S | 1 |
| Poomtong, T | 1 |
| Sobhon, P | 1 |
| Ambrosi, G | 2 |
| Kustrimovic, N | 1 |
| Rasini, E | 1 |
| Dicorato, G | 1 |
| Caputo, S | 1 |
| Marino, F | 1 |
| Cosentino, M | 1 |
| Becker, G | 2 |
| Bahri, MA | 1 |
| Hustadt, F | 1 |
| Garraux, G | 1 |
| Luxen, A | 1 |
| Lemaire, C | 1 |
| Plenevaux, A | 1 |
| Jensen, P | 1 |
| Pedersen, EG | 1 |
| Zimmer, J | 2 |
| Widmer, HR | 3 |
| Meyer, M | 3 |
| Locke, CJ | 1 |
| Fox, SA | 1 |
| Caldwell, GA | 3 |
| Caldwell, KA | 3 |
| Cao, JP | 1 |
| Wang, HJ | 1 |
| Yu, JK | 1 |
| Liu, HM | 1 |
| Kelly, AM | 1 |
| Kennedy, GA | 2 |
| Matsumoto, M | 1 |
| Tanaka, H | 1 |
| Mitsui, T | 1 |
| Yoshioka, M | 2 |
| Nonomura, K | 1 |
| Hovakimyan, M | 1 |
| Schmitt, O | 2 |
| Gerber, B | 1 |
| Andressen, C | 1 |
| Meng, JL | 1 |
| Ma, YY | 1 |
| Luo, HY | 1 |
| Kong, SZ | 1 |
| He, YW | 1 |
| Dong, BC | 1 |
| Wu, SH | 1 |
| Pontis, S | 3 |
| Pinna, A | 3 |
| Dagda, RK | 1 |
| Kulich, SM | 2 |
| Chu, CT | 5 |
| Armentero, MT | 7 |
| Martignoni, E | 1 |
| McCoy, MK | 2 |
| Ruhn, KA | 3 |
| Martinez, TN | 2 |
| McAlpine, FE | 1 |
| Blesch, A | 2 |
| Tansey, MG | 4 |
| Fiorentini, C | 1 |
| Busi, C | 1 |
| Spano, P | 1 |
| Missale, C | 1 |
| Rodriguez-Blanco, J | 1 |
| Martín, V | 1 |
| Herrera, F | 1 |
| García-Santos, G | 1 |
| Antolín, I | 2 |
| Rodriguez, C | 2 |
| Yuan, WJ | 1 |
| Shingo, T | 7 |
| Muraoka, K | 5 |
| Uozumi, T | 1 |
| Tajiri, N | 1 |
| Morimoto, T | 1 |
| Jing, M | 1 |
| Baba, T | 1 |
| Leung, H | 1 |
| Matsui, T | 5 |
| Miyoshi, Y | 5 |
| Soderstrom, KE | 1 |
| Meredith, G | 1 |
| Freeman, TB | 2 |
| McGuire, SO | 1 |
| Vercammen, L | 3 |
| Brundin, P | 7 |
| Vorobyov, V | 1 |
| Sengpiel, F | 1 |
| De Leonibus, E | 1 |
| Managò, F | 1 |
| Giordani, F | 1 |
| Petrosino, F | 1 |
| Oliverio, A | 1 |
| Mele, A | 1 |
| Ossola, B | 2 |
| Kääräinen, TM | 1 |
| Raasmaja, A | 2 |
| Männistö, PT | 6 |
| Leaver, KR | 1 |
| Allbutt, HN | 2 |
| Creber, NJ | 1 |
| Kassiou, M | 1 |
| Henderson, JM | 2 |
| Bacci, JJ | 1 |
| Jouve, L | 2 |
| Westerlund, M | 1 |
| Ran, C | 1 |
| Borgkvist, A | 1 |
| Sterky, FH | 1 |
| Lindqvist, E | 1 |
| Lundströmer, K | 1 |
| Pernold, K | 1 |
| Brené, S | 1 |
| Kallunki, P | 1 |
| Galter, D | 1 |
| Kelsey, JE | 3 |
| Langelier, NA | 1 |
| Oriel, BS | 1 |
| Reedy, C | 1 |
| Tadaiesky, MT | 1 |
| Dombrowski, PA | 2 |
| Figueiredo, CP | 2 |
| Cargnin-Ferreira, E | 1 |
| Grealish, S | 2 |
| Xie, L | 1 |
| Kelly, M | 1 |
| Dupre, KB | 3 |
| Eskow, KL | 2 |
| Barnum, CJ | 4 |
| Lu, YF | 1 |
| Gong, QH | 1 |
| Shi, JS | 1 |
| Winkler, C | 7 |
| Kirik, D | 7 |
| Monville, C | 3 |
| Pekarik, V | 1 |
| Avila, I | 2 |
| Reilly, MP | 1 |
| Sanabria, F | 1 |
| Posadas-Sánchez, D | 1 |
| Chavez, CL | 1 |
| Banerjee, N | 1 |
| Killeen, P | 1 |
| Castañeda, E | 2 |
| Zang, D | 1 |
| Jin, ZH | 2 |
| Isacson, O | 7 |
| Kordower, JH | 3 |
| Nilsson, A | 1 |
| Fälth, M | 1 |
| Kultima, K | 1 |
| Sköld, K | 1 |
| Svenningsson, P | 4 |
| Andrén, PE | 7 |
| Sadan, O | 1 |
| Bahat-Stromza, M | 1 |
| Levy, YS | 1 |
| Pisnevsky, A | 1 |
| Peretz, H | 1 |
| Ilan, AB | 1 |
| Bulvik, S | 1 |
| Shemesh, N | 1 |
| Krepel, D | 1 |
| Cohen, Y | 1 |
| Di Matteo, V | 2 |
| Pierucci, M | 2 |
| Benigno, A | 1 |
| Esposito, E | 2 |
| Poloskey, SL | 1 |
| Bergstrom, DA | 2 |
| Fuentes, R | 1 |
| Petersson, P | 1 |
| Siesser, WB | 1 |
| Nicolelis, MA | 1 |
| Echeverry, MB | 1 |
| Del-Bel, EA | 1 |
| López, IP | 1 |
| Kachidian, P | 1 |
| Rico, AJ | 1 |
| Gómez-Bautista, V | 1 |
| Coulon, P | 1 |
| Ito, M | 2 |
| Fujita, Y | 1 |
| Ichihara, M | 1 |
| Masuda, A | 1 |
| Suzuki, Y | 1 |
| Maesawa, S | 2 |
| Kajita, Y | 2 |
| Hirayama, M | 1 |
| Ohsawa, I | 1 |
| Ohta, S | 1 |
| Ohno, K | 1 |
| Walker, RH | 2 |
| Koch, RJ | 2 |
| Sweeney, JE | 1 |
| Gregório, ML | 1 |
| Wietzikoski, EC | 1 |
| Ferro, MM | 2 |
| Silveira, JL | 1 |
| Vital, MA | 2 |
| Kasture, S | 1 |
| Schintu, N | 2 |
| Spina, L | 1 |
| Longoni, R | 1 |
| Ballero, M | 1 |
| Noras, L | 1 |
| Jochem, J | 1 |
| Brus, H | 1 |
| Körossy, E | 1 |
| Drab, J | 1 |
| Andereggen, L | 1 |
| Guzman, R | 1 |
| Ducray, AD | 1 |
| Young, CK | 1 |
| Koke, SJ | 1 |
| Kiss, ZH | 1 |
| Bland, BH | 1 |
| Toriumi, H | 1 |
| Yoshikawa, M | 1 |
| Matsuda, R | 1 |
| Nishimura, F | 1 |
| Yamada, S | 1 |
| Hirabayashi, H | 1 |
| Nakase, H | 1 |
| Nonaka, J | 1 |
| Ouji, Y | 1 |
| Ishizaka, S | 1 |
| Sakaki, T | 1 |
| Chan, WS | 1 |
| Durairajan, SS | 1 |
| Xie, LX | 1 |
| Kum, WF | 1 |
| Koo, I | 1 |
| Yung, KK | 1 |
| Harris, O | 1 |
| Cassin, J | 1 |
| Cho, SH | 2 |
| Shin, KY | 2 |
| Cho, D | 1 |
| Simon, A | 1 |
| Kirkham, M | 1 |
| Engler, H | 1 |
| Doenlen, R | 1 |
| Riether, C | 1 |
| Engler, A | 1 |
| Niemi, MB | 1 |
| Besedovsky, HO | 1 |
| del Rey, A | 2 |
| Pacheco-López, G | 1 |
| Feldon, J | 1 |
| Schedlowski, M | 1 |
| Camp, DM | 1 |
| Loeffler, DA | 1 |
| Farrah, DM | 1 |
| Borneman, JN | 1 |
| LeWitt, PA | 1 |
| Zhang, QJ | 5 |
| Ali, U | 5 |
| Wu, ZH | 2 |
| Gui, ZH | 5 |
| Hui, YP | 2 |
| Huang, R | 1 |
| Han, L | 1 |
| Ren, F | 1 |
| Ke, W | 1 |
| Jiang, C | 1 |
| Pei, Y | 1 |
| Ming, M | 1 |
| Fan, X | 1 |
| Gu, Q | 1 |
| Yeh, CB | 1 |
| Chen, CC | 1 |
| Shen, LH | 1 |
| Liu, JC | 3 |
| Ikeda, K | 2 |
| Yoshikawa, S | 1 |
| Kurokawa, T | 1 |
| Yuzawa, N | 1 |
| Nakao, K | 1 |
| Mochizuki, H | 2 |
| Xu, SL | 1 |
| Shim, JS | 1 |
| Kim, HG | 4 |
| Ju, MS | 2 |
| Jeong, SY | 1 |
| Stahl, K | 2 |
| Skare, Ø | 2 |
| Torp, R | 2 |
| Poremsky, E | 1 |
| Kidd, S | 1 |
| Schneider, JS | 1 |
| Iacovitti, L | 3 |
| Balestra, B | 1 |
| Levandis, G | 3 |
| Cervio, M | 1 |
| Greco, R | 2 |
| Tassorelli, C | 2 |
| Colucci, M | 1 |
| Faniglione, M | 1 |
| Bazzini, E | 2 |
| Nappi, G | 4 |
| Clavenzani, P | 1 |
| Vigneri, S | 1 |
| De Giorgio, R | 1 |
| Tonini, M | 1 |
| Mabandla, MV | 1 |
| Kellaway, LA | 1 |
| Daniels, WM | 2 |
| Russell, VA | 2 |
| Kalivendi, SV | 1 |
| Yedlapudi, D | 1 |
| Kalyanaraman, B | 1 |
| Cova, L | 2 |
| Zennaro, E | 2 |
| Bossolasco, P | 2 |
| Calzarossa, C | 2 |
| Giuseppe, B | 1 |
| Deliliers, GL | 2 |
| Polli, E | 2 |
| Silani, V | 2 |
| Song, N | 1 |
| Branchi, I | 1 |
| D'Andrea, I | 1 |
| Armida, M | 1 |
| Carnevale, D | 1 |
| Ajmone-Cat, MA | 1 |
| Pèzzola, A | 2 |
| Potenza, RL | 2 |
| Morgese, MG | 1 |
| Minghetti, L | 1 |
| Popoli, P | 3 |
| Alleva, E | 1 |
| Pérez-Alcázar, M | 1 |
| Nicolás, MJ | 1 |
| Valencia, M | 1 |
| Alegre, M | 1 |
| López-Azcárate, J | 1 |
| Iriarte, J | 1 |
| Artieda, J | 1 |
| Volpini, R | 1 |
| Cristalli, G | 1 |
| Kim, SY | 3 |
| Woo, MS | 1 |
| Park, JS | 1 |
| Bazinet, RP | 1 |
| Rapoport, SI | 1 |
| Bhattacharjee, AK | 1 |
| Chung, CY | 2 |
| Koprich, JB | 2 |
| Hallett, PJ | 1 |
| Li, XH | 1 |
| Wang, JY | 2 |
| Chang, JY | 2 |
| Woodward, DJ | 2 |
| Chao, J | 1 |
| Lau, WK | 1 |
| Huie, MJ | 1 |
| Ho, YS | 1 |
| Yu, MS | 1 |
| Lai, CS | 1 |
| Yuen, WH | 1 |
| Lam, WH | 1 |
| Chan, TH | 1 |
| Chang, RC | 1 |
| Andersson, DR | 1 |
| Lagerkvist, S | 1 |
| Nissbrandt, H | 2 |
| Ganser, C | 1 |
| Just, L | 1 |
| Jackson-Lewis, V | 4 |
| Przedborski, S | 4 |
| Mnich, K | 1 |
| Mackie, K | 1 |
| Gorman, AM | 2 |
| Finn, DP | 1 |
| Rauch, F | 1 |
| Hsu, SH | 1 |
| Chuang, CF | 1 |
| Na, SJ | 1 |
| DiLella, AG | 1 |
| Lis, EV | 1 |
| Jones, K | 1 |
| Levine, DM | 1 |
| Stone, DJ | 1 |
| Hess, JF | 1 |
| Um, JW | 2 |
| Jeon, I | 1 |
| Lee, G | 1 |
| Lee, PH | 1 |
| Herrera-Marschitz, M | 4 |
| Arbuthnott, G | 1 |
| Ungerstedt, U | 4 |
| Diaz-Corrales, FJ | 2 |
| Kimoto, N | 1 |
| Kikkawa, Y | 1 |
| Murata, M | 1 |
| Gil, S | 1 |
| Park, C | 1 |
| Koh, H | 1 |
| O'Sullivan, DB | 1 |
| Harrison, PT | 1 |
| Kuranuki, S | 1 |
| Arai, C | 1 |
| Terada, S | 1 |
| Aoyama, T | 1 |
| Boulamery, A | 1 |
| Simon, N | 1 |
| Vidal, J | 1 |
| Bruguerolle, B | 1 |
| Lopes, FM | 1 |
| Schröder, R | 1 |
| da Frota, ML | 1 |
| Zanotto-Filho, A | 1 |
| Müller, CB | 1 |
| Pires, AS | 1 |
| Meurer, RT | 1 |
| Colpo, GD | 1 |
| Kapczinski, F | 1 |
| Moreira, JC | 1 |
| Fernandes, Mda C | 1 |
| Klamt, F | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 2 |
| Fuxe, K | 4 |
| Rivera, A | 1 |
| Cordeiro, KK | 1 |
| Tenório, SB | 1 |
| Dragani, LK | 1 |
| Murzilli, S | 1 |
| Poggi, A | 1 |
| Kobylecki, C | 2 |
| Crossman, AR | 3 |
| Yasuda, T | 1 |
| Uthayathas, S | 1 |
| Watts, RL | 1 |
| Mouradian, MM | 1 |
| Papa, SM | 1 |
| Hwang, DS | 1 |
| Oh, H | 1 |
| Park, H | 1 |
| Cho, JH | 1 |
| Jang, JB | 1 |
| Draxler, P | 1 |
| Somoza, R | 1 |
| Baes, M | 1 |
| Wyneken, U | 1 |
| Rubio, FJ | 1 |
| Argüelles, S | 1 |
| Venero, JL | 1 |
| García-Rodriguez, S | 1 |
| Tomas-Camardiel, M | 1 |
| Cano, J | 1 |
| Machado, A | 1 |
| Zou, Z | 1 |
| Ke, Y | 1 |
| Xu, R | 1 |
| Fang, X | 1 |
| Sugiyama, K | 1 |
| Akamine, S | 1 |
| Namba, H | 1 |
| Li, LB | 2 |
| Hou, C | 3 |
| Banegas, I | 1 |
| Prieto, I | 1 |
| Vives, F | 1 |
| Alba, F | 1 |
| de Gasparo, M | 1 |
| Duran, R | 1 |
| Segarra, AB | 1 |
| Ramírez, M | 1 |
| Villar-Cheda, B | 2 |
| Lima, MM | 1 |
| Moreira, CG | 1 |
| Avila, TV | 1 |
| Allemand, A | 1 |
| Mendes, DA | 1 |
| Marti, M | 2 |
| Sarubbo, S | 1 |
| Latini, F | 1 |
| Cavallo, M | 1 |
| Eleopra, R | 1 |
| Biguzzi, S | 1 |
| Lettieri, C | 1 |
| Conti, C | 1 |
| Simonato, M | 1 |
| Zucchini, S | 1 |
| Quatrale, R | 1 |
| Sensi, M | 1 |
| Candeletti, S | 1 |
| Romualdi, P | 1 |
| Füllhase, C | 1 |
| Santos, C | 1 |
| Kravitz, AV | 1 |
| Freeze, BS | 1 |
| Parker, PR | 1 |
| Kay, K | 1 |
| Thwin, MT | 1 |
| Deisseroth, K | 1 |
| Kreitzer, AC | 2 |
| Belujon, P | 1 |
| Lodge, DJ | 1 |
| Grace, AA | 1 |
| Cho, KH | 1 |
| Park, W | 1 |
| Zhou, T | 1 |
| Hider, RC | 1 |
| Campbell, B | 1 |
| Hobbs, CJ | 1 |
| Rose, S | 4 |
| Jairaj, M | 1 |
| Tayarani-Binazir, KA | 1 |
| Syme, A | 1 |
| Lessner, G | 1 |
| Mikkat, S | 1 |
| Kreutzer, M | 1 |
| Glocker, MO | 1 |
| Akazawa, YO | 1 |
| Saito, Y | 1 |
| Hamakubo, T | 1 |
| Masuo, Y | 1 |
| Yoshida, Y | 1 |
| Nishio, K | 1 |
| Shichiri, M | 1 |
| Miyasaka, T | 1 |
| Iwanari, H | 1 |
| Mochizuki, Y | 1 |
| Kodama, T | 1 |
| Noguchi, N | 1 |
| Niki, E | 1 |
| Steiner, JP | 3 |
| Payne, KB | 1 |
| Main, CD | 1 |
| D'Alfonso, S | 1 |
| Jacobsen, KX | 1 |
| Hicks, TP | 1 |
| Staines, WA | 1 |
| Poulter, MO | 1 |
| Perez, XA | 1 |
| Bordia, T | 1 |
| McIntosh, JM | 1 |
| Quik, M | 2 |
| Xiao, D | 1 |
| Cassin, JJ | 1 |
| Healy, B | 1 |
| Burdett, TC | 1 |
| Chen, JF | 1 |
| Fredholm, BB | 1 |
| Schwarzschild, MA | 2 |
| Button, T | 1 |
| Deak, T | 1 |
| Tobón-Velasco, JC | 1 |
| Carmona-Aparicio, L | 1 |
| Ali, SF | 1 |
| Rylander, D | 1 |
| Parent, M | 1 |
| O'Sullivan, SS | 1 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Cannon, JR | 2 |
| Greenamyre, JT | 3 |
| Lelos, M | 1 |
| Huang, YM | 1 |
| Yin, ZQ | 1 |
| Harms, AS | 1 |
| Varghese, S | 1 |
| Treviño, I | 1 |
| Liu, YY | 1 |
| Ji, C | 1 |
| Zuo, PP | 1 |
| Oses, JP | 1 |
| Batassini, C | 1 |
| Pochmann, D | 1 |
| Böhmer, AE | 1 |
| Vuaden, FC | 1 |
| Silvestrin, RB | 1 |
| Oliveira, A | 1 |
| Bonan, CD | 1 |
| Bogo, MR | 1 |
| Souza, DO | 1 |
| Portela, LV | 1 |
| Sarkis, JJ | 1 |
| Mello e Souza, T | 1 |
| Chan, CS | 1 |
| Glajch, KE | 1 |
| Gertler, TS | 1 |
| Guzman, JN | 1 |
| Mercer, JN | 1 |
| Lewis, AS | 1 |
| Goldberg, AB | 1 |
| Tkatch, T | 1 |
| Shigemoto, R | 1 |
| Fleming, SM | 2 |
| Chetkovich, DM | 1 |
| Osten, P | 1 |
| Kita, H | 1 |
| Mittermeyer, G | 1 |
| Hadaczek, P | 1 |
| Kells, AP | 2 |
| Bankiewicz, KS | 5 |
| Laganiere, J | 1 |
| Lai, JT | 1 |
| Guschin, D | 1 |
| Paschon, DE | 1 |
| Fong, LK | 1 |
| Rebar, EJ | 1 |
| Gregory, PD | 1 |
| Zhang, HS | 1 |
| Gil, SJ | 1 |
| Lee, JE | 2 |
| Minn, YK | 1 |
| Koh, HC | 2 |
| Cadet, JL | 3 |
| Brannock, C | 2 |
| Krasnova, IN | 1 |
| Ladenheim, B | 1 |
| McCoy, MT | 1 |
| Chou, J | 2 |
| Lehrmann, E | 1 |
| Wood, WH | 1 |
| Becker, KG | 1 |
| Broom, L | 1 |
| Marinova-Mutafchieva, L | 1 |
| Sadeghian, M | 1 |
| Davis, JB | 1 |
| Medhurst, AD | 1 |
| Dexter, DT | 6 |
| Gao, DM | 1 |
| Reimers, D | 1 |
| Osuna, C | 1 |
| Gonzalo-Gobernado, R | 1 |
| Herranz, AS | 1 |
| Diaz-Gil, JJ | 1 |
| Jimenez-Escrig, A | 1 |
| Asensio, MJ | 1 |
| Miranda, C | 1 |
| Rodriguez-Serrano, M | 1 |
| Bazan, E | 1 |
| Kim, MC | 1 |
| Yang, WM | 1 |
| Huh, Y | 1 |
| Yong, Y | 1 |
| Fan, Z | 1 |
| Ke, ZJ | 1 |
| Hu, X | 1 |
| Weng, Z | 2 |
| Cao, G | 1 |
| Signore, A | 1 |
| Hastings, T | 2 |
| Madete, JK | 2 |
| Fuller, A | 1 |
| Trueman, RC | 1 |
| Holt, CA | 2 |
| Huang, LZ | 1 |
| Campos, C | 1 |
| Ly, J | 1 |
| Ivy Carroll, F | 1 |
| Mylonakou, MN | 1 |
| Amiry-Moghaddam, M | 1 |
| Pabon, MM | 1 |
| Bachstetter, AD | 1 |
| Hudson, CE | 1 |
| Gemma, C | 1 |
| Bickford, PC | 2 |
| Gerlach, M | 3 |
| Beck, J | 1 |
| van den Buuse, M | 2 |
| de Iure, A | 3 |
| Di Filippo, M | 2 |
| Tantucci, M | 3 |
| Costa, C | 2 |
| Borsini, F | 1 |
| Giampà, C | 2 |
| Fusco, FR | 2 |
| Danielyan, L | 1 |
| Schäfer, R | 1 |
| von Ameln-Mayerhofer, A | 1 |
| Bernhard, F | 1 |
| Verleysdonk, S | 1 |
| Buadze, M | 1 |
| Lourhmati, A | 1 |
| Klopfer, T | 1 |
| Schaumann, F | 1 |
| Koehle, C | 1 |
| Proksch, B | 1 |
| Weissert, R | 1 |
| Reichardt, HM | 1 |
| van den Brandt, J | 1 |
| Buniatian, GH | 1 |
| Schwab, M | 1 |
| Gleiter, CH | 1 |
| Niu, XL | 1 |
| Feng, JJ | 2 |
| Recchia, A | 2 |
| Popovic, N | 1 |
| Andersson, D | 1 |
| Palomo-Garo, C | 1 |
| García-Arencibia, M | 2 |
| Ramos, J | 1 |
| Pertwee, R | 1 |
| Cordellini, MF | 1 |
| Piazzetta, G | 1 |
| Pinto, KC | 1 |
| Matheussi, F | 1 |
| Carolino, RO | 1 |
| Szawka, RE | 1 |
| Anselmo-Franci, JA | 2 |
| Nguyen, HN | 1 |
| Byers, B | 1 |
| Cord, B | 1 |
| Shcheglovitov, A | 1 |
| Byrne, J | 1 |
| Gujar, P | 1 |
| Kee, K | 1 |
| Schüle, B | 1 |
| Dolmetsch, RE | 1 |
| Langston, W | 1 |
| Palmer, TD | 1 |
| Pera, RR | 1 |
| Soria, G | 1 |
| Tudela, R | 1 |
| Mullol, J | 1 |
| Planas, AM | 1 |
| McCourt, AD | 1 |
| Yee, BJ | 1 |
| Gonzalez, RT | 1 |
| Liang, Z | 1 |
| Shi, F | 1 |
| Chiasserini, D | 1 |
| Susta, F | 1 |
| Orvietani, PL | 1 |
| Koya, K | 1 |
| Binaglia, L | 1 |
| Ye, N | 1 |
| Gao, B | 1 |
| Zhen, X | 3 |
| Zhang, A | 1 |
| Siew, CJ | 2 |
| Mitra, NK | 1 |
| Rodriguez-Pallares, J | 1 |
| Parga, JA | 1 |
| Joglar, B | 1 |
| Gleave, JA | 1 |
| Farncombe, TH | 1 |
| Saab, C | 1 |
| Doering, LC | 2 |
| Cheng, W | 1 |
| Zhu, C | 1 |
| Wu, A | 1 |
| Xiong, Z | 2 |
| Yenari, MA | 1 |
| Yang, YG | 1 |
| Ying, W | 1 |
| Oh, CK | 1 |
| Choi, WS | 1 |
| Youdim, MB | 7 |
| Oh, YJ | 2 |
| Bethel-Brown, CS | 1 |
| Morris, JK | 1 |
| Stanford, JA | 1 |
| Hamamichi, S | 1 |
| Lee, BD | 1 |
| Ray, A | 1 |
| Dawson, TM | 1 |
| Smith, WW | 1 |
| Dawson, VL | 1 |
| Kabuto, H | 2 |
| Yamanushi, TT | 2 |
| Chabeauti, PY | 1 |
| Frangeul, L | 1 |
| Thiriet, N | 1 |
| Herzog, H | 1 |
| Sgobio, C | 3 |
| Pendolino, V | 3 |
| Kääriäinen, TM | 3 |
| Käenmäki, M | 1 |
| Oinas, N | 1 |
| Tammimäki, A | 1 |
| Collins, GC | 1 |
| Lei, Z | 1 |
| Li, T | 1 |
| Zeng, S | 1 |
| Bagetta, V | 2 |
| Marinucci, S | 1 |
| Jadiya, P | 1 |
| Chatterjee, M | 1 |
| Sammi, SR | 1 |
| Palit, G | 1 |
| Nazir, A | 1 |
| Cho, EG | 1 |
| Zaremba, JD | 1 |
| McKercher, SR | 1 |
| Talantova, M | 1 |
| Tu, S | 1 |
| Masliah, E | 2 |
| Chan, SF | 1 |
| Nakanishi, N | 1 |
| Terskikh, A | 1 |
| Lipton, SA | 1 |
| Tucci, ML | 1 |
| Harrington, AJ | 1 |
| McFarland, K | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| Tan, SK | 1 |
| Hartung, H | 1 |
| Visser-Vandewalle, V | 1 |
| Steinbusch, HW | 2 |
| Temel, Y | 1 |
| Sharp, T | 1 |
| Kalve, I | 1 |
| Nobre, A | 1 |
| Jungnickel, J | 1 |
| Köster-Patzlaff, C | 1 |
| Baron, O | 1 |
| Lieu, CA | 1 |
| Subramanian, T | 1 |
| Safi, R | 1 |
| Panahi, Y | 1 |
| Zaefizadeh, M | 1 |
| Gharib, E | 1 |
| Bhide, N | 1 |
| Surrena, MA | 1 |
| Tignor, S | 1 |
| Klioueva, A | 1 |
| Walters, H | 1 |
| Kareva, T | 1 |
| Yarygina, O | 1 |
| Kholodilov, N | 1 |
| Proft, J | 1 |
| Faraji, J | 1 |
| Robbins, JC | 1 |
| Zucchi, FC | 1 |
| Metz, GA | 4 |
| Braun, JE | 1 |
| Matsumoto, Y | 1 |
| Murakami, H | 1 |
| Hattori, N | 1 |
| Yoshimoto, K | 5 |
| Asano, S | 1 |
| Inden, M | 6 |
| Takahashi, K | 1 |
| Takata, K | 6 |
| Ito, N | 1 |
| Niwa, R | 1 |
| Funayama, R | 1 |
| Nishimura, K | 2 |
| Taniguchi, T | 3 |
| Honda, T | 1 |
| Taira, T | 3 |
| Ariga, H | 3 |
| Kim, TW | 1 |
| Moon, Y | 1 |
| Rhyu, IJ | 1 |
| Kang, EJ | 1 |
| Lee, YH | 1 |
| Lee, YM | 1 |
| Kumar, BM | 1 |
| Jeon, BG | 1 |
| Ock, SA | 1 |
| Rho, GJ | 1 |
| Thompson, AD | 1 |
| Dickerson, JW | 1 |
| Turle-Lorenzo, N | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Guhathakurta, S | 1 |
| Joh, TH | 1 |
| Beal, MF | 1 |
| Nahimi, A | 1 |
| Høltzermann, M | 1 |
| Simonsen, M | 1 |
| Jakobsen, S | 1 |
| Alstrup, AK | 1 |
| Vang, K | 1 |
| Møller, A | 1 |
| Wegener, G | 1 |
| Gjedde, A | 1 |
| Doudet, DJ | 1 |
| Vairetti, M | 1 |
| Ferrigno, A | 1 |
| Rizzo, V | 1 |
| Bianchi, A | 1 |
| Richelmi, P | 1 |
| Diana, V | 1 |
| Blesa, J | 1 |
| Khan, MM | 2 |
| Raza, SS | 1 |
| Ahmad, A | 4 |
| Khan, A | 2 |
| Islam, F | 4 |
| Safhi, MM | 2 |
| Tieu, K | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Rokosik, SL | 2 |
| Napier, TC | 2 |
| Spieles-Engemann, AL | 1 |
| Behbehani, MM | 1 |
| Wohlgenant, SL | 1 |
| Kemp, CJ | 1 |
| Cole-Strauss, A | 1 |
| Levine, ND | 2 |
| Gombash, SE | 1 |
| Thompson, VB | 1 |
| Lipton, JW | 2 |
| Lindemann, C | 1 |
| Grau, CM | 1 |
| Thiele, SL | 1 |
| Warre, R | 1 |
| Nash, JE | 2 |
| Davies, G | 1 |
| Dirling, LB | 1 |
| Costello, DJ | 1 |
| Hurley, FM | 1 |
| Kaindlstorfer, C | 1 |
| García, J | 4 |
| Wenning, GK | 3 |
| Döbrössy, MD | 1 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Doller, D | 1 |
| Sossi, V | 1 |
| Dinelle, K | 1 |
| Jivan, S | 1 |
| Fischer, K | 1 |
| Holden, JE | 1 |
| Doudet, D | 1 |
| Dong, FY | 1 |
| Abe, M | 1 |
| Minamino, H | 1 |
| Tooyama, I | 1 |
| Siliquini, S | 1 |
| Spillantini, MG | 1 |
| Latagliata, EC | 1 |
| Pascucci, T | 1 |
| Puglisi-Allegra, S | 1 |
| Halley, P | 1 |
| Sheline, CT | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Dimatelis, JJ | 1 |
| Hendricks, S | 1 |
| Hsieh, J | 1 |
| Vlok, NM | 1 |
| Bugarith, K | 1 |
| Fouillet, A | 1 |
| Levet, C | 1 |
| Virgone, A | 1 |
| Robin, M | 1 |
| Dourlen, P | 1 |
| Rieusset, J | 1 |
| Belaidi, E | 1 |
| Ovize, M | 1 |
| Mollereau, B | 1 |
| Riddle, JL | 1 |
| Rampersaud, N | 1 |
| Harkavyi, A | 1 |
| Giordano, G | 1 |
| Lever, R | 1 |
| Whitton, J | 1 |
| Whitton, P | 1 |
| Kemeny, S | 1 |
| Dery, D | 1 |
| Loboda, Y | 1 |
| Rovner, M | 1 |
| Lev, T | 1 |
| Zuri, D | 1 |
| Larisch, S | 1 |
| Zhang, LJ | 1 |
| Xue, YQ | 1 |
| Yang, C | 1 |
| Yang, WH | 1 |
| Qu, TY | 1 |
| Zhao, LR | 1 |
| Duan, WM | 1 |
| Shrivastava, P | 1 |
| Vaibhav, K | 1 |
| Tabassum, R | 1 |
| Ishrat, T | 1 |
| Solesio, ME | 2 |
| Saez-Atienzar, S | 1 |
| Jordán, J | 2 |
| Galindo, MF | 2 |
| Prime, TA | 1 |
| Logan, A | 1 |
| Del Mar Arroyo-Jimenez, M | 1 |
| Aristieta, A | 1 |
| Azkona, G | 1 |
| Sagarduy, A | 1 |
| Miguelez, C | 1 |
| Sanchez-Pernaute, R | 3 |
| Pilosof, NS | 1 |
| Ickowicz, D | 1 |
| Cohen, HY | 1 |
| Bunk, EC | 1 |
| Hemmer, K | 1 |
| Rajendra Kopalli, S | 1 |
| Koppula, S | 1 |
| Noh, SJ | 1 |
| Jin, Q | 1 |
| Hwang, BY | 1 |
| Berghauzen, K | 1 |
| Schulze, G | 1 |
| Patel, VP | 1 |
| Defranco, DB | 1 |
| Dun, Y | 1 |
| Feng, M | 1 |
| Ma, R | 1 |
| Gao, HC | 1 |
| Song, CY | 1 |
| Xiang, Y | 1 |
| Yan, ZH | 1 |
| Bai, GH | 1 |
| Ye, FQ | 1 |
| Li, XK | 1 |
| Denora, N | 1 |
| Laquintana, V | 1 |
| Lopalco, A | 1 |
| Trapani, A | 1 |
| Cimmino, CS | 1 |
| Laconca, L | 1 |
| Trapani, G | 1 |
| Zhang, YN | 1 |
| Sun, DJ | 1 |
| Fu, SB | 1 |
| Ma, L | 2 |
| Jiang, LH | 1 |
| Cui, C | 1 |
| Ding, HF | 1 |
| Rath, A | 1 |
| Pruszak, J | 1 |
| Krause, M | 1 |
| Maciaczyk, J | 1 |
| Yasui, H | 1 |
| Ashihara, E | 1 |
| Pandey, N | 1 |
| Fahey, MT | 1 |
| Jong, YJ | 1 |
| Yin, LH | 1 |
| Shen, H | 2 |
| Diaz-Ruiz, O | 1 |
| Bäckman, CM | 1 |
| Bae, E | 1 |
| Lopes-Borges, J | 1 |
| Luciano, T | 1 |
| Trom, CB | 1 |
| Silva, LA | 1 |
| Lira, FS | 1 |
| Ueda, Y | 1 |
| Tokashiki, S | 1 |
| Kanemaru, A | 1 |
| Kojima, T | 1 |
| Papathanou, M | 1 |
| van der Laan, R | 1 |
| Tao, CC | 1 |
| Chang, YP | 1 |
| García-Montes, JR | 1 |
| López-Colomé, AM | 1 |
| Bargas, J | 1 |
| Ziavra, D | 1 |
| Makri, G | 1 |
| Thomaidou, D | 1 |
| Lu, C | 1 |
| Roisen, F | 1 |
| Neto, SC | 1 |
| Salti, A | 1 |
| Puschban, Z | 2 |
| Stefanova, N | 2 |
| Nat, R | 1 |
| Dechant, G | 1 |
| Rendón, WO | 1 |
| Martínez-Alonso, E | 1 |
| Tomás, M | 1 |
| Martínez-Martínez, N | 1 |
| Martínez-Menárguez, JA | 1 |
| Suzuki, S | 1 |
| Kawamata, J | 1 |
| Matsushita, T | 1 |
| Hisahara, S | 1 |
| Kem, W | 1 |
| Giuliani, P | 1 |
| Romano, S | 1 |
| Ballerini, P | 1 |
| Ciccarelli, R | 1 |
| Petragnani, N | 1 |
| Cicchitti, S | 1 |
| Zuccarini, M | 1 |
| Rathbone, MP | 1 |
| Caciagli, F | 1 |
| Di Iorio, P | 1 |
| Grespi, F | 1 |
| Melino, G | 1 |
| Apple, DM | 1 |
| Jefferis, R | 1 |
| Geissler, SA | 1 |
| Pranski, EL | 1 |
| Dalal, NV | 1 |
| Sanford, CV | 1 |
| Herskowitz, JH | 1 |
| Gearing, M | 1 |
| Lazo, C | 1 |
| Miller, GW | 2 |
| Lah, JJ | 1 |
| Levey, AI | 2 |
| Betarbet, RS | 1 |
| Ribeiro, RP | 1 |
| Moreira, EL | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Dos Santos, AA | 1 |
| Peres, KC | 1 |
| Farina, M | 1 |
| Janjua, N | 1 |
| Takayama, F | 1 |
| Mankura, M | 1 |
| Ponnusamy, K | 1 |
| Abedi, PM | 1 |
| Delaville, C | 1 |
| De Deurwaerdère, P | 1 |
| Benjelloun, W | 1 |
| Thomas Tayra, J | 1 |
| Kadota, T | 1 |
| Kikuchi, Y | 1 |
| Liang, H | 1 |
| Vcelar, B | 1 |
| Weik, R | 1 |
| Pioli, EY | 1 |
| Porras, G | 1 |
| Ferreira, AF | 1 |
| Chaves-Kirsten, GP | 1 |
| Torrão, AS | 1 |
| Pires, RS | 1 |
| Bertrand, A | 1 |
| Heim, C | 1 |
| Sova, L | 1 |
| Kurz, T | 1 |
| Schwegler, H | 1 |
| Sontag, KH | 1 |
| Jacoby, DB | 1 |
| Lindberg, C | 1 |
| Ratliff, J | 1 |
| Wetzel, K | 1 |
| Stewart, GR | 1 |
| Dinsmore, J | 1 |
| Oiwa, Y | 1 |
| Yoshimura, R | 1 |
| Nakai, K | 3 |
| Itakura, T | 4 |
| Marco, S | 1 |
| Saura, J | 1 |
| Pérez-Navarro, E | 1 |
| José Martí, M | 1 |
| Agrawal, AK | 2 |
| Aziz, MH | 1 |
| Shukla, Y | 2 |
| Mathur, N | 1 |
| Seth, PK | 2 |
| Lorigados Pedre, L | 1 |
| Pavón Fuentes, N | 1 |
| Alvarez González, L | 1 |
| McRae, A | 1 |
| Serrano Sánchez, T | 1 |
| Blanco Lescano, L | 1 |
| Macías González, R | 1 |
| Alves Da Costa, C | 2 |
| Paitel, E | 1 |
| Vincent, B | 1 |
| Checler, F | 3 |
| Torres, C | 1 |
| Cai, G | 1 |
| Emerich, DF | 1 |
| Bartus, RT | 1 |
| Ryu, EJ | 2 |
| Harding, HP | 1 |
| Angelastro, JM | 2 |
| Vitolo, OV | 1 |
| Ron, D | 1 |
| Brederlau, A | 1 |
| Faigle, R | 1 |
| Kaplan, P | 1 |
| Funa, K | 1 |
| Klintenberg, R | 2 |
| Arts, J | 1 |
| Jongsma, M | 1 |
| Wikström, H | 1 |
| Gunne, L | 2 |
| Orr, CF | 1 |
| Rowe, DB | 1 |
| Halliday, GM | 1 |
| Triarhou, LC | 1 |
| Kannari, K | 1 |
| Yamato, H | 1 |
| Arai, A | 1 |
| Matsunaga, M | 2 |
| Vorobyov, VV | 1 |
| Schibaev, NV | 1 |
| Murray, TK | 1 |
| Whalley, K | 1 |
| Robinson, CS | 1 |
| Ward, MA | 1 |
| Hicks, CA | 1 |
| Lodge, D | 1 |
| Vandergriff, JL | 1 |
| Baumbarger, P | 1 |
| Siuda, E | 1 |
| Gates, M | 1 |
| Ogden, AM | 1 |
| Skolnick, P | 1 |
| Zimmerman, DM | 1 |
| Nisenbaum, ES | 1 |
| Bleakman, D | 1 |
| Lebsanft, HB | 1 |
| Mayerhofer, A | 1 |
| Kovar, KA | 1 |
| Schmidt, WJ | 2 |
| Ugarte, SD | 1 |
| Lin, E | 1 |
| Klann, E | 1 |
| Zigmond, MJ | 8 |
| Perez, RG | 1 |
| da Costa, CA | 1 |
| Xianwen, C | 1 |
| Dehua, X | 1 |
| Zhenguo, L | 1 |
| Lingfei, X | 1 |
| Smith, SW | 1 |
| Zhongcheng, Z | 1 |
| Yoshimura, N | 1 |
| Kuno, S | 3 |
| Chancellor, MB | 1 |
| De Groat, WC | 1 |
| Seki, S | 1 |
| Atsumi, M | 1 |
| Kawakami, J | 1 |
| Sugiyama, E | 1 |
| Kotaki, H | 1 |
| Sawada, Y | 1 |
| Sato, H | 2 |
| Yamada, Y | 1 |
| Iga, T | 1 |
| Galeffi, F | 1 |
| Bianchi, L | 2 |
| Bolam, JP | 2 |
| Della Corte, L | 1 |
| Darbaky, Y | 1 |
| Forni, C | 3 |
| Höglinger, G | 1 |
| Rousselet, E | 1 |
| Breidert, T | 1 |
| Parain, K | 1 |
| Feger, J | 4 |
| Ruberg, M | 3 |
| Prigent, A | 1 |
| Cohen-Salmon, C | 1 |
| Launay, JM | 1 |
| Venhuis, BJ | 1 |
| Dijkstra, D | 1 |
| Wustrow, D | 1 |
| Meltzer, LT | 1 |
| Wise, LD | 1 |
| Johnson, SJ | 1 |
| Wikström, HV | 1 |
| Cao, F | 1 |
| Tong, ET | 1 |
| Ferrer, B | 1 |
| Asbrock, N | 1 |
| Kathuria, S | 1 |
| Piomelli, D | 1 |
| Donaldson, AE | 2 |
| Fink, DJ | 1 |
| Glorioso, J | 1 |
| Mata, M | 1 |
| Feeley Kearney, JA | 1 |
| Albin, RL | 1 |
| Hara, H | 2 |
| Ohta, M | 2 |
| Ohta, K | 2 |
| Adachi, T | 2 |
| Zhuo, M | 1 |
| Yu, FR | 1 |
| Xu, DH | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Forsback, S | 1 |
| Niemi, R | 1 |
| Marjamäki, P | 1 |
| Eskola, O | 1 |
| Bergman, J | 1 |
| Grönroos, T | 1 |
| Haaparanta, M | 1 |
| Haapalinna, A | 1 |
| Rinne, J | 1 |
| Solin, O | 1 |
| Chouvet, G | 1 |
| Urbain, N | 1 |
| Vautrelle, N | 1 |
| Dahan, L | 1 |
| Astier, B | 1 |
| Renaud, B | 1 |
| Depino, AM | 1 |
| Earl, C | 1 |
| Kaczmarczyk, E | 1 |
| Ferrari, C | 1 |
| Besedovsky, H | 1 |
| Pitossi, FJ | 2 |
| Kase, H | 1 |
| Aoyama, S | 1 |
| Ichimura, M | 1 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koga, K | 1 |
| Koike, N | 1 |
| Kurokawa, M | 1 |
| Kuwana, Y | 1 |
| Mori, A | 1 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 1 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shindou, T | 1 |
| Shiozaki, S | 1 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 1 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 2 |
| Chase, TN | 3 |
| Dunah, AW | 1 |
| Sirianni, AC | 1 |
| Fienberg, AA | 1 |
| Bastia, E | 1 |
| Nakagawa, M | 1 |
| Ohgoh, M | 1 |
| Nishizawa, Y | 1 |
| Ogura, H | 1 |
| Sajadi, A | 1 |
| Aebischer, P | 4 |
| Ling, ZD | 1 |
| Chang, Q | 1 |
| Tong, CW | 1 |
| Landers, TM | 1 |
| Carvey, PM | 2 |
| Mague, SD | 1 |
| Pijanowski, RS | 1 |
| Harris, RC | 1 |
| Kleckner, NW | 1 |
| Matthews, RT | 1 |
| Burnstein, RM | 1 |
| Foltynie, T | 1 |
| He, X | 1 |
| Menon, DK | 1 |
| Svendsen, CN | 1 |
| Milton, AL | 1 |
| Marshall, JW | 1 |
| Cummings, RM | 1 |
| Baker, HF | 4 |
| Ridley, RM | 4 |
| Meng, CH | 1 |
| Ding, JH | 1 |
| He, HR | 1 |
| Yang, YL | 1 |
| Gu, B | 1 |
| Schlachetzki, F | 1 |
| Zhang, YF | 1 |
| Boado, RJ | 1 |
| Pardridge, WM | 1 |
| Kobayashi, K | 2 |
| Takeuchi, A | 3 |
| Yano, A | 3 |
| Hamada, H | 3 |
| Kaneoke, Y | 1 |
| Usui, N | 1 |
| Misawa, N | 1 |
| Nakayama, A | 1 |
| Yoshida, J | 1 |
| Claus, P | 1 |
| Werner, S | 1 |
| Timmer, M | 1 |
| Srinivasan, J | 1 |
| Lubics, A | 3 |
| Szalontay, L | 2 |
| Lengvári, I | 3 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Bower, KA | 1 |
| Fang, S | 1 |
| Thiele, CJ | 1 |
| Datla, KP | 4 |
| Bennett, RD | 1 |
| Zbarsky, V | 3 |
| Ke, B | 1 |
| Liang, YF | 1 |
| Higa, T | 1 |
| Bahorun, T | 1 |
| Aruoma, OI | 2 |
| Centonze, D | 2 |
| Rossi, S | 2 |
| Bernardi, G | 3 |
| Gluck, MR | 1 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 1 |
| Alemdar, AY | 1 |
| Sadi, D | 2 |
| McAlister, VC | 1 |
| Mendez, I | 2 |
| Yurek, DM | 2 |
| Fletcher-Turner, A | 2 |
| Nakao, N | 2 |
| Shintani-Mizushima, A | 1 |
| Kakishita, K | 1 |
| Delfino, MA | 1 |
| Stefano, AV | 1 |
| Ferrario, JE | 1 |
| Shi, LH | 1 |
| Anstrom, K | 1 |
| Ahn, TB | 1 |
| Kim, JM | 1 |
| Kwon, KM | 1 |
| Jeon, BS | 2 |
| Krishnamurthi, R | 2 |
| Stott, S | 1 |
| Maingay, M | 1 |
| Faull, RL | 3 |
| McCarthy, D | 1 |
| Gluckman, P | 2 |
| Guan, J | 2 |
| Baker, SA | 1 |
| Baker, KA | 1 |
| Hagg, T | 1 |
| Gillies, GE | 1 |
| Murray, HE | 1 |
| Dexter, D | 1 |
| McArthur, S | 1 |
| Linazasoro, G | 1 |
| Corvol, JC | 1 |
| Muriel, MP | 2 |
| Valjent, E | 1 |
| Hanoun, N | 2 |
| Girault, JA | 1 |
| Hervé, D | 1 |
| Leo, G | 1 |
| Vergoni, AV | 1 |
| Martínez, E | 1 |
| Hockemeyer, J | 1 |
| Lluis, C | 1 |
| Ferré, S | 2 |
| Mark, A | 1 |
| Chen, GJ | 1 |
| Schwartz, JP | 1 |
| Kim, MS | 1 |
| Lee, JI | 1 |
| Lee, WY | 1 |
| Sarre, S | 3 |
| Ebinger, G | 3 |
| Michotte, Y | 3 |
| Piecharka, DM | 1 |
| Whishaw, IQ | 3 |
| Manyam, BV | 1 |
| Dhanasekaran, M | 1 |
| Hare, TA | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Marshall, CE | 1 |
| Georgievska, B | 4 |
| Lacar, B | 1 |
| Delville, Y | 1 |
| Keep, RF | 1 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Xi, G | 1 |
| Ichinohe, N | 1 |
| Baba, M | 1 |
| Szegezdi, E | 1 |
| Quigney, DJ | 1 |
| Samali, A | 1 |
| Elkon, H | 2 |
| Wenji, Y | 1 |
| Yao, G | 1 |
| Haque, S | 1 |
| Sha, L | 1 |
| Kumaravel, G | 1 |
| Engber, TM | 3 |
| Whalley, ET | 1 |
| Conlon, PR | 1 |
| Chang, H | 1 |
| Kiesman, WF | 1 |
| Petter, RC | 1 |
| Eslamboli, A | 2 |
| Muzyczka, N | 3 |
| Burger, C | 2 |
| Mandel, RJ | 3 |
| Annett, L | 1 |
| Ogura, T | 1 |
| Ogata, M | 1 |
| Akita, H | 1 |
| Jitsuki, S | 1 |
| Akiba, L | 1 |
| Noda, K | 1 |
| Hoka, S | 1 |
| Saji, M | 1 |
| wen Ji, Y | 2 |
| Nishio, S | 1 |
| Manáková, S | 1 |
| Kääriäinen, T | 1 |
| Taari, H | 1 |
| Kulkarni, SK | 1 |
| Rafuse, VF | 1 |
| Soundararajan, P | 1 |
| Leopold, C | 1 |
| Robertson, HA | 3 |
| Setsuie, R | 1 |
| Kabuta, T | 1 |
| Wada, K | 1 |
| Nomoto, M | 1 |
| Nagai, M | 1 |
| Zheng, JS | 1 |
| Tang, LL | 1 |
| Zheng, SS | 1 |
| Zhan, RY | 1 |
| Zhou, YQ | 1 |
| Goudreau, J | 1 |
| Kaufman, D | 1 |
| Chen, AF | 1 |
| Parisi, S | 1 |
| Persico, MG | 1 |
| Arenas, E | 1 |
| Minchiotti, G | 1 |
| Mohapel, P | 2 |
| Frielingsdorf, H | 1 |
| Iwakura, Y | 1 |
| Piao, YS | 1 |
| Mizuno, M | 1 |
| Takei, N | 1 |
| Kakita, A | 1 |
| Takahashi, H | 1 |
| Nawa, H | 1 |
| Mignon, LJ | 1 |
| Wolf, WA | 2 |
| Sung, JY | 1 |
| Lee, ST | 1 |
| Paik, SR | 1 |
| Pelled, G | 2 |
| Bergman, H | 2 |
| Ben-Hur, T | 2 |
| Goelman, G | 2 |
| Duan, C | 1 |
| Ji, M | 1 |
| Domenici, MR | 1 |
| Martire, A | 1 |
| Coccurello, R | 1 |
| Reggio, R | 1 |
| Tebano, MT | 1 |
| Iancu, R | 1 |
| Das, T | 1 |
| Ravindran, A | 1 |
| Agarwal, AK | 1 |
| Dikshit, M | 2 |
| Jakel, RJ | 1 |
| Kern, JT | 1 |
| Johnson, DA | 1 |
| Johnson, JA | 1 |
| Shimizu, M | 1 |
| Tanaka, K | 2 |
| Ogawa, N | 2 |
| Kress, GJ | 1 |
| Reynolds, IJ | 1 |
| Thompson, L | 1 |
| Barraud, P | 1 |
| Andersson, E | 1 |
| Cheetham, SC | 1 |
| Kong, L | 1 |
| Lu, XG | 1 |
| Gao, Q | 1 |
| Geller, AI | 1 |
| Ridet, JL | 1 |
| Bensadoun, JC | 2 |
| Zurn, AD | 2 |
| Hayase, H | 1 |
| Yoo, YM | 1 |
| Lee, U | 1 |
| Brizard, M | 1 |
| Bemelmans, AP | 1 |
| Feuerstein, C | 1 |
| Mallet, J | 4 |
| Maries, E | 1 |
| Chu, Y | 1 |
| Olaru, E | 1 |
| Shannon, K | 1 |
| Tse, A | 1 |
| Ballermann, M | 1 |
| Smith, LK | 1 |
| Fouad, K | 1 |
| Tarohda, T | 1 |
| Yamamoto, M | 1 |
| Amano, R | 1 |
| Meissner, KK | 1 |
| Kirkham, DL | 1 |
| Fitzpatrick, E | 1 |
| Ashkan, K | 1 |
| Wallace, BA | 1 |
| Benabid, AL | 1 |
| Mitrofanis, J | 1 |
| Vernon, AC | 2 |
| Palmer, S | 1 |
| Croucher, MJ | 2 |
| Harrower, TP | 1 |
| Tyers, P | 1 |
| Hooks, Y | 1 |
| Johansson, S | 1 |
| Spenger, C | 1 |
| Goren, B | 1 |
| Kahveci, N | 1 |
| Eyigor, O | 1 |
| Alkan, T | 1 |
| Korfali, E | 1 |
| Ozluk, K | 1 |
| Parkar, S | 1 |
| Rai, DK | 1 |
| Noh, YH | 1 |
| Lee, DY | 1 |
| Chung, YH | 1 |
| Lee, WB | 1 |
| Kim, SS | 1 |
| Lowenstein, PR | 1 |
| Castro, MG | 1 |
| Petersén, A | 1 |
| Poewe, W | 1 |
| Hosman, K | 1 |
| Siebert, E | 1 |
| Kempermann, G | 1 |
| Petrus, DS | 1 |
| Kupsch, A | 4 |
| Hanrott, K | 1 |
| Gudmunsen, L | 1 |
| Wonnacott, S | 1 |
| Rodriguez-Oroz, MC | 1 |
| Takata, MK | 1 |
| Yamaguchi, F | 1 |
| Nakanose, K | 1 |
| Watanabe, Y | 1 |
| Hatano, N | 1 |
| Tsukamoto, I | 1 |
| Nagata, M | 1 |
| Izumori, K | 1 |
| Tokuda, M | 1 |
| Lehmensiek, V | 1 |
| Tan, EM | 1 |
| Liebau, S | 1 |
| Lenk, T | 1 |
| Zettlmeisl, H | 1 |
| González, S | 1 |
| Scorticati, C | 1 |
| de Miguel, R | 1 |
| Ramos, JA | 1 |
| Phillips, JM | 1 |
| Lam, HA | 1 |
| Ackerson, LC | 1 |
| Maidment, NT | 1 |
| Dunys, J | 1 |
| Brau, F | 1 |
| Wilk, S | 1 |
| Cappai, R | 1 |
| Fitzsimmons, DF | 1 |
| Moloney, TC | 1 |
| Ouyang, M | 1 |
| Nair, VD | 1 |
| Dekundy, A | 1 |
| Pietraszek, M | 1 |
| Schaefer, D | 1 |
| Danysz, W | 1 |
| Chalovich, EM | 1 |
| Zhu, JH | 1 |
| Caltagarone, J | 1 |
| Bowser, R | 1 |
| Kearns, SM | 1 |
| Scheffler, B | 1 |
| Goetz, AK | 1 |
| Lin, DD | 1 |
| Baker, HD | 1 |
| Roper, SN | 1 |
| Steindler, DA | 1 |
| Punati, A | 1 |
| Newman, MB | 1 |
| Soderstrom, K | 1 |
| Smith, MP | 2 |
| Antonelli, T | 1 |
| Agnati, L | 1 |
| Mazzoni, E | 1 |
| Tanganelli, S | 1 |
| Tomasini, MC | 1 |
| Ferraro, L | 1 |
| Saavedra, A | 1 |
| Baltazar, G | 1 |
| Santos, P | 1 |
| Carvalho, CM | 1 |
| Duarte, EP | 1 |
| Yamamuro, A | 1 |
| Yoshioka, Y | 1 |
| Ogita, K | 1 |
| Maeda, S | 1 |
| Knyihár-Csillik, E | 1 |
| Chadaide, Z | 1 |
| Mihály, A | 1 |
| Krisztin-Péva, B | 1 |
| Fenyo, R | 1 |
| Vécsei, L | 1 |
| Koike, H | 1 |
| Ishida, A | 1 |
| Shimamura, M | 1 |
| Mizuno, S | 1 |
| Ogihara, T | 1 |
| Kaneda, Y | 1 |
| Morishita, R | 1 |
| Aguiar, LM | 2 |
| Nobre, HV | 1 |
| Oliveira, AA | 2 |
| Freitas, RM | 1 |
| Vasconcelos, SM | 2 |
| Cunha, GM | 1 |
| Sousa, FC | 1 |
| Viana, GS | 2 |
| Yanagida, T | 2 |
| Tsuchiya, D | 1 |
| Yanagisawa, D | 1 |
| Kiso, Y | 1 |
| Agatsuma, T | 1 |
| Koide-Yoshida, S | 1 |
| Iguchi-Ariga, SM | 1 |
| Toth, G | 1 |
| Vaudano, E | 1 |
| Gijsbers, R | 1 |
| Debyser, Z | 1 |
| Van den Haute, C | 1 |
| Field, EF | 1 |
| Pellis, SM | 2 |
| Liu, WG | 1 |
| Lu, GQ | 1 |
| Li, B | 1 |
| Chen, SD | 2 |
| Ahmad, R | 1 |
| Mathur, D | 1 |
| Sagar, RK | 1 |
| Krishana, B | 1 |
| Latchoumycandane, C | 1 |
| Kaul, S | 1 |
| Wilhelm, M | 1 |
| Kukekov, NV | 1 |
| Gire, S | 1 |
| Zhou, FC | 2 |
| Rolland, AS | 1 |
| Herrero, MT | 1 |
| Garcia-Martinez, V | 1 |
| Gonzalez, D | 1 |
| Miyamoto, O | 1 |
| Touge, T | 1 |
| Sumitani, K | 1 |
| Kuriyama, S | 1 |
| Itano, T | 1 |
| Angelucci, ME | 1 |
| Canteras, NS | 1 |
| Lee, DC | 1 |
| Womble, TA | 1 |
| Mason, CW | 1 |
| Jackson, IM | 1 |
| Lamango, NS | 1 |
| Severs, WB | 1 |
| Palm, DE | 1 |
| Mignon, L | 1 |
| Malenka, RC | 1 |
| Christakou, A | 1 |
| Chudasama, Y | 1 |
| Robbins, TW | 2 |
| Matsuya, T | 1 |
| Takuma, K | 2 |
| Asai, M | 1 |
| Miyoshi, S | 1 |
| Noda, A | 1 |
| Nagai, T | 1 |
| Mizoguchi, H | 1 |
| Nishimura, S | 1 |
| Yamada, K | 2 |
| Zhang, JJ | 1 |
| Liu, GT | 1 |
| Wei, P | 1 |
| Zhou, HL | 1 |
| Han, ZT | 1 |
| Wu, QY | 1 |
| Pang, JX | 1 |
| Wang, TH | 1 |
| Marvanova, M | 1 |
| Nichols, CD | 1 |
| Negron, G | 1 |
| Matsukawa, N | 1 |
| Maki, M | 1 |
| Hara, K | 1 |
| Yu, G | 1 |
| Kim, KM | 1 |
| Morgan, JC | 1 |
| Sethi, KD | 1 |
| Tian, YY | 1 |
| Tang, CJ | 1 |
| Wang, JN | 1 |
| Chen, XW | 1 |
| Qiao, X | 1 |
| Sun, SG | 1 |
| Yamada, H | 1 |
| Aimi, Y | 1 |
| Nagatsu, I | 2 |
| Taki, K | 1 |
| Kudo, M | 1 |
| Arai, R | 1 |
| Laurén, J | 1 |
| Leppänen, VM | 1 |
| Andressoo, JO | 1 |
| Lindahl, M | 1 |
| Janhunen, S | 1 |
| Timmusk, T | 1 |
| Zhang, HL | 1 |
| Ren, HM | 1 |
| Su, YR | 1 |
| Jiang, YP | 1 |
| Yang, T | 1 |
| Bychkov, E | 1 |
| Ahmed, MR | 1 |
| Dalby, KN | 1 |
| Gurevich, EV | 1 |
| Kitayama, T | 1 |
| Onitsuka, Y | 1 |
| Morita, K | 1 |
| Dohi, T | 1 |
| Endo, S | 1 |
| Sullivan, LF | 1 |
| Lewin, AS | 1 |
| Terpstra, BT | 1 |
| Marchionini, DM | 1 |
| Sharma, R | 1 |
| McMillan, CR | 1 |
| Niles, LP | 1 |
| Li, QJ | 1 |
| Tang, YM | 1 |
| Zhou, DY | 1 |
| Li, XP | 1 |
| Xiao, SH | 1 |
| Jian, DX | 1 |
| Xing, YG | 1 |
| Fancellu, R | 1 |
| Sandrini, G | 1 |
| Signore, AP | 1 |
| Yin, XM | 1 |
| Lane, E | 1 |
| Dunnett, S | 1 |
| Lauwers, E | 1 |
| Bormans, G | 1 |
| Takano, K | 1 |
| Kitao, Y | 1 |
| Tabata, Y | 1 |
| Miura, H | 1 |
| Hibino, S | 1 |
| Choshi, T | 1 |
| Iinuma, M | 1 |
| Suzuki, H | 1 |
| Murakami, R | 1 |
| Yamada, M | 1 |
| Ogawa, S | 1 |
| Liu, CQ | 1 |
| Liu, FX | 1 |
| Hu, DN | 1 |
| Luo, JH | 1 |
| Gómez-Santos, C | 1 |
| Francisco, R | 1 |
| Giménez-Xavier, P | 1 |
| Ambrosio, S | 3 |
| Mocchetti, I | 1 |
| Bachis, A | 1 |
| Nosheny, RL | 1 |
| Tanda, G | 1 |
| García-Horsman, JA | 1 |
| Piltonen, M | 2 |
| Huotari, M | 2 |
| Paillé, V | 1 |
| Barone, I | 1 |
| Angela Cenci, M | 1 |
| Alvarez-Fischer, D | 1 |
| Henze, C | 1 |
| Strenzke, C | 1 |
| Westrich, J | 1 |
| Hartmann, A | 1 |
| Wrage, PC | 1 |
| Keefer, EW | 1 |
| Botterman, BR | 1 |
| Tansey, KE | 1 |
| Quinn, M | 1 |
| Mukhida, K | 1 |
| Hong, M | 1 |
| de Sousa, FC | 1 |
| Aponso, PM | 1 |
| Connor, B | 2 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Ferrante, RJ | 1 |
| Darmopil, S | 1 |
| Muñetón-Gómez, VC | 1 |
| de Ceballos, ML | 1 |
| Bernson, M | 1 |
| Rota, D | 1 |
| Debetto, P | 1 |
| Peroni, D | 1 |
| Guidolin, D | 1 |
| Skaper, SD | 2 |
| Giusti, P | 2 |
| Kuramoto, S | 1 |
| Kekki, H | 1 |
| Lehtonen, S | 1 |
| Nenonen, T | 1 |
| Lecklin, A | 1 |
| Miller, RL | 1 |
| James-Kracke, M | 1 |
| Sun, GY | 1 |
| Sun, AY | 1 |
| Chergui, K | 1 |
| Li, LY | 1 |
| Zhao, XL | 1 |
| Fei, XF | 1 |
| Gu, ZL | 1 |
| Qin, ZH | 1 |
| Liang, ZQ | 1 |
| Fantin, M | 1 |
| Auberson, YP | 1 |
| Zhu, WM | 1 |
| Horne, MH | 1 |
| Henderson, J | 1 |
| Lawrence, AJ | 1 |
| O'Connor, L | 1 |
| Drago, J | 1 |
| Horne, MK | 1 |
| Haik, KL | 1 |
| Shear, DA | 1 |
| Hargrove, C | 1 |
| Patton, J | 1 |
| Mazei-Robison, M | 1 |
| Dunbar, GL | 1 |
| Taverna, S | 1 |
| Ilijic, E | 1 |
| Pott Godoy, MC | 1 |
| Tarelli, R | 1 |
| Ferrari, CC | 1 |
| Sarchi, MI | 1 |
| Duvoisin, RC | 1 |
| Heikkila, RE | 1 |
| Manzino, L | 1 |
| Stricker, EM | 3 |
| Acheson, AL | 1 |
| Stachowiak, MK | 1 |
| Cohen, G | 2 |
| Hultgren, L | 1 |
| Olsson, D | 1 |
| Bagli, J | 1 |
| Bogri, T | 1 |
| Voith, K | 1 |
| Schneider, MB | 2 |
| Murrin, LC | 2 |
| Pfeiffer, RF | 2 |
| Deupree, JD | 1 |
| Atadzhanov, M | 1 |
| Lin, JC | 1 |
| Chiou, AL | 1 |
| Moukhles, H | 1 |
| Nieoullon, A | 2 |
| Daszuta, A | 1 |
| Yanai, J | 1 |
| Silverman, WF | 1 |
| Shamir, D | 1 |
| Goldstein, DS | 1 |
| Kopin, IJ | 2 |
| Fornaguera, J | 1 |
| Carey, RJ | 5 |
| Schwarting, RK | 2 |
| Ueda, H | 1 |
| Okumura, F | 1 |
| Inoue, A | 1 |
| Nakata, Y | 1 |
| Ozaki, N | 1 |
| Yue, JL | 1 |
| Misu, Y | 1 |
| Levivier, M | 3 |
| Ferreira, M | 1 |
| Donaldson, D | 2 |
| Togasaki, DM | 1 |
| Carroll, CB | 1 |
| Holloway, V | 1 |
| Mitchell, IJ | 1 |
| Horellou, P | 2 |
| Vigne, E | 1 |
| Castel, MN | 1 |
| Barnéoud, P | 1 |
| Colin, P | 2 |
| Perricaudet, M | 1 |
| Delaère, P | 1 |
| Espino, A | 1 |
| Llorens, J | 1 |
| Calopa, M | 2 |
| Bartrons, R | 1 |
| Rodriguez-Farré, E | 1 |
| Lindner, MD | 1 |
| Winn, SR | 2 |
| Baetge, EE | 1 |
| Hammang, JP | 1 |
| Gentile, FT | 1 |
| Doherty, E | 1 |
| McDermott, PE | 1 |
| Frydel, B | 1 |
| Ullman, MD | 1 |
| Olsson, M | 1 |
| Bentlage, C | 2 |
| May, CH | 1 |
| Guilarte, TR | 1 |
| Wagner, HN | 1 |
| Vogel, S | 1 |
| Silverman, PB | 1 |
| Boldry, RC | 1 |
| Annett, LE | 2 |
| Martel, FL | 2 |
| Rogers, DC | 2 |
| Diederich, NJ | 1 |
| Goetz, CG | 1 |
| Andrew, R | 1 |
| Watson, DG | 1 |
| Best, SA | 1 |
| Midgley, JM | 1 |
| Wenlong, H | 1 |
| Petty, RK | 1 |
| Hossain, MA | 1 |
| Weiner, N | 1 |
| Hudson, JL | 1 |
| van Horne, CG | 1 |
| Brock, S | 1 |
| Clayton, J | 1 |
| Masserano, J | 1 |
| Ben-Shachar, D | 1 |
| Eshel, G | 1 |
| Plunkett, RJ | 2 |
| Jacobowitz, DM | 1 |
| Oldfield, EH | 1 |
| Löschmann, PA | 1 |
| Eblen, F | 1 |
| Wachtel, H | 1 |
| Kockgether, T | 1 |
| Bencsics, C | 1 |
| Kang, UJ | 1 |
| Efange, SM | 1 |
| Langason, RB | 1 |
| Khare, AB | 1 |
| Low, WC | 1 |
| Earl, CD | 1 |
| Reum, T | 2 |
| Sautter, J | 2 |
| Morgenstern, R | 2 |
| Schuller, JJ | 1 |
| Marshall, JF | 1 |
| Bernard, V | 2 |
| Gardiol, A | 1 |
| Faucheux, B | 1 |
| Bloch, B | 2 |
| Agid, Y | 5 |
| Schwarz, SC | 1 |
| Kupsch, AR | 1 |
| Banati, R | 1 |
| Linert, W | 3 |
| Herlinger, E | 2 |
| Jameson, RF | 2 |
| Kienzl, E | 4 |
| Jellinger, K | 4 |
| Anglade, P | 1 |
| Mouatt-Prigent, A | 1 |
| Hirsch, E | 1 |
| Linert, L | 1 |
| Puchinger, L | 1 |
| Stachelberger, H | 2 |
| Cahill, DW | 1 |
| Sanberg, PR | 1 |
| Zetterström, RH | 1 |
| Williams, R | 1 |
| Perlmann, T | 1 |
| Martens, DJ | 1 |
| Miklyaeva, EI | 1 |
| Papa, S | 1 |
| Bonastre, M | 1 |
| Möller, JC | 1 |
| Choi-Lundberg, DL | 1 |
| Chang, YN | 1 |
| Chiang, YL | 1 |
| Hay, CM | 1 |
| Mohajeri, H | 1 |
| Davidson, BL | 1 |
| Bohn, MC | 2 |
| Hamilton, GS | 2 |
| Ross, DT | 2 |
| Valentine, HL | 1 |
| Guo, H | 2 |
| Connolly, MA | 1 |
| Liang, S | 1 |
| Ramsey, C | 1 |
| Li, JH | 1 |
| Howorth, P | 2 |
| Soni, R | 1 |
| Fuller, M | 1 |
| Sauer, H | 1 |
| Nowotnik, AC | 1 |
| Suzdak, PD | 1 |
| Bodis-Wollner, I | 1 |
| Glinka, Y | 1 |
| Gassen, M | 1 |
| Bowenkamp, KE | 1 |
| Lapchak, PA | 2 |
| Miller, PJ | 1 |
| Hastings, TG | 3 |
| Dluzen, D | 1 |
| Araujo, DM | 1 |
| Hilt, DC | 1 |
| Sheng, J | 1 |
| Jiao, S | 1 |
| Ogura, M | 1 |
| Consales, A | 1 |
| Lauretti, L | 1 |
| Henry, B | 1 |
| Mayo, JC | 1 |
| Sainz, RM | 1 |
| Uria, H | 1 |
| Esteban, MM | 1 |
| Turgut, M | 1 |
| Blanco, L | 1 |
| Pavón, N | 1 |
| Alvaŕez, P | 1 |
| Castellano, O | 1 |
| Castillo, L | 1 |
| de la Cuétara, K | 1 |
| Macías, R | 1 |
| Sañudo-Peña, MC | 1 |
| Patrick, SL | 1 |
| Khen, S | 1 |
| Patrick, RL | 1 |
| Tsou, K | 1 |
| Walker, JM | 1 |
| Izurieta-Sánchez, P | 1 |
| Mirochnitchenko, O | 1 |
| Inouye, M | 1 |
| Riedl, AG | 1 |
| Watts, PM | 1 |
| Edwards, RJ | 1 |
| Schulz-Utermoehl, T | 1 |
| Boobis, AR | 1 |
| Marsden, CD | 6 |
| Hanson, GR | 1 |
| Keefe, KA | 2 |
| Reader, TA | 1 |
| Dewar, KM | 1 |
| Rodríguez-Puertas, R | 1 |
| Koistinaho, J | 1 |
| Hökfelt, T | 1 |
| Hebb, MO | 1 |
| Laribi, O | 1 |
| Abrous, DN | 1 |
| Hassani, OK | 2 |
| Double, KL | 1 |
| Riederer, PF | 1 |
| Grote, C | 1 |
| Rausch, WD | 1 |
| Mäurer, M | 1 |
| Wesemann, W | 1 |
| Tolwani, RJ | 1 |
| Petzinger, GM | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Cunningham, MG | 1 |
| Corti, O | 1 |
| Sánchez-Capelo, A | 1 |
| Hamon, M | 1 |
| Klein, RL | 1 |
| Lewis, MH | 1 |
| Meyer, EM | 1 |
| McNaught, KS | 2 |
| de Groote, C | 1 |
| Löchmann, PA | 1 |
| Luiten, PG | 1 |
| Klockgether, T | 1 |
| Zeng, BY | 2 |
| Dass, B | 2 |
| Owen, A | 2 |
| Cannizzaro, C | 2 |
| Tel, BC | 2 |
| Casas, M | 1 |
| Prat, G | 1 |
| Robledo, P | 1 |
| Barbanoj, M | 1 |
| Jané, F | 1 |
| Ekesbo, A | 1 |
| Gunne, LM | 1 |
| Sonesson, C | 1 |
| Tedroff, J | 1 |
| Waldvogel, HJ | 1 |
| Clark, R | 1 |
| Soto-Otero, R | 1 |
| Méndez-Alvarez, E | 1 |
| Hermida-Ameijeiras, A | 1 |
| Muñoz-Patiño, AM | 1 |
| Sherki, Y | 1 |
| Fridkin, M | 1 |
| Brenneman, DE | 1 |
| Su, TP | 1 |
| Schicatano, EJ | 1 |
| Peshori, KR | 1 |
| Gopalaswamy, R | 1 |
| Sahay, E | 1 |
| Hurlbert, MS | 1 |
| Schaack, J | 1 |
| Prasad, KN | 1 |
| Freed, CR | 2 |
| Tsuboi, K | 2 |
| Kimber, TA | 1 |
| Shults, CW | 3 |
| Grünblatt, E | 1 |
| Mandel, S | 1 |
| Shen, Y | 1 |
| Muramatsu, SI | 1 |
| Ikeguchi, K | 2 |
| Fujimoto, KI | 1 |
| Fan, DS | 1 |
| Ogawa, M | 1 |
| Mizukami, H | 2 |
| Urabe, M | 1 |
| Kume, A | 2 |
| Urano, F | 2 |
| Suzuki, T | 1 |
| Ichinose, H | 2 |
| Nagatsu, T | 2 |
| Monahan, J | 1 |
| Nakano, I | 2 |
| Ozawa, K | 2 |
| Bauer, M | 1 |
| Grimm, L | 1 |
| Meitinger, T | 1 |
| Ueffing, M | 1 |
| Aoi, M | 1 |
| Tomita, S | 1 |
| Ohmoto, T | 1 |
| Kozlowski, DA | 1 |
| Tillerson, JL | 2 |
| Anichtchik, OV | 1 |
| Peitsaro, N | 1 |
| Haycock, JW | 1 |
| Müller, CE | 1 |
| Ray, J | 1 |
| Gage, FH | 2 |
| Choi, HY | 1 |
| Song, JH | 1 |
| Park, DK | 1 |
| Ross, GM | 1 |
| Meissner, W | 1 |
| Reese, R | 1 |
| Sohr, R | 1 |
| Le, WD | 1 |
| Jankovic, J | 1 |
| Xie, W | 1 |
| Appel, SH | 1 |
| Bas, J | 1 |
| Mestre, M | 1 |
| Molleví, DG | 1 |
| Cutillas, B | 1 |
| Buendia, E | 1 |
| Dabbeni-Sala, F | 1 |
| Franceschini, D | 1 |
| Roedter, A | 1 |
| Samii, M | 1 |
| Walter, GF | 1 |
| Brandis, A | 1 |
| Yu, TS | 1 |
| Wang, SD | 1 |
| Yin, HS | 1 |
| Pollack, AE | 1 |
| Haisley, EC | 1 |
| Costantini, LC | 2 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Rodríguez Díaz, M | 1 |
| Abdala, P | 2 |
| González-Hernández, T | 2 |
| Rosenblad, C | 2 |
| Holm, KH | 1 |
| Cicchetti, F | 2 |
| Bjorklund, L | 1 |
| Boonman, Z | 1 |
| Tandon, P | 1 |
| Deacon, TW | 1 |
| Huang, X | 1 |
| Chen, DF | 1 |
| Blunt, SB | 2 |
| Cohen, AD | 1 |
| Philhower, J | 1 |
| Hayes, J | 1 |
| Corte, LD | 1 |
| Naoi, M | 2 |
| Maruyama, W | 2 |
| Wu, JN | 1 |
| Cherng, TL | 1 |
| Kasanetz, F | 1 |
| Kargieman, L | 1 |
| Pazo, JH | 1 |
| Riquelme, LA | 1 |
| Magill, PJ | 1 |
| Sieroń, A | 1 |
| Plech, A | 1 |
| Kubański, N | 1 |
| Cieślar, G | 1 |
| Carvalho, GA | 1 |
| Harvey-White, J | 1 |
| Cunningham, J | 1 |
| Mouroux, M | 1 |
| Bohme, GA | 1 |
| Stutzmann, JM | 1 |
| Barthwal, MK | 1 |
| Bjorklund, LM | 1 |
| Andersson, T | 1 |
| Chen, IY | 1 |
| Brownell, AL | 2 |
| Jenkins, BG | 1 |
| Wahlestedt, C | 1 |
| Araki, T | 1 |
| Matsubara, M | 1 |
| Fujihara, K | 1 |
| Kato, H | 1 |
| Itoyama, Y | 1 |
| Riobó, NA | 1 |
| Schöpfer, FJ | 1 |
| Boveris, AD | 1 |
| Cadenas, E | 1 |
| Poderoso, JJ | 1 |
| Sakata, M | 1 |
| Sei, H | 1 |
| Toida, K | 1 |
| Fujihara, H | 1 |
| Urushihara, R | 1 |
| Morita, Y | 1 |
| Oya-Ito, T | 1 |
| Shamoto-Nagai, M | 1 |
| Osawa, T | 1 |
| Fujita, N | 1 |
| Williams, K | 1 |
| Chen, YI | 1 |
| Livni, E | 1 |
| Wu, HQ | 1 |
| Rassoulpour, A | 1 |
| Schwarcz, R | 1 |
| Muramatsu, S | 1 |
| Fujimoto, K | 1 |
| Okada, T | 1 |
| Hanazono, Y | 1 |
| Manrique, C | 1 |
| Veng, LM | 1 |
| Bjugstad, KB | 1 |
| Marrack, P | 1 |
| Clarkson, ED | 1 |
| Bell, KP | 1 |
| Hutt, C | 1 |
| Zawada, WM | 1 |
| Paul, ML | 1 |
| Graybiel, AM | 1 |
| David, JC | 1 |
| Ewing, SE | 1 |
| Weber, RJ | 1 |
| Zauner, A | 1 |
| Pifl, C | 1 |
| Reither, H | 1 |
| Hornykiewicz, O | 1 |
| Abercrombie, ED | 1 |
| Carman, LS | 1 |
| Cozzolino, A | 1 |
| Di Chiara, G | 1 |
| Martinez-Mir, MI | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
| Jolicoeur, FB | 2 |
| Rivest, R | 2 |
| Drumheller, A | 1 |
| Blunt, S | 1 |
| St-Pierre, S | 1 |
| García-Hernández, F | 1 |
| Mendoza-Ramírez, JL | 1 |
| Pacheco-Cano, MT | 1 |
| Komisaruk, BR | 1 |
| Becker, JB | 1 |
| Curran, EJ | 1 |
| Freed, WJ | 1 |
| Poltorak, M | 1 |
| Nishino, H | 1 |
| Hashitani, T | 1 |
| Kumazaki, M | 1 |
| Hida, H | 1 |
| Makino, T | 1 |
| Sakurai, T | 1 |
| Furuyama, F | 1 |
| Isobe, Y | 1 |
| Vermeulen, RJ | 1 |
| Tonnaer, JA | 1 |
| Mempel, E | 1 |
| Wieczorek, M | 1 |
| Jedrzejewska, A | 1 |
| Dymecki, J | 3 |
| Kebabian, JW | 1 |
| Briggs, C | 1 |
| Britton, DR | 1 |
| Asin, K | 1 |
| DeNinno, M | 1 |
| MacKenzie, RG | 1 |
| McKelvy, JF | 1 |
| Schoenleber, R | 1 |
| Mayo, W | 1 |
| Brice, A | 1 |
| Duyckaerts, C | 1 |
| Hauw, JJ | 1 |
| Simon, H | 1 |
| LeMoal, M | 1 |
| Lindefors, N | 1 |
| Brodin, E | 1 |
| Tossman, U | 1 |
| Segovia, J | 1 |
| Fitzgerald, LR | 1 |
| Glick, SD | 1 |
| Schneider, AS | 1 |
| Wahlberg, L | 1 |
| Tresco, PA | 1 |
| Salamone, JD | 1 |
| Huffaker, TK | 1 |
| Boss, BD | 1 |
| Morgan, AS | 1 |
| Neff, NT | 1 |
| Strecker, RE | 2 |
| Spence, MS | 1 |
| Miao, R | 1 |
| Apicella, P | 1 |
| Legallet, E | 1 |
| Trouche, E | 1 |
| Xu, DL | 1 |
| Yu, WC | 1 |
| Pan, GB | 1 |
| Cooper, DR | 1 |
| Marrel, C | 1 |
| van de Waterbeemd, H | 1 |
| Testa, B | 1 |
| Boyce, S | 1 |
| Kenny, AM | 1 |
| Baden, DR | 1 |
| Cash, R | 1 |
| Raisman, R | 1 |
| Lanfumey, L | 1 |
| Ploska, A | 1 |
| Hassan, MN | 1 |
| Higgins, D | 1 |
| Traub, M | 1 |
| Fahn, S | 1 |
| Kamei, I | 1 |
| Naka, Y | 1 |
| Nakakita, K | 1 |
| Imai, H | 1 |
| Komai, N | 1 |
| Clarke, DJ | 1 |
| Nilsson, OG | 1 |
| Lindvall, O | 1 |
| Baumeister, AA | 1 |
| Frye, GD | 1 |
| Schoemaker, H | 1 |
| Pimoule, C | 1 |
| Arbilla, S | 1 |
| Scatton, B | 1 |
| Javoy-Agid, F | 1 |
| Langer, SZ | 1 |
| Markiewicz, D | 2 |
| Półtorak, M | 2 |
| Puciłowski, O | 2 |
| Kostowski, W | 2 |
| Bidziński, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Different Physical Therapies and Dance on Clinical and Functional Parameters, Muscle Quality, Pendular Mechanism of the Gait and Brain-derived Neurotrophic Factor in People With Parkinson's Disease[NCT03860649] | 100 participants (Actual) | Interventional | 2018-08-01 | Active, not recruiting | |||
| The Impact of Video Dance Class and Unsupervised Physical Activity on Parkinson's People During the Covid-19 Pandemic: Interventional[NCT04422353] | 60 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | |||
| Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease[NCT01341431] | Phase 2 | 50 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures[NCT05696665] | 120 participants (Anticipated) | Interventional | 2022-07-05 | Recruiting | |||
| Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease[NCT03079310] | 15 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.[NCT03526991] | 10 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease[NCT04956770] | 2 participants (Actual) | Interventional | 2021-06-14 | Active, not recruiting | |||
| Effects of Repetitive Trans Spinal Magnetic Stimulation Associated With Treadmill Gait Training on Gait Disorders in Patients With Parkinson's Disease[NCT05938673] | 76 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | |||
| Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease; a Randomized, Crossover, Double Blinded, Placebo-Controlled Study[NCT05148468] | 12 participants (Anticipated) | Interventional | 2021-11-30 | Active, not recruiting | |||
| Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease[NCT02388204] | 20 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| Efficacy of Repetitive Trans-spinal Magnetic Stimulation on Gait Abnormalities in Parkinson's Disease Patients: A Double-blinded Randomized Controlled Trial[NCT05271513] | 38 participants (Actual) | Interventional | 2023-01-01 | Completed | |||
| PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.[NCT01446614] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease[NCT04506073] | Phase 2 | 45 participants (Actual) | Interventional | 2020-11-09 | Completed | ||
| Phase II Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through the Vitamin D Pathway[NCT01499940] | Phase 2 | 9 participants (Actual) | Interventional | 2012-01-31 | Terminated (stopped due to Research cancelled - no funding identified.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
NCI CTCAE Version 4.0 (NCT01499940)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Vitamin D3 2000 IU/Day | 5 |
80 reviews available for oxidopamine and Parkinson Disease
| Article | Year |
|---|---|
Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Neurotoxins; Oxidopamine; Parkinson | 2022 |
The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine- Induced Parkinson's Disease in Zebrafish: The Current Applications and Perspectives.
Topics: Acetylcholinesterase; Animals; Disease Models, Animal; Dopaminergic Neurons; Humans; Neuroprotection | 2023 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Electron Tr | 2023 |
Application of neurotoxin- and pesticide-induced animal models of Parkinson's disease in the evaluation of new drug delivery systems.
Topics: Animals; Disease Models, Animal; Neurotoxins; Oxidopamine; Parkinson Disease; Pesticides | 2022 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Lev | 2023 |
6-Hydroxydopamine: a far from simple neurotoxin.
Topics: Animals; Disease Models, Animal; Humans; Neurotoxins; Oxidopamine; Parkinson Disease | 2020 |
Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Disease Models, Animal; Do | 2020 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; M | 2020 |
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2020 |
Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gene Knockdown Techniques; Neurotox | 2020 |
Deep brain stimulation in Parkinson's disease patients and routine 6-OHDA rodent models: Synergies and pitfalls.
Topics: Animals; Deep Brain Stimulation; Humans; Oxidopamine; Parkinson Disease; Rodentia; Subthalamic Nucle | 2021 |
Synaptic Zinc: An Emerging Player in Parkinson's Disease.
Topics: Animals; Basal Ganglia; Cation Transport Proteins; Cerebral Cortex; Chelating Agents; Corpus Striatu | 2021 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dys | 2021 |
Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
Topics: Animals; Axons; Brain; Disease Models, Animal; Dopaminergic Neurons; Humans; Nerve Regeneration; Oxi | 2018 |
Classic animal models of Parkinson's disease: a historical perspective.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Oxidopamine; | 2019 |
In vivo, in vitro and pharmacologic models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Humans; MPTP Poisoning; Oxidopamine; Parkinson Disease | 2019 |
NanoCsA improves the survival of human iPSC transplant in hemiparkinsonian rats.
Topics: Animals; Cell Differentiation; Corpus Striatum; Cyclosporine; Disease Models, Animal; Graft Survival | 2019 |
A secret that underlies Parkinson's disease: The damaging cycle.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; alpha-Synuclein; Antiparkinson Agents; Biog | 2019 |
What basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Biological Clocks; Disease Mod | 2013 |
[Dopaminergic neuroprotection via Nrf2-ARE pathway activation: identification of an activator from green perilla leaves].
Topics: Acetylcysteine; Animals; Antioxidant Response Elements; Cell Death; Chalcones; Dopaminergic Neurons; | 2013 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Park | 2014 |
Parkinson's disease and enhanced inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyto | 2015 |
The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model.
Topics: Adrenergic Agents; Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Humans; N | 2017 |
Changes in Rat 50-kHz Ultrasonic Vocalizations During Dopamine Denervation and Aging: Relevance to Neurodegeneration.
Topics: Adrenergic Agents; Aging; Animals; Denervation; Dopamine; Neurodegenerative Diseases; Oxidopamine; P | 2015 |
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Topics: alpha-Synuclein; Animals; Cholecystokinin; Efferent Pathways; Enteric Nervous System; Gastric Emptyi | 2015 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; D | 2008 |
The 6-hydroxydopamine model: news from the past.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Humans; Oxidopamine; Parkinson Disease | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2008 |
Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Disease Models, Animal; Dopamine; Intralaminar Thala | 2009 |
Not lost in translation Sensing the loss and filling the gap during regeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Mesencephalon | 2009 |
Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models.
Topics: Animals; Biomarkers; Cell Death; Central Nervous System; Free Radicals; Humans; MPTP Poisoning; Oxid | 2010 |
Neurotoxic in vivo models of Parkinson's disease recent advances.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; MPTP Poisoning; Neurotoxicity Syndromes; Neurotox | 2010 |
Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease.
Topics: Animals; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Learning; M | 2010 |
Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dopamine; Humans; Inflammation; Lipopolysaccha | 2010 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; L | 2011 |
Clinical and experimental experiences of graft-induced dyskinesia.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesias; Humans; Oxidopamine; Par | 2011 |
The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; N | 2012 |
Animal models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Humans; Insecticides; Methamphetamine; MPTP Poisoning; Oxidopamine; | 2012 |
A guide to neurotoxic animal models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Haplorhini; Lewy Bodies; Mice; MPTP Poisoning; Neu | 2011 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modifie | 2012 |
Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Genetic Vectors; Humans; Oxidopamine; Parkinson Di | 2012 |
An inflammatory review of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Gangliosides; Humans; Immunologic Surv | 2002 |
[Parkinson's disease and oxidative stress].
Topics: Antioxidants; Humans; Oxidative Stress; Oxidopamine; Parkinson Disease | 1999 |
Histochemical properties of intrastriatal mesencephalic grafts.
Topics: Animals; Dopamine; Graft Survival; Humans; Mice; Mice, Neurologic Mutants; Nerve Tissue Proteins; Ox | 2002 |
Animal models of Parkinson's disease in rodents induced by toxins: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Basal Ganglia; Brain Stem; | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dose-Response | 2004 |
Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Estrogens; Female; Male; Neuroprotective Agents; Oxidopamine; Parki | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
The potential role of vascular endothelial growth factor in the central nervous system.
Topics: Animals; Central Nervous System; Dopamine; Humans; Nerve Regeneration; Neural Networks, Computer; Ne | 2004 |
Marmoset monkey models of Parkinson's disease: which model, when and why?
Topics: alpha-Synuclein; Animals; Callithrix; Disease Models, Animal; Humans; Oxidopamine; Parkinson Disease | 2005 |
Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Humans; Motor Activity; Oxidop | 2006 |
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Disease Progre | 2006 |
Neural repair strategies for Parkinson's disease: insights from primate models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Deep Brain Stimulation; | 2006 |
The 6-hydroxydopamine model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Humans; Oxidopamine; Parkinson Disease | 2007 |
Nonhuman primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavioral Symptoms; Disease Models, Animal; | 2007 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Dr | 2008 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysac | 2009 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease M | 1994 |
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; | 1993 |
[Fetal and adrenal transplantation in Parkinson disease: theoretical bases and clinical results].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Aged; Animals; Dopamine; Fetal Tissue | 1993 |
Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Basal Ganglia; Brain Tissue | 1993 |
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine Agonists; Functional Laterality; Humans; Levodopa; Mo | 1996 |
Potential of neurotrophic factors in therapy of Parkinson's disease.
Topics: Adrenal Medulla; Animals; Cells, Cultured; Dopamine; Drug Evaluation, Preclinical; Drug Synergism; G | 1996 |
Electrophysiological assessment of retinal dopaminergic deficiency.
Topics: Animals; Aphakia; Dopamine; Dopamine Antagonists; Electrodiagnosis; Electroretinography; Evoked Pote | 1996 |
Mechanism of 6-hydroxydopamine neurotoxicity.
Topics: Animals; Brain; Chelating Agents; Free Radical Scavengers; Free Radicals; Humans; Mitochondria; Mode | 1997 |
Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.
Topics: Animals; Antioxidants; Dopamine; Humans; Incidence; Levodopa; Middle Aged; Neurons; Neurotoxins; Oxi | 1997 |
Gene therapy for Parkinson's disease.
Topics: Adenoviruses, Human; Animals; Astrocytes; Cell Survival; Cell Transplantation; Cells, Cultured; Corp | 1997 |
Free radicals and the pathobiology of brain dopamine systems.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyampheta | 1998 |
Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease.
Topics: Animals; Animals, Newborn; Denervation; Dopamine; Humans; Neostriatum; Oxidopamine; Parkinson Diseas | 1999 |
Role of iron in 6-hydroxydopamine neurotoxicity.
Topics: Animals; Dopamine; Humans; Iron; Neurotoxins; Oxidopamine; Parkinson Disease | 1999 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
Topics: Animals; Disease Models, Animal; Humans; MPTP Poisoning; Neuroprotective Agents; Oxidopamine; Parkin | 2000 |
From arousal to cognition: the integrative position of the prefrontal cortex.
Topics: Acetylcholine; Animals; Arousal; Attention; Brain Mapping; Cognition; Corpus Striatum; Dopamine; Dop | 2000 |
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Pa | 1992 |
A68930: a potent and specific agonist for the D-1 dopamine receptor.
Topics: Animals; Benzopyrans; Chromans; Corpus Striatum; Denervation; Dopamine; Hydroxydopamines; Oxidopamin | 1990 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocripti | 1988 |
The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome.
Topics: Adenine Nucleotides; Animals; Central Nervous System; Child; Child, Preschool; Clonidine; Corpus Str | 1985 |
3 trials available for oxidopamine and Parkinson Disease
| Article | Year |
|---|---|
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla | 2004 |
Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation.
Topics: Animals; Brain; Cyclosporine; Dextroamphetamine; Dopamine Agonists; Immunosuppressive Agents; Locomo | 1996 |
Reflex excitability regulates prepulse inhibition.
Topics: Acoustic Stimulation; Aged; Animals; Blinking; Electromyography; Female; Humans; Male; Middle Aged; | 2000 |
1374 other studies available for oxidopamine and Parkinson Disease
| Article | Year |
|---|---|
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
Topics: Acetylcysteine; Active Transport, Cell Nucleus; Adrenergic Agents; Animals; Cell Nucleus; Cysteine P | 2007 |
Exercise increases striatal Glu reuptake and improves motor dysfunction in 6-OHDA-induced Parkinson's disease rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Oxidopamine; Parkinson Disease; Rats; Rats, Spragu | 2021 |
Neuroprotective effect of α-pinene self-emulsifying nanoformulation against 6-OHDA induced neurotoxicity on human SH-SY5Y cells and its in vivo validation for anti-Parkinson's effect.
Topics: Bicyclic Monoterpenes; Cell Line, Tumor; Emulsions; Humans; Nanostructures; Neuroprotective Agents; | 2021 |
Neuroprotective effect of bone marrow-derived mesenchymal stem cell secretome in 6-OHDA-induced Parkinson's disease.
Topics: Animals; Bone Marrow; Disease Models, Animal; Mesenchymal Stem Cells; Neuroprotective Agents; Oxidop | 2021 |
The effect of URB597, exercise or their combination on the performance of 6-OHDA mouse model of Parkinson disease in the elevated plus maze, tail suspension test and step-down task.
Topics: Animals; Behavior, Animal; Benzamides; Carbamates; Disease Models, Animal; Elevated Plus Maze Test; | 2021 |
Therapeutic potentials of human microfluidic encapsulated conjunctival mesenchymal stem cells on the rat model of Parkinson's disease.
Topics: Animals; Conjunctiva; Corpus Striatum; Disease Models, Animal; Humans; Mesenchymal Stem Cell Transpl | 2021 |
Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson's disease.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; Bromelains; Cell Line, Tumor; Cell Survival; Huma | 2021 |
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease.
Topics: Animals; Biomechanical Phenomena; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Light; Loc | 2021 |
Effect of Roucongrong (Herba Cistanches Deserticolae) decoction on the substantia nigra through Wnt/β-catenin signaling pathway in rats with Parkinson's disease induced by 6-hydroxydopamine hydrochloride.
Topics: Animals; Cistanche; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Wnt Signaling Pathway | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopam | 2021 |
Green coffee extract attenuates Parkinson's-related behaviors in animal models.
Topics: Animals; Behavior, Animal; Coffee; Disease Models, Animal; Mice; Models, Animal; Oxidopamine; Parkin | 2021 |
Severity Assessment of Complex and Repeated Intracranial Surgery in Rats.
Topics: Animals; Body Weight; Disease Models, Animal; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Spra | 2023 |
Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis.
Topics: Adrenergic Agents; Animals; Anxiety; Arginine; Disease Models, Animal; Dopamine Agonists; Dopamine A | 2021 |
Anti-inflammatory and Neuroprotective Effects of Transcranial Ultrasound Stimulation on Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Neuroprotective Agents; Oxidopamine; Park | 2022 |
Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson's Disease.
Topics: Animals; Bilirubin; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Oxidopamine; Parkinson D | 2022 |
The 6-hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Medial Forebrain Bundle; Oxidopamin | 2021 |
Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson's disease via inhibiting p38MAPK/NF-κB signaling pathway.
Topics: Animals; Lipopolysaccharides; Male; MAP Kinase Signaling System; Microglia; Neuroinflammatory Diseas | 2022 |
Inhibition of anandamide hydrolysis does not rescue respiratory abnormalities observed in an animal model of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Disease Models, Animal; Endocannabinoids; Hydrolysis; Oxidopamine; Parki | 2022 |
Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease.
Topics: Alarmins; Animals; Antibodies, Neutralizing; Corpus Striatum; Disease Models, Animal; Dopaminergic N | 2022 |
Chlorogenic acid delays the progression of Parkinson's disease via autophagy induction in
Topics: Animals; Animals, Genetically Modified; Autophagy; Caenorhabditis elegans; Chlorogenic Acid; Disease | 2023 |
Imaging of cerebral tryptophan metabolism using 7-[
Topics: Animals; Disease Models, Animal; Fluorine Radioisotopes; Hippocampus; Kynurenine; Male; Melatonin; O | 2022 |
The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Humans; Mice; Neuroprotective Agents; Oxidopa | 2021 |
Cryopreservation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurospheres for Clinical Application.
Topics: Animals; Cell Differentiation; Cryopreservation; Dopamine; Dopaminergic Neurons; Humans; Induced Plu | 2022 |
N-acetylcysteine decreases dopamine transporter availability in the non-lesioned striatum of the 6-OHDA hemiparkinsonian rat.
Topics: Acetylcysteine; Animals; Antioxidants; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; | 2022 |
Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-α and IL-1β; evidence from early experimental model of Parkinson's disease.
Topics: Animals; Cytokines; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Interleukin-1beta; Oxido | 2022 |
Inhibition of TRPM2 by AG490 Is Neuroprotective in a Parkinson's Disease Animal Model.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Glycogen Synthase Kinase 3 beta; Mice; Mice, | 2022 |
Neuroprotective effects of catechins in an experimental Parkinson's disease model and SK-N-AS cells: evaluation of cell viability, anti-inflammatory and anti-apoptotic effects.
Topics: Anti-Inflammatory Agents; Apoptosis; Catechin; Cell Survival; Dopamine; Humans; Neuroprotective Agen | 2022 |
Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mammals; Oxidopamine; Parkinson Disease; Zebr | 2021 |
Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.
Topics: Acetylcholinesterase; Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Male; Model | 2022 |
Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson's models.
Topics: Animals; Autophagy; Curcumin; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats | 2022 |
Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease via inhibiting oxidative stress.
Topics: Animals; Humans; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Thy | 2022 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonis | 2022 |
Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Histone Deacetylase Inhibito | 2022 |
Ferulic Acid Exerts Neuroprotective Effects via Autophagy Induction in
Topics: alpha-Synuclein; Animals; Apoptosis; Autophagy; Caenorhabditis elegans; Caenorhabditis elegans Prote | 2022 |
Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Disease Models, Animal; Humans; Lipids; Metab | 2022 |
Therapeutic function of iPSCs-derived primitive neuroepithelial cells in a rat model of Parkinson's disease.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Dopaminergic Neurons; Induced Pluripotent Ste | 2022 |
Comparative analysis of striatal [
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Male; Oxidopamine; Parkinson Disease; Positron-Emi | 2022 |
Central dopaminergic control of cell proliferation in the colonic epithelium.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Epithelium; Mic | 2022 |
6-Hydroxydopamine Induces Neurodegeneration in Terminally Differentiated SH-SY5Y Neuroblastoma Cells via Enrichment of the Nucleosomal Degradation Pathway: a Global Proteomics Approach.
Topics: Apoptosis; Cell Line, Tumor; Chromatography, Liquid; Dopaminergic Neurons; Histones; Humans; Neurobl | 2022 |
Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Female; Male; Oxidopamine; | 2022 |
Nano-MgO composites containing plasmid DNA to silence SNCA gene displays neuroprotective effects in Parkinson's rats induced by 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; DNA; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Plasmids; Rat | 2022 |
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor S | 2022 |
Impaired nitrergic relaxation in pyloric sphincter of the 6-OHDA Parkinson's disease rat.
Topics: Animals; Gastroparesis; Humans; Nitric Oxide Synthase Type I; Oxidopamine; Parkinson Disease; Pyloru | 2022 |
Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2022 |
Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson's Disease.
Topics: Animals; Brain Tissue Transplantation; Cell Transplantation; Fetal Tissue Transplantation; Mesenceph | 2022 |
Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells.
Topics: Animals; Antioxidants; Humans; Levodopa; Mice; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disea | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Indu | 2022 |
Solid-state-cultured mycelium of Antrodia camphorata exerts potential neuroprotective activities against 6-hydroxydopamine-induced toxicity in PC12 cells.
Topics: Animals; Antrodia; Mycelium; Oxidopamine; Parkinson Disease; PC12 Cells; Polyporales; Rats | 2022 |
Human neural stem cell-derived extracellular vesicles protect against Parkinson's disease pathologies.
Topics: Animals; Extracellular Vesicles; Humans; Mice; MicroRNAs; Neural Stem Cells; Oxidopamine; Parkinson | 2022 |
S-adenosyl methionine improves motor co-ordination with reduced oxidative stress, dopaminergic neuronal loss, and DNA methylation in the brain striatum of 6-hydroxydopamine-induced neurodegeneration in rats.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; DNA Methylation; Dopamine; Glutathione; Methio | 2023 |
Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Intralaminar Thalamic Nuclei; Mice; Mice, | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitat | 2022 |
Angiotensin-Converting Enzyme 2 Activation Mitigates Behavioral Deficits and Neuroinflammatory Burden in 6-OHDA Induced Experimental Models of Parkinson's Disease.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Diminazene; Mice; Models, Theoretical; Oxid | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskines | 2022 |
Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Animals; Astrocytes; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Heterogeneous-Nucle | 2022 |
Sorting Nexin 5 Plays an Important Role in Promoting Ferroptosis in Parkinson's Disease.
Topics: Animals; Ferroptosis; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Rats; Sorting Nexi | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice | 2022 |
Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Oxidopamine; Parkin | 2022 |
Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I
Topics: Animals; Brain; Humans; Imidazolines; Ligands; Mice; Oxidopamine; Parkinson Disease | 2022 |
Neuroprotective Effect of Dioscin against Parkinson's Disease via Adjusting Dual-Specificity Phosphatase 6 (DUSP6)-Mediated Oxidative Stress.
Topics: Animals; Diosgenin; Dual Specificity Phosphatase 6; Kelch-Like ECH-Associated Protein 1; Neuroprotec | 2022 |
Task-specific effects of biological sex and sex hormones on object recognition memories in a 6-hydroxydopamine-lesion model of Parkinson's disease in adult male and female rats.
Topics: Animals; Estradiol; Male; Memory, Short-Term; Oxidopamine; Parkinson Disease; Rats; Spatial Memory | 2022 |
Potential anti-Parkinsonian's effect of S-(+)-linalool from Cinnamomum osmophloeum ct. linalool leaves are associated with mitochondrial regulation via gas-1, nuo-1, and mev-1 in Caenorhabditis elegans.
Topics: Acyclic Monoterpenes; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cinnamomum; | 2022 |
High-Frequency Repetitive Transcranial Magnetic Stimulation Regulates Astrocyte Activation by Modulating the Endocannabinoid System in Parkinson's Disease.
Topics: Animals; Astrocytes; Endocannabinoids; Gliosis; Oxidopamine; Parkinson Disease; Rats; Transcranial M | 2022 |
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Extracellular Vesicles; Mice; MicroRNAs; Neur | 2022 |
Neural stem cell secretome exerts a protective effect on damaged neuron mitochondria in Parkinson's disease model.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Dopaminergic Neurons; Mitochondria; Neural | 2022 |
The modulatory effect of 100 Hz electroacupuncture on striatal synaptic plasticity in unilateral lesioned 6-OHDA rats.
Topics: Animals; Corpus Striatum; Electroacupuncture; Glutamic Acid; Humans; Long-Term Potentiation; Oxidopa | 2022 |
[Inhibition connexin 43 by mimetic peptide Gap27 mediates protective effects on 6-hydroxydopamine induced Parkinson's disease mouse model].
Topics: Animals; Connexin 43; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Oxidop | 2022 |
Evaluation of betulinic acid effects on pain, memory, anxiety, catalepsy, and oxidative stress in animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Anxiety; Betulinic Acid; Brain-Derived Neurotrophic Factor; Catalepsy; Diseas | 2023 |
Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread.
Topics: alpha-Synuclein; Animals; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substant | 2022 |
Dual-Hit Model of Parkinson's Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice-Neuroprotective and Anti-Inflammatory Effects of Butyrate.
Topics: Animals; Anti-Inflammatory Agents; Butyrates; Dysbiosis; Inflammation; Mice; Oxidopamine; Parkinson | 2022 |
Enteric glial cell reactivity in colonic layers and mucosal modulation in a mouse model of Parkinson's disease induced by 6-hydroxydopamine.
Topics: Animals; Disease Models, Animal; Enteric Nervous System; Inflammation; Male; Mice; Neuroglia; Occlud | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; | 2022 |
Inhibition of Wnt/β-catenin signaling attenuates axonal degeneration in models of Parkinson's disease.
Topics: Animals; beta Catenin; Glycogen Synthase Kinase 3 beta; Oxidopamine; Parkinson Disease; Rats; Wnt Si | 2022 |
Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats.
Topics: Animals; Male; Nitrites; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2022 |
Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson's Disease: The Implication of Lipid Droplets and Lipophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Humans; Linoleic Acid; Lipid Droplets; Mice; Neuroblastoma; Ne | 2022 |
Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson's Disease.
Topics: Animals; Mitochondria; Monocarboxylic Acid Transporters; Neuroprotective Agents; Oxidopamine; Parkin | 2022 |
In vitro and in vivo neuroprotective effect of novel mPGES-1 inhibitor in animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Neuroprotective Agents; Oxidopamine; Pa | 2022 |
Oxidative Stress Inhibition Via Apocynin Prevents Medullary Respiratory Neurodegeneration and Respiratory Pattern Dysfunction in a 6-Hydroxydopamine Animal Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Drinking Water; NADPH Oxidases; Oxidative Str | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Le | 2022 |
Proteomic and Targeted Metabolomic Studies on a Silkworm Model of Parkinson's Disease.
Topics: Animals; Bombyx; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Oxidopamine; Parkin | 2022 |
Human gingival mesenchymal stem cells improve movement disorders and tyrosine hydroxylase neuronal damage in Parkinson disease rats.
Topics: Animals; Calcium; Gingiva; Glial Fibrillary Acidic Protein; Humans; Mesenchymal Stem Cells; Mice; Mi | 2022 |
Chronic Cerebral Hypoperfusion Aggravates Parkinson's Disease Dementia-Like Symptoms and Pathology in 6-OHDA-Lesioned Rat through Interfering with Sphingolipid Metabolism.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Dementia; Disease Models, Animal; Lipid Metabolism; Male | 2022 |
Celastrol attenuates 6-hydroxydopamine-induced neurotoxicity by regulating the miR-146a/PI3K/Akt/mTOR signaling pathways in differentiated rat pheochromocytoma cells.
Topics: Adrenal Gland Neoplasms; Animals; Apoptosis; MicroRNAs; Neuroprotective Agents; Oxidopamine; Parkins | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
Novel cudraisoflavone J derivatives as potent neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/HO-1 signaling.
Topics: Animals; Antioxidants; Cytochrome P-450 CYP2B1; Heme Oxygenase-1; Neuroprotective Agents; Neurotoxin | 2022 |
Respiratory deficits in a female rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Female; Hormones; Hypercapnia; Male; Oxidopamine; Parkinson Disease | 2022 |
The ubiquitin-proteasome system and autophagy mutually interact in neurotoxin-induced dopaminergic cell death models of Parkinson's disease.
Topics: Autophagy; Cell Death; Dopamine; Humans; Neurotoxins; Oxidopamine; Parkinson Disease; Proteasome End | 2022 |
Citronellol Prevents 6-OHDA-Induced Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in Parkinson Disease Model of SH-SY5Y Cells via Modulating ROS-NO, MAPK/ERK, and PI3K/Akt Signaling Pathways.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Mitochondria; Neuroblastoma; Oxidative Stress; O | 2022 |
Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Dopamine; Dopaminergic Neurons; Mice; Oxidopamine; Parkinson Disease; Rats | 2023 |
Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antioxidants; Caenorhabditis elegans; Cannabidiol; Disease Models, Animal; | 2022 |
L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson's Disease Models.
Topics: Aspartic Acid; Calcium; Dipeptides; Dopaminergic Neurons; Fluorescent Dyes; Homeostasis; Humans; Mit | 2022 |
Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
Topics: Animals; Disease Models, Animal; Humans; Motor Disorders; Oxidative Stress; Oxidopamine; Parkinson D | 2022 |
6-Hydroxydopamine-Induced Neurotoxicity in Rat Model of Parkinson's Disease: Is Reversed via Anti-Oxidative Activities of Curcumin and Aerobic Exercise Therapy.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Curcumin; Disease Models, Animal; Glutathione P | 2022 |
Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dopamine; Hyperalgesia; Ondansetron; Oxidopamine; P | 2022 |
Topics: Animals; Base Composition; Clostridiales; Dextroamphetamine; Disease Models, Animal; Dopaminergic Ne | 2022 |
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipruritics; Corpus Striatum; Des | 2022 |
A time-course study of urodynamic analyses in rat models with dopaminergic depletion induced through unilateral and bilateral 6-hydroxydopamine injections.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Oxidopamine; Parkinson Disease; Rat | 2023 |
Scorpion venom heat-resistant synthetic peptide protects dopamine neurons against 6-hydroxydopamine neurotoxicity in C. elegans.
Topics: Animals; Caenorhabditis elegans; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Hot Tempera | 2022 |
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Facto | 2022 |
The effects of regular swimming exercise and melatonin on the neurons localized in the striatum of hemiparkinsonian rats.
Topics: Animals; Male; Melatonin; Neurons; Oxidopamine; Parkinson Disease; Physical Conditioning, Animal; Ra | 2023 |
Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons.
Topics: Cell Differentiation; Dopamine; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Mesenc | 2022 |
The Therapeutic Potential of Naturally Occurring Peptides in Counteracting SH-SY5Y Cells Injury.
Topics: Antioxidants; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Humans; Neuroblastoma; Neuropro | 2022 |
Design and synthesis of benzo[d]thiazol-2-yl-methyl-4-(substituted)-piperazine-1-carbothioamide as novel neuronal nitric oxide inhibitors and evaluation of their neuroprotecting effect in 6-OHDA-induced unilateral lesioned rat model of Parkinson's disease
Topics: Animals; Enzyme Inhibitors; HEK293 Cells; Humans; Mammals; Neurons; Nitric Oxide; Nitric Oxide Synth | 2022 |
Effect of Subthalamic Stimulation and Electrode Implantation in the Striatal Microenvironment in a Parkinson's Disease Rat Model.
Topics: Amino Acid Transport Systems; Animals; Cytokines; Deep Brain Stimulation; Electrodes; gamma-Aminobut | 2022 |
Therapeutic function of a novel rat induced pluripotent stem cell line in a 6‑OHDA‑induced rat model of Parkinson's disease.
Topics: Animals; Cell Differentiation; Dopaminergic Neurons; gamma-Aminobutyric Acid; Induced Pluripotent St | 2022 |
Continuous SGB Inhibits Occurrence and Maintenance of Mechanical Hyperalgesia via Reducing Inflammatory Cytokines in Striatum and PAG of PD Nociception Rat Models.
Topics: Animals; Cytokines; Hyperalgesia; Interleukin-6; Nociception; Oxidopamine; Pain Threshold; Parkinson | 2023 |
Patterned Stimulation of the Chrimson Opsin in Glutamatergic Motor Thalamus Neurons Improves Forelimb Akinesia in Parkinsonian Rats.
Topics: Animals; Deep Brain Stimulation; Forelimb; Humans; Motor Neurons; Opsins; Oxidopamine; Parkinson Dis | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Exercise improves the body function and protects the neuronal injury in Parkinson's disease rats by activating calpain 1 and kallikrein 6.
Topics: Animals; Calpain; Disease Models, Animal; Exercise; Kallikreins; Mice; Motor Activity; Neurodegenera | 2022 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levod | 2023 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects.
Topics: Adenylyl Cyclases; Animals; Colforsin; Mitochondria; Oxidopamine; Parkinson Disease; Rats | 2022 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Nerve Growth Factors; Neuroblastoma; Oxidopamine; P | 2023 |
Preventive effects of nano-graphene oxide against Parkinson's disease via reactive oxygen species scavenging and anti-inflammation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Humans; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Pa | 2023 |
Preventive effects of nano-graphene oxide against Parkinson's disease via reactive oxygen species scavenging and anti-inflammation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Humans; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Pa | 2023 |
Preventive effects of nano-graphene oxide against Parkinson's disease via reactive oxygen species scavenging and anti-inflammation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Humans; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Pa | 2023 |
Preventive effects of nano-graphene oxide against Parkinson's disease via reactive oxygen species scavenging and anti-inflammation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Humans; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Pa | 2023 |
Transplantation of ERK gene-modified bone marrow mesenchymal stem cells ameliorates cognitive deficits in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cognition; Cognitive Dysfunction; Mesenchym | 2023 |
Transplantation of ERK gene-modified bone marrow mesenchymal stem cells ameliorates cognitive deficits in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cognition; Cognitive Dysfunction; Mesenchym | 2023 |
Transplantation of ERK gene-modified bone marrow mesenchymal stem cells ameliorates cognitive deficits in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cognition; Cognitive Dysfunction; Mesenchym | 2023 |
Transplantation of ERK gene-modified bone marrow mesenchymal stem cells ameliorates cognitive deficits in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cognition; Cognitive Dysfunction; Mesenchym | 2023 |
Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Macaca fasc | 2023 |
Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Macaca fasc | 2023 |
Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Macaca fasc | 2023 |
Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Macaca fasc | 2023 |
p-Hydroxybenzyl Alcohol Antagonized the ROS-Dependent JNK/Jun/Caspase-3 Pathway to Produce Neuroprotection in a Cellular Model of Parkinson's Disease.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases | 2022 |
p-Hydroxybenzyl Alcohol Antagonized the ROS-Dependent JNK/Jun/Caspase-3 Pathway to Produce Neuroprotection in a Cellular Model of Parkinson's Disease.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases | 2022 |
p-Hydroxybenzyl Alcohol Antagonized the ROS-Dependent JNK/Jun/Caspase-3 Pathway to Produce Neuroprotection in a Cellular Model of Parkinson's Disease.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases | 2022 |
p-Hydroxybenzyl Alcohol Antagonized the ROS-Dependent JNK/Jun/Caspase-3 Pathway to Produce Neuroprotection in a Cellular Model of Parkinson's Disease.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases | 2022 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.
Topics: alpha-Synuclein; Animals; Autism Spectrum Disorder; Caenorhabditis elegans; Caenorhabditis elegans P | 2023 |
Behavioral context improves optogenetic stimulation of transplanted dopaminergic cells in unilateral 6-OHDA rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Optogenetics; Oxidopamine; | 2023 |
The cannabinoid CB
Topics: Angiotensins; Animals; Cannabinoids; Corpus Striatum; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2023 |
Restraint Stress Exacerbates Apoptosis in a 6-OHDA Animal Model of Parkinson Disease.
Topics: Acetylcholinesterase; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Dopamine; Male; Oxidopa | 2023 |
Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Disease Models, Ani | 2023 |
Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Interleukin-6; Molecular Docking Simulation; Oxidopa | 2023 |
Microglial depletion exacerbates motor impairment and dopaminergic neuron loss in a 6-OHDA model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Mice; Microglia; Motor Disorders; O | 2023 |
The Pedunculopontine Tegmental Nucleus is not Important for Breathing Impairments Observed in a Parkinson's Disease Model.
Topics: Animals; Cholinergic Agents; Dopaminergic Neurons; Hypercapnia; Hypoxia; Male; Mice; Oxidopamine; Pa | 2023 |
Carnosic acid attenuated cytochrome c release through the mitochondrial structural protein Mic60 by PINK1 in SH-SY5Y cells.
Topics: Apoptosis; Cell Line, Tumor; Colforsin; Cytochromes c; Humans; Mitochondria; Mitochondrial Proteins; | 2023 |
A transcriptome based approach to predict candidate drug targets and drugs for Parkinson's disease using an
Topics: Humans; Oxidopamine; Parkinson Disease; Pharmaceutical Preparations; Protein Interaction Maps; Trans | 2023 |
5-(4-Hydroxy-3-dimethoxybenzylidene)-thiazolidinone improves motor functions and exerts antioxidant potential in hemiparkinsonian rats.
Topics: Animals; Antioxidants; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Le | 2023 |
The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Iron; Leucine-Rich Repeat Serine-Threonine Pr | 2023 |
Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Exosomes; Humans; Mesenchymal Stem Cells; Neuroprotective Agents; Oxidopa | 2023 |
Neural pathway connectivity and discharge changes between M1 and STN in hemiparkinsonian rats.
Topics: Animals; Dopamine; Humans; Neural Pathways; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleu | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Dru | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskin | 2023 |
Neural stem cells transplantation combined with ethyl stearate improve PD rats motor behavior by promoting NSCs migration and differentiation.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Dopaminergic Neurons; Neural Stem Cells; Oxid | 2023 |
Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine.
Topics: Alzheimer Disease; cdc25 Phosphatases; Dopamine; Humans; Nerve Growth Factor; Neurodegenerative Dise | 2023 |
Progesterone exerts a neuroprotective action in a Parkinson's disease human cell model through membrane progesterone receptor α (mPRα/PAQR7).
Topics: Humans; Oxidopamine; Parkinson Disease; Phosphatidylinositol 3-Kinases; Progesterone; Progestins; Re | 2023 |
Protective effects of 24-epibrassinolide against the 6-OHDA zebrafish model of Parkinson's disease.
Topics: Animals; Brassinosteroids; Oxidative Stress; Oxidopamine; Parkinson Disease; Zebrafish | 2023 |
Menstrual blood-derived endometrial stem cells alleviate neuroinflammation by modulating M1/M2 polarization in cell and rat Parkinson's disease models.
Topics: Animals; Female; Humans; Microglia; Neuroinflammatory Diseases; Oxidopamine; Parkinson Disease; Phos | 2023 |
CtBP Neuroprotective Role in Toxin-Based Parkinson's Disease Models: From Expression Pattern to Dopaminergic Survival.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Neuroprot | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levod | 2023 |
Assessing the Location, Relative Expression and Subclass of Dopamine Receptors in the Cerebellum of Hemi-Parkinsonian Rats.
Topics: Animals; Cerebellum; Disease Models, Animal; Dopamine; Humans; Male; Neurodegenerative Diseases; Oxi | 2023 |
Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine; Gain of Function Mutation; Levodopa; Oxidopamine; Parkinson Dise | 2023 |
Activated Microglia in the Early Stage of a Rat Model of Parkinson's Disease: Revealed by PET-MRI Imaging by [
Topics: Animals; Carrier Proteins; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; M | 2023 |
Optogenetic Globus Pallidus Stimulation Improves Motor Deficits in 6-Hydroxydopamine-Lesioned Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Dopamine; Globus Pallidus; Hypokinesia; Mice; Optogenetics; Oxidopamine; P | 2023 |
Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
Topics: Animals; Corpus Striatum; Glial Cell Line-Derived Neurotrophic Factor; Oxidopamine; Parkinson Diseas | 2023 |
In Search of a Feedback Signal for Closed-Loop Deep Brain Stimulation: Stimulation of the Subthalamic Nucleus Reveals Altered Glutamate Dynamics in the Globus Pallidus in Anesthetized, 6-Hydroxydopamine-Treated Rats.
Topics: Animals; Deep Brain Stimulation; Feedback; Globus Pallidus; Glutamic Acid; Oxidopamine; Parkinson Di | 2023 |
Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Neuroblastoma; Neuroprotect | 2023 |
Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Dysbiosis; Gastrointestinal Microbiome; NAD; Nicotinamide-Nucleotide Adenylyltransferase; O | 2023 |
Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson's disease models.
Topics: Animals; Mice; Neuroprotective Agents; Oxidopamine; Parkinson Disease; PPAR-beta; Proteasome Endopep | 2023 |
Unveiling the mechanism of platelet dysfunction in Parkinson's disease: The effect of 6-hydroxydopamine on human blood platelets.
Topics: Blood Platelets; Dopaminergic Neurons; Humans; Oxidopamine; Parkinson Disease; Reactive Oxygen Speci | 2023 |
DRD1 signaling modulates TrkB turnover and BDNF sensitivity in direct pathway striatal medium spiny neurons.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Humans; Medium Spiny Neurons; | 2023 |
Exercise Improves Orofacial Pain and Modifies Neuropeptide Expression in a Rat Model of Parkinson's Disease.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Facial Pain; Neuropeptides; Oxidop | 2023 |
Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Inverse Agonism; Hippocampus; Male; Oxidopami | 2023 |
Subthalamic nucleus deep brain stimulation induces nigrostriatal dopaminergic plasticity in a stable rat model of Parkinson's disease.
Topics: Animals; Deep Brain Stimulation; Dopamine; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; S | 2023 |
Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
Topics: alpha-Synuclein; Animals; Brain; Colon; Dopamine; Oxidopamine; Parkinson Disease; Rats | 2023 |
Intermittent Theta Burst Stimulation Improves Motor and Behavioral Dysfunction through Modulation of NMDA Receptor Subunit Composition in Experimental Model of Parkinson's Disease.
Topics: Animals; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; | 2023 |
Effectiveness of Albumin-Fused Thioredoxin against 6-Hydroxydopamine-Induced Neurotoxicity In Vitro.
Topics: Albumins; Animals; Immunologic Factors; Mice; Neurons; Oxidative Stress; Oxidopamine; Parkinson Dise | 2023 |
Zooming into Gut Dysbiosis in Parkinson's Disease: New Insights from Functional Mapping.
Topics: Animals; Butyrates; Dysbiosis; Mice; Oxidopamine; Parkinson Disease; Phylogeny | 2023 |
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; L | 2023 |
Repetitive transcranial magnetic stimulation alleviates glial activation through suppressing HMGB1/TLR4 pathway in a rat model of Parkinson's disease.
Topics: Animals; HMGB1 Protein; Neuroinflammatory Diseases; Oxidopamine; Parkinson Disease; Rats; Rats, Spra | 2023 |
3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Neuroprotection; Neuroprotective Ag | 2023 |
The α1 and γ2 subunit-containing GABA
Topics: Animals; Anxiety; Dopamine; Dorsal Raphe Nucleus; gamma-Aminobutyric Acid; Oxidopamine; Parkinson Di | 2023 |
Co-transplantation of autologous T
Topics: Animals; Cell Death; Cell Proliferation; Cell- and Tissue-Based Therapy; Dopamine; Dopaminergic Neur | 2023 |
Dihydroisotanshinone I and BMAL-SIRT1 Pathway in an In Vitro 6-OHDA-Induced Model of Parkinson's Disease.
Topics: Apoptosis; ARNTL Transcription Factors; Caspase 3; Cell Line, Tumor; Humans; Neuroblastoma; Neuropro | 2023 |
The Effects of Carvacrol on Transient Receptor Potential (TRP) Channels in an Animal Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Oxidopamine; Parkinson Disease; Rats; S | 2023 |
Role of cardiac β
Topics: Adrenergic Agents; Animals; Arrhythmias, Cardiac; Oxidopamine; Parkinson Disease; Rats; Receptors, P | 2023 |
Expression of RAD9B in the mesostriatal system of rats and humans: Overexpression in a 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Oxidopami | 2023 |
Dipeptide mimetic of BDNF ameliorates motor dysfunction and striatal apoptosis in 6-OHDA-induced Parkinson's rat model: Considering Akt and MAPKs signaling.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Brain-Derived Neurotrophic Factor; Dipeptides; Dopam | 2023 |
The nonsynaptic plasticity in Parkinson's disease: Insights from an animal model.
Topics: Adenosine Triphosphatases; Animals; Chlorides; Disease Models, Animal; Male; Oxidopamine; Parkinson | 2023 |
Identification of Clec7a as the therapeutic target of rTMS in alleviating Parkinson's disease: targeting neuroinflammation.
Topics: Animals; Dopaminergic Neurons; Neurodegenerative Diseases; Neuroinflammatory Diseases; Oxidopamine; | 2023 |
Oral administration of Limonin (LM) exerts neuroprotective effects by inhibiting neuron autophagy and microglial activation in 6-OHDA-injected rats.
Topics: Administration, Oral; Aged; Animals; Autophagy; Humans; Inflammation; Limonins; Microglia; Middle Ag | 2023 |
PACAP/PAC1-R activation contributes to hyperalgesia in 6-OHDA-induced Parkinson's disease model rats via promoting excitatory synaptic transmission of spinal dorsal horn neurons.
Topics: Animals; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperalgesia; Oxidopamine; Pain; Parkin | 2023 |
Parkinson's Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model.
Topics: Alanine; Animals; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life; Rats | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug | 2023 |
Increased expression of Nav1.6 of reactive astrocytes in the globus pallidus is closely associated with motor deficits in a model of Parkinson's disease.
Topics: Aged; Animals; Astrocytes; Disease Models, Animal; Globus Pallidus; Mammals; NAV1.6 Voltage-Gated So | 2023 |
Evoked responses to single pulse electrical stimulation reveal impaired striatal excitability in a rat model of Parkinson's disease.
Topics: Animals; Dopamine; Electric Stimulation; Levodopa; Oxidopamine; Parkinson Disease; Quality of Life; | 2023 |
Subthalamic nucleus deep brain stimulation does not alter growth factor expression in a rat model of stable dopaminergic deficiency.
Topics: Animals; Brain-Derived Neurotrophic Factor; Deep Brain Stimulation; Glial Cell Line-Derived Neurotro | 2023 |
6-hydroxydopamine affects multiple pathways to induce cytotoxicity in differentiated LUHMES dopaminergic neurons.
Topics: alpha-Synuclein; Apoptosis; Dopaminergic Neurons; Humans; Oxidopamine; Parkinson Disease | 2023 |
Syringin Prevents 6-Hydroxydopamine Neurotoxicity by Mediating the MiR-34a/SIRT1/Beclin-1 Pathway and Activating Autophagy in SH-SY5Y Cells and the
Topics: alpha-Synuclein; Animals; Autophagy; Beclin-1; Caenorhabditis elegans; Humans; MicroRNAs; Neuroblast | 2023 |
Uridine as a Regulator of Functional and Ultrastructural Changes in the Brain of Rats in a Model of 6-OHDA-Induced Parkinson's Disease.
Topics: Adenosine Triphosphate; Animals; Brain; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Uridine | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxid | 2023 |
Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
Topics: alpha-Synuclein; Animals; Dopamine; Feasibility Studies; Mesencephalon; Mice; Nerve Degeneration; Ox | 2023 |
Key Subdomains of Cerebral Dopamine Neurotrophic Factor Regulate Its Protective Function in 6-Hydroxydopamine-Lesioned PC12 Cells.
Topics: Animals; Dopamine; Humans; Nerve Growth Factors; Oxidopamine; Parkinson Disease; PC12 Cells; Rats | 2023 |
Regulation of the Endogenous Opiate Signaling Pathway against Oxidative Stress and Inflammation: A Considerable Approach for Exploring Preclinical Treatment of Parkinson's Disease.
Topics: Animals; Dopaminergic Neurons; Humans; Inflammation; Morphine; Naloxone; Neuroprotective Agents; NG- | 2023 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; | 2023 |
Behavioral, neural and ultrastructural alterations in a graded-dose 6-OHDA mouse model of early-stage Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Mice; Oxidopamine; Parkinson Diseas | 2023 |
Treating Parkinson's Disease with Human Bone Marrow Mesenchymal Stem Cell Secretome: A Translational Investigation Using Human Brain Organoids and Different Routes of In Vivo Administration.
Topics: Brain; Humans; Mesenchymal Stem Cells; Organoids; Oxidopamine; Parkinson Disease; Secretome | 2023 |
[Dopamine D2 receptor may be involved in the regulation of cortical-striatum synaptic transmission and autonomic activity in PD mice by exercise].
Topics: Animals; Corpus Striatum; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Physical C | 2019 |
Voltage-Gated Sodium Channels Are Involved in Cognitive Impairments in Parkinson's Disease- like Rats.
Topics: Animals; Cognition; Hippocampus; Male; Neurons; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley | 2019 |
Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.
Topics: Animals; Apoptosis; Cell Line; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Diseas | 2020 |
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Topics: Animals; Cyclic AMP; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Medial Forebrain B | 2019 |
The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study.
Topics: Aged; Aged, 80 and over; Animals; Behavior Observation Techniques; Behavior, Animal; Case-Control St | 2019 |
Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson's Disease.
Topics: Cell Line, Tumor; Cholesterol; Humans; Lipidomics; Lipids; Models, Biological; Oxidopamine; Parkinso | 2020 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
Electrocortical high frequency activity and respiratory entrainment in 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Motor Cortex | 2019 |
Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson's Disease.
Topics: Apoptosis; Astrocytes; beta Catenin; Cell Line; Coculture Techniques; Dopaminergic Neurons; Excitato | 2019 |
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Lignans; Male; Neuroprotecti | 2020 |
The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease.
Topics: Animals; Axons; Biomarkers; Disease Models, Animal; Dopaminergic Neurons; Humans; Mice, Inbred C57BL | 2020 |
Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine | 2020 |
Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease.
Topics: Administration, Intranasal; Adrenergic Agents; Animals; Cell Survival; Disease Models, Animal; Dopam | 2020 |
The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K/AKT and IKK/IκBα/NF-κB pathway.
Topics: Animals; Corpus Striatum; Cyclooctanes; I-kappa B Kinase; Lignans; Male; Mice; Mice, Inbred C57BL; N | 2019 |
Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopaminergic Ne | 2020 |
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Disease Models, Animal; DNA Glyc | 2020 |
Mesenchymal Stem Cells with Granulocyte Colony-Stimulating Factor Reduce Stress Oxidative Factors in Parkinson's Disease
Topics: Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Glutathione; Glutathione Peroxidase; Gr | 2020 |
Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease.
Topics: Animals; Cell Line, Tumor; Coumarins; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Inbred | 2019 |
The effect of preventive exercise on the neuroprotection in 6-hydroxydopamine-lesioned rat brain.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Fibronectins; Male; Maze Learning; Memory Disorde | 2019 |
Protective effects of 6,7,4'-trihydroxyisoflavone, a major metabolite of daidzein, on 6-hydroxydopamine-induced neuronal cell death in SH-SY5Y human neuroblastoma cells.
Topics: Antineoplastic Agents; Cell Death; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitum | 2019 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Hyperalgesia; | 2020 |
A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease.
Topics: 2,4-Dinitrophenol; Animals; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Mice, Inbred C | 2020 |
Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Benzimidazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Ethylenediamines; Male; | 2019 |
[Polyphenols from Toona sinensis seeds alleviate neuroinflammation in rats with Parkinson's disease via inhibiting p38MAPK signaling pathway].
Topics: Animals; Dopaminergic Neurons; Male; MAP Kinase Signaling System; Meliaceae; Oxidopamine; Parkinson | 2019 |
mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative Di | 2020 |
Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cation Transport Proteins; Cognition; Corpus Striatum; Disease Models, An | 2020 |
A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death.
Topics: Animals; Cell Line; Cell Survival; Cycloaddition Reaction; Cysteine; Disease Models, Animal; Dopamin | 2020 |
The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson's Disease Model.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Behavior Rating Scale; Brain; Calcium-Binding Protei | 2019 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Ne | 2020 |
Anthraquinone from Edible Fungi Pleurotus ostreatus Protects Human SH-SY5Y Neuroblastoma Cells Against 6-Hydroxydopamine-Induced Cell Death-Preclinical Validation of Gene Knockout Possibilities of PARK7, PINK1, and SNCA1 Using CRISPR SpCas9.
Topics: Aged; Aged, 80 and over; Apoptosis; Caspase 3; Cell Death; Cell Survival; Clustered Regularly Inters | 2020 |
Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrophic Facto | 2020 |
Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gait; Gait Analysi | 2019 |
In vivo validation of a new portable stimulator for chronic deep brain stimulation in freely moving rats.
Topics: Animals; Deep Brain Stimulation; Humans; Movement; Oxidopamine; Parkinson Disease; Rats; Subthalamic | 2020 |
Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration.
Topics: Animals; Autopsy; Biomarkers; CD36 Antigens; Disease Models, Animal; Heart; Inflammation; Macaca mul | 2020 |
Baicalin attenuated substantia nigra neuronal apoptosis in Parkinson's disease rats via the mTOR/AKT/GSK-3β pathway.
Topics: Animals; Apoptosis; Behavior, Animal; Disease Models, Animal; Female; Flavonoids; Glycogen Synthase | 2019 |
Exercise Promotes Neurite Extensions from Grafted Dopaminergic Neurons in the Direction of the Dorsolateral Striatum in Parkinson's Disease Model Rats.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Embryo, Mammalian; Exercise Therapy; Graft Su | 2020 |
L-linalool exerts a neuroprotective action on hemiparkinsonian rats.
Topics: Acyclic Monoterpenes; Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine; Lipid Peroxidat | 2020 |
p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Animals, Newborn; Dopamine; Exocyt | 2020 |
Protective effect of hydralazine on a cellular model of Parkinson's disease: a possible role of hypoxia-inducible factor (HIF)-1α.
Topics: Antioxidants; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dopamine; Humans; Hydralazin | 2020 |
Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian's Disease.
Topics: Animals; Cell Proliferation; Corpus Striatum; Cytokines; Dopaminergic Neurons; Humans; Mesenchymal S | 2020 |
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induce | 2020 |
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Humans; Levodopa; Mesenchymal Stem Cell Transplantation; Mesenchyma | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-In | 2020 |
Optogenetic inactivation of the entopeduncular nucleus improves forelimb akinesia in a Parkinson's disease model.
Topics: Animals; Brain; Deep Brain Stimulation; Disease Models, Animal; Entopeduncular Nucleus; Forelimb; GA | 2020 |
Effects on goal directed behavior and habit in two animal models of Parkinson's disease.
Topics: Animals; Conditioning, Operant; Disease Models, Animal; Extinction, Psychological; Goals; Habits; Li | 2020 |
A co-culture nanofibre scaffold model of neural cell degeneration in relevance to Parkinson's disease.
Topics: Acrylic Resins; Astrocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cocul | 2020 |
Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease.
Topics: Anhedonia; Animals; Dopamine; Dopaminergic Neurons; Male; Models, Theoretical; Neural Pathways; Oxid | 2020 |
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration.
Topics: Animals; Anoctamin-1; Colon; Dopamine; Dopaminergic Neurons; Fibrosis; Gastrointestinal Diseases; Ga | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, D | 2020 |
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; | 2020 |
Assessment of vitamin D and inflammatory markers profile in cardiac tissue on Parkinson disease animal model.
Topics: Animals; Biomarkers; C-Reactive Protein; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamin | 2020 |
Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain; Disease Models, Animal; Dopamine; Hypoglossal Nerve; Hypoxia; Mal | 2020 |
Neuroprotective effect of regular swimming exercise on calretinin-positive striatal neurons of Parkinsonian rats.
Topics: Animals; Calbindin 2; Corpus Striatum; Disease Models, Animal; Interneurons; Male; Neuroprotection; | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Le | 2020 |
Early Expression of Neuronal Dopaminergic Markers in a Parkinson's Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs).
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Enteric Nervous System; Male; Neura | 2020 |
Reversal of hyperactive subthalamic circuits differentially mitigates pain hypersensitivity phenotypes in parkinsonian mice.
Topics: Animals; Basal Ganglia; Disease Models, Animal; Dopamine Antagonists; Globus Pallidus; Humans; Hyper | 2020 |
Comparison between Tail Suspension Swing Test and Standard Rotation Test in Revealing Early Motor Behavioral Changes and Neurodegeneration in 6-OHDA Hemiparkinsonian Rats.
Topics: Animals; Behavior, Animal; Biomarkers; Case-Control Studies; Corpus Striatum; Disease Models, Animal | 2020 |
Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Disease Models, Animal; Eugenol; Glutathione; Levodop | 2020 |
Tormentic acid confers protection against oxidative stress injury in rats with Parkinson's disease by targeting the Wnt/β-catenin signaling pathway.
Topics: Animals; Behavior, Animal; Cell Survival; Female; Glutathione Peroxidase; Male; Malondialdehyde; Mem | 2020 |
Time-Dependent Memory and Gait Improvement by Intranasally-Administered Extracellular Vesicles in Parkinson's Disease Model Rats.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Child; Corpus Striatum; Disease Models, Anima | 2021 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; | 2020 |
Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Topics: Aging; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Hum | 2020 |
Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.
Topics: Animals; Cardiotonic Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Heart Rate; Male; Ne | 2020 |
Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair.
Topics: Animals; Biomarkers; Cell Differentiation; Disease Models, Animal; Dopaminergic Neurons; Heterograft | 2020 |
Editorial for the Special Issue "Animal Models of Parkinson's Disease and Related Disorders".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Early Diagnosis; Huma | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Do | 2020 |
Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease.
Topics: Antiparkinson Agents; Apoptosis; Apoptosis Regulatory Proteins; Caffeic Acids; Cell Line, Tumor; Hum | 2020 |
The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Female; Ivermectin; | 2020 |
Cardiovascular evaluation of female rats with 6-OHDA-induced parkinsonism: Possible protection by ovarian hormones and participation of nitric oxide.
Topics: Animals; Blood Pressure; Cardiovascular System; Corpus Striatum; Disease Models, Animal; Dopamine; D | 2020 |
Oxidative stress in the medullary respiratory neurons contributes to respiratory dysfunction in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Oxidative Stress; Oxidopamine; Pa | 2020 |
Effects of Subthalamic Deep Brain Stimulation With Different Frequencies in a Parkinsonian Rat Model.
Topics: Animals; Deep Brain Stimulation; Diffusion Tensor Imaging; Humans; Oxidopamine; Parkinson Disease; R | 2021 |
6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels.
Topics: Apoptosis; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cell Survival; Hesperidin; Humans; N | 2020 |
The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
Topics: Adrenergic Agents; Animals; Case-Control Studies; Corpus Striatum; Disease Models, Animal; Ligands; | 2021 |
The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Benzaldehydes; Corpus Striatum; Disease Models, Animal; Dopamine; Immunoh | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Corpus Striatum; Curcumin; Disease Models, Animal; | 2020 |
Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease.
Topics: Animals; Carnosine; Cell Death; Cell Line; Cytokines; Gene Expression Regulation; Humans; MAP Kinase | 2020 |
Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1α by parkin as a mechanism of neuroprotection by carnosic acid.
Topics: Abietanes; Apoptosis; Cell Line, Tumor; DNA-Binding Proteins; Dopaminergic Neurons; Humans; Mitochon | 2021 |
Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Apomorphine; Astrocytes; Disease M | 2021 |
Neuroprotective effects of probiotics bacteria on animal model of Parkinson's disease induced by 6-hydroxydopamine: A behavioral, biochemical, and histological study.
Topics: Animals; Behavior, Animal; Bifidobacterium bifidum; Cognition; Dietary Supplements; Disease Models, | 2021 |
Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine.
Topics: Administration, Intravenous; Animals; Antioxidants; Behavior, Animal; Cell Death; Cell Differentiati | 2020 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-I | 2021 |
Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection.
Topics: Animals; Antioxidants; Astrocytes; Cells, Cultured; Dopamine; Dopaminergic Neurons; Female; Male; Me | 2020 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopami | 2021 |
Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Topics: Animals; Axons; Calcium Signaling; Cells, Cultured; Excitatory Amino Acid Antagonists; Extracellular | 2021 |
The voiding efficiency in rat models with dopaminergic brain lesions induced through unilateral and bilateral intrastriatal injections.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Electromyography; Male; Oxi | 2020 |
Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment.
Topics: Animals; Benzoquinones; Chitosan; Disease Models, Animal; Drug Stability; Drug Synergism; Emulsions; | 2021 |
Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor.
Topics: Action Potentials; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; Electrodes; Immunohisto | 2021 |
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Cannabinoids; Cell Line, Tumor; Humans; Male; Mice; Mice, Inbred C57B | 2021 |
The Effect of Levosimendan on Two Distinct Rodent Models of Parkinson's Disease.
Topics: Animals; Apomorphine; Cardiotonic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Male; N | 2020 |
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Oxidopamine; | 2021 |
Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Brain; Male; Melatonin; Memory; Movement; Neurotransmitter Agents; Ox | 2021 |
Inhibition of striatal dopamine D
Topics: Animals; Benzazepines; Dopamine; Dopamine Antagonists; Levodopa; Male; Oxidopamine; Parkinson Diseas | 2021 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; | 2021 |
Protective Effect of Nervonic Acid Against 6-Hydroxydopamine-Induced Oxidative Stress in PC-12 Cells.
Topics: Animals; Antioxidants; Brain; Cell Membrane; Cell Survival; Fatty Acids, Monounsaturated; Glutamate- | 2021 |
Therapeutic Potential of Magnetic Nanoparticle-Based Human Adipose-Derived Stem Cells in a Mouse Model of Parkinson's Disease.
Topics: Adipose Tissue; Animals; Brain; Cell- and Tissue-Based Therapy; Disease Models, Animal; Fluorescent | 2021 |
pH-Responsive Redox Nanoparticles Protect SH-SY5Y Cells at Lowered pH in a Cellular Model of Parkinson's Disease.
Topics: Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Humans; Hydrogen-Ion Concentration; Mo | 2021 |
Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; F | 2021 |
Peptide Profile of Zebrafish Brain in a 6-OHDA-Induced Parkinson Model.
Topics: Animals; Brain; Oxidopamine; Parkinson Disease; Peptides; Zebrafish | 2021 |
Motor Thalamic Deep Brain Stimulation Alters Cortical Activity and Shows Therapeutic Utility for Treatment of Parkinson's Disease Symptoms in a Rat Model.
Topics: Animals; Deep Brain Stimulation; Humans; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleus; | 2021 |
miR‑335 promotes ferroptosis by targeting ferritin heavy chain 1 in
Topics: Animals; Apoferritins; Disease Models, Animal; Ferroptosis; Iron; Lipid Peroxidation; Male; Membrane | 2021 |
The association of enteric neuropathy with gut phenotypes in acute and progressive models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Cell Count; Chronic Disease; C | 2021 |
Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Disease Models, Animal; NF-kappa B; Nuclear Receptor | 2021 |
Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Disease Models, Animal; | 2021 |
Protective effect of caffeine and/or taurine on the 6-hydroxydopamine-induced rat model of Parkinson's disease: Behavioral and neurochemical evidence.
Topics: Animals; Apomorphine; Behavior, Animal; Caffeine; Corpus Striatum; Disease Models, Animal; Dopamine; | 2021 |
Intranasal delivery of mitochondria for treatment of Parkinson's Disease model rats lesioned with 6-hydroxydopamine.
Topics: Administration, Intranasal; Animals; Corpus Striatum; Cytokines; Disease Models, Animal; Dopaminergi | 2021 |
Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats.
Topics: Animals; Dopamine; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrophic Factor; Humans; Mice; | 2021 |
Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Male; Mice; | 2021 |
Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Male; Neuroprotective Agents | 2021 |
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's Disease.
Topics: Administration, Oral; Animals; Benzamides; Camphanes; Cannabidiol; Cannabinoids; Cell Line, Tumor; C | 2021 |
Protective effects of repetitive transcranial magnetic stimulation against 6-OHDA-induced Parkinson's symptoms in a mice model: the key role of miR-409-3p/PDHB axis.
Topics: Animals; Brain; Mice; MicroRNAs; Oxidopamine; Parkinson Disease; Transcranial Magnetic Stimulation | 2023 |
Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Exosomes; Humans; Levodopa; Liposomes; Male; Oxidop | 2021 |
Low-Intensity Pulsed Ultrasound Enhances Neurotrophic Factors and Alleviates Neuroinflammation in a Rat Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glial Cell Line-Derived Neurotrophic Factor; Neuro | 2021 |
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; | 2021 |
Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP.
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Dopaminergic Neurons; Humans; Male; Microtubules; O | 2021 |
Neuroprotective effects of coenzyme Q10 in Parkinson's model via a novel Q10/miR-149-5p/MMPs pathway.
Topics: Animals; Disease Models, Animal; Matrix Metalloproteinases; MicroRNAs; Neurodegenerative Diseases; N | 2021 |
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A | 2021 |
Disrupted basal ganglia output during movement preparation in hemiparkinsonian mice is consistent with behavioral deficits.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL | 2021 |
Neurorescue Effects of Frondoside A and Ginsenoside Rg3 in
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Apoptosis; Caenorhabditis elegans; Caenorha | 2021 |
Lactiplantibacillus plantarum PS128 Alleviates Exaggerated Cortical Beta Oscillations and Motor Deficits in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Deep Brain Stimulation; Dopamine; Levodopa; Oxidopamine; Parkinson Disease; Rats; Subthalam | 2023 |
Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; Ind | 2017 |
Intrastriatal Transplantation of Human Neural Stem Cells Restores the Impaired Subventricular Zone in Parkinsonian Mice.
Topics: Animals; Corpus Striatum; Female; Glucose; Humans; Lateral Ventricles; Mice, Inbred C57BL; Neural St | 2017 |
Serotonergic system in hypoxic ventilatory response in unilateral rat model of Parkinson's disease.
Topics: Amphetamines; Animals; Brain Stem; Corpus Striatum; Hypoxia; Ketanserin; Male; Organ Specificity; Ox | 2017 |
Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
Topics: Adrenergic Agents; Animals; Antioxidants; Cell Line, Transformed; Cell Survival; DNA-Binding Protein | 2017 |
Newborn dopaminergic neurons are associated with the migration and differentiation of SVZ-derived neural progenitors in a 6-hydroxydopamin-injected mouse model.
Topics: AC133 Antigen; Adrenergic Agents; Animals; Cell Differentiation; Corpus Striatum; Disease Models, An | 2017 |
Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.
Topics: Anesthesia; Animals; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; | 2017 |
FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Fibroblast Growth Factors; Male; Mo | 2017 |
Dopamine Depletion Impairs Bilateral Sensory Processing in the Striatum in a Pathway-Dependent Manner.
Topics: Animals; Dopamine; Dopamine Agents; Functional Laterality; Levodopa; Mice; Neostriatum; Neural Pathw | 2017 |
Geminin Participates in Differentiation Decisions of Adult Neural Stem Cells Transplanted in the Hemiparkinsonian Mouse Brain.
Topics: Adult Stem Cells; Animals; Brain; Cell Proliferation; Cells, Cultured; Dopaminergic Neurons; Geminin | 2017 |
Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units.
Topics: alpha-Synuclein; Animals; Autophagy; Caspase 3; Chick Embryo; Chorioallantoic Membrane; Cystatin C; | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2017 |
Differential expression of PARK2 splice isoforms in an in vitro model of dopaminergic-like neurons exposed to toxic insults mimicking Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Alternative Splicing; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell D | 2018 |
Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease.
Topics: Animals; Behavior; Disease Models, Animal; GTP-Binding Proteins; Mice; Molecular Targeted Therapy; N | 2017 |
The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson's disease.
Topics: Animals; Avoidance Learning; Cognition Disorders; Disease Models, Animal; Male; Microinjections; Mot | 2017 |
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopaminergic Neurons; Male; O | 2017 |
Systemic Analysis of miRNAs in PD Stress Condition: miR-5701 Modulates Mitochondrial-Lysosomal Cross Talk to Regulate Neuronal Death.
Topics: Apoptosis; Autophagosomes; Cell Line, Tumor; Humans; Lysosomes; Membrane Fusion; MicroRNAs; Mitochon | 2018 |
6-OHDA Induces Oxidation of F-box Protein Fbw7β by Chaperone-Mediated Autophagy in Parkinson's Model.
Topics: Aged; Aged, 80 and over; Animals; Autophagy; Cell Line; Dopaminergic Neurons; F-Box-WD Repeat-Contai | 2018 |
Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Cytokines; Disease Models, Animal; Gene Expression Regulation; Oxidopamine | 2017 |
Neuronal firing activity in the basal ganglia after striatal transplantation of dopamine neurons in hemiparkinsonian rats.
Topics: Action Potentials; Animals; Basal Ganglia; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; | 2017 |
Treadmill Exercise Prevents Increase of Neuroinflammation Markers Involved in the Dopaminergic Damage of the 6-OHDA Parkinson's Disease Model.
Topics: Animals; Dopaminergic Neurons; Male; Oxidopamine; Parkinson Disease; Physical Conditioning, Animal; | 2017 |
Selective cholinergic depletion of pedunculopontine tegmental nucleus aggravates freezing of gait in parkinsonian rats.
Topics: Acetylcholine; Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Dopamine; Gait; Immunotoxi | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephal | 2017 |
Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation.
Topics: Animals; Cytokines; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Inflammation Mediators; | 2017 |
Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Male; Oxid | 2017 |
Purinergic Antagonism Prevents Mitochondrial Dysfunction and Behavioral Deficits Associated with Dopaminergic Toxicity Induced by 6-OHDA in Rats.
Topics: Adenosine Triphosphate; Animals; Corpus Striatum; Dopamine; Male; Mitochondria; Neurons; Oxidative S | 2017 |
Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Inflammation; Male; Neuroprotection; Neuroprotecti | 2017 |
An optimized method for counting dopaminergic neurons in zebrafish.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Oxidopamine; Parkinson Disease; Protein Serin | 2017 |
Loss of Hyperdirect Pathway Cortico-Subthalamic Inputs Following Degeneration of Midbrain Dopamine Neurons.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Dopaminergic Neurons; Gene Knockdown Te | 2017 |
Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine.
Topics: Adipose Tissue; Animals; Antioxidants; Cattle; Cell Line; Collagen Type I; Delayed-Action Preparatio | 2017 |
Effects of Electroacupuncture on Metabolic Changes in Motor Cortex and Striatum of 6-Hydroxydopamine-Induced Parkinsonian Rats.
Topics: Animals; Corpus Striatum; Electroacupuncture; Male; Motor Activity; Motor Cortex; Oxidopamine; Parki | 2020 |
Alpha Lipoamide Ameliorates Motor Deficits and Mitochondrial Dynamics in the Parkinson's Disease Model Induced by 6-Hydroxydopamine.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apomorphine; Cell Death; Disease Models, Animal; Dopa | 2018 |
Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model.
Topics: Animals; Astrocytes; Disease Models, Animal; Dopamine; Male; Neostriatum; Oxidopamine; Parkinson Dis | 2017 |
CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; CCAAT-Enhancer-Binding Protein-beta; Cells, Cultured; Disease M | 2017 |
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Lev | 2018 |
5-HT
Topics: Animals; Carbazoles; Corpus Striatum; Fluorobenzenes; Locomotion; Male; Mice; Mitochondria; Organell | 2018 |
Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mot | 2018 |
Protective Effect of Curcumin Against Oxidative Stress-Induced Injury in Rats with Parkinson's Disease Through the Wnt/ β-Catenin Signaling Pathway.
Topics: Animals; Apoptosis; Astrocytes; Behavior, Animal; beta Catenin; Cell Adhesion; Cells, Cultured; Curc | 2017 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug | 2017 |
PARKIN overexpression in human mesenchymal stromal cells from Wharton's jelly suppresses 6-hydroxydopamine-induced apoptosis: Potential therapeutic strategy in Parkinson's disease.
Topics: Apoptosis; Caspase 3; Cell Survival; Humans; Hydrogen Peroxide; Membrane Potential, Mitochondrial; M | 2018 |
Acacetin inhibits neuronal cell death induced by 6-hydroxydopamine in cellular Parkinson's disease model.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flavones; Humans; Mem | 2017 |
The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
Topics: Animals; Apoptosis; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Cycl | 2017 |
Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease.
Topics: Animals; Male; Melatonin; Oxidopamine; Parkinson Disease; Pars Compacta; Prefrontal Cortex; Rats; Ra | 2017 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Re | 2018 |
Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dop | 2018 |
Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.
Topics: Animals; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gels; I | 2018 |
The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease.
Topics: Animals; Chemoreceptor Cells; Disease Models, Animal; GABA Agonists; Glutamate Decarboxylase; Gray M | 2018 |
Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease.
Topics: Animals; Brassica; Cell Line, Tumor; Dopaminergic Neurons; Glutathione; Humans; Isothiocyanates; Mal | 2018 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Glycogen Synthase Kinase-3β Regulates Equilibrium Between Neurogenesis and Gliogenesis in Rat Model of Parkinson's Disease: a Crosstalk with Wnt and Notch Signaling.
Topics: Animals; Cell Cycle; Cell Differentiation; Cell Movement; Dendrites; Disease Models, Animal; Glycoge | 2018 |
Neuroprotective Effects of Betulin in Pharmacological and Transgenic Caenorhabditis elegans Models of Parkinson's Disease.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Disease Models, Animal; Dopaminergic | 2017 |
Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.
Topics: Animals; Colon; Disease Models, Animal; Dopamine; Gastrointestinal Tract; Inflammation; Male; Mice, | 2018 |
Protective role of microRNA-221 in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Survival; Humans; MicroRNAs; Oxidopamine; Parkinson Disease; PC12 Cells; PT | 2018 |
Voluntary Physical Exercise Improves Subsequent Motor and Cognitive Impairments in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Disease Models, Animal; Dop | 2018 |
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
Topics: Activating Transcription Factor 4; Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Animals; | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cor | 2018 |
Chronic treatment with carvacrol improves passive avoidance memory in a rat model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Cymenes; Disease Models, Animal; Lipid Peroxidation; Ma | 2018 |
Aspidosperma pyrifolium Mart: neuroprotective, antioxidant and anti-inflammatory effects in a Parkinson's disease model in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aspidosperma; Behavior, Animal; Corpus Striatum; Di | 2018 |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprag | 2021 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprot | 2018 |
Intrastriatal transplantation of stem cells from human exfoliated deciduous teeth reduces motor defects in Parkinsonian rats.
Topics: Animals; Behavior, Animal; Cell Differentiation; Cell Survival; Child; Child, Preschool; Corpus Stri | 2018 |
Proteomic analysis of human glutathione transferase omega (hGSTO1) stable transfection in a 6-hydroxydopamine-induced neuronal cells.
Topics: Cell Line; Glutathione; Glutathione Transferase; Humans; Neurons; Oxidative Stress; Oxidopamine; Par | 2018 |
Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson's disease.
Topics: Animals; Brain; Cognition; Cognitive Dysfunction; Disease Models, Animal; Dopamine; Dopaminergic Neu | 2019 |
Extracellular Zn
Topics: Animals; Calcium; Chelating Agents; Disease Models, Animal; Dopaminergic Neurons; Ethylenediamines; | 2019 |
Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopam | 2018 |
Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Glutathione Reductase; Male; Oxidative St | 2018 |
Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Administration, Intranasal; Animals; Brain; Disease Models, Animal; DNA; Dopaminergic Neurons; Glial | 2019 |
Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
Topics: Animals; Apoptosis; Autophagy; Beclin-1; Caspases; Deep Brain Stimulation; Male; Neuroprotective Age | 2018 |
MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1α.
Topics: Animals; Antioxidants; Cell Line; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; GTP P | 2018 |
Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease.
Topics: Animals; Brain; Cell Death; Cell Differentiation; Cell Survival; Cells, Cultured; Cellular Microenvi | 2018 |
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson's disease.
Topics: Animals; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Male; Mice, Inbred C57BL; Motor Ac | 2018 |
Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dopaminergic Neurons; Drug Tolerance; | 2019 |
Can we conclude a potential therapeutic action for Parkinson's disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin?
Topics: Autopsy; Humans; Neurotoxins; Oxidopamine; Parkinson Disease; Substantia Nigra | 2018 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; | 2019 |
Efficient treatment of Parkinson's disease using ultrasonography-guided rhFGF20 proteoliposomes.
Topics: Animals; Cell Line, Tumor; Corpus Striatum; Fibroblast Growth Factors; Humans; Liposomes; Male; Mice | 2018 |
The Protective Role of Brain CYP2J in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Apomorphine; Brain; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytoc | 2018 |
Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemi-Parkinsonian rats.
Topics: Animals; Behavior, Animal; Biocompatible Materials; Collagen; Disease Models, Animal; Dopaminergic N | 2019 |
Correlation between neuroanatomical and functional respiratory changes observed in an experimental model of Parkinson's disease.
Topics: Animals; Astrocytes; Corpus Striatum; Homeodomain Proteins; Hypercapnia; Male; Models, Theoretical; | 2018 |
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration.
Topics: Animals; Circadian Clocks; Dopaminergic Neurons; Mice; Neurodegenerative Diseases; Nuclear Receptor | 2018 |
Serotonin₆ Receptors in the Prelimbic Cortex are Involved in the Regulation of Anxiety-Like Behaviors in the Rat 6-Hydroxydopamine Parkinson’s Disease Model.
Topics: Animals; Anxiety; Oxidopamine; Parkinson Disease; Rats; Receptors, Serotonin; Serotonin | 2018 |
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus | 2018 |
Punicalagin Exerts Beneficial Functions in 6-Hydroxydopamine-Treated SH-SY5Y Cells by Attenuating Mitochondrial Dysfunction and Inflammatory Responses.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Hydrolyzable Tann | 2018 |
Evaluation of phytomedicinal potential of perillyl alcohol in an in vitro Parkinson's Disease model.
Topics: Cell Line; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Humans; Membrane Potentia | 2018 |
Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Topics: Animals; Anisotropy; Case-Control Studies; Corpus Striatum; Disease Models, Animal; Magnetic Resonan | 2018 |
Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation.
Topics: Animals; Biphenyl Compounds; Gliosis; Lignans; Longevity; Male; Mice; Motor Activity; NADPH Oxidases | 2018 |
Re-expression of voltage-gated sodium channel subtype Nav1.3 in the substantia nigra after dopamine depletion.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; NAV1.3 Voltage-Gated Sodium C | 2018 |
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopam | 2018 |
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation.
Topics: Amphetamine; Animals; Antioxidants; Corpus Striatum; Dopamine; Dopamine Agents; Dopaminergic Neurons | 2019 |
Auricular Vagus Nerve Stimulation Exerts Antiinflammatory Effects and Immune Regulatory Function in a 6-OHDA Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Neuroprotective Agents; Oxidopamine; Pa | 2018 |
Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Humans; Models, Biologica | 2018 |
Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches.
Topics: Animals; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transpo | 2019 |
Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model.
Topics: Animals; Blood-Brain Barrier; Male; Neuroprotective Agents; Neurotensin; Oxidopamine; Parkinson Dise | 2018 |
Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Dopaminergic Neurons; Female; Humans; Male; Mice, Inbred C5 | 2019 |
GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration.
Topics: Animals; Female; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Lentivirus; Oxidopami | 2019 |
Baicalin alleviates 6-hydroxydopamine-induced neurotoxicity in PC12 cells by down-regulation of microRNA-192-5p.
Topics: Animals; Apoptosis; Autophagy; Cell Survival; Flavonoids; MicroRNAs; Neurotoxicity Syndromes; Oxidop | 2019 |
Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/α-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.
Topics: alpha-Synuclein; Apoptosis; Cell Line, Tumor; Down-Regulation; Humans; Leucine-Rich Repeat Serine-Th | 2019 |
Endoplasmic reticulum stress induced autophagy in 6-OHDA-induced Parkinsonian rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Endoplasmic Reticulum; Endop | 2019 |
Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Dopamine; Male; Oxidopamine; Parkinson Disease; Pars Compacta; Rats, Spra | 2019 |
Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Male; Mice; Olfaction Disor | 2019 |
Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats.
Topics: Administration, Intranasal; Aged; Animals; Corpus Striatum; Disease Models, Animal; Extracellular Ve | 2019 |
Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Female; MicroRNAs; Oxidopamine; Parkinson Disease; Protein Interaction Maps; Proto-Oncogene | 2019 |
Effects of Preventive Treadmill Exercise on the Recovery of Metabolic and Mitochondrial Factors in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Brain; Disease Models, Animal; Exercise Test; Male; Mitochondria; Oxidopamine; Parkinson Di | 2019 |
Down-Regulation of m6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death.
Topics: Adenosine; Animals; Apoptosis; Brain; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Down | 2019 |
Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Prote | 2019 |
Effects of subthalamic deep brain stimulation with gabapentin and morphine on mechanical and thermal thresholds in 6-hydroxydopamine lesioned rats.
Topics: Animals; Chronic Pain; Deep Brain Stimulation; Disease Models, Animal; Gabapentin; Male; Morphine; O | 2019 |
Rhododendrin-Induced RNF146 Expression via Estrogen Receptor β Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
Topics: Animals; Cell Line, Tumor; Dopaminergic Neurons; Estrogen Receptor beta; Gene Expression Regulation, | 2019 |
Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.
Topics: Animals; Axotomy; Collagen; Dopamine; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrophic Fac | 2019 |
Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Cells, Cultured; Dopaminergic Neur | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Lev | 2019 |
Effects of exercise on mGluR-mediated glutamatergic transmission in the striatum of hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Exercise Therapy; Glutamic Acid; Locomotion; Male; Medial Forebrain Bundle | 2019 |
Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
Topics: Administration, Intranasal; Animals; Antioxidants; Behavior, Animal; Emulsions; Female; Flavanones; | 2019 |
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Male; Microglia; Motor Activity; Neuroprotective Agents; NF-kappa B | 2019 |
Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corpus St | 2019 |
In Vitro and In Vivo Neuroprotective Effects of Stellettin B Through Anti-Apoptosis and the Nrf2/HO-1 Pathway.
Topics: Animals; Apoptosis; Aquatic Organisms; Cell Line; Cell Survival; Disease Models, Animal; Heme Oxygen | 2019 |
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Topics: Albuterol; Animals; Brain; Computer Simulation; Corpus Striatum; Dimethadione; Dopaminergic Neurons; | 2019 |
Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Caenorhabditis elegans; Cell Line, Tumor; Chromon | 2019 |
Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells.
Topics: Caspase 3; Caspase 7; Cell Line, Tumor; Disulfides; Esters; Glutathione; Humans; L-Lactate Dehydroge | 2019 |
Multiple stimulation parameters influence efficacy of deep brain stimulation in parkinsonian mice.
Topics: Animals; Behavior, Animal; Deep Brain Stimulation; Disease Models, Animal; Electrodes; Humans; Hypok | 2019 |
Topics: Acetylcysteine; Animals; Antiparkinson Agents; Brain; Female; Metabolome; Oxidative Stress; Oxidopam | 2019 |
Gastrodin protects dopaminergic neurons via insulin-like pathway in a Parkinson's disease model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Benzyl Alcohols; Caenorhabditis elegans; Ca | 2019 |
Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine.
Topics: Anhedonia; Animals; Brain; Corpus Striatum; Depression; Disease Models, Animal; Dopamine; Guanosine; | 2019 |
Resveratrol delays 6-hydroxydopamine-induced apoptosis by activating the PI3K/Akt signaling pathway.
Topics: Animals; Apoptosis; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; | 2019 |
Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model.
Topics: Animals; Azepines; Benzamides; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Locus Coeru | 2019 |
Complementation of dopaminergic signaling by Pitx3-GDNF synergy induces dopamine secretion by multipotent Ntera2 cells.
Topics: Animals; Astrocytoma; Behavior, Animal; Cell Differentiation; Cell Line, Tumor; Culture Media, Condi | 2020 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunol | 2019 |
Maladaptive Downregulation of Autonomous Subthalamic Nucleus Activity following the Loss of Midbrain Dopamine Neurons.
Topics: Animals; Dopaminergic Neurons; Down-Regulation; Hydrogen Peroxide; Ion Channel Gating; KATP Channels | 2019 |
Sex-specific neuroprotection by inhibition of the Y-chromosome gene,
Topics: Animals; Disease Models, Animal; DNA Damage; Female; Genes, Y-Linked; Humans; Inflammation; Male; Mi | 2019 |
Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine; | 2019 |
Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats.
Topics: Animals; Gallic Acid; Humans; Male; Memory; Neuroprotective Agents; Oxidative Stress; Oxidopamine; P | 2013 |
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
Topics: Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cell Line, Tumor; Cell Survival; | 2013 |
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
Topics: Benzamides; Cell Differentiation; Cells, Cultured; Diphenylamine; Dopamine; Extracellular Signal-Reg | 2013 |
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Analysis of Variance; | 2013 |
Neuroprotective effects of aqueous extracts of Uncaria tomentosa: Insights from 6-OHDA induced cell damage and transgenic Caenorhabditis elegans model.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Cat's Claw; Cell Survival; Membrane Potential, Mit | 2013 |
Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease.
Topics: Actinin; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Caspase 3; Disease Models, A | 2013 |
Transplantation of mouse CGR8 embryonic stem cells producing GDNF and TH protects against 6-hydroxydopamine neurotoxicity in the rat.
Topics: Animals; Cell Line; Cell Survival; Corpus Striatum; Disease Models, Animal; Embryonic Stem Cells; Fe | 2013 |
Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity.
Topics: Animals; Astrocytes; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Heme Oxygenase-1; | 2013 |
Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish.
Topics: Animals; Antioxidant Response Elements; Cell Death; Dopaminergic Neurons; Drugs, Chinese Herbal; Hem | 2013 |
Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons.
Topics: Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Dopaminergic Neurons; Dual Specificity Pho | 2013 |
Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Brain; Cyclooxygenase 2; Disease Models, Animal; D | 2013 |
A comparison of voluntary and forced exercise in protecting against behavioral asymmetry in a juvenile hemiparkinsonian rat model.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Male; Neuroprotective Agents; Ox | 2013 |
The antioxidant activities and neuroprotective effect of polysaccharides from the starfish Asterias rollestoni.
Topics: Animals; Antioxidants; Cell Line, Tumor; Cell Survival; Free Radicals; Neuroprotective Agents; Oxido | 2013 |
Conditioned medium from human amniotic epithelial cells may induce the differentiation of human umbilical cord blood mesenchymal stem cells into dopaminergic neuron-like cells.
Topics: Amnion; Analysis of Variance; Animals; Apomorphine; Brain-Derived Neurotrophic Factor; Cell Differen | 2013 |
In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease.
Topics: Animals; Immunohistochemistry; Luminescent Measurements; Male; Mice; Mice, Inbred C57BL; Neural Stem | 2013 |
Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Behavior, Animal; Disease Models, Animal; Dopamine; I | 2013 |
Enhanced prostacyclin synthesis by adenoviral gene transfer reduced glial activation and ameliorated dopaminergic dysfunction in hemiparkinsonian rats.
Topics: Adenoviridae; Animals; Benzophenones; Carbon Isotopes; Cell Proliferation; Cells, Cultured; Cyclooxy | 2013 |
[Synchrotron radiation-based FTIR microspectroscopy study of 6-hydroxydopamine induced Parkinson's disease cell model].
Topics: Cell Line, Tumor; Humans; Neuroblastoma; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein S | 2013 |
Switching ability of over trained movements in a Parkinson's disease rat model.
Topics: Acoustic Stimulation; Animals; Attention; Corpus Striatum; Cues; Disease Models, Animal; Functional | 2013 |
Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Bone Marrow Transplantation; Catalase; Corpus Stri | 2013 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Ameliorating effects of curcumin on 6-OHDA-induced dopaminergic denervation, glial response, and SOD1 reduction in the striatum of hemiparkinsonian mice.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Curcumin; Male; Mice; Mice, Inbred ICR; Neurogli | 2013 |
Exercise-induced rescue of tongue function without striatal dopamine sparing in a rat neurotoxin model of Parkinson disease.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Elect | 2013 |
Effects of glial cell line-derived neurotrophic factor on microRNA expression in a 6-hydroxydopamine-injured dopaminergic cell line.
Topics: Animals; Cell Line; Dopaminergic Neurons; Gene Expression Regulation; Glial Cell Line-Derived Neurot | 2013 |
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Re | 2013 |
Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Catalysis; Cells, Cultured; Chromatography, High Pressure Liquid; D | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
The potential neuroprotection mechanism of GDNF in the 6-OHDA-induced cellular models of Parkinson's Disease.
Topics: Animals; Apoptosis; Cell Line; Cluster Analysis; Cyclins; Gene Expression Regulation; Gene Knockdown | 2013 |
Dynamic expressions of Beclin 1 and tyrosine hydroxylase in different areas of 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Animals; Apoptosis Regulatory Proteins; Beclin-1; Brain; Female; Flow Cytometry; Immunohistochemistr | 2013 |
Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antigens, Differentiation; Apomorp | 2013 |
D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model.
Topics: Animals; Carotenoids; Disease Models, Animal; Dopamine Agonists; Indoles; Lycopene; Mitogen-Activate | 2013 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum | 2012 |
Neuronal firing activity and gene expression changes in the subthalamic nucleus after transplantation of dopamine neurons in hemiparkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Cells, Cultured; Corpus Striatum; Disease Models, Ani | 2013 |
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiogenesis Inducing Agents; Animals; Becaplermin; Ce | 2011 |
Striatal dopamine depletion induces forelimb motor impairments and disrupts forelimb movement representations within the motor cortex.
Topics: Animals; Corpus Striatum; Densitometry; Disease Models, Animal; Dopamine; Electric Stimulation; Feed | 2011 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dise | 2011 |
The expression and release of Hsp60 in 6-OHDA induced in vivo and in vitro models of Parkinson's disease.
Topics: Animals; Chaperonin 60; Disease Models, Animal; Dopaminergic Neurons; Male; Microglia; Mitochondrial | 2013 |
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce | 2013 |
3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.
Topics: Buthionine Sulfoximine; Caffeic Acids; Cell Line, Tumor; Dose-Response Relationship, Drug; Glutathio | 2014 |
Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease.
Topics: Animals; Bone Marrow; Cell- and Tissue-Based Therapy; Disease Models, Animal; Female; Flow Cytometry | 2014 |
Inhibiting subthalamic D5 receptor constitutive activity alleviates abnormal electrical activity and reverses motor impairment in a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Animals, Newborn; Disease Models, Animal; Dopamine Agonists; Dopamine An | 2013 |
The roles of cyclic AMP-ERK-Bad signaling pathways on 6-hydroxydopamine-induced cell survival and death in PC12 cells.
Topics: Animals; bcl-Associated Death Protein; Calcium; Caspase 3; Cell Death; Cell Line, Tumor; Cell Surviv | 2013 |
In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
Topics: Action Potentials; alpha-Synuclein; Animals; Beta Rhythm; Humans; Male; Mice; Motor Cortex; Neurons; | 2013 |
Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Inflammation; M | 2013 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dysk | 2014 |
Oxidation of survival factor MEF2D in neuronal death and Parkinson's disease.
Topics: Animals; Autophagy; Cell Death; Cell Line; Dopaminergic Neurons; Humans; MEF2 Transcription Factors; | 2014 |
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biogenic Monoamines; Brain; Cell Line, Tumor; Disease Models, Animal; Dopa | 2014 |
Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Corpus Striatum; Disease Models, Animal; Glial C | 2014 |
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig | 2014 |
Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
Topics: Animals; Behavior, Animal; Desipramine; Dopamine; Dopamine Agonists; Exploratory Behavior; Female; H | 2014 |
Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Be | 2014 |
Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Astrocytes; Corpus Striatum; Dendr | 2014 |
6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Protein Receptors, Type II | 2014 |
NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice.
Topics: Animals; Apomorphine; CD11b Antigen; Dopaminergic Neurons; Enzyme Activation; Glial Fibrillary Acidi | 2013 |
Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Apomorphine; Benzeneacetamides; Cell Death; Disease Models, Animal; Dopami | 2014 |
Serum melatonin is an alternative index of Parkinson's disease severity.
Topics: Aged; Aged, 80 and over; Animals; Apomorphine; Biomarkers; Dopamine Agonists; Female; Humans; Male; | 2014 |
EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.
Topics: Animals; Apoptosis; Chromones; Erythropoietin; Forkhead Box Protein O3; Forkhead Transcription Facto | 2014 |
n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.
Topics: alpha-Synuclein; Angelica sinensis; Animals; Antiparkinson Agents; Caenorhabditis elegans; Caenorhab | 2014 |
Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
Topics: Adenoviridae; Analysis of Variance; Animals; Disease Models, Animal; Dopamine; Functional Laterality | 2014 |
Upregulation of β1-adrenoceptors is involved in the formation of gastric dysmotility in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Gastric Emptying; Gastroparesis; | 2014 |
Parkinson's disease, lights and melanocytes: looking beyond the retina.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Light; Male; | 2014 |
Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease.
Topics: Animals; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neuron | 2014 |
Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Brain; Caffeine; Cytokines; | 2014 |
Neuroprotective potentials of neurotrophin rich olfactory ensheathing cell's conditioned media against 6OHDA-induced oxidative damage.
Topics: Animals; Cell Line, Tumor; Culture Media, Conditioned; Humans; Oxidative Stress; Oxidopamine; Parkin | 2014 |
miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.
Topics: Brain; Cells, Cultured; Dopaminergic Neurons; Down-Regulation; Gene Expression Regulation; Humans; I | 2014 |
Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Dopam | 2014 |
Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.
Topics: Animals; Brain; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2014 |
High-frequency stimulation of the subthalamic nucleus counteracts cortical expression of major histocompatibility complex genes in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Electric Stimulation Therapy; Electrodes; Electro | 2014 |
Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Ani | 2015 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Lev | 2014 |
Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Excitatory A | 2014 |
Respiratory activity in the 6-hydroxydopamine model of Parkinson's disease in the rat.
Topics: Adrenergic Agents; Animals; Blood Gas Analysis; Blood Pressure; Disease Models, Animal; Functional L | 2014 |
Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Injec | 2014 |
Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; AMP-Activated Protein Kinases; Animals; Apoptosis; Carrier Proteins; Ca | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Ani | 2014 |
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1.
Topics: Animals; Cell Survival; DNA-Binding Proteins; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Ge | 2014 |
Two-step grafting significantly enhances the survival of foetal dopaminergic transplants and induces graft-derived vascularisation in a 6-OHDA model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Emb | 2014 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Neurotropic and neuroprotective activities of the earthworm peptide Lumbricusin.
Topics: Amino Acid Sequence; Animals; Antimicrobial Cationic Peptides; Apoptosis; Cell Line; Cell Proliferat | 2014 |
Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.
Topics: Apoptosis; Cell Survival; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Oxidopamine; Par | 2014 |
The restorative effect of intramuscular injection of tetanus toxin C-fragment in hemiparkinsonian rats.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Cell Count; Disease Models, Animal; Functional Lat | 2014 |
Intrastriatal grafts of fetal ventral mesencephalon improve allodynia-like withdrawal response to mechanical stimulation in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Fetal Tissue Transplantation; Hyperalgesia; Male; Mesencephalon; Oxidopami | 2014 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine | 2014 |
Firing pattern modulation through SK channel current increase underlies neuronal survival in an organotypic slice model of Parkinson's disease.
Topics: Action Potentials; Animals; Calcium; Cell Death; Cell Survival; Disease Models, Animal; Dopaminergic | 2015 |
Differential expression of synaptic proteins in unilateral 6-OHDA lesioned rat model-A comparative proteomics approach.
Topics: Animals; Basal Ganglia; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Proteome; Prote | 2014 |
Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Topics: Administration, Intranasal; Animals; Body Weight; Cell Count; Disease Models, Animal; Dopaminergic N | 2014 |
Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Animals, Newborn; Brefeldin A; Calnexin; Calreticulin; Cells, Cultured; | 2014 |
Protective effects of the thioredoxin and glutaredoxin systems in dopamine-induced cell death.
Topics: Animals; Antioxidants; Apoptosis; Caenorhabditis elegans; Cell Line, Tumor; Cell Survival; Dopamine; | 2014 |
Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease.
Topics: Albizzia; Animals; Disease Models, Animal; Flavonoids; Humans; Male; Medicine, African Traditional; | 2014 |
The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons.
Topics: Adrenergic Agents; Animals; Axonal Transport; Disease Models, Animal; Dopaminergic Neurons; Mice; Mi | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models | 2015 |
PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Biolo | 2015 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonist | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid | 2014 |
Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease.
Topics: Animals; Brain; Curcumin; Deferoxamine; Disease Models, Animal; Dopamine; Drug Interactions; Male; N | 2014 |
Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat.
Topics: Animals; Behavior, Animal; Cell Transplantation; Disease Models, Animal; Homocysteine; Male; Oxidopa | 2014 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Stria | 2014 |
Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Nerve Growth Factors; Nervous System; Oxi | 2014 |
Lentivirus-mediated delivery of sonic hedgehog into the striatum stimulates neuroregeneration in a rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Genetic Vectors; Glial Fibrilla | 2014 |
Analysis of volatile organic compounds in rats with dopaminergic lesion: Possible application for early detection of Parkinson's disease.
Topics: Animals; Early Diagnosis; Gas Chromatography-Mass Spectrometry; Male; Oxidopamine; Parkinson Disease | 2014 |
Survival and engraftment of dopaminergic neurons manufactured by a Good Manufacturing Practice-compatible process.
Topics: Animals; Biotechnology; Cell Line; Cell Survival; Corpus Striatum; Cryopreservation; Disease Models, | 2014 |
Brain-specific delivery of dopamine mediated by n,n-dimethyl amino group for the treatment of Parkinson's disease.
Topics: Animals; Apoptosis; Brain; Cell Line, Tumor; Corpus Striatum; Dopamine; Endothelial Cells; Humans; L | 2014 |
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.
Topics: Animals; Apoptosis; Brain; HEK293 Cells; Humans; Leupeptins; Mice; Mice, Knockout; Neurons; Oxidopam | 2014 |
Quercetin glycosides induced neuroprotection by changes in the gene expression in a cellular model of Parkinson's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Glycosides; Microtubule-Associated Proteins; Neurons; Oxidop | 2015 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levod | 2016 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimida | 2014 |
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; | 2016 |
Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Conditioning, Operant; Disease Models | 2014 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo | 2014 |
Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.
Topics: Animals; Apomorphine; Apoptosis; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Gl | 2014 |
Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Exercise Therapy; Ma | 2014 |
Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Exercise Therapy; Ma | 2014 |
Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Exercise Therapy; Ma | 2014 |
Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Exercise Therapy; Ma | 2014 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpu | 2014 |
Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cell Line; Disease Models, Animal; Gene Expression; Gene Order; Genetic V | 2015 |
Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations.
Topics: Animals; Behavior, Animal; Bone Marrow Cells; Corpus Striatum; Disease Models, Animal; Dopaminergic | 2015 |
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Female; Levodopa; Mitogen-Activated Protein Kinase | 2014 |
Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Female; Immunohistochemistry; I | 2014 |
Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; CD11b Antigen; Disease Model | 2014 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Mem | 2014 |
Dysautonomias in Parkinson's disease: cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra.
Topics: Adrenergic Antagonists; Animals; Baroreflex; Blood Pressure; Cardiovascular System; Heart Rate; Male | 2015 |
β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Dop | 2015 |
Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats.
Topics: Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Dopaminergic Neurons; Estrogen Receptor | 2015 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induc | 2016 |
Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease: involvement of antioxidative enzymes induction.
Topics: Abietanes; Animals; Antioxidants; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; D | 2015 |
Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease.
Topics: Animals; Cell Count; Gait; Male; Neurons; Oxidopamine; Parkinson Disease; Putamen; Rats, Sprague-Daw | 2015 |
Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: a model for early Parkinson's disease.
Topics: Animals; Conditioning, Operant; Denervation; Discrimination, Psychological; Disease Models, Animal; | 2015 |
Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning.
Topics: Adipose Tissue; Adult; Animals; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cell- and Tis | 2015 |
Ndfip1 attenuated 6-OHDA-induced iron accumulation via regulating the degradation of DMT1.
Topics: Animals; Carrier Proteins; Cation Transport Proteins; Cell Line; Dopaminergic Neurons; Gene Expressi | 2015 |
Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Disease Models, Anim | 2016 |
Transplantation of fetal ventral mesencephalic progenitor cells overexpressing high molecular weight fibroblast growth factor 2 isoforms in 6-hydroxydopamine lesioned rats.
Topics: Animals; Cells, Cultured; Dopaminergic Neurons; Female; Fibroblast Growth Factor 2; Mesencephalon; M | 2015 |
The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Mesencephal | 2015 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Pr | 2014 |
Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Malondialdehyd | 2014 |
Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Topics: Animals; Brain; Catalase; Dopamine; Female; Glutathione; Indazoles; Lipid Peroxidation; Motor Skills | 2015 |
PPARβ/δ and γ in a rat model of Parkinson's disease: possible involvement in PD symptoms.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Male; Oxidopa | 2015 |
Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.
Topics: Animals; Gene Expression Regulation; Humans; Male; Nerve Growth Factor; Neural Stem Cells; Olfactory | 2015 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; In | 2015 |
Neural code alterations and abnormal time patterns in Parkinson's disease.
Topics: Action Potentials; Adaptation, Physiological; Animals; Computer Simulation; Female; Globus Pallidus; | 2015 |
Neural mechanism underlying hyperalgesic response to orofacial pain in Parkinson's disease model rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Facial Pain; Formaldehyde; Hyperalgesia; Male; Oxi | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesi | 2015 |
Spatial distribution of 5-hydroxymethyl cytosine in rat brain and temporal distribution in striatum.
Topics: 5-Methylcytosine; Animals; Brain; Corpus Striatum; Cytosine; Male; Oxidopamine; Parkinson Disease; R | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Effects of subthalamic deep brain stimulation on blink abnormalities of 6-OHDA lesioned rats.
Topics: Adrenergic Agents; Animals; Biophysics; Blinking; Deep Brain Stimulation; Disease Models, Animal; Fo | 2015 |
Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Topics: Adrenergic Agents; Animals; Apomorphine; Brain; Carbon Radioisotopes; Disease Models, Animal; Dopami | 2015 |
Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration.
Topics: Animals; Apoptosis; Cell Survival; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkin | 2015 |
Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Brain; Brain-Derived Neurotrophic Factor; Male; Oxido | 2015 |
Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: Aged; Animals; Cell Differentiation; Dopaminergic Neurons; Female; Fibroblasts; Humans; Immunohistoc | 2015 |
Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats.
Topics: Animals; Biogenic Monoamines; Colon; Gastrointestinal Motility; Male; Norepinephrine; Oxidopamine; P | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Ph | 2015 |
Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glial | 2015 |
Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.
Topics: Animals; Blood-Brain Barrier; Cell Line, Tumor; Dopamine; Dopaminergic Neurons; Drug Carriers; Drug | 2015 |
Respiratory deficits in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Hydrogen-Ion Concen | 2015 |
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Carbidopa; Chromatography, High Pre | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Dru | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, | 2015 |
The degeneration of dopaminergic synapses in Parkinson's disease: A selective animal model.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Gliosis; Infusio | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disea | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, | 2016 |
Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis.
Topics: Apoptosis; Caspase 3; Cell Culture Techniques; Cell-Derived Microparticles; Cells, Cultured; Child; | 2015 |
PET Imaging of Serotonin Transporters With 4-[(18)F]-ADAM in a Parkinsonian Rat Model With Porcine Neural Xenografts.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; | 2016 |
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
Topics: Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Co | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dop | 2015 |
Low-frequency stimulation of the pedunculopontine nucleus affects gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats.
Topics: Acetylcholine; Animals; Electric Stimulation; Gait; Male; Neurotransmitter Agents; Norepinephrine; O | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Ac | 2015 |
Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Catalase; Corpus Striatum; Disease Models, Animal; Ethanol; Glutathione; Hyper | 2016 |
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
Topics: Amodiaquine; Animals; Behavior, Animal; Chloroquine; Disease Models, Animal; Ligands; Neurogenesis; | 2015 |
Investigating the role of Sirt1-modulated oxidative stress in relation to benign paroxysmal positional vertigo and Parkinson's disease.
Topics: Adrenergic Agents; Adult; Age Factors; Aged; Animals; bcl-2-Associated X Protein; Benign Paroxysmal | 2015 |
Medial frontal ∼4-Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical dopamine depletion.
Topics: Animals; Antiparkinson Agents; Conditioning, Operant; Delta Rhythm; Dopamine; Electroencephalography | 2015 |
Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats?
Topics: Adrenergic Agents; Animals; Brain; Ceruloplasmin; Disease Models, Animal; Female; Immunohistochemist | 2015 |
Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
Topics: Animals; Cell Fractionation; Cells, Cultured; Cytokines; Disease Models, Animal; Encephalitis; Lipop | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antag | 2015 |
Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.
Topics: Animals; Caspases; Cell Survival; Dopamine Agonists; Dopaminergic Neurons; Extracellular Signal-Regu | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Male; Molecular Structure; Neuroprote | 2016 |
Efficient Expression of Igf-1 from Lentiviral Vectors Protects In Vitro but Does Not Mediate Behavioral Recovery of a Parkinsonian Lesion in Rats.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Insulin-Like Gro | 2015 |
ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Antioxidants; Ataxia; Axons; Behavior, Animal; Brain; Cell Nucleus; Diseas | 2016 |
Systemic human CD34(+) cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration.
Topics: Animals; Antigens, CD34; Brain; Cell Differentiation; Cell Line; Cell Movement; Cord Blood Stem Cell | 2015 |
Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease.
Topics: Adipocytes; Animals; Disease Models, Animal; Dopaminergic Neurons; Electron Transport Complex I; Hum | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dop | 2015 |
L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.
Topics: Adrenergic Agents; Animals; Caspase 3; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopam | 2016 |
[The alterations of apoptosis factor Bcl-2/Bax in the early Parkinson's disease rats and the protective effect of scorpion venom derived activity peptide].
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Disease Models, Animal; Down-Regulation; Male; Neuro | 2015 |
Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Deep Brain Stimulation; Disease Models, Animal; Dy | 2016 |
Neuroprotective Effects of Tanshinone I Against 6-OHDA-Induced Oxidative Stress in Cellular and Mouse Model of Parkinson's Disease Through Upregulating Nrf2.
Topics: Abietanes; Animals; Antioxidant Response Elements; Cell Death; Cell Line, Tumor; Corpus Striatum; Hu | 2016 |
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.
Topics: Animals; Cholinergic Neurons; Dopaminergic Neurons; Macaca fascicularis; Male; Oxidopamine; Parkinso | 2016 |
Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
Topics: Action Potentials; Animals; Basal Ganglia; Bee Venoms; Catalepsy; Disease Models, Animal; Dopamine A | 2015 |
Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Deep Brain Stimulation; Dopamine; Glutami | 2016 |
NMR-Based Metabolomics Reveal a Recovery from Metabolic Changes in the Striatum of 6-OHDA-Induced Rats Treated with Basic Fibroblast Growth Factor.
Topics: Animals; Corpus Striatum; Discriminant Analysis; Fibroblast Growth Factor 2; Least-Squares Analysis; | 2016 |
Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Transplantation; Cells, Cultured; Cognition Disorders; Cyclosporine; | 2015 |
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Axons; Cell Line, Tumor; Cell Survival; Dopam | 2016 |
Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat.
Topics: Administration, Oral; Animals; Apoptosis; Corpus Striatum; Glial Fibrillary Acidic Protein; Gliosis; | 2016 |
Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Disease Mode | 2016 |
Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity.
Topics: Animals; Calbindins; Cell Transplantation; Cysteamine; Dopaminergic Neurons; Female; Humans; Mitocho | 2016 |
Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Animals; Animals, Newborn; Cell Count; Cell Survival; Cells, Cultured; Cytokines; Disease Models, An | 2016 |
Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Animals; Heat-Shock Proteins; HEK293 Cells; Humans; Lysine; Mi | 2016 |
Upregulation and axonal transport of synaptotagmin-IV in the direct-pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulation.
Topics: Animals; Axonal Transport; Benzazepines; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; M | 2016 |
The ameliorative effect of Monascus purpureus NTU 568-fermented rice extracts on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and the rat model of Parkinson's disease.
Topics: Animals; Fermentation; Glutathione Reductase; Humans; Male; Monascus; Oryza; Oxidative Stress; Oxido | 2016 |
Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease.
Topics: Animals; Calbindins; Cognition Disorders; Disease Models, Animal; Dopaminergic Neurons; Female; Fetu | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase | 2016 |
A biophysical model of the cortex-basal ganglia-thalamus network in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Biophysics; Cerebral Cortex; Deep Brain Stimulation; Disease Models, Animal; | 2016 |
Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Flavanones; Mice; Mice, Inbred C57BL; Ne | 2016 |
Electroacupuncture Produces the Sustained Motor Improvement in 6-Hydroxydopamine-Lesioned Mice.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Electroacupuncture | 2016 |
Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats.
Topics: Animals; Behavior, Animal; Biomarkers; Caspase 3; Cell Line; Disease Models, Animal; Dopaminergic Ne | 2016 |
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrop | 2016 |
Altered neuronal activity in the pedunculopontine nucleus: An electrophysiological study in a rat model of Parkinson's disease.
Topics: Action Potentials; Adrenergic Agents; Animals; Disease Models, Animal; Electric Stimulation; Male; M | 2016 |
6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
Topics: Animals; Astrocytes; Cell Proliferation; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2016 |
Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Cognition Disorders; Disease Models, Animal; Escap | 2016 |
Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Topics: Animals; Brain; Dopamine; Dopaminergic Neurons; Flavonoids; Humans; Mice; Mice, Inbred C57BL; Neurop | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; | 2016 |
Parkinson's disease-like forelimb akinesia induced by BmK I, a sodium channel modulator.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Exploratory Behavior; Forel | 2016 |
Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats.
Topics: Acetylglucosaminidase; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Corpus Striatum; Dep | 2016 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Glio | 2016 |
Down-regulation of p21-activated serine/threonine kinase 1 is involved in loss of mesencephalic dopamine neurons.
Topics: Animals; Apoptosis; Behavior, Animal; Calcineurin; Calcineurin Inhibitors; Cell Survival; Disease Mo | 2016 |
Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models.
Topics: Animals; Apoptosis; Cell Line; Fructosediphosphates; Gene Expression Regulation; Glycolysis; Humans; | 2016 |
The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Disease Models, Animal; Levodopa; Male; Motor Cortex; Ox | 2016 |
Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model.
Topics: Animals; Choline O-Acetyltransferase; Disease Models, Animal; Dopamine; Male; Neuroanatomical Tract- | 2016 |
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; | 2016 |
A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease.
Topics: Amino Acids; Animals; Disease Models, Animal; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wist | 2016 |
Daphnane Diterpenes from Daphne genkwa Activate Nurr1 and Have a Neuroprotective Effect in an Animal Model of Parkinson's Disease.
Topics: Animals; Daphne; Disease Models, Animal; Diterpenes; Dopamine; Dopaminergic Neurons; Molecular Struc | 2016 |
Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
Topics: Administration, Intranasal; Animals; Brain; Cell Line, Tumor; Corpus Striatum; Disease Models, Anima | 2016 |
A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
Topics: Antiparkinson Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; | 2016 |
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test.
Topics: Animals; Deep Brain Stimulation; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Subt | 2016 |
Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease.
Topics: Animals; Becaplermin; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Medial Forebrain Bund | 2016 |
In Vivo Neural Tissue Engineering: Cylindrical Biocompatible Hydrogels That Create New Neural Tracts in the Adult Mammalian Brain.
Topics: Aging; Animals; Behavior, Animal; Biocompatible Materials; Brain; Cell Movement; Female; Fibrin; Hyd | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Ind | 2016 |
[Effect of 5-HT7 receptor agonist on pyramidal neurons in the medial frontal cortex in a rat model of Parkinson's disease].
Topics: Action Potentials; Animals; Oxidopamine; Parkinson Disease; Prefrontal Cortex; Pyramidal Cells; Rats | 2016 |
Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.
Topics: Action Potentials; Animals; Benzoxazoles; Globus Pallidus; Haloperidol; Male; Naphthyridines; Neuron | 2016 |
Subthalamic deep brain stimulation alters neuronal firing in canonical pain nuclei in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Action Potentials; Adrenergic Agents; Animals; Brain; Deep Brain Stimulation; Disease Models, Animal | 2016 |
Chronic D
Topics: Animals; Choice Behavior; Corpus Striatum; Dopamine; Dopamine Agonists; Indoles; Male; Neostriatum; | 2017 |
Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
Topics: Amphetamine; Animals; CHO Cells; Cricetulus; Disease Models, Animal; Drug Design; Genetic Variation; | 2016 |
Dimerumic Acid and Deferricoprogen Activate Ak Mouse Strain Thymoma/Heme Oxygenase-1 Pathways and Prevent Apoptotic Cell Death in 6-Hydroxydopamine-Induced SH-SY5Y Cells.
Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Cell Survival; Diketopiperazines; Heme Oxygenase-1; Human | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cata | 2016 |
Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Acid Sensing Ion Channels; Animals; Autophagy; Bridged-Ring Compounds; Dopamine; Dopaminergic Neuron | 2016 |
Optogenetic stimulation of cortico-subthalamic projections is sufficient to ameliorate bradykinesia in 6-ohda lesioned mice.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Humans; Hypokinesia; Male; Mice, Inbred C57 | 2016 |
Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Cells, Cultured; Cerebellar Cortex; Disease Progression; Female; H | 2016 |
Neuroprotective effect of Portulaca oleracea extracts against 6-hydroxydopamine-induced lesion of dopaminergic neurons.
Topics: Animals; Dopaminergic Neurons; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pars Co | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Po | 2016 |
Oleuropein Prevents Neuronal Death, Mitigates Mitochondrial Superoxide Production and Modulates Autophagy in a Dopaminergic Cellular Model.
Topics: Animals; Autophagy; Cell Death; Iridoid Glucosides; Iridoids; Mitochondria; Nerve Degeneration; Oxid | 2016 |
Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease.
Topics: Animals; Cattle; Cell- and Tissue-Based Therapy; Chromaffin Cells; Disease Models, Animal; Dopamine; | 2016 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Fema | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Choliner | 2016 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-R | 2016 |
Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
Topics: Adrenergic Agents; Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelo | 2016 |
Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Topics: Animals; Apoptosis; Behavior, Animal; Calcium-Binding Proteins; Caspase 3; Cell Line, Tumor; Cell Mo | 2016 |
Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7.
Topics: Animals; Apoptosis; Cell Proliferation; Cell Survival; Down-Regulation; Humans; MicroRNAs; Neurons; | 2016 |
Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.
Topics: Caffeine; Cysteine; Dopamine; Iron; Melanins; Nicotine; Oxidopamine; Parkinson Disease; Polymerizati | 2016 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2016 |
Neuroprotective effects of fingolimod in mouse models of Parkinson's disease.
Topics: Animals; Cell Line, Tumor; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Male; Mice; | 2017 |
Step Sequence Is a Critical Gait Parameter of Unilateral 6-OHDA Parkinson's Rat Models.
Topics: Animals; Disease Models, Animal; Gait; Locomotion; Male; Mesencephalon; Methamphetamine; Neurons; Ox | 2017 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Sys | 2016 |
Neuroprotective Effects of Ellagic Acid in a Rat Model of Parkinson's Disease.
Topics: Animals; Antioxidants; Brain; Corpus Striatum; Ellagic Acid; Glutathione Peroxidase; Male; Malondial | 2016 |
Effects of crocin on brain oxidative damage and aversive memory in a 6-OHDA model of Parkinson's disease.
Topics: Animals; Antioxidants; Carotenoids; Cerebral Cortex; Disease Models, Animal; Glutathione Peroxidase; | 2016 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxid | 2016 |
Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dopamine Agents; Levodopa; Male; Neurons; Oxidopami | 2017 |
A New Danshensu Derivative Protects Against 6-Hydroxydopamine-Induced Neurotoxicity In Vitro and In Vivo.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Dopaminergic Neurons; Lacta | 2016 |
Axon guidance molecule expression after cell therapy in a mouse model of Parkinson's disease.
Topics: Animals; Brain; Disease Models, Animal; Embryo, Mammalian; Ephrin-A2; Ephrin-A3; Female; Gene Expres | 2016 |
Impact of the Chronic Omega-3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6-Hydroxydopamine in Rats.
Topics: Animals; Apomorphine; Biogenic Monoamines; Brain; Dietary Supplements; Disease Models, Animal; Fatty | 2017 |
Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Cell Line; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glio | 2018 |
Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Feeding Beha | 2017 |
Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dopaminergic N | 2017 |
Therapeutic Potential of Induced Neural Stem Cells for Parkinson's Disease.
Topics: Animals; Cell Differentiation; Cell Lineage; Cell Movement; Cell Shape; Disease Models, Animal; Dopa | 2017 |
Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Gene Expression; Immunohistochemistry; M | 2017 |
Humulus japonicus Prevents Dopaminergic Neuron Death in 6-Hydroxydopamine-Induced Models of Parkinson's Disease.
Topics: Animals; Cell Death; Dopamine; Dopaminergic Neurons; Humans; Humulus; Male; Mice; Mice, Inbred C57BL | 2017 |
Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson's disease model.
Topics: Animals; Antioxidants; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Reg | 2017 |
Dissociation between dopaminergic response and motor behavior following intrastriatal, but not intravenous, transplant of bone marrow mononuclear stem cells in a mouse model of Parkinson's disease.
Topics: Administration, Intravenous; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine | 2017 |
Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Acetates; Adrenergic Agents; Animals; Calcium-Binding Proteins; Cyclopropanes; Cytokines; Disease Mo | 2017 |
Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Astrocytes; Corpus Striatum; Disease Models, Animal | 2018 |
Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling.
Topics: Animals; Antioxidants; Apoptosis; Corpus Striatum; Dopaminergic Neurons; Ellagic Acid; Estrogen Rece | 2017 |
The Impact of Short and Long-Term Exercise on the Expression of Arc and AMPARs During Evolution of the 6-Hydroxy-Dopamine Animal Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Cytoskeletal Proteins; Male; Motor Activity; Motor Cortex; Nerve Tissue Pr | 2017 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease | 2017 |
Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Biological Products; Caenorhabditis elegans; Disease | 2018 |
Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson's disease: Possible involvement of PI3K/ERβ signaling.
Topics: Animals; Biomarkers; Disease Models, Animal; Dose-Response Relationship, Drug; Estrogen Receptor bet | 2017 |
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.
Topics: Adaptive Immunity; Animals; Antigens, CD; Astrocytes; Corpus Striatum; Disease Models, Animal; Disea | 2017 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, | 2017 |
Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Cells, Cultured; Central Nervous System S | 2008 |
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Topics: Acetaminophen; Adrenergic Agents; alpha-Synuclein; Analgesics, Non-Narcotic; Animals; Animals, Genet | 2008 |
The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA neurons in early PD rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Glial Cell Li | 2008 |
Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Circadian Rhythm; Disease Models | 2008 |
GABAergic mechanism mediated via D receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study.
Topics: Animals; Benzazepines; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Extracel | 2008 |
Mesencephalic human neural progenitor cells transplanted into the adult hemiparkinsonian rat striatum lack dopaminergic differentiation but improve motor behavior.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cells, Cultured; Dopamine; Humans; Male | 2008 |
[Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Estrogens; Evoked Potentials, Auditory; Femal | 2008 |
Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease.
Topics: Animals; Autophagy; Biomarkers; Cell Line; Cytoplasmic Granules; Enzyme Activation; Humans; Lysosome | 2008 |
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Cell Nucleus; Cells, Cultured; Cytoplasm; Dependoviru | 2008 |
Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine.
Topics: Animals; Caspases; Cell Cycle; Cell Death; Cell Differentiation; Cyclin D1; Cyclin-Dependent Kinase | 2008 |
Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Topics: Animals; Antipyrine; Cell Survival; Cells, Cultured; Dopamine; Edaravone; Female; Mice; Mice, Inbred | 2008 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Ani | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkins | 2008 |
Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.
Topics: Alpha Rhythm; Animals; Apomorphine; Behavior, Animal; Beta Rhythm; Cerebral Cortex; Corpus Striatum; | 2008 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2009 |
Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells.
Topics: Animals; Antioxidants; Caspase 3; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Resp | 2008 |
Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Benzamidines; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Neuroprote | 2008 |
Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; | 2008 |
The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; | 2009 |
Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.
Topics: Adrenergic Agents; Affective Symptoms; Analysis of Variance; Animals; Behavior, Animal; Brain; Brain | 2008 |
Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat.
Topics: Adrenergic Agents; Animals; Axons; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Humans | 2008 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxyg | 2008 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa | 2009 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; F | 2009 |
Modeling operant behavior in the Parkinsonian rat.
Topics: Animals; Conditioning, Operant; Disease Models, Animal; Dopamine; Food; Male; Memory, Short-Term; Mi | 2009 |
Response of neural precursor cells in the brain of Parkinson's disease mouse model after LIF administration.
Topics: Adrenergic Agents; Adult Stem Cells; Analysis of Variance; Animals; Cell Count; Cell Differentiation | 2009 |
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Death; Cells, Cultured; Gene Expression Regula | 2008 |
Future of cell and gene therapies for Parkinson's disease.
Topics: Adult; Animals; Cell Transplantation; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Gene | 2008 |
Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.
Topics: Amino Acid Sequence; Animals; Cholecystokinin; Chromogranin B; Disease Models, Animal; Enkephalins; | 2009 |
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.
Topics: Animals; Behavior, Animal; Cells, Cultured; Disease Models, Animal; Humans; Magnetic Resonance Imagi | 2009 |
Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study .
Topics: Animals; Corpus Striatum; Indazoles; Male; Molsidomine; Nitric Oxide; Nitric Oxide Donors; Oxidopami | 2009 |
Parafascicular thalamic nucleus activity in a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Basal Ganglia; Biological Clocks; Denervation; Disease Models, Animal; I | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; En | 2009 |
Changes to interneuron-driven striatal microcircuits in a rat model of Parkinson's disease.
Topics: Animals; Calbindin 2; Cell Count; Choline O-Acetyltransferase; Densitometry; Disease Models, Animal; | 2009 |
Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Topics: Administration, Oral; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, An | 2009 |
Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Down-Regulation; Electric Stimulation; Glutamic Acid; Male; Neur | 2009 |
Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Chromatography, Hig | 2009 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2009 |
Histaminergic activity in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Animals, Newborn; Apomorphine; Brain; Disease Models, Animal; Dopamine; | 2009 |
Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Brain; Cell Survival; Cells, Cultured; Central Nervous System Stimulants; Dise | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Deep brain stimulation of the posterior hypothalamic nucleus reverses akinesia in bilaterally 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Avoidance Learning; Catheterization; Deep Brain Stimulation; Electrod | 2009 |
Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement.
Topics: Animals; Apomorphine; Corpus Striatum; Cyclosporine; Disease Models, Animal; Embryonic Stem Cells; I | 2009 |
Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Topics: Animals; Animals, Newborn; Cell Death; Cell Differentiation; Cells, Cultured; Dopamine; Dose-Respons | 2009 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxido | 2009 |
Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Cell Death; Disease Models, Animal; Embryo, Mammalian; Eye Proteins; Fem | 2009 |
Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP.
Topics: alpha-Synuclein; Animals; Brain; Cell Movement; Cell Transplantation; Cells, Cultured; Culture Media | 2009 |
Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Cell Count; Corpus Striatum; Corticoste | 2009 |
Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Corpus Striatum; Disease Models, Animal; Do | 2009 |
In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Genetic Therapy; Glial Cell Line-Derived Neurotro | 2009 |
Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Culture Media, Condi | 2009 |
Dual-isotope single-photon emission computed tomography for dopamine and serotonin transporters in normal and Parkinsonian monkey brains.
Topics: Animals; Brain; Cinanserin; Dopamine Plasma Membrane Transport Proteins; Feasibility Studies; Macaca | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Lev | 2009 |
[Dual effects of different concentrations of alpha-synuclein on the neurotoxicity of 6-hydroxydopamine in SH-SY5Y cells].
Topics: Acetylcysteine; alpha-Synuclein; Apoptosis; Cell Survival; Cells, Cultured; Dose-Response Relationsh | 2009 |
Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Cell Line; Cell Survival; Disease Models, Animal; Gluta | 2009 |
Organotypic cultures as a model of Parkinson s disease. A twist to an old model.
Topics: Animals; Blotting, Western; Female; Male; Microelectrodes; Microscopy, Confocal; Microscopy, Fluores | 2009 |
Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Biomarkers; Cell Culture Techniques; Cell Differentiation; Cell Line; Do | 2010 |
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease.
Topics: Animals; Colon; Disease Models, Animal; Enteric Nervous System; Gastrointestinal Diseases; Gastroint | 2009 |
Effect of exercise on dopamine neuron survival in prenatally stressed rats.
Topics: Animals; Cell Survival; Denervation; Disease Models, Animal; Dopamine; Exercise Therapy; Female; For | 2009 |
Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; alpha-Synuclein; Alternative Splici | 2010 |
Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.
Topics: Animals; Behavior, Animal; Biomarkers; Cell Differentiation; Corpus Striatum; Disease Models, Animal | 2010 |
Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease.
Topics: Animals; Cation Transport Proteins; Cell Line; Disease Models, Animal; Gene Expression Regulation; H | 2010 |
Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Brain-Derived Ne | 2010 |
Cortical oscillations scan using chirp-evoked potentials in 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Acoustic Stimulation; Animals; Auditory Cortex; Disease Models, Animal; Electroencephalography; Evok | 2010 |
Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat.
Topics: Action Potentials; Animals; Antiparkinson Agents; Basal Ganglia; Beta Rhythm; Dopamine; Electromyogr | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
Regulation of matrix metalloproteinase-9 gene expression in MPP+- or 6-OHDA-treated human neuroblastoma SK-N-BE(2)C cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Line; Enzyme Inhibitors; Gene Expression Regulation, Enzy | 2010 |
Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease.
Topics: Animals; Arachidonic Acid; Blotting, Western; Brain; Cyclooxygenase 2; Disease Models, Animal; Male; | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expressi | 2009 |
High-frequency stimulation of the subthalamic nucleus restores neural and behavioral functions during reaction time task in a rat model of Parkinson's disease.
Topics: Animals; Cognition Disorders; Deep Brain Stimulation; Disease Models, Animal; Electric Stimulation T | 2010 |
A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine.
Topics: Caspase 3; Catechin; Cell Line, Tumor; Central Nervous System Agents; Dose-Response Relationship, Dr | 2010 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodo | 2010 |
Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Topics: Adrenergic Agents; Animals; Caspase 3; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; | 2010 |
The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
Topics: Animals; Chromatography, Liquid; Corpus Striatum; Cyclooxygenase 2; Disease Models, Animal; Dopamine | 2010 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximi | 2010 |
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
Topics: Adrenergic Agents; Animals; Axons; Corpus Striatum; Disease Models, Animal; Gene Expression; Male; M | 2010 |
Effect of deep brain stimulation in the pedunculopontine nucleus on motor function in the rat 6-hydroxydopamine Parkinson model.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Electrodes, Implanted; Forelimb; Male; Moto | 2010 |
Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopamine; Embryonic Stem Cells; Female; Gait; Ga | 2010 |
Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Gene Expression Profiling; Inflammation; | 2010 |
Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Cell Line; Disease Models, Animal; Humans; Leupeptins; | 2010 |
The rotational model and microdialysis: Significance for dopamine signalling, clinical studies, and beyond.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine Agents; Gene Expression Regulation; History, 20t | 2010 |
Neuroprotective effects of zonisamide target astrocyte.
Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models | 2010 |
Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; Mal | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Fem | 2010 |
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Dyskinesia, Drug-In | 2010 |
Possible regulatory factors for intra-abdominal fat mass in a rat model of Parkinson's disease.
Topics: Animals; Body Weight; Digestion; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Lipogenesis; | 2011 |
Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
Topics: Animals; Circadian Rhythm; Corpus Striatum; Dopamine; Humans; Levodopa; Motor Activity; Oxidopamine; | 2010 |
Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies.
Topics: Adrenergic Agents; Animals; Biomarkers; Cattle; Cell Differentiation; Cell Line, Tumor; Cell Prolife | 2010 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Graft-mediated functional recovery on a skilled forelimb use paradigm in a rodent model of Parkinson's disease is dependent on reward contingency.
Topics: Animals; Brain Tissue Transplantation; Cell Transplantation; Disability Evaluation; Disease Models, | 2010 |
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L | 2009 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix | 2010 |
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functio | 2010 |
Protective effect of Cyperi rhizoma against 6-hydroxydopamine-induced neuronal damage.
Topics: Animals; Cell Survival; Cells, Cultured; Cresols; Cyperus; Female; Humans; Male; Mesencephalon; Neur | 2010 |
Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agen | 2010 |
Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.
Topics: Actins; Animals; Brain Injuries; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proli | 2010 |
Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease.
Topics: Animals; Biomarkers; Dopamine; Early Diagnosis; Electrophoresis, Gel, Two-Dimensional; Functional La | 2010 |
Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson's disease--a rat model study.
Topics: Animals; Behavior, Animal; Bone Marrow Transplantation; Brain Chemistry; Cell Differentiation; Dopam | 2010 |
The different performance among motor tasks during the increasing current intensity of deep brain stimulation of the subthalamic nucleus in rats with different degrees of the unilateral striatal lesion.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Deep Brain Stimulation; Disease Models, | 2010 |
In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Action Potentials; Animals; Cell Count; Dopamine; Interneurons; Male; Oxidopamine; Parkinson Disease | 2010 |
Lateralized response of oxytocinase activity in the medial prefrontal cortex of a unilateral rat model of Parkinson's disease.
Topics: Animals; Cystinyl Aminopeptidase; Disease Models, Animal; Functional Laterality; Male; Oxidopamine; | 2010 |
Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Cell Death; Dopamine; Estradiol; Estrog | 2010 |
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.
Topics: Adrenergic Agents; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agen | 2010 |
Development of bladder dysfunction in a rat model of dopaminergic brain lesion.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopamine; Female; Medial Forebrain Bundle; Micro | 2011 |
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.
Topics: Animals; Basal Ganglia; Channelrhodopsins; Chromosomes, Artificial, Bacterial; Disease Models, Anima | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; | 2010 |
Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Caspa | 2010 |
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Topics: Amides; Animals; Drug Design; Levodopa; Male; Oxidopamine; Parkinson Disease; Prodrugs; Rats; Rats, | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transp | 2010 |
Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes.
Topics: Amino Acid Sequence; Animals; Calcium; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional | 2010 |
Effects of GPi and STN inactivation on physiological, motor, cognitive and motivational processes in animal models of Parkinson's disease.
Topics: Animals; Cognition; Disease Models, Animal; Electric Stimulation Therapy; Globus Pallidus; Humans; M | 2010 |
Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Chromatography, High P | 2010 |
GPI-1046 increases presenilin-1 expression and restores NMDA channel activity.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonis | 2010 |
α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Topics: Action Potentials; Animals; Autoradiography; Binding Sites; Corpus Striatum; Dopamine; Dopamine Plas | 2010 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; | 2011 |
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Topics: Amygdala; Animals; Anxiety; Behavioral Research; Biogenic Monoamines; Chromatography, High Pressure | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Co | 2012 |
Minor retinal degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans; | 2011 |
Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Animals; Astrocytes; Cell Death; Disease Models, Animal; Dopamine; Female; Gene Transfer Techniques; | 2011 |
[Relationship of oxidative DNA damage and expression of mitochondrial apoptotic proteins in rat striatum induced by 6-hydroxydopamine].
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Corpus Striatum; Cytochromes c; DNA Damage; Male; Mitochon | 2010 |
The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 5'-Nucleotidase; Acid Anhydride Hydrolases; Adenine; Adrenergic Agents; Animals; Corpus Striatum; Di | 2011 |
HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease.
Topics: Animals; Calcium; Channelopathies; Dependovirus; Disease Models, Animal; Dopamine; Down-Regulation; | 2011 |
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.
Topics: Animals; Axonal Transport; Basal Ganglia; Dependovirus; Entopeduncular Nucleus; Gene Expression; Gen | 2011 |
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Line; Disease Models, Animal; Dopamine Agents; Enzyme-Linked Immunosorben | 2010 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; | 2011 |
Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; DNA-Binding Proteins; Dopamine; Dopa | 2010 |
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease.
Topics: Animals; Cytoprotection; Disease Models, Animal; Immunohistochemistry; Male; Matrix Metalloproteinas | 2011 |
[Effects of unilateral lesion of the nigrostriatal pathway by 6-OHDA on the neuronal activities of the pedunculopontine nucleus and the ventrolateral thalamic nucleus].
Topics: Action Potentials; Animals; Corpus Striatum; Male; Neural Pathways; Neurons; Oxidopamine; Parkinson | 2009 |
Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson's disease.
Topics: Animals; Bilirubin; Cell Differentiation; Cell Survival; Corpus Striatum; Disease Models, Animal; Do | 2012 |
Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Caspase 3; Cell Death; D | 2011 |
Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Glycogen Synthase Kinase 3; Glycoge | 2011 |
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Apomorphine; Brain; Cell Differentiation; Ce | 2011 |
Challenges facing quantification of rat locomotion along beams of varying widths.
Topics: Animals; Disease Models, Animal; Fiducial Markers; Gait; Image Processing, Computer-Assisted; Locomo | 2010 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Do | 2011 |
Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Dopamine; Female; Fluorescent Antibod | 2011 |
In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression.
Topics: Animals; Autophagy; Biomarkers; Blotting, Western; Male; Oxidative Stress; Oxidopamine; Parkinson Di | 2011 |
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
Topics: Amygdala; Animals; Anxiety Disorders; Disease Models, Animal; Excitatory Amino Acid Antagonists; Mal | 2011 |
CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.
Topics: Animals; Chemokine CX3CL1; Corpus Striatum; Disease Models, Animal; Humans; Male; Microglia; Nerve D | 2011 |
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Re | 2011 |
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Cells, Cultured; Cholinergic Agents; Corpus Striatum; Dendrit | 2011 |
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.
Topics: Administration, Intranasal; Animals; Blotting, Western; Cell Proliferation; Disease Models, Animal; | 2011 |
The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson's disease.
Topics: Action Potentials; Analysis of Variance; Animals; Bicuculline; Disease Models, Animal; Dopamine; Dos | 2011 |
Three-dimensional motion analysis of postural adjustments during over-ground locomotion in a rat model of Parkinson's disease.
Topics: Adaptation, Physiological; Animals; Behavior, Animal; Biomechanical Phenomena; Disease Models, Anima | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal | 2011 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Gl | 2011 |
Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Estrog | 2011 |
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.
Topics: Amides; Amino Acid Substitution; Animals; Cell Death; Cell Differentiation; Dopamine; Female; Humans | 2011 |
In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6-
Topics: Animals; Basal Ganglia; Behavior, Animal; Chlorides; Diffusion Tensor Imaging; Dopamine Plasma Membr | 2011 |
Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavioral Symptoms; Cell Count; Central Nervous System Stimulants; Disease Mo | 2011 |
Neuroprotective effects of tenuigenin in a SH-SY5Y cell model with 6-OHDA-induced injury.
Topics: Antioxidants; Cell Line, Tumor; Drugs, Chinese Herbal; Humans; Neurons; Neuroprotective Agents; Neur | 2011 |
Mortalin inhibition in experimental Parkinson's disease.
Topics: Action Potentials; Animals; Antiparasitic Agents; Cerebral Cortex; Corpus Striatum; Disease Models, | 2011 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Criceti | 2011 |
Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats.
Topics: Action Potentials; Adrenergic Agents; Amygdala; Animals; Antiparkinson Agents; Apomorphine; Behavior | 2011 |
Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum.
Topics: Animals; Biomarkers; Cell Survival; Corpus Striatum; Glutathione; Lipid Peroxides; Male; Neurons; Ne | 2011 |
Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease.
Topics: Aging; Angiotensin II; Animals; Cells, Cultured; Dopaminergic Neurons; Fluorescence; Humans; Immunoh | 2012 |
Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's.
Topics: Animals; Behavior, Animal; Biomarkers; Cocaine; Disease Models, Animal; Dopamine; Dopamine Plasma Me | 2011 |
Induction of dopaminergic neuronal-like cells from CD44+ human amniotic fluids that are ameliorative to behavioral recovery in a Parkinson's disease rat model.
Topics: Alkaline Phosphatase; Amniotic Fluid; Animals; Blotting, Western; Cell Differentiation; Dopaminergic | 2011 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Model | 2011 |
Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 2; Caspase Inhibitors; Cell Line; Cytochrome | 2011 |
Young and middle-aged rats exhibit isometric forelimb force control deficits in a model of early-stage Parkinson's disease.
Topics: Adrenergic Agents; Aging; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Forelimb; Male | 2011 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Di | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; E | 2011 |
Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Animals, Newborn; Arginine; Autoradiography; Cell | 2012 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent | 2012 |
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Topics: Administration, Oral; Animals; Corpus Striatum; Disease Models, Animal; Injections, Intraperitoneal; | 2012 |
Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line.
Topics: Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Protein Receptors, Type II; Cell Di | 2012 |
Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Cells, Cultured; Disease Models, Animal | 2011 |
Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease.
Topics: Analysis of Variance; Animals; Avoidance Learning; Biophysical Phenomena; Corpus Striatum; Disease M | 2011 |
Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Caloric Restriction; Disease Model | 2011 |
MEF2C enhances dopaminergic neuron differentiation of human embryonic stem cells in a parkinsonian rat model.
Topics: Animals; Cell Differentiation; Dopaminergic Neurons; Electrophysiology; Embryonic Stem Cells; Humans | 2011 |
Modeling dopamine neuron degeneration in Caenorhabditis elegans.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Disease Models, Animal; Dopaminergic Neurons; Gene | 2011 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission.
Topics: Action Potentials; Adrenergic Agents; Analysis of Variance; Animals; Biophysics; Brain; Chromatograp | 2012 |
The colayer method as an efficient way to genetically modify mesencephalic progenitor cells transplanted into 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Cells, Cultured; Dopaminergic Neurons | 2012 |
Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity.
Topics: Animals; Apoptosis; Astrocytes; Astrocytoma; Cell Death; Cell Line, Tumor; Cytoprotection; Feasibili | 2012 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, An | 2012 |
AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.
Topics: Adaptor Proteins, Signal Transducing; Animals; Axons; Carrier Proteins; Cell Cycle Proteins; Corpus | 2012 |
Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Fem | 2011 |
Excessive expression of hippocampal ezrin is induced by intrastriatal injection of 6-hydroxydopamine.
Topics: Adrenergic Agents; Animals; Cytoskeletal Proteins; Dopamine; Hippocampus; Male; Memory Disorders; Mi | 2011 |
Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
Topics: Animals; Behavior, Animal; Benzamides; Benzodioxoles; CD11b Antigen; Cell Line, Tumor; Disease Model | 2011 |
Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Atrophy; bcl-2-Associated X Protein; Disease Models, | 2011 |
Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Biomarkers; Bone Marrow Cells; Cell Differentiation; Cell Lineage; Diseas | 2013 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease.
Topics: Animals; Cell Death; Cell Line; Cell Nucleus; Corpus Striatum; DNA Damage; Dopaminergic Neurons; Gen | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autorad | 2012 |
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
Topics: Adenosine Triphosphate; Animals; Cytokines; Dopamine; Dopaminergic Neurons; Liver; Male; Membrane Po | 2012 |
Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease.
Topics: Animals; Cell Differentiation; Cell Survival; Cells, Cultured; Coculture Techniques; Dopamine Plasma | 2012 |
Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Inflammation; Male; Neuropr | 2012 |
HtrA2/Omi is involved in 6-OHDA-induced endoplasmic reticulum stress in SH-SY5Y cells.
Topics: Cell Line, Tumor; Endoplasmic Reticulum Stress; Genetic Predisposition to Disease; High-Temperature | 2012 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benzothiazoles; Biophysics; | 2012 |
Subthalamic nucleus stimulation increases brain derived neurotrophic factor in the nigrostriatal system and primary motor cortex.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Deep Brain Stimulation; Disease Models, | 2011 |
Deep brain stimulation of the subthalamic nucleus in the 6-hydroxydopamine rat model of Parkinson's disease: effects on sensorimotor gating.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Deep Brain Stimulation; Disease Models, Animal; | 2012 |
Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Culture Techniques; Cell Survival; Neurons; Neuroprotecti | 2012 |
Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Medial Forebrain Bundle; Mice; Mice, Transgenic; Oxidopam | 2012 |
Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat.
Topics: Afferent Pathways; Analysis of Variance; Animals; Basal Ganglia; Cerebral Cortex; Deep Brain Stimula | 2012 |
Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Cell Survival; CHO Cells; | 2012 |
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopami | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET.
Topics: Animals; Carbon Radioisotopes; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; | 2012 |
[The change of immunoreactivity in glia cells and its sense by using early Parkinson's disease rat model].
Topics: Animals; Astrocytes; Male; Microglia; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-D | 2012 |
[Synchrotron radiation-based FTIR microspectroscopy study of the hippocampus of 6-hydroxydopamine-lesioned rats].
Topics: Animals; Disease Models, Animal; Hippocampus; Lipids; Neurons; Oxidopamine; Parkinson Disease; Prote | 2012 |
Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Fluoxetine; Histones; Levodopa; Ma | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Pheno | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Exercise partly reverses the effect of maternal separation on hippocampal proteins in 6-hydroxydopamine-lesioned rat brain.
Topics: Animals; Cytoskeletal Proteins; Disease Models, Animal; Energy Metabolism; Hippocampus; Male; Matern | 2013 |
ER stress inhibits neuronal death by promoting autophagy.
Topics: Animals; Autophagy; Cytoprotection; Disease Models, Animal; Drosophila melanogaster; Endoplasmic Ret | 2012 |
Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Association Learning; Benzothiazoles; Conditioning | 2012 |
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplan | 2012 |
Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
Topics: Animals; Behavior, Animal; Benzylamines; Cerebrum; Disease Models, Animal; Dopamine; Exenatide; Male | 2012 |
Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein.
Topics: Animals; Apoptosis; Brain; Cell Line; Disease Models, Animal; Humans; Male; Mitochondria; Mitochondr | 2012 |
Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo.
Topics: Albumins; Animals; Caspase 3; Cell Line, Tumor; Dextroamphetamine; Disease Models, Animal; Dopaminer | 2012 |
Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Apomorphine; Apoptosis; Behavior, Animal; Benzodioxole | 2013 |
Characterization of mitophagy in the 6-hydoxydopamine Parkinson's disease model.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Mitophagy; Oxidopamine; Parkinson Disease; React | 2012 |
The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease.
Topics: Antioxidants; Cell Line; Humans; Mitochondria; Mitochondrial Dynamics; Organophosphorus Compounds; O | 2013 |
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; O | 2012 |
DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.
Topics: Adrenergic Agents; Aging; Animals; Blotting, Western; Cell Line; Disease Models, Animal; Dopamine; I | 2013 |
Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Brain; Disease Models, Animal; Mice; Minocyclin | 2012 |
SF-6 attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Cell Line, Tumor; Cell | 2012 |
6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Central Nervous System Stimulants; Cereb | 2012 |
Altered transcription factor trafficking in oxidatively-stressed neuronal cells.
Topics: Active Transport, Cell Nucleus; Cell Line, Tumor; Gene Expression; Humans; Neuroblastoma; NF-E2-Rela | 2012 |
Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats.
Topics: Animals; beta Catenin; Dopaminergic Neurons; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 | 2012 |
Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; M | 2013 |
Novel codrugs with GABAergic activity for dopamine delivery in the brain.
Topics: 1-Octanol; Acetamides; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2012 |
The Raf-1 inhibitor GW5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine.
Topics: Apoptosis; Bisbenzimidazole; Blotting, Western; Butadienes; Cell Survival; Enzyme Inhibitors; Flow C | 2012 |
Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Embryo, Mammalian; Female; Graft Sur | 2013 |
Detoxification of 6-hydroxydopamine-induced dopaminergic neurodegeneration by 5,5-dimethyl-1-pyrroline N-oxide, a radical trapper, in hemiparkinsonian rats.
Topics: Animals; Antioxidants; Behavior, Animal; Cyclic N-Oxides; Disease Models, Animal; Dose-Response Rela | 2012 |
Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death.
Topics: Algorithms; Amino Acid Sequence; Animals; Cell Death; Cell Line, Tumor; Humans; Mesencephalon; Mice; | 2012 |
Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopaminer | 2012 |
Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal | 2012 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therap | 2012 |
Neuroprotective effects of erucin against 6-hydroxydopamine-induced oxidative damage in a dopaminergic-like neuroblastoma cell line.
Topics: Adrenergic Agents; Antioxidants; Cell Death; Cell Line, Tumor; Dopaminergic Neurons; Glutathione; Hu | 2012 |
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskines | 2013 |
PET imaging of serotonin transporters with 4-[18F]-ADAM in a Parkinsonian rat model.
Topics: ADAM Proteins; Animals; Brain; Disease Models, Animal; Dopaminergic Neurons; Fluorine Radioisotopes; | 2013 |
Is nicotine protective against Parkinson's disease? An experimental analysis.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease | 2012 |
Neural stem cells transplanted in a mouse model of Parkinson's disease differentiate to neuronal phenotypes and reduce rotational deficit.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cell Differentiation; Cells, Cultured; | 2012 |
Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease.
Topics: Adult; Amphetamine; Animals; Behavior, Animal; Cell Differentiation; Cell Movement; Cell Survival; C | 2012 |
Cell fate analysis of embryonic ventral mesencephalic grafts in the 6-OHDA model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamines; Animals; Cell Transplantation; Chickens; Dyskinesias; Gene Expressi | 2012 |
Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease.
Topics: Animals; Golgi Apparatus; Homeostasis; Methamphetamine; Models, Biological; Oxidopamine; Parkinson D | 2013 |
3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Female; Neurodegenerative D | 2013 |
Protective activity of guanosine in an in vitro model of Parkinson's disease.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; DNA Fragmentation; Do | 2012 |
P73 and age-related diseases: is there any link with Parkinson Disease?
Topics: Animals; Cell Line, Tumor; DNA-Binding Proteins; Gene Expression Regulation; Mice; Mice, Inbred C57B | 2012 |
Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Topics: Animals; Biological Transport; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport | 2012 |
The role of central amygdala dopamine in disengagement behavior.
Topics: Amphetamine; Amygdala; Animals; Behavior, Animal; Dopamine; Dopamine Antagonists; Dopamine Uptake In | 2013 |
RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.
Topics: Adrenergic Agents; Aged; Aged, 80 and over; Animals; Carrier Proteins; DNA-Binding Proteins; Dopamin | 2013 |
Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Catalase; Corpus Striatum; Dopaminergic Neurons; Lipid Peroxidation; Male; Mice; Motor Acti | 2013 |
Effects of squalene/squalane on dopamine levels, antioxidant enzyme activity, and fatty acid composition in the striatum of Parkinson's disease mouse model.
Topics: Administration, Oral; Animals; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Fatty Ac | 2013 |
Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Deferoxamine; Disease Models, Animal; Dopamine; Drug The | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease M | 2013 |
Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats.
Topics: Amphetamines; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopami | 2013 |
Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.
Topics: Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Dopamine; Globus Pallidus; Injecti | 2013 |
The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Anim | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Carbazoles; Corpus Striatum; Disease Models, Animal; Enz | 2013 |
Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.
Topics: Affect; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic N | 2014 |
Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agonists; Male; Maz | 2002 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationsh | 2002 |
Comparison of fresh and cryopreserved porcine ventral mesencephalon cells transplanted in A rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cell Culture Techniques; Corpus Striatum; Cryopreserva | 2002 |
Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cell Death; Corpus Striatum; Disease Models, Anima | 2002 |
Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Drosophila Proteins; Glial Cell Line-Derived Neu | 2002 |
Induced expression of early response genes/oxidative injury in rat pheochromocytoma (PC12) cell line by 6-hydroxydopamine: implication for Parkinson's disease.
Topics: Animals; GAP-43 Protein; Gene Expression Regulation, Neoplastic; Genes, fos; Genes, jun; Oxidative S | 2002 |
Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats.
Topics: Adult; Animals; Disease Models, Animal; Humans; Immunoenzyme Techniques; Middle Aged; Nerve Growth F | 2002 |
Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease.
Topics: alpha-Synuclein; Apoptosis; Caspase 3; Caspases; Cell Line; Cells, Cultured; Humans; Kidney; Kinetic | 2002 |
Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Oxidopamine; | 2002 |
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Blood-Brain Barrier; Bradykinin; Calcineurin; Corpus S | 2002 |
Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cells, Cultured; Dose-Response Relationship, Drug; | 2002 |
Bone morphogenetic proteins but not growth differentiation factors induce dopaminergic differentiation in mesencephalic precursors.
Topics: Animals; Bone Morphogenetic Proteins; Brain Tissue Transplantation; Cell Differentiation; Cell Survi | 2002 |
Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism.
Topics: Animals; Callithrix; Disease Models, Animal; Dopamine; Dyskinesias; Female; Indans; Male; Motor Acti | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; | 2003 |
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Animals; Apomorphine; | 2003 |
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 2003 |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Citalopram | 2003 |
Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK.
Topics: Animals; Butadienes; Cell Death; Cell Line; Cell Survival; Chromones; Dopamine; Enzyme Inhibitors; G | 2003 |
Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.
Topics: alpha-Synuclein; Apoptosis; beta-Synuclein; Caspase 3; Caspases; Enzyme Activation; Humans; Nerve Ti | 2003 |
Behavioral correction of Parkinsonian rats following the transplantation of immortalized fibroblasts genetically modified with TH and GCH genes.
Topics: Animals; Behavior, Animal; Biopterins; Brain; Cell Line, Transformed; Cell Transplantation; Denervat | 2003 |
Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzopyrans; Disease Models, An | 2003 |
Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agonists; Dose-Response Relati | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; | 2003 |
High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Catalepsy; Ch | 2003 |
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Cell Line; CHO Cells; Cricetinae; Disease Model | 2003 |
Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats.
Topics: Animals; Apoptosis; Dihydroxyphenylalanine; Drug Interactions; Drugs, Chinese Herbal; Ginkgo biloba; | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Ch | 2003 |
Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells.
Topics: Animals; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Differentiation; Cell Size; C | 2003 |
Therapeutic gene transfer with herpes-based vectors: studies in Parkinson's disease and motor nerve regeneration.
Topics: Animals; Behavior, Animal; Cell Count; Cell Death; Disease Models, Animal; Fluorescent Dyes; Genetic | 2003 |
mGluRs: a target for pharmacotherapy in Parkinson disease.
Topics: Amino Acids, Dicarboxylic; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Disease Models | 2003 |
Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells.
Topics: Antiparkinson Agents; Apomorphine; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Glutathione; Huma | 2003 |
Baculovirus p35 gene greatly enhances PC12 cell's resistance against oxidative stress.
Topics: Animals; Cell Death; Cell Size; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Drug Resi | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central | 2004 |
Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells.
Topics: Antioxidants; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Glutathione; Humans; H | 2003 |
[Wakefulness and central basal nuclei: experimental observations and possible implications in Parkinson's disease].
Topics: Animals; Humans; Iontophoresis; Neurons; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pa | 2003 |
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Blotting, Northern; Bromodeoxyuridine; Corpus Striatum; Disease Models, | 2003 |
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Gene Expression; | 2004 |
Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Disease Models, Animal; Dizocilpine Maleate; | 2004 |
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Immunohistochemistry; Mice; M | 2004 |
Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain.
Topics: Animals; Animals, Newborn; Cell Death; Disease Models, Animal; Dopamine; Encephalitis; Endotoxins; F | 2004 |
NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats.
Topics: Adrenergic Agents; Animals; Brain; Dizocilpine Maleate; Dopamine Agents; Drug Interactions; Gait; Le | 2004 |
Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson's disease.
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Movement; Corpus Striatum; Disease Mode | 2004 |
Dissociation of hemi-spatial and hemi-motor impairments in a unilateral primate model of Parkinson's disease.
Topics: Animals; Callithrix; Conditioning, Operant; Disease Models, Animal; Dopamine; Female; Functional Lat | 2004 |
[Relationship between neurotoxicity of 6-hydroxydopamine and glutamate transport].
Topics: Amino Acid Transport System X-AG; Animals; Apoptosis; Corpus Striatum; Glutamic Acid; Male; Oxidopam | 2003 |
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Topics: Animals; Antibodies, Monoclonal; Blood-Brain Barrier; Cell Nucleus; Central Nervous System Neoplasms | 2004 |
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Body Weight; Brain; Capsules; Cell Count; | 2004 |
Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Electric Stimulation Therapy; Humans; Motor Skil | 2004 |
Expression of the fibroblast growth factor-2 isoforms and the FGF receptor 1-4 transcripts in the rat model system of Parkinson's disease.
Topics: Animals; Blotting, Western; Cell Count; Corpus Striatum; Disease Models, Animal; Fibroblast Growth F | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Behavioral Symptoms | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; CCAAT-Enhancer-Binding Proteins; Cells, Cultu | 2004 |
The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Beverages; Corpus Striatum; Dopamine; Dose-Re | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic A | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts.
Topics: Adrenergic Agents; Animals; Brain; Cell Growth Processes; Cell Survival; Cell Transplantation; Dopam | 2004 |
Comparison of embryonic stem cell-derived dopamine neuron grafts and fetal ventral mesencephalic tissue grafts: morphology and function.
Topics: Amphetamines; Animals; Brain Tissue Transplantation; Cell Differentiation; Cell Growth Processes; Ce | 2004 |
Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A | 2004 |
High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions.
Topics: Animals; Dopamine; Electric Stimulation Therapy; Forelimb; Male; Motor Skills; Oxidopamine; Parkinso | 2004 |
Survival and migration of transplanted neural stem cell-derived dopamine cells in the brain of parkinsonian rat.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Brain; Cell Differentiation; Cell Movement; Cell Survi | 2004 |
N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats.
Topics: Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dose-Response Relati | 2004 |
Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone.
Topics: Animals; Bromodeoxyuridine; Cell Count; Cell Division; Corpus Striatum; Disease Models, Animal; Dopa | 2004 |
Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transp | 2004 |
Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Female; GTP-Binding Protein | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apom | 2004 |
Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bone Morphogenetic Protein 7; Bone Morphogenetic Prote | 2004 |
Gene expression profiles of reactive astrocytes in dopamine-depleted striatum.
Topics: Adrenergic Agents; Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopamine; Gene Expr | 2004 |
Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease.
Topics: Animals; Brain Diseases; Disease Models, Animal; Gait; Ginkgo biloba; Male; Neuroprotective Agents; | 2004 |
Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressur | 2004 |
Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Brain; Brain Mapping; Cell Count; Dise | 2004 |
Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Topics: Animals; Dose-Response Relationship, Drug; Levodopa; Male; Mitochondria; Mucuna; Neuroprotective Age | 2004 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo.
Topics: Animals; Brain; Cell Differentiation; Cell Movement; Cell Survival; Cell Transplantation; Dopamine; | 2004 |
Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Cell Tr | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Dise | 2005 |
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
Topics: Animals; Corpus Striatum; Dopamine; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Ra | 2005 |
Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Dyskinesias; Globus Pallidus; Hypertrophy; Levodopa; Male; Oxidopamine; Parkinson Disease; | 2004 |
Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspase 3; Caspase Inhibitors; | 2005 |
Analysis of gene expression changes in a cellular model of Parkinson disease.
Topics: Animals; Cell Cycle; Cell Death; Cell Differentiation; Cell Survival; Dopamine; Gene Expression Prof | 2005 |
Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
Topics: Animals; Antioxidants; Caspase 3; Caspases; Cell Survival; Chymotrypsin; Dopamine; Dose-Response Rel | 2004 |
Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Cell Line; Cell Transplantation; Disease | 2005 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Corte | 2005 |
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Topics: Animals; Appetitive Behavior; Callithrix; Choice Behavior; Dependovirus; Disease Models, Animal; Dop | 2005 |
Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.
Topics: Amino Acid Sequence; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatography, Liquid | 2005 |
Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Cell Count; Cell Survival; Central Nervous System Stimulants | 2005 |
The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respons | 2005 |
Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
Topics: Animals; Apomorphine; Behavior, Animal; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Disease M | 2005 |
Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog.
Topics: Animals; Antimetabolites; Blotting, Western; Bromodeoxyuridine; Cell Count; Cell Survival; Cells, Cu | 2005 |
Does proteasome [corrected] inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?
Topics: Acetylcysteine; Animals; Apoptosis; Cysteine Proteinase Inhibitors; Dopamine; Humans; Leupeptins; Le | 2005 |
Proteasome function and pathological proteins in the pathogenesis of Parkinson's disease.
Topics: Animals; Apoptosis; Disease Models, Animal; Dopamine; Humans; Lewy Bodies; Mutation; Neurotoxins; Ox | 2005 |
Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Topics: Adenoviridae; Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus | 2005 |
Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease.
Topics: Animals; Brain; Brain Neoplasms; Cell Differentiation; Dopamine; Embryo, Mammalian; Epidermal Growth | 2005 |
Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats.
Topics: Adrenergic Agents; Animals; Behavioral Research; Dopamine; Exploratory Behavior; Functional Laterali | 2005 |
The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Dis | 2005 |
Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Bromodeoxyuridine; Cell Count; Corpus | 2005 |
Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Ce | 2005 |
Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
Topics: Adrenergic Agents; Aged; Aged, 80 and over; Animals; Blotting, Western; Disease Models, Animal; Drug | 2005 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Diseas | 2005 |
Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Catalytic Dom | 2005 |
Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Functional Laterality; Image Pr | 2005 |
Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.
Topics: Animals; Bone Marrow Cells; Chromatography, High Pressure Liquid; Dependovirus; Dopamine; Genetic Th | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Ex | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement | 2005 |
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Be | 2005 |
Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease.
Topics: Animals; Brain; Female; Lipopolysaccharides; Male; Neurodegenerative Diseases; NG-Nitroarginine Meth | 2005 |
Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro.
Topics: Animals; Antioxidants; Apoptosis; Astrocytes; Brain Stem; Corpus Striatum; DNA-Binding Proteins; Fem | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |
Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Brain; Cell Death; Cell Nucleus; Cerebral Co | 2005 |
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections.
Topics: Age Factors; Animals; Animals, Newborn; Axonal Transport; Axons; Brain Tissue Transplantation; Calbi | 2005 |
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Topics: Adrenergic Agents; Animals; Behavior, Animal; Chlorobenzenes; Cyclobutanes; Disease Models, Animal; | 2006 |
Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Brain-Derived Neuro | 2005 |
Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease.
Topics: Animals; Antioxidants; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Enzymol | 2006 |
Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain; | 2005 |
The change of the neuron-glia differentiation rate in human neural precursor cells (HPCs) and Ad-BDNF-/-GDNF-infected HPCs following the administration of a neurotoxin.
Topics: Adenoviridae; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cells, Cultured; Dose-Respons | 2005 |
Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Genetic Therapy; Glial Cell Line-Derived | 2006 |
Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway.
Topics: Annexin A5; Apoptosis; Blotting, Western; Calcium; Cell Line, Tumor; Cell Survival; Coloring Agents; | 2005 |
Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Do | 2006 |
The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists | 2005 |
Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats.
Topics: Adrenergic Agents; Amygdala; Animals; Copper; Globus Pallidus; Iron; Manganese; Mass Spectrometry; O | 2005 |
Transplants of neurosphere cell suspensions from aged mice are functional in the mouse model of Parkinson's.
Topics: Aging; Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Behavioral Symptoms; Corpus | 2005 |
Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Cell Survival; Disease Mod | 2005 |
Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Topics: Animals; Brain Chemistry; Cell Death; Chromatography, High Pressure Liquid; Diagnostic Imaging; Dise | 2005 |
Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease.
Topics: Animals; Brain; CD8 Antigens; Cell Differentiation; Cyclosporine; Ectodysplasins; Embryo, Mammalian; | 2006 |
Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions.
Topics: Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Brain; Cell Culture Techniques; Cel | 2005 |
Effects of intranigral vs intrastriatal fetal mesencephalic neural grafts on motor behavior disorders in a rat Parkinson model.
Topics: Adrenergic Agents; Animals; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Female; F | 2005 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F | 2005 |
Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells.
Topics: Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Survival; Enzyme Activation; Flavano | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dysk | 2005 |
Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age.
Topics: Adenoviridae; Amphetamine; Animals; Cell Count; Disease Models, Animal; Dopamine; Female; Fetal Tiss | 2005 |
Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
Topics: Amphetamine; Animals; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Male; | 2005 |
Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antigens; Behavior, Animal; Bromodeox | 2006 |
6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta.
Topics: Acetophenones; Animals; Apoptosis; Benzopyrans; Caspase 3; Caspase 7; Caspases; Enzyme Activation; E | 2006 |
Neuroprotective effect of D-psicose on 6-hydroxydopamine-induced apoptosis in rat pheochromocytoma (PC12) cells.
Topics: Adrenergic Agents; Animals; Apoptosis; Fructose; Glutathione; Humans; Neuroprotective Agents; Oxidop | 2005 |
Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Topics: Adenosine Triphosphate; alpha-Synuclein; Cell Line; Dopamine; Dopamine Plasma Membrane Transport Pro | 2006 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatog | 2006 |
Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug | 2006 |
6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Disease Models, Animal; Herbicides | 2006 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra | 2006 |
Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells.
Topics: Cell Line, Tumor; Dopamine; Down-Regulation; Enzyme Inhibitors; Free Radical Scavengers; Gene Expres | 2006 |
Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease.
Topics: Animals; Apoptosis; Cells, Cultured; Mice; Neurons; Oxidopamine; Parkinson Disease; PC12 Cells; Rats | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Nucleus; Cyclic AMP; Cyclic AMP Response Element-Binding | 2006 |
A method for a more complete in vitro Parkinson's model: slice culture bioassay for modeling maintenance and repair of the nigrostriatal circuit.
Topics: Animals; Animals, Newborn; Cell Count; Corpus Striatum; Disease Models, Animal; Embryo, Mammalian; G | 2006 |
Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cocaine; Diseas | 2006 |
Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Calcitriol; Disease Models, Animal; Dopamine; Gli | 2006 |
Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Chromatography, High Press | 2006 |
Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
Topics: Animals; Animals, Newborn; Antibodies; Astrocytes; Cell Communication; Cell Survival; Cells, Culture | 2006 |
Involvement of endoplasmic reticulum stress on the cell death induced by 6-hydroxydopamine in human neuroblastoma SH-SY5Y cells.
Topics: Acetylcysteine; Activating Transcription Factor 6; Adrenergic Agents; Animals; Cell Death; Cell Line | 2006 |
Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.
Topics: Aging; Animals; Behavior, Animal; Brain; Castration; Dopamine; Female; Gonads; Male; Motor Activity; | 2006 |
Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Topics: Adrenergic Agents; Animals; Gene Expression Regulation, Enzymologic; Immunohistochemistry; Male; Neu | 2006 |
Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.
Topics: Animals; Cell Death; DNA; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Genetic Thera | 2006 |
Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
Topics: Animals; Apomorphine; Brain; Brain Diseases; Caffeine; Disease Models, Animal; Dopamine Agents; Male | 2006 |
PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model.
Topics: Animals; Antibodies, Blocking; Behavior, Animal; Cell Death; Cells, Cultured; Dopamine; Dopamine Age | 2006 |
Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease.
Topics: Aging; Animals; Behavior, Animal; Disease Models, Animal; Male; Orchiectomy; Oxidopamine; Parkinson | 2006 |
Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.
Topics: Animals; Apoptosis; Brain; Cell Line; Disease Models, Animal; Gene Expression Regulation; Genetic Th | 2006 |
Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Biomechanical Phenomena; Disease Model | 2006 |
Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Cognition; Conditioning, Psychological; Disease Models, Animal; Exercise Test; Female; Loco | 2007 |
Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Cell Count; Cell Line; Disease Models, An | 2007 |
Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Topics: Aging; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models | 2006 |
Distribution of DJ-1, Parkinson's disease-related protein PARK7, and its alteration in 6-hydroxydopamine-treated hemiparkinsonian rat brain.
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Immunohistochemistry; Male; Mesencephalon; | 2006 |
A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caspase Inhibitors; Cells, Cultured; Disease Models | 2006 |
Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Green Fluorescent Proteins; Humans; JNK Mi | 2007 |
Bridging nigrostriatal pathway with fibroblast growth factor-primed peripheral nerves and fetal ventral mesencephalon transplant recuperates from deficits in parkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Cell Transplantation; Corpus Striatum; Fetus; Fibroblast Gro | 2006 |
GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Drug Interactions; Functional L | 2007 |
Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
Topics: Animals; Basal Ganglia; Cerebellum; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agen | 2007 |
Unilateral ibotenic acid lesions of the prefrontal cortex reduce rotational behavior in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Agonists | 2006 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
6-Hydroxydopamine induces cystatin C-mediated cysteine protease suppression and cathepsin D activation.
Topics: Animals; Caspase 3; Cathepsin B; Cathepsin D; Cell Death; Cystatin C; Cystatins; Cysteine Endopeptid | 2007 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemi | 2007 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |
Bilateral high-frequency stimulation of the subthalamic nucleus on attentional performance: transient deleterious effects and enhanced motivation in both intact and parkinsonian rats.
Topics: Analysis of Variance; Animals; Attention; Behavior, Animal; Choice Behavior; Discrimination, Psychol | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Anima | 2007 |
The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Benzeneacetamides; Caspase 3; Cell Line; Cell Survival; Cytoch | 2007 |
Effects of engrafted neural stem cells derived from GFP transgenic mice in Parkinson's diseases rats.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Apomorphine; Behavior, Animal; Disease Models, Anim | 2007 |
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pres | 2007 |
Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA.
Topics: Animals; Bromocriptine; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cell Line; Dopamine | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatogra | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2007 |
Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Animals, Genetically Modified; Antiparkinson Agents; Behavior, Animal; D | 2007 |
Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Cell Proliferation; Dependovirus | 2007 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug In | 2007 |
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
Topics: Amino Acid Sequence; Animals; Brain; Cloning, Molecular; Conserved Sequence; Corpus Striatum; Diseas | 2007 |
Therapeutic effect of microencapsulated porcine retinal pigmented epithelial cells transplantation on rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Cell Transplantation; Cells, Cultured | 2007 |
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway.
Topics: Adrenergic Agents; Animals; Antioxidants; Behavior, Animal; Disease Models, Animal; Flavonoids; In S | 2007 |
Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Enzyme Activation; Glycogen | 2007 |
Assessing an eating disorder induced by 6-OHDA and the possibility of nerve regeneration therapy by transplantation of neural progenitor cells in rats.
Topics: Animals; Disease Models, Animal; Feeding and Eating Disorders; Male; Nerve Regeneration; Neurons; Ox | 2007 |
An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Female; Humans; Leupeptins; Mice; Nerve Tissue Proteins; Oxidopamin | 2007 |
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Dependovirus; Disease Models, Animal; Dopamine; Gen | 2007 |
Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons.
Topics: Animals; Brain Tissue Transplantation; Cell Count; Cell Culture Techniques; Cell Proliferation; Cell | 2007 |
Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cell Line; Disease Models, Animal; Male; Melatonin; Neurons; Oxidopamine; | 2007 |
Cell stress induced by the parkinsonian mimetic, 6-hydroxydopamine, is concurrent with oxidation of the chaperone, ERp57, and aggresome formation.
Topics: Animals; Cell Line, Transformed; Cells, Cultured; Culture Media, Serum-Free; Deoxyribonucleases; Imm | 2007 |
Treatment of Parkinson disease with C17.2 neural stem cells overexpressing NURR1 with a recombined republic-deficit adenovirus containing the NURR1 gene.
Topics: Adenoviridae; Adrenergic Agents; Animals; Behavior, Animal; Cell Differentiation; Cell Line, Transfo | 2007 |
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Biomarkers; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Hyp | 2007 |
Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling.
Topics: Adipocytes; Animals; Apoptosis; Caspase 3; Caspase 9; Catecholamines; Cell Line; Cell Survival; CREB | 2007 |
Manganese-enhanced MRI in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Brain; Cell Nucleus; Disease Models, Animal; Dopamine; Magnetic Resonance Im | 2007 |
Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease.
Topics: Animals; Behavior, Animal; Cocaine; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Trans | 2008 |
A dibenzoylmethane derivative protects dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress.
Topics: Animals; Cell Death; Chalcones; Dopamine; Embryonal Carcinoma Stem Cells; Endoplasmic Reticulum; Gen | 2007 |
Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Cell Count; Disease Models, Animal; Dopamine | 2007 |
Dopamine induces TNFalpha and TNF-R1 expression in SH-SY5Y human neuroblastoma cells.
Topics: 1-Methyl-4-phenylpyridinium; Antibodies; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Sur | 2007 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Mo | 2008 |
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2007 |
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Rel | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Resp | 2008 |
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Topics: Adrenergic Agents; alpha-Synuclein; Animals; Behavior, Animal; Brain Chemistry; Corpus Striatum; Dis | 2008 |
Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease.
Topics: Adipose Tissue; Adrenergic Agents; Animals; CD11b Antigen; Cell Count; Cell Differentiation; Cell Tr | 2008 |
Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Survival; Cell Transplantation; C | 2008 |
CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Behavior, Animal; Biogenic Monoamines; Caffeine; Disease Mo | 2008 |
Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Topics: Adrenergic Agents; Adult Stem Cells; Analysis of Variance; Animals; Astrocytes; Bromodeoxyuridine; C | 2008 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |
Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Count; Cell Proliferation; Corpus Striatum; Denervation | 2008 |
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
Topics: Aminobutyrates; Animals; Brain; Cytoprotection; Disease Models, Animal; Drug Therapy, Combination; E | 2008 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; A | 2008 |
Intrapallidal metabotropic glutamate receptor activation in a rat model of Parkinson's disease: behavioral and histological analyses.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Dioxolanes; Disease Models, Anim | 2008 |
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
Topics: Amphetamine; Animals; Antioxidants; Apomorphine; Behavior, Animal; Cell Line, Tumor; Corpus Striatum | 2008 |
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Calcium-Calmodulin-Dependent Prote | 2008 |
Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Topics: Animals; Cyclopentanes; Disease Models, Animal; Dose-Response Relationship, Drug; Furans; Ginkgolide | 2008 |
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Excitatory Am | 2008 |
Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Topics: Animals; Callithrix; Corpus Striatum; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Models, Ani | 2008 |
7-nitroindazole attenuates 6-hydroxydopamine-induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Indazoles; Learni | 2008 |
Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.
Topics: Animals; Animals, Newborn; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Excitatory Ami | 2008 |
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.
Topics: Animals; Cells, Cultured; Dexamethasone; Disease Models, Animal; Disease Progression; Enzyme-Linked | 2008 |
Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway.
Topics: Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Ergolines; Female; Hydroxydopamines; Oxido | 1982 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; | 1984 |
Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism.
Topics: Animals; Corpus Striatum; Dopamine; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Rats; Ra | 1984 |
Oxy-radical toxicity in catecholamine neurons.
Topics: Animals; Catecholamines; Dopamine; Free Radicals; Humans; Hydroxydopamines; Hydroxylation; Monoamine | 1984 |
Adrenal medullary implants in the dopamine-denervated rat striatum. I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis.
Topics: Adrenal Medulla; Animals; Catecholamines; Caudate Nucleus; Disease Models, Animal; Dopamine; Epineph | 1984 |
Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics.
Topics: Adrenal Medulla; Animals; Disease Models, Animal; Flupenthixol; Haloperidol; Hydroxydopamines; Male; | 1984 |
Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
Topics: Animals; Bromocriptine; Cycloheptanes; Disease Models, Animal; Hydroxydopamines; Male; Oxidopamine; | 1984 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dop | 1984 |
Human ventromesencephalic grafts restore dopamine release and clearance in hemiparkinsonian rats.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Fetal Tiss | 1995 |
6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death.
Topics: Animals; Cell Death; Disease Models, Animal; Nerve Degeneration; Nerve Endings; Neurons; Oxidopamine | 1995 |
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal | 1995 |
An avian model for the reversal of 6-hydroxydopamine induced rotating behaviour by neural grafting.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transplantation; Chickens; Disease Mod | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill | 1995 |
Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Dopamine; Erg | 1995 |
Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agon | 1995 |
Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Disease Models, Animal; Dose-Response Relat | 1995 |
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding, Competitive; Corpus Striatum; Dose- | 1995 |
Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease.
Topics: Adenoviridae; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Brain; Corpus Striatum; De | 1994 |
Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; gam | 1995 |
Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms.
Topics: Animals; Base Sequence; Behavior, Animal; Capsules; Cell Line; Cloning, Molecular; Corpus Striatum; | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 1995 |
Intrastriatal infusion of lisuride--a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats.
Topics: Animals; Autoradiography; Corpus Striatum; Infusions, Parenteral; Lisuride; Male; Motor Activity; Ox | 1994 |
On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Bromocriptine; Cocaine; Dopamin | 1993 |
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain Disease | 1993 |
Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway.
Topics: Animals; Behavior, Animal; Brain Diseases; Brain Tissue Transplantation; Callithrix; Caudate Nucleus | 1994 |
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
Topics: Biogenic Monoamines; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxydopamines; Levod | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc | 1993 |
Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Female; Male; Motor Activity; Oxidopam | 1993 |
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
Topics: Animals; Deferoxamine; Dominance, Cerebral; Ferritins; Free Radicals; Humans; Hydrogen Peroxide; Hyd | 1993 |
Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Lamotrigine; Male; Mot | 1995 |
Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Fibroblasts; | 1995 |
The vesamicol receptor ligand (+)-meta-[125I]iodobenzyltrozamicol [(+)-[125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson'
Topics: Animals; Brain Diseases; Cholinergic Fibers; Corpus Striatum; Disease Models, Animal; Dopamine Antag | 1996 |
Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; Oxidop | 1996 |
Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Oxidopamine; Parkinson Dise | 1995 |
Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion.
Topics: Animals; Basal Ganglia; Case-Control Studies; Corpus Striatum; Denervation; Dopamine; Gene Expressio | 1996 |
Cellular immune reactions in brain transplantation: effects of graft pooling and immunosuppression in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Female; Immunosuppression Therapy; Mi | 1996 |
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease.
Topics: Catalysis; Dopamine; Humans; Hydroxylation; Iron; Melanins; Neurons; Oxidation-Reduction; Oxidopamin | 1996 |
Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Autopsy; Caudate Nucleus; Dendrites; Female; Humans; Male; Microsc | 1996 |
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
Topics: Dopamine; Electron Transport; Ferric Compounds; Ferritins; Hydroxydopamines; Hydroxyl Radical; In Vi | 1995 |
The role of transition metals in the pathogenesis of Parkinson's disease.
Topics: Adrenergic Agents; Aged; Chromatography, High Pressure Liquid; Dopamine; Electron Probe Microanalysi | 1995 |
Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system.
Topics: Animals; Animals, Newborn; Brain; Corpus Striatum; DNA-Binding Proteins; Dopamine; Enzyme Induction; | 1996 |
Spatio-temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue: relevance to axial apraxia in humans.
Topics: Animals; Apraxias; Disease Models, Animal; Dopamine; Female; Hindlimb; Humans; Motor Activity; Movem | 1996 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxi | 1996 |
Dopaminergic neurons protected from degeneration by GDNF gene therapy.
Topics: Adenoviridae; Animals; Corpus Striatum; Dopamine; Gene Expression; Genetic Therapy; Genetic Vectors; | 1997 |
Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cells, Cultured; Chickens; | 1997 |
Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dis | 1997 |
Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology.
Topics: Animals; Corpus Striatum; Dopamine; Models, Neurological; Nerve Degeneration; Neurons; Oxidopamine; | 1998 |
Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Estradio | 1997 |
Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; Apomorphine; Behavior, Animal; Disease Models | 1997 |
Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Basal Ganglia; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopami | 1998 |
Experiments in a Parkinson's rat model.
Topics: Animals; Dopamine; Fluorescent Dyes; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neuro | 1997 |
Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Apomorphine; Brain; Caudate Nucleus; Disease Models, Animal; Enkephalins; Gene Expression R | 1998 |
Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; DNA Fragmentation; Melatonin; Neurons; Oxidopami | 1998 |
Asymmetry of sympathetic activity in a rat model of Parkinson's disease induced by 6-hydroxydopamine: haemodynamic, electrocardiographic and biochemical changes.
Topics: Animals; Apomorphine; Behavior, Animal; Catecholamines; Disease Models, Animal; Electrocardiography; | 1998 |
[Transplantation of fetal dopaminergic cells simultaneously to the corpus striatum and pars reticularis of the substantia nigra in hemi-parkinsonian rats].
Topics: Adrenergic Agents; Analysis of Variance; Animals; Cell Count; Chromatography, High Pressure Liquid; | 1998 |
Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Cyclohexanols; Globus Pallidus; Injections, I | 1998 |
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; D | 1998 |
Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice.
Topics: Acyl Coenzyme A; Animals; Cell Count; Cell Size; Corpus Striatum; Crosses, Genetic; Disease Models, | 1998 |
Expression and localisation of CYP2D enzymes in rat basal ganglia.
Topics: Animals; Antibody Specificity; Basal Ganglia; Brain Chemistry; Clozapine; Cytochrome P-450 Enzyme Sy | 1999 |
Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway.
Topics: Animals; Benzazepines; Caudate Nucleus; Dopamine; Dopamine Agonists; Dopamine D2 Receptor Antagonist | 1999 |
Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine; Dopa | 1999 |
Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
Topics: Animals; Behavior, Animal; Brain; Brain Mapping; Corpus Striatum; Dextroamphetamine; Disease Models, | 1999 |
Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Humans; Immunohistochemistry; Male; Oxidopamine; | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study.
Topics: Adrenergic Agents; Animals; Apomorphine; Benzazepines; Dopamine Agonists; Male; Oxidopamine; Parkins | 1999 |
Iron accumulation in the substantia nigra in rats visualized by ultrasound.
Topics: Animals; Deferoxamine; Dose-Response Relationship, Drug; Ferritins; Humans; Iron; Oxidopamine; Parki | 1999 |
Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Topics: Age Factors; Animals; Animals, Newborn; Behavior, Animal; Brain Tissue Transplantation; Corpus Stria | 1999 |
Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.
Topics: Adenoviridae; Animals; Anti-Bacterial Agents; Antiparkinson Agents; Apomorphine; Corpus Striatum; Di | 1999 |
Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer.
Topics: Adrenergic Agents; Amphetamine; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System S | 1999 |
Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
Topics: Aged; Aged, 80 and over; Brain; Catalysis; Dopamine; Electron Probe Microanalysis; Humans; Hydroxydo | 1999 |
Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Astrocytes; Buthionine Sulfoximine; Cells, Cultured | 1999 |
Functional characterization and expression of thalamic GABA(B) receptors in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; GABA Antagonists; Male; Oxidopamine; Parkinson Disease | 1999 |
Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundl | 1999 |
Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Caffeine; Central Nervous System Stimul | 1999 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose- | 2000 |
N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.
Topics: Animals; Cell Count; Denervation; Dopamine; Immunohistochemistry; Insulin-Like Growth Factor I; Male | 2000 |
Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Cysteine; Female; Free Radical Scavengers; Glu | 2000 |
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cerebellum; Dopamine; Dopamine Antagonists; Glutat | 2000 |
Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons.
Topics: Adrenergic Agents; Age Factors; Animals; Brain Tissue Transplantation; Cell Death; Cell Survival; Ce | 2000 |
Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Topics: Adenoviridae; alpha-Synuclein; Animals; Apoptosis; Cell Line, Transformed; Dopamine; Embryo, Mammali | 2000 |
Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion.
Topics: Animals; Axons; Calbindin 2; Calbindins; Dopamine; Drug Resistance; Female; Neostriatum; Nerve Degen | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Biopterins; Cell Line; Corpus Striatum; Dependovirus; | 2000 |
Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson's disease.
Topics: Animals; beta-Galactosidase; Cell Line; Cell Survival; Cells, Cultured; Disease Models, Animal; Gene | 2000 |
GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration.
Topics: Adrenergic Agents; Animals; Brain-Derived Neurotrophic Factor; Cell Division; Disease Models, Animal | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; | 2000 |
Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Topics: Animals; Dopamine; Fluorescent Dyes; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; M | 2000 |
Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats.
Topics: Amygdala; Animals; Brain; Corpus Striatum; Disease Models, Animal; Functional Laterality; Gene Expre | 2000 |
Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum.
Topics: Adenosine; Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Functional Later | 2000 |
Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine.
Topics: Adrenergic Agents; Animals; beta-Galactosidase; Corpus Striatum; Female; Fibroblast Growth Factor 2; | 2000 |
The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics.
Topics: Animals; Ascorbic Acid; Buthionine Sulfoximine; Dopamine; Dose-Response Relationship, Drug; Drug Int | 2000 |
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Denervation; Dopamine; Electric Stimulation Therapy; Globus | 2000 |
The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats.
Topics: Animals; Corpus Striatum; Ligands; Male; Nerve Degeneration; Nerve Fibers; Nerve Regeneration; Oxido | 2001 |
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Topics: Animals; Antioxidants; Benzothiazoles; Cell Line; Cell Survival; Dopamine; Dopamine D2 Receptor Anta | 2000 |
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.
Topics: Aged; Animals; CD4-Positive T-Lymphocytes; Disease Models, Animal; Humans; Leukocyte Common Antigens | 2001 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron | 2001 |
Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.
Topics: Adrenergic Agents; Animals; Caudate Nucleus; Corpus Striatum; Female; Motor Activity; Motor Skills; | 2001 |
Changes in the gene expression of GABA(A) receptor alpha1 and alpha2 subunits and metabotropic glutamate receptor 5 in the basal ganglia of the rats with unilateral 6-hydroxydopamine lesion and embryonic mesencephalic grafts.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Brain Tissue Transplantation; Fetal Tissue Transplantatio | 2001 |
NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Denervation; Dizocilpine Maleate; Dopamine | 2001 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain; Cell Count; Disease Models, Animal; Dopamine; Injections, Intrave | 2001 |
Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.
Topics: Animals; Behavior, Animal; Calbindin 2; Calbindins; Cell Count; Cell Size; Disease Models, Animal; D | 2001 |
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Glial Cell Line-Derived Neurotrophic Factor | 2001 |
Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease.
Topics: Animals; Cell Line; Cell Survival; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Fla | 2001 |
Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum.
Topics: Animals; Brain Tissue Transplantation; Cells, Cultured; Denervation; Dopamine; Female; Fetus; Graft | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chro | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Complexities in the neurotoxic actions of 6-hydroxydopamine in relation to the cytoprotective properties of taurine.
Topics: Aconitate Hydratase; Adrenergic Agents; Animals; Dopamine; Extracellular Space; gamma-Aminobutyric A | 2001 |
Future of neuroprotection in Parkinson's disease.
Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamin | 2001 |
Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
Topics: Animals; Cells, Cultured; Cholecalciferol; Dopamine; Drug Interactions; Glial Cell Line-Derived Neur | 2001 |
Subthalamic nucleus lesions reduce low frequency oscillatory firing of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Biological Clocks; Disease Models, Animal; Excitatory Amino Acid Agonist | 2001 |
Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network.
Topics: Action Potentials; Anesthetics, Intravenous; Animals; Biological Clocks; Cerebral Cortex; Corpus Cal | 2001 |
Influence of alternating low frequency magnetic fields on reactivity of central dopamine receptors in neonatal 6-hydroxydopamine treated rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Electromagnetic Fields; Humans; Male; Neurons; Ox | 2001 |
Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions.
Topics: Animals; Cell Count; Corpus Striatum; Female; Functional Laterality; Ibotenic Acid; Models, Animal; | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Do | 2001 |
Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.
Topics: Adrenergic Agents; Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Male; Models, | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.
Topics: Adrenergic Agents; Amphetamine; Animals; Cell Culture Techniques; Cell Transplantation; Dopamine; Do | 2002 |
Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.
Topics: Animals; Dopamine; Dopamine Uptake Inhibitors; Down-Regulation; Flunitrazepam; GABA Agonists; GABA M | 2002 |
The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cattle; Nerve Tissue Proteins; Nitric Oxide; Oxidation-Reduction; Oxidopam | 2002 |
Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Chronobiology Disorders; Circadian | 2002 |
Glyceraldehyde-3-phospate dehydrogenase is translocated into nuclei through Golgi apparatus during apoptosis induced by 6-hydroxydopamine in human dopaminergic SH-SY5Y cells.
Topics: Active Transport, Cell Nucleus; Apoptosis; Dopamine; Glyceraldehyde-3-Phosphate Dehydrogenases; Golg | 2002 |
GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum.
Topics: Animals; Antioxidants; Catalase; Dopamine; Dopamine Agents; Glutamate-Cysteine Ligase; Glutathione; | 2002 |
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents; Avian Proteins; | 2002 |
Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Topics: Animals; Corpus Striatum; Dopamine; Female; Gene Transfer Techniques; Genetic Vectors; Glial Cell Li | 2002 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, | 2002 |
6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats.
Topics: alpha-Synuclein; Animals; Dopamine; Dopamine Agents; Drug Administration Schedule; Male; Neostriatum | 2002 |
Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Topics: Animals; Dependovirus; Disease Progression; Dopamine; Gene Expression; Genetic Therapy; Genetic Vect | 2002 |
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Rela | 2001 |
High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat.
Topics: Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Dopamine; Electric Stimulation; Electron | 2002 |
Xenografts of MHC-deficient mouse embryonic mesencephalon improve behavioral recovery in hemiparkinsonian rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Histocompatibility Antigens Class II; Immunohi | 2002 |
D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amino Acid Sequence; Animals; Behavior, | 1992 |
Recovery in hemiparkinsonian rats following intrastriatal implantation of activated leukocytes.
Topics: Animals; Caudate Nucleus; Corpus Striatum; Denervation; Dextroamphetamine; Ganglia, Spinal; Lectins; | 1992 |
Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat.
Topics: Adenylyl Cyclases; Animals; Corpus Striatum; Male; Motor Activity; Oxidopamine; Parkinson Disease; R | 1992 |
Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.
Topics: Amphetamine; Animals; Apomorphine; Axons; Denervation; Disease Models, Animal; Female; Motor Activit | 1991 |
Positive and negative interactions in the behavioural expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Antagonists; | 1991 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Res | 1991 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transp | 1991 |
Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat.
Topics: Animals; Cerebral Ventricles; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxydopam | 1991 |
Possible mechanisms of action of adrenal transplants in Parkinson's disease.
Topics: Adrenal Medulla; Aging; Animals; Apomorphine; Brain Tissue Transplantation; Bucladesine; Caudate Nuc | 1990 |
Antiparkinsonian effects of caffeine depend upon pavlovian drug conditioning processes.
Topics: Animals; Apomorphine; Caffeine; Conditioning, Classical; Functional Laterality; Hydroxydopamines; Ma | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus | 1990 |
Mechanisms of action of adrenal medulla grafts: the possible role of peripheral and central dopamine systems.
Topics: Adrenal Medulla; Adrenalectomy; Amphetamine; Animals; Apomorphine; Blood-Brain Barrier; Cerebral Ven | 1990 |
Phenotypic plasticity of locus coeruleus noradrenergic neurons after transplantation into the dopamine-depleted caudate in the rat.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Caudate Nucleus; Dopamine; Female; Fetal Tissue | 1990 |
A functional assessment of embryonic dopaminergic grafts in the marmoset.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Callitrichinae; Corpus Striatum; Di | 1990 |
Basic fibroblast growth factor enhances survival and sprouting of fetal dopaminergic cells implanted in the denervated rat caudate-putamen: preliminary observations.
Topics: Animals; Axons; Caudate Nucleus; Cell Survival; Drug Synergism; Fetal Tissue Transplantation; Fibrob | 1990 |
Parkinson's syndrome induced in cats by the use of 6-hydroxydopamine. Observations of behavior and motor disorders.
Topics: Animals; Behavior, Animal; Brain; Cats; Disease Models, Animal; Motor Activity; Muscle Tonus; Neurot | 1990 |
Intrastriatal grafts of adrenal medulla in hemiparkinsonian rats--ultrastructural study.
Topics: Adrenal Medulla; Animals; Corpus Striatum; Graft Survival; Neurotoxins; Oxidopamine; Parkinson Disea | 1990 |
Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Brain Injuries; Choline O-Acetyltransferase; Fe | 1990 |
Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Hydroxydopamines; Male; Neurokinin A; O | 1989 |
Effect of striatal implantation of bovine adrenal chromaffin cells on turning behavior in a rat model of Parkinson's disease.
Topics: Adrenal Glands; Amphetamines; Animals; Cattle; Cell Separation; Corpus Striatum; Female; Graft Survi | 1989 |
An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats.
Topics: Acrylic Resins; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug | 1989 |
Paradoxical kinesia in parkinsonism is not caused by dopamine release. Studies in an animal model.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Hydroxydopamines; Male; Motor Activity; Ox | 1989 |
Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease.
Topics: Animals; Cell Count; Cyclosporins; Disease Models, Animal; Female; Graft Rejection; Hydroxydopamines | 1989 |
Differential time-course of reaction time recovery depending on variations in the amplitude of a goal-directed movement after nigrostriatal lesion in monkeys.
Topics: Animals; Brain Diseases; Caudate Nucleus; Corpus Striatum; Dopamine; Hydroxydopamines; Motor Activit | 1986 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; L | 1987 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; M | 1987 |
An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction.
Topics: Animals; Brain; Dopamine; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred | 1986 |
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Culture Techniques; Dopamine; Humans; | 1987 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D | 1986 |
Cellular localization of adrenergic receptors in rat and human brain.
Topics: Animals; Brain Chemistry; Cerebellum; Cerebral Cortex; Corpus Striatum; Hippocampus; Humans; Hydroxy | 1986 |
The potential use of vitamin E and selenium in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Hydroxydopami | 1986 |
A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.
Topics: Animals; Apomorphine; Conditioning, Classical; Corpus Striatum; Dopamine; Hydroxydopamines; Male; Ox | 1986 |
Chronic treatment with bromocriptine induces behavioral supersensitivity in rats.
Topics: Animals; Apomorphine; Bromocriptine; Dopamine Antagonists; Humans; Hydroxydopamines; Male; Oxidopami | 1986 |
Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Cerebral Cor | 1988 |
Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry.
Topics: Animals; Corpus Striatum; Dopamine; Female; Fetus; Humans; Hydroxydopamines; Mesencephalon; Microsco | 1988 |
Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease.
Topics: Animals; Binding Sites; Biological Transport; Cocaine; Corpus Striatum; Dopamine; Humans; Hydroxydop | 1985 |
Effects of intracerebral transplantation of immature substantia nigra in rats with experimentally induced Parkinson's disease. I Comparative evaluation of two models of Parkinson's disease induced by unilateral stereotaxic lesion of the substantia nigra w
Topics: Animals; Disease Models, Animal; Electrocoagulation; Hydroxydopamines; Nerve Degeneration; Oxidopami | 1985 |
Effects of intracerebral transplantation of immature substantia nigra in rats with experimentally induced Parkinson's disease. II. Results of histopathological and histofluorescent studies.
Topics: Animals; Animals, Newborn; Corpus Striatum; Fluorescence; Follow-Up Studies; Graft Survival; Hydroxy | 1985 |